UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10
GENERAL FORM FOR REGISTRATION OF SECURITIES
Pursuant to Section 12(b) or (g) of The Securities Exchange Act of 1934
|
Innovest Global, Inc. |
|
(Exact name of registrant as specified in its charter) |
|
Nevada |
|
82-0777948 |
|
(State of incorporation) |
|
(I.R.S. Employer Identification No.) |
|
8834 Mayfield Road, Chesterland, Ohio 44026 |
|
|
(Address of principal executive offices) (Zip Code) |
|
|
|
|
|
Registrant’s telephone number, including area code: |
440-644-1027 |
|
Christopher J. Hubbert, Esq., CJH@KJK.com, 216-736-7215 Kohrman Jackson & Krantz LLP, 1375 East 9th Street, 29th Floor, Cleveland Ohio 44114 |
|
|
(Contact for Securities and Exchange Commission correspondence) |
|
Securities to be registered pursuant to Section 12(b) of the Act: None
Securities to be registered pursuant to Section 12(g) of the Act:
|
Common Stock, Par Value $0.001 per share |
|
(Title of class) |
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
|
Large accelerated filer ☐ |
Accelerated filer ☐ |
|
Non-accelerated filer ☐ |
Smaller reporting company ☒ |
|
Emerging growth company ☐ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Table of Contents
|
Forward-Looking Statements |
1 |
|
Item 1. Business. |
1 |
|
Business Overview |
1 |
|
Corporate Information |
1 |
|
Growth Strategy |
1 |
|
Historical Acquisitions |
2 |
|
Chagrin Safety Supply |
2 |
|
Contact Source Solutions |
2 |
|
Shepherd Energy Solutions and the Innovest Energy Group |
2 |
|
HP Technologies |
3 |
|
Primary Metering Systems |
3 |
|
Midwest Curtainwalls |
3 |
|
Authority National Supply |
3 |
|
StemVax |
3 |
|
Segments Overview |
4 |
|
Commercial Solutions |
4 |
|
Wholesale Purchasing |
4 |
|
Manufacturing and Raw Materials |
4 |
|
Concentration of Sales |
4 |
|
Seasonality |
4 |
|
Employees |
4 |
|
Intellectual Property |
5 |
|
Competition |
5 |
|
Regulatory Compliance |
5 |
|
Item 1A. Risk Factors. |
5 |
|
Risks Related to Our Company and Our Business |
6 |
|
Risks Related to the Securities Markets and Ownership of Our Stock |
11 |
|
Item 2. Financial Information. |
14 |
|
Critical Accounting Policies and Estimates |
15 |
|
Basis of Presentation |
15 |
|
Principles of Consolidation |
15 |
|
Cash Equivalents |
15 |
|
Trade Accounts Receivable |
15 |
|
Investments |
15 |
|
Inventory |
15 |
|
Property and Equipment |
15 |
|
Goodwill |
16 |
|
Intangible Assets |
16 |
|
Revenue Recognition |
16 |
|
Management’s Discussion and Analysis of Results of Operations |
16 |
|
Net Sales |
16 |
|
Cost of Sales and Operating Expenses |
17 |
|
Non-Operating Income (Expense) |
17 |
|
Net Income |
17 |
|
Liquidity and Capital Resources |
17 |
|
Going Concern |
17 |
|
Cash Flows from Operating Activities |
18 |
|
Cash Flows from Investing Activities |
18 |
|
Cash Flows from Financing Activities |
18 |
|
12-Month Plan of Operation |
18 |
|
Item 3. Properties. |
19 |
|
Item 4. Security Ownership of Certain Beneficial Owners and Management. |
19 |
|
Item 5. Directors and Executive Officers. |
20 |
|
Board of Directors |
20 |
|
Executive Officers |
21 |
|
Item 6. Executive Compensation. |
22 |
|
Executive Officers |
22 |
|
Employment Agreements |
22 |
|
Benefit Plans |
22 |
|
Equity Compensation Plan Information |
23 |
|
Outstanding Equity Awards |
23 |
|
Board of Directors |
23 |
|
Item 7. Certain Relationships and Related Transactions, and Director Independence. |
23 |
|
Transactions with Related Parties |
23 |
|
Director Independence |
24 |
|
Item 8. Legal Proceedings. |
24 |
|
Item 9. Market Price of and Dividends on the Registrant’s Common Equity and Related Stockholder Matters. |
24 |
|
Stockholders |
24 |
|
Dividends |
24 |
|
Securities Authorized for Issuance Under Equity Compensation Plans |
24 |
|
Item 10. Recent Sales of Unregistered Securities. |
25 |
|
Item 11. Description of Registrant’s Securities to be Registered. |
26 |
|
Common Stock |
27 |
|
Voting |
27 |
|
Dividends |
27 |
|
Liquidation Rights |
27 |
|
Series A Preferred Stock |
27 |
|
Voting |
27 |
|
Conversion |
27 |
|
Dividends |
27 |
|
Liquidation |
27 |
|
Item 12. Indemnification of Directors and Officers. |
27 |
|
Item 13. Financial Statements and Supplementary Data. |
29 |
|
Item 14. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure. |
29 |
|
Item 15. Financial Statements and Exhibits. |
30 |
|
Financial Statements |
30 |
|
Exhibit Index |
30 |
|
Signatures |
32 |
Forward-Looking Statements
This Form 10 (“Form 10”) contains forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, that involve risks and uncertainties. Many of the forward-looking statements are located in “Item 2. Financial Information” beginning on page of this Form 10. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Forward-looking statements can also be identified by words such as “future,” “anticipates,” “believes,” “estimates,” “expects,” “intends,” “plans,” “predicts,” “will,” “would,” “could,” “can,” “may,” and similar terms. Although we believe the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance or achievements. Factors that might cause such differences include, but are not limited to, those discussed in “Item 1A. Risk Factors” beginning on page of this Form 10. We assume no obligation to revise or update any forward-looking statements for any reason, except as required by law.
In this Form 10 the terms “our company,” “we,” “us,” “our,” the “Company” and “Innovest” refer collectively to Innovest Global, Inc. and its wholly owned subsidiaries, unless otherwise stated.
Item 1. Business.
Business Overview
Innovest builds long-term shareholder value by acquiring established businesses on favorable terms, realizing synergies and achieving organic growth through investments in innovative technology and business systems. Our Commercial Solutions segment encompasses businesses that provide products and services to companies in various commercial markets including manufacturing, municipalities and construction. The Commercial Solutions segment includes a fabricator of large curtainwall systems and a division providing energy consumption solutions for high-use commercial and industrial customers to lower demand, improve utilization and drastically reduce spending. Our Wholesale Purchasing segment includes a national distributor of roofing, windows, fasteners and associated tools and materials. We have also made a strategic investment in a cutting-edge biotechnology company that is developing novel therapies for brain tumor patients.
Corporate Information
The Company was incorporated in 1999 as International Sports Marketing Group, Inc. In August 2016, we refocused our business to operate as a diversified industrials company and changed our name to Innovest Global, Inc.
We are publicly traded on the OTC Markets under the ticker symbol “IVST.” Our corporate headquarters is located at 8834 Mayfield Road, Chesterland, Ohio 44026. Our telephone number is 440-644-1027 and our website is www.InnovestGlobal.com. The information on our website is not incorporated by reference in or considered to be a part of this Form 10. The OTC Markets’ website, www.OTCMarkets.com, includes information regarding companies that file electronically, including Innovest.
Growth Strategy
Based on historic market data relative to market performance of stocks of diversified companies serving our markets, we believe that large, multinational conglomerates often are valued below what their segmented business units would otherwise be worth individually. This is due to the perceived inability of the large whole to effectively manage diverse objectives. Alternatively, smaller, more focused companies with diverse revenue streams such as Innovest tend to trade at a premium to what their individual business units would be worth individually, because of the efficiencies gained by a central operating structure and diversified risk profile. This is central to our value creation strategy of growth by acquisition, followed by operational improvements.
Previously, Innovest acquired entities ranging from $350,000 to $27.0 million in annual sales. We are now seeking profitable, synergistic companies with annual sales of $10.0 million and higher. Acquisition candidate companies will generally have an established business and good name recognition within their industry.
Acquisitions of small and midsized private companies are at attractive valuation points due to their falling behind large multinational competitors in marketing savvy, lead generation and operational efficiencies. Our acquisition strategy consists of the following:
|
● |
Build a core platform of companies in the industrial, commercial durable goods, energy and nonprofessional services markets. |
|
● |
The acquisition candidates will have revenue range of $10.0 million or more, depending on the industry, with positive earnings and cash flow. |
|
● |
The acquisition candidates will be compatible with our strategic integration criteria for synergies with our other core companies. |
|
● |
The acquisition candidates will typically not have an active succession plan in place and the existing owners seek to remain involved in managing their businesses. |
|
● |
The owners are open to becoming an equity participant as part of the acquisition process versus traditional all cash transactions at time of closing. |
The following section briefly describes the acquisitions that we have made to date.
Historical Acquisitions
Chagrin Safety Supply
Chagrin Safety Supply, LLC (“Chagrin Safety”) has a 30-year history of providing personal protection equipment and apparel from head to toe servicing small and large municipal, commercial and industrial organizations. We acquired substantially all of the assets and assumed certain liabilities of Chagrin Safety on October 23, 2017. As a result of this acquisition, we were able to gain entry into new product categories and access to a new customer base. The purchase price consisted of cash, shares of our common stock and a stock price guarantee. The acquisition of Chagrin Safety established the basis for Innovest on which to build future acquisitions and growth. The operating results and financial performance of Chagrin Safety are reported under our Commercial Solutions segment because the primary customers in this space are commercial companies.
Chagrin Safety’s major products include, hearing protection, respiratory protections, fall and hand protection, protective work wear, first aid and biohazard, spill control and containment, facility safety and signage, construction and traffic safety, clean room protection and apparel. In the near term, strategies include growth in sales by further account penetration with existing customers, and enhanced marketing techniques to reach new customers. As a result of the COVID-19 pandemic, Chagrin Safety is seeing significant growth in demand for its products, although sales are limited by its ability to source manufactured items in a timely manner. Beyond the pandemic, Chagrin Safety’s operational focus and 2020 strategies include marketing, personal protective equipment, medical and dental safety, industrial safety and traffic and construction safety products.
Contact Source Solutions
Contact Source Solutions, LLC (“Contact Source Solutions”) offers inbound and outbound call services customized to individual client needs on a short or long-term basis. We acquired Contact Source Solutions (previously known as Call Center Resources, Inc.) to increase our revenue streams and to obtain a company that could provide marketing solutions for our other business units, on January 15, 2018. The purchase price consisted of shares of our common stock and a stock price guarantee. The operating results and financial performance of Contact Source Solutions are reported under the Commercial Solutions segment of Innovest Global because Contact Source Solutions’ primary customers are commercial companies.
Contact Source Solutions has also seen a significant increase in demand for its services as a result of the COVID-19 pandemic because a portion of the call center business is HIPAA certified and approved to handle sensitive health services discussions and confidential patient information. In 2020, Innovest will make use of the call center platform, including marketing the service as a “contact” center to highlight the various ways Contact Source Solutions can help companies use technology as touch points to enhance results. Contact Source Solutions will also target new customers through the marketing channels of our other Innovest subsidiaries.
Shepherd Energy Solutions and the Innovest Energy Group
Shepherd Energy Solutions, LLC (“Shepherd Energy”) provides an all-in-one offering of procurement and efficiency solutions for commercial and industrial customers with a relatively recent expansion into LED lighting and retrofits. We acquired Shepherd Energy primarily to launch a commercial energy division and further diversify our portfolio, on January 1, 2018. The purchase price consisted of shares of our common stock and a stock price guarantee.
After the acquisition of Primary Metering Systems in early 2019, we consolidated the operations of Primary Metering Systems, HP Technologies and Shepherd Energy into the newly-formed Innovest Energy Group, LLC (“Innovest Energy Group”). Innovest Energy Group is an infrastructure services company which creates custom-tailored solutions to drastically reduce customers energy spend, protect infrastructure investment, and provide sources of project funding. Innovest Energy Group has three primary service offerings: LED lighting projects, custom electrical projects and energy brokerage services all of which reduce energy consumption and costs for commercial and industrial customers. The operating results and financial performance of the Innovest Energy Group are reported under our Commercial Solutions segment primarily because the customers serviced by the Innovest Energy Group are in the commercial in nature.
In 2019, we established a technology driven marketing system to identify strategic sales leads to further expand lighting and custom electrical projects towards prime commercial and industrial companies with an increased focus on government municipalities. In 2020, Innovest Energy Group plans to capitalize on this new system for obtaining leads while further expanding the service offerings into new markets and territories with a continued underlying focus on energy consumption and cost reduction.
HP Technologies
H.P. Technologies, Inc. (“HP Technologies”) provides competitive electricity and natural gas purchase programs for residential and commercial consumers, while giving energy suppliers the opportunity to extend special offers and savings to potential new customers. Our utility consulting process is a turnkey approach to utility savings that can be tailored to fit the client’s needs. We acquired HP Technologies primarily to strengthen the commercial energy division and further diversify our portfolio, on March 22, 2018. The purchase price consisted of shares of our common stock and a stock price guarantee. We subsequently moved HP Technologies into the Innovest Energy Group, which is reported under our Commercial Solutions segment.
Primary Metering Systems
Primary Metering Solutions, LLC (“Primary Metering Solutions”) provides custom electric solutions for utility-owned infrastructure and passes direct cost savings on to customers. We acquired certain contracts and assets of Primary Metering Solutions primarily to provide additional growth opportunities for Innovest Energy Group, on January 1, 2019. The purchase price consisted of shares of our common stock. We subsequently moved Primary Metering Solutions into Innovest Energy Group, which is reported under our Commercial Solutions segment.
Midwest Curtainwalls
For almost 40 years, Midwest Curtainwalls, LLC (“Midwest Curtainwalls”) has been designing, engineering, testing and manufacturing curtainwall systems that perform. We acquired Midwest Curtainwalls primarily to expand our penetration in the building materials segment, as well as geographic reach, on December 1, 2018. The purchase price consisted of shares of our common stock, contingent consideration and a stock price guarantee.
In 2019, Midwest Curtainwalls upgraded its facility and operations to a larger industrial space which allowed for more efficient and process-oriented fabrication. The larger facility allows us to fabricate multiple large projects in tandem, increasing fixed cost leverage and generating more overall profits for the business. The operating results and financial performance of Midwest Curtainwalls are reported under our Commercial Solutions segment primarily because the customers served by Midwest Curtainwalls are in the commercial building industry.
Authority National Supply
Authority National Supply, LLC (“Authority National Supply” or “ANS”) is a national distributor of roofing, windows, fasteners and associated tools and materials. Authority National Supply was established to create purchasing power amongst a group of independent building material providers by obtaining discounts from suppliers based on the collective buying power of its members. We acquired Authority National Supply primarily to expand our footprint within the building supply distribution industry, on November 5, 2018. The purchase price consisted of cash, shares of our common stock and a stock price guarantee.
ANS provides us with the opportunity to partner with key manufacturers that recognize the efficiency of a central negotiation business model. Today, ANS focuses on a variety of exterior building products, including roofing, siding, windows and tools, on behalf of its customers. The opportunity for future growth lies in our ability to expand the product offerings and grow the existing customer base by attracting more independent building materials customers. The operating results and financial performance of Authority National Supply are reported under our Wholesale Purchasing segment.
StemVax
StemVax, LLC (“StemVax”) is a biotechnology company developing novel therapies for brain tumor patients and holds a related patent license from Cedars-Sinai Medical Center in Los Angeles, California. We acquired 20% of StemVax for shares of our common stock and a small cash payment on July 17, 2018. We acquired the remaining 80% of StemVax for 7.5 million warrants with an exercise price of $0.18 a share on February 1, 2020. StemVax is in the development state and does not currently have any revenues. We are exploring strategic options to maximize the value of StemVax’s intellectual property rights.
Segments Overview
We are a diversified industrial platform doing business through our subsidiary companies. Our current business units operate within the following segments:
Commercial Solutions
The Commercial Solutions segment provides products and services, including energy, building materials, call center services and safety supplies, to companies within various commercial markets including manufacturing, municipalities and construction. This segment includes the Innovest Energy Group, Midwest Curtainwalls, Contact Source Solutions and Chagrin Safety Solutions. For information about our business lines, please turn to “Historical Acquisitions” beginning on page .
Wholesale Purchasing
The Wholesale Purchasing segment is composed of Authority National Supply. For information about ANS, please turn to “Authority National Supply” on page .
Manufacturing and Raw Materials
Our revenue is derived primarily from part sales, services and the design and light assembly of custom products.
Midwest Curtainwalls designs and assembles custom products utilizing primarily glass and aluminum parts that are readily available. Innovest Energy Group provides lighting and installation services as well as custom meter solutions to commercial and industrial customers. The main materials utilized in these services include readily available LED lights, ballasts, transformers and meters.
Authority National Supply business is a distributor of building materials including roofing, windows, fasteners and associated tools and materials. Chagrin Safety is a safety supply distribution that largely drop ships materials from vendors to meet customer needs.
Suppliers are competitively selected based on cost, quality and service. All significant raw materials that we use are available through multiple sources. We purchase most raw materials and other components on the open market and rely on third parties to provide certain finished goods. While these items are generally available from multiple sources, the cost of products sold may be affected by changes in the market price of raw materials and tariffs on certain raw materials, particularly imports from China, as well as disruptions in availability of raw materials, components and sourced finished goods. Currently Chagrin Safety is experiencing difficulty in obtaining some products, such as masks, gowns and other safety apparel, due to the COVID-19 pandemic.
We monitor and explore alternative suppliers and materials based on numerous attributes including quality, service and price. We currently source raw materials and components from a number of suppliers, but our ongoing efforts to improve the cost effectiveness of our products and services may result in a reduction in the number of our suppliers.
Concentration of Sales
We serve a broad customer base, both in terms of industries and geographic regions. As of December 31, 2018, $2.8 million of the outstanding accounts receivable balance is from a single customer of Midwest Curtainwalls.
Seasonality
Our business is affected to some extent by seasonal fluctuations that impact our production levels and our customers’ business needs. For example, demand for many of the products we sell in the construction and building materials sectors tends to correlate with construction activity, which is lowest in the first and fourth quarter due to cooler weather.
Employees
As of April 1, 2020, we have approximately 80 full-time employees throughout each of our business segments as well as corporate management team. We engage consultants and employ temporary employees as needed. Midwest Curtainwalls historically has employed members of Iron Workers Regional Shop Local Union No. 851 who are subject to collective bargaining agreements.
We believe that our people are our greatest asset and strive to maintain good relations with our workforce and active dialogue with employees and provide salaried and hourly employees a comprehensive benefits package, which includes medical, dental and vision insurance. We believe that the strong relationship that we have with our employees has been a key factor in Innovest’s growth.
Intellectual Property
Our business is not generally dependent on intellectual property. However, StemVax, our biotechnology company, holds a patent license from Cedars-Sinai Medical Center that may be used in developing novel therapies for brain tumor patients.
Competition
Many factors influence our competitive position, including pricing, product quality and service.
Principal competitors of Midwest Curtainwalls are other midsized, light assembly businesses operating primarily in the United States, China and Italy. These competitors offer products with similar characteristics to our products, but we believe our over 40 years of experience in building curtainwall systems and an extensive portfolio of premium completed jobs give us a competitive advantage. In 2018 and 2019, Midwest Curtainwalls began experiencing greater competition from Chinese manufactures at lower prices than it had historically experienced. However, after the COVID-19 pandemic and potential delays in delivery of products manufactured overseas, we are experiencing increased demand for products made in the United States.
Principal competitors of Contact Source Solutions include competing outsourced service providers as well as the risk of our customers insourcing their call center solutions. We believe that our team has invested in human capital and smart technologies to deliver a competitive edge for our clients, including our own Innovest businesses. Most outsourced call centers feature either high price domestic agents located in a call center facility in the United States or lower priced agents located outside the United States. Contact Source Solutions features an advanced operating and technology infrastructure which allows our call center representatives to operate from their homes, reducing our overhead and ultimately the cost to our customers. In addition, Contact Source Solutions offers differentiated services by being PCI Compliant (able to accept payment) and HIPAA Certified (able to have discussions related to confidential healthcare information).
Innovest Energy Group provides energy efficiency solutions in a highly fragmented market, competing primarily with other local and regional companies who seek to provide similar products and services to commercial and industrial clients. For our high efficiency lighting products, we compete with lighting manufacturers, electric contractors and consultants. In our metering business, we compete against larger regional consultants and electric companies, but competition remains localized due to the regional nature of utility providers.
Principal competitors in our Wholesale Purchasing segment are “cooperatives” and traditional wholesalers of construction materials. We believe we provide a unique customer advantage by targeting smaller independently owned business as customers for these distribution services and providing our customers with unique pricing and product opportunities. Cooperatives in this industry typically place limitations on their participants, while wholesalers typically charge higher prices. ANS provides non-exclusive access to original equipment manufacturers buying contracts which achieve volume-based pricing discounts with limited additional fees or conditions.
Regulatory Compliance
We believe that we are in compliance in all material respects with the laws and regulations applicable to our businesses. Our light assembly and fabricating activities do not involve heavy manufacturing and our primary compliance requirements are consistent with service and assembly businesses, including safety regulations. The current cost and impact on our operations of complying with applicable environment laws is not material for our businesses. Future acquisitions, the evolution of our operations or new regulatory developments could significantly increase the cost and burden of compliance with laws applicable to our businesses.
Item 1A. Risk Factors.
Investing in Innovest involves a high degree of risk. You should carefully consider each of the following risks, together with all other information set forth in this Form 10, including the consolidated financial statements and the related notes, before making a decision to buy our common stock. If any of the following risks actually occurs, our business could be harmed. In that case, the trading price of our stock could decline, and you may lose all or part of your investment.
This Form 10 contains forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, that involve risks and uncertainties. Although we believe the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance or achievements. We caution you not to place undue reliance on the forward-looking statements, which speak only as of the date of this Form 10. We assume no obligation to revise or update any forward-looking statements for any reason, except as required by law.
Factors that might cause such differences include those discussed in this section of the Form 10. While we believe we have identified material risks, these risks and uncertainties are not exhaustive. Other sections of this Form 10 describe additional factors that could adversely impact our business and financial performance. Moreover, we operate in a very competitive and rapidly changing environment. New risks and uncertainties emerge from time to time, and it is not possible to predict all risks and uncertainties, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.
Risks Related to Our Company and Our Business
Innovest has a limited operating history
Innovest has a limited operating history and there can be no assurance that our proposed plan of business can be realized in the manner contemplated and, if it cannot be, shareholders may lose all or a substantial part of their investment. There is no guarantee that it will ever realize any significant operating revenues or that its operations will ever be profitable.
We are dependent upon our management, founders, key personnel and consultants to execute our business plan
Our success is heavily dependent upon the continued active participation of our current executive officers as well as other key personnel and consultants. Loss of the services of one or more of these individuals could have a material adverse effect upon our business, financial condition or results of operations. Further, our success and achievement of our growth plans depend on our ability to recruit, hire, train and retain other highly qualified personnel. Competition for qualified employees and consultants among companies in the applicable industries is intense, and the loss of any of such persons, or an inability to attract, retain and motivate any additional highly skilled employees and consultants required for the initiation and expansion of Innovest’s activities, could have a materially adverse effect on it. The inability to attract and retain the necessary personnel, consultants and advisors could have a material adverse effect on our business, financial condition or results of operations.
Innovest is subject to income taxes as well as non-income based taxes, such as payroll, sales, use, value-added, net worth, property and goods and services taxes
Significant judgment is required in determining our provision for income taxes and other tax liabilities. In the ordinary course of our business, there are many transactions and calculations where the ultimate tax determination is uncertain. Although we believe that our tax estimates will be reasonable: there is no assurance that the final determination of tax audits or tax disputes will not be different from what is reflected in our income tax provisions, expense amounts for non-income based taxes and accruals and any material differences could have an adverse effect on our financial position and results of operations in the period or periods for which determination is made.
Innovest has engaged in certain transactions with related persons
We have engaged in transactions with our officers and significant shareholders. For additional information please turn to “Item 7. Certain Relationships and Related Transactions, and Director Independence” on page 23.
Changes in laws or regulations could harm our performance
Various federal and state laws, including labor laws, govern our relationship with our employees and affect operating costs. These laws may include minimum wage requirements, overtime pay, healthcare reform and the implementation of various federal and state healthcare laws, unemployment tax rates, workers’ compensation rates, citizenship requirements, union membership and sales taxes. A number of factors could adversely affect our operating results, including additional government-imposed increases in minimum wages, overtime pay, paid leaves of absence and mandated health benefits, mandated training for employees, changing regulations from the National Labor Relations Board, increased employee litigation including claims relating to the Fair Labor Standards Act and changes relating to the COVID-19 pandemic.
We have incurred debt
We have incurred secured debt and will likely incur additional debt in the future and in the continuing operations of its business. Complying with obligations under our indebtedness may have a material adverse effect on Innovest and our operations.
Our expenses could increase without a corresponding increase in revenues
Our operating and other expenses could increase without a corresponding increase in revenues, which could have a material adverse effect on our financial results and on your investment. Factors which could increase operating and other expenses include, but are not limited to (1) increases in the rate of inflation, (2) increases in taxes and other statutory charges, (3) changes in laws, regulations or government policies which increase the costs of compliance with such laws, regulations or policies, (4) significant increases in insurance premiums, (5) increases in borrowing costs, and (5) unexpected increases in costs of supplies, goods, materials, construction, equipment or distribution.
We may not be able to obtain adequate financing to continue our operations
We will require additional debt and/or equity financing to pursue our growth and business strategies. Given our limited operating history and existing losses, we cannot be certain that additional financing will be available, or, if available, that the terms will be acceptable to us. Lack of additional funding could force us to curtail substantially our growth plans. Furthermore, the issuance by us of any additional securities pursuant to any future fundraising activities undertaken by us would dilute the ownership of existing shareholders and may reduce the price of our shares.
Terms of subsequent financing, if any, may adversely impact your investment
We may have to engage in common equity, preferred stock or debt financings in the future. Your rights and the value of your investment in our common stock could be reduced by the dilution caused by future equity issuances. Interest on debt securities could increase costs and negatively impact operating results. We may issue preferred stock with rights and preferences determined by our board to raise capital. The terms of preferred stock would be more advantageous to those investors than to the holders of common stock. In addition, if we need to raise more equity capital from the sale of common stock, institutional or other investors may negotiate terms at least as, and possibly more, favorable than the terms of your investment. Shares of common stock which we sell could be sold into the market, which could adversely affect the market price.
Our CEO controls a substantial portion of our voting rights
Our CEO Daniel Martin beneficially owns shares of our preferred stock which limits your ability and the ability of our other shareholders, whether acting alone or together, to propose or direct the management or overall direction of Innovest. Additionally, this concentration of voting control could discourage or prevent a potential takeover of our company that might otherwise result in an investor receiving a premium over the market price for its shares. If you acquire our shares, you will have no effective voice in the management of Innovest. Such concentrated control of our company may adversely affect the price of our shares. Mr. Martin may be able to control matters requiring approval by our shareholders, including the election of directors, mergers or other business combinations. Such concentrated control may also make it difficult for our shareholders to receive a premium for their shares in the event that we merge with a third party or enter into different transactions which require shareholder approval. These provisions could also limit the price that investors might be willing to pay in the future for our shares.
If our assumptions or analyses that we relied on to develop our operating plan prove to be incorrect, our actual operating results may be materially different from our forecasted results
Whether actual operating results and business developments will be consistent with our expectations and assumptions as reflected in our forecast depends on a number of factors, many of which are outside our control, including:
|
● |
whether we can obtain sufficient capital to sustain and grow our business and fund acquisitions |
|
● |
our ability to identify and successfully acquire new companies |
|
● |
our ability to manage the Company’s growth and integrate acquired companies |
|
● |
whether we can manage relationships with key vendors |
|
● |
demand for our products and services |
|
● |
competition |
|
● |
our ability to retain existing key management, to integrate recent hires and to attract, retain and motivate qualified personnel |
|
● |
the overall strength and stability of domestic and international economies |
Unfavorable changes in any of these or other factors, most of which are beyond our control, could materially and adversely affect its business, results of operations and financial condition.
To date, we had had operating losses and do not expect to be initially profitable for at least the foreseeable future, and cannot accurately predict when we might become profitable
We have been operating at a loss since Innovest’s inception, and we expect to continue to incur losses as we grow our business and make additional acquisitions. Further, we may not be able to generate significant revenues in the future. In addition, we expect to incur substantial operating expenses in order to fund the expansion of our business. As a result, we expect to continue to experience substantial negative cash flow for at least the foreseeable future and cannot predict when, or even if, Innovest might become profitable.
We face competition from many companies, some of which have greater financial, research and development, production and other resources than we do
In many cases, our competitors have longer operating histories, established ties to the market and consumers, greater brand awareness, and greater financial, technical and marketing resources. Our ability to compete depends, in part, upon a number of factors outside our control, including the ability of our competitors to develop alternatives that are superior. If we fail to successfully compete in our markets, or if we incur significant expenses in order to compete, it could have a material adverse effect on our results of operations.
A data security breach or cyber-attack could expose Innovest to liability and protracted and costly litigation, and could adversely affect our reputation and operating revenues
Our business activities involve the storage and transmission of confidential customer and other information. Encryption software and the other technologies used to provide security for storage, processing and transmission of confidential customer and other information may not be effective to protect against data security breaches by third parties. The risk of unauthorized circumvention of such security measures has been heightened by advances in computer capabilities and the increasing sophistication of hackers. A data security breach or cyber-attack of the systems on which sensitive account information are stored could lead to fraudulent activity involving our products and services, reputational damage, and claims or regulatory actions against us. If we are sued in connection with any data security breach, we could be involved in protracted and costly litigation. If unsuccessful in defending that litigation, we might be forced to pay damages and/or change our business practices or pricing structure, any of which could have a material adverse effect on our operating revenues and profitability. We could also have to pay fines, penalties and/or other assessments imposed as a result of any data security breach.
Our annual and quarterly revenues and operating results are inherently unpredictable and subject to fluctuations
Our annual and quarterly recurring and non-recurring revenues may fluctuate due to our inability to deliver, achieve specific milestones and obtain formal customer acceptance of specific elements of the overall completion of projects. As we provide such services and products, the timing of delivery and acceptance, changed conditions with the customers and projects could negatively impact our operating results. We may also experience seasonality in revenues. For example, demand for many of the products we sell in the construction and building materials sectors tends to correlate with construction activity, which is lowest in the first and fourth quarter due to cooler weather. These seasonal variations may lead to fluctuations in our annual and quarterly revenues and operating results. As a result, we believe that period-to-period comparisons of our results of operations are not necessarily meaningful and should not be relied upon as indications of our future performance. If our operating results fail to meet the expectations of public market analysts and investors, the price of our common stock may decline or experience volatility.
Our lengthy sales cycle for our products makes it difficult for us to forecast revenue and exacerbates the variability of quarterly fluctuations
The sales cycle of our products for some of our offerings can average several months and may sometimes be significantly longer. We are generally required to provide a significant level of education regarding the use and benefits of some of our products, and potential customers tend to engage in extensive internal reviews before making purchase decisions. In addition, the purchase of some of our products typically involves a significant commitment by our customers of capital and other resources and is therefore subject to delays that are beyond our control, such as customers’ internal budgetary procedures and the testing and acceptance of new technologies that affect key operations. In addition, our sales cycle can be lengthier due to the decision process in large organizations. As a result of our products’ long sales cycles, we face difficulty predicting the quarter in which sales to expected customers may occur. If anticipated sales from a specific customer for a particular quarter are not realized in that quarter, our operating results for that quarter could fall below the expectations of financial analysts and investors, which could cause our stock price to decline.
Developments in our markets may harm our operating results, which could cause a decline in the price of our common stock
In view of changing market trends, including consolidations, the competitive environment growth rate and potential size of the market are difficult to assess. The growth of the market is dependent upon the willingness of businesses and consumers to purchase complex goods and services. In addition, companies that have already invested substantial resources in other methods of selling may be reluctant or slow to adopt a new approach.
Our failure to meet customer expectations on deployment of our products could result in negative publicity and reduced sales, both of which would significantly harm our business and operating results
Failing to meet customer expectations on deployment of our products could result in a loss of customers and negative publicity regarding us and our products, which could adversely affect our ability to attract new customers. In addition, time-consuming deployments may also increase the amount of service personnel we must allocate to each customer, thereby increasing our costs and adversely affecting our business and operating results.
Our operations and financial performance are directly impacted by changes in the economy
An economic decline resulting from the COVID-19 pandemic or alternative catastrophic events could negatively affect our business and results of operations. The volatility of the current economic climate makes it difficult for us to predict our results of operations. In periods of economic uncertainty, our customers may face financial difficulties, including the unavailability of or reduction in commercial credit, or both, that may result in decreased sales by our company. Certain of our customers may cease operations or seek bankruptcy protection, which would reduce our cash flows and adversely impact our results of operations. Our customers that are financially viable and that do not experience economic distress may nevertheless elect to reduce the volume of orders for our products or close facilities in an effort to remain financially stable or as a result of the unavailability of commercial credit, which would negatively affect our results of operations.
We may also have difficulty accessing the global credit markets due to the tightening of commercial credit availability and the financial difficulties of our customers. In addition, we may experience challenges in forecasting revenues and operating results due to these global economic conditions. The difficulty in forecasting revenues and operating results may result in volatility in the market price of our common stock.
The non-residential building construction market continues to experience a downturn which could materially and adversely affect our business, liquidity and results of operations
Many of our business units are dependent on the non-residential building construction market and the slowdown and volatility of the United States economy in general is having an adverse effect on our business units that serve this industry. From time to time, our business units that serve the non-residential building construction market have also been adversely affected in various parts of the country by declines in non-residential building construction starts due to, among other things, changes in tax laws affecting the real estate industry, high interest rates and the level of residential construction activity. Continued uncertainty about current economic conditions will continue to pose a risk to our business units that serve the non-residential building construction market as participants in this industry may postpone spending in response to tighter credit, negative financial news and/or declines in income or asset values, which could have a continued material negative effect on the demand for our products and services.
We cannot predict the duration of the current market conditions, or the timing or strength of any future recovery of non-residential building construction activity in our markets. Continued weakness in the non-residential building construction market would have a significant adverse effect on our business, financial condition and operating results. In addition, because of these factors, there may be fluctuations in our operating results, and the results for any historical period may not be indicative of results for any future period.
Future strategic transactions could impact our reputation, business, financial position, results of operations and cash flows and we may not achieve the acquisition component of our growth strategy
We intend to pursue strategic transactions in the future, which could involve acquisitions or dispositions of businesses or assets. Any future strategic transaction could involve integration or implementation challenges, business disruption or other risks, or change our business profile significantly. Any inability on our part to successfully implement strategic transactions could have an adverse impact on our reputation, business, financial position, results of operations and cash flows. Any acquisition that we make may not provide us with the benefits that were anticipated when entering into such acquisition. Any future disposition transactions could also impact our business and may subject us to various risks, including failure to obtain appropriate value for the disposed businesses, post-closing claims being levied against us and disruption to our other businesses during the sale process or thereafter.
In addition, although acquisitions may continue to be an important component of our growth strategy, there can be no assurance that we will be able to continue to grow our business through acquisitions as we have done historically or that any businesses acquired will perform in accordance with expectations or that business judgments concerning the value, strengths and weaknesses of businesses acquired will prove to be correct. Future acquisitions may result in the incurrence of debt and contingent liabilities, an increase in interest expense and amortization expense and significant charges relative to integration costs. Our strategy could be impeded if we do not identify suitable acquisition candidates and our financial condition and results of operations will be adversely affected if we overpay for acquisitions.
Acquisitions involve a number of special risks, including:
|
● |
problems implementing disclosure controls and procedures for the newly acquired business; |
|
● |
unforeseen difficulties extending internal control over financial reporting and performing the required assessment at the newly acquired business; |
|
● |
potential adverse short-term effects on operating results through increased costs or otherwise; |
|
● |
diversion of management’s attention and failure to recruit new, and retain existing, key personnel of the acquired business; |
|
● |
failure to successfully implement infrastructure, logistics and systems integration; |
|
● |
our business growth could outpace the capability of our systems; and |
|
● |
the risks inherent in the systems of the acquired business and risks associated with unanticipated events or liabilities, any of which could have a material adverse effect on our business, financial condition and results of operations. In addition, we may not be able to obtain financing necessary to complete acquisitions on attractive terms or at all. |
We rely on third-party suppliers and long supply chains, and if we fail to identify and develop relationships with a sufficient number of qualified suppliers, or if there is a significant interruption in our supply chains, our ability to timely and efficiently access products that meet our standards for quality could be adversely affected
We buy our products and supplies from suppliers located throughout the world. These suppliers manufacture and source products from the United States and abroad. Our ability to identify and develop relationships with qualified suppliers who can satisfy our standards for quality and our need to access products and supplies in a timely and efficient manner is a significant challenge. We may be required to replace a supplier if their products do not meet our quality or safety standards. In addition, our suppliers could discontinue selling products at any time for reasons that may or may not be in our control or the suppliers’ control. Our operating results and inventory levels could suffer if we are unable to promptly replace a supplier who is unwilling or unable to satisfy our requirements with a supplier providing similar products. Our suppliers’ ability to deliver products may also be affected by financing constraints caused by credit market conditions, which could negatively impact our revenue and cost of products sold, at least until alternate sources of supply are arranged.
In addition, since some of the products that we distribute are produced in foreign countries, we are dependent on long supply chains for the successful delivery of many of our products. The length and complexity of these supply chains make them vulnerable to numerous risks, many of which are beyond our control, which could cause significant interruptions or delays in delivery of our products. Factors such as political instability, the financial instability of suppliers, suppliers’ noncompliance with applicable laws, trade restrictions, labor disputes, currency fluctuations, changes in tariff or import policies, severe weather, terrorist attacks and transport capacity and cost may disrupt these supply chains and our ability to access products and supplies.
Risks Related to the Securities Markets and Ownership of Our Stock
As a holding company, revenues are generated from our subsidiaries
As a holding company, we do not create direct revenues from operations or hold any direct ownership of any material assets. In order to cover costs and expenses related to the operations of the parent company, we must rely upon our subsidiary holdings for cash flows not derived from financing activities. Our subsidiaries may be limited in their ability to free up sufficient cash flow to maintain operations.
Our stock is thinly traded, so you may be unable to sell at or near ask prices or at all if you need to sell your shares to raise money or otherwise desire to liquidate your shares
Our common stock has historically been sporadically traded on the OTC Pink Open Market, meaning that the number of persons interested in purchasing our shares at or near ask prices at any given time may be relatively small or non-existent. This situation is attributable to a number of factors, including the fact that we are a small company which is relatively unknown to stock analysts, stock brokers, institutional investors and others in the investment community that generate or influence sales volume, and that even if we came to the attention of such persons, they tend to be risk-averse and would be reluctant to follow an unproven company such as ours or purchase or recommend the purchase of our shares until such time as we became more seasoned and viable. As a consequence, there may be periods of several days or more when trading activity in our shares is minimal or non-existent, as compared to a seasoned issuer which has a large and steady volume of trading activity that will generally support continuous sales without an adverse effect on share price. We cannot give you any assurance that a broader or more active public trading market for our common shares will develop or be sustained, or that current trading levels will be sustained.
The market price for our stock is particularly volatile given our status as a relatively unknown company with a small and thinly traded public float, limited operating history and lack of revenue, which could lead to wide fluctuations in our share price. The price at which you purchase our shares may not be indicative of the price that will prevail in the trading market. You may be unable to sell your shares at or above your purchase price, which may result in substantial losses to you.
The market for our shares is characterized by significant price volatility when compared to seasoned issuers, and we expect that our share price will continue to be more volatile than a seasoned issuer for the indefinite future. The volatility in our share price is attributable to a number of factors. First, as noted above, our shares are sporadically traded. Because of this lack of liquidity, the trading of relatively small quantities of shares may disproportionately influence the price of those shares in either direction. The price for our shares could, for example, decline precipitously in the event that a large number of our shares are sold on the market without commensurate demand, as compared to a seasoned issuer which could better absorb those sales without adverse impact on its share price. Secondly, we are a speculative investment due to, among other matters, our limited operating history and lack of revenue or profit to date. As a consequence of this enhanced risk, more risk-averse investors may, under the fear of losing all or most of their investment in the event of negative news or lack of progress, be more inclined to sell their shares on the market more quickly and at greater discounts than would be the case with the securities of a seasoned issuer. The following factors may add to the volatility in the price of our shares: actual or anticipated variations in our quarterly or annual operating results; announcements of significant acquisitions, strategic partnerships or joint ventures; our capital commitments and additions or departures of our key personnel. Many of these factors are beyond our control and may decrease the market price of our shares regardless of our operating performance. We cannot make any predictions or projections as to what the prevailing market price for our shares will be at any time, including as to whether our shares will sustain their current market prices, or as to what effect the sale of shares or the availability of shares for sale at any time will have on the prevailing market price.
Shareholders should be aware that, according to SEC Release No. 34-29093, the market for penny stocks has suffered in recent years from patterns of fraud and abuse. Such patterns include (1) control of the market for the security by one or a few broker-dealers that are often related to the promoter or issuer; (2) manipulation of prices through prearranged matching of purchases and sales and false and misleading press releases; (3) boiler room practices involving high-pressure sales tactics and unrealistic price projections by inexperienced sales persons; (4) excessive and undisclosed bid-ask differential and markups by selling broker-dealers; and (5) the wholesale dumping of the same securities by promoters and broker-dealers after prices have been manipulated to a desired level, along with the resulting inevitable collapse of those prices and with consequent investor losses. Our management is aware of the abuses that have occurred historically in the penny stock market. Although we do not expect to be in a position to dictate the behavior of the market or of broker-dealers who participate in the market, management will strive within the confines of practical limitations to prevent the described patterns from being established with respect to our securities. The occurrence of these patterns or practices could increase the volatility of our share price.
The market price of our stock may be volatile and adversely affected by several factors
The market price of our stock could fluctuate significantly in response to various factors and events, including, but not limited to:
|
● |
our ability to integrate operations, technology, products and services; |
|
● |
our ability to execute our business plan; |
|
● |
operating results below expectations; |
|
● |
our issuance of additional securities, including debt or equity or a combination thereof; |
|
● |
loss of any strategic relationship; |
|
● |
industry developments, including, without limitation, changes in government policies or practices; |
|
● |
economic and other external factors; |
|
● |
period-to-period fluctuations in our financial results; and |
|
● |
whether an active trading market in our common stock develops and is maintained. |
In addition, the securities markets have from time to time experienced significant price and volume fluctuations that are unrelated to the operating performance of particular companies. These market fluctuations may also materially and adversely affect the market price of our common stock.
Our issuance of additional shares of our stock, or options or warrants to purchase those shares, would dilute your proportionate ownership and voting rights
The number of authorized shares available for issuance is limited by our articles of incorporation. We are currently entitled under our amended and restated articles of incorporation to issue up to 500.0 million shares of common stock. As of April 1, 2020, we have issued and outstanding, 163,802,125 shares of common stock. Our board may generally issue shares of common stock, preferred stock or options or warrants to purchase those shares, without further approval by our shareholders based upon factors our board of directors considers relevant at that time. It is likely that we will be required to issue a large amount of additional securities to acquire companies and raise capital to further our development. It is also likely that we will issue a large amount of additional securities to directors, officers, employees and consultants as compensatory grants in connection with their services, both in the form of stand-alone grants or under our stock plans.
The elimination of monetary liability against our directors, officers and employees under our articles of incorporation and the existence of indemnification rights to our directors, officers and employees may result in substantial expenditures by our company and may discourage lawsuits against our directors, officers and employees
Our articles of incorporation contain provisions that eliminate the liability of our directors for monetary damages to our company and shareholders. Our articles also require us to indemnify our officers and directors. We may also have contractual indemnification obligations under our agreements with our directors, officers and employees. These indemnification obligations could result in our incurring substantial expenditures to cover the cost of settlement or damage awards against directors, officers and employees that we may be unable to recoup. These provisions and resultant costs may also discourage our company from bringing a lawsuit against directors, officers and employees for breaches of their fiduciary duties, and may similarly discourage the filing of derivative litigation by our shareholders against our directors, officers and employees even though such actions, if successful, might otherwise benefit our company and shareholders.
Anti-takeover provisions may impede the acquisition of Innovest
Nevada general statutes have anti-takeover effects and may inhibit a non-negotiated merger or other business combination. These provisions are intended to encourage any person interested in acquiring us to negotiate with, and to obtain the approval of, our board of directors in connection with such a transaction. However, certain of these provisions may discourage a future acquisition of us, including an acquisition in which the shareholders might otherwise receive a premium for their shares. As a result, shareholders who might desire to participate in such a transaction may not have the opportunity to do so.
We may become involved in securities class action litigation that could divert management’s attention and harm our business
The stock market in general, and the shares of early stage development companies in particular, have experienced extreme price and volume fluctuations. These fluctuations have often been unrelated or disproportionate to the operating performance of the companies involved. If these fluctuations occur in the future, the market price of our shares could fall regardless of our operating performance. In the past, following periods of volatility in the market price of a particular company’s securities, securities class action litigation has often been brought against that company. If the market price or volume of our shares suffers extreme fluctuations, then we may become involved in this type of litigation, which would be expensive and divert management’s attention and resources from managing our business.
As a public company, we may also from time to time make forward-looking statements about future operating results and provide some financial guidance to the public markets. Our management has limited experience as a management team in a public company and as a result, projections may not be made timely or set at expected performance levels and could materially affect the price of our shares. Any failure to meet published forward-looking statements that adversely affect the stock price could result in losses to investors, stockholder lawsuits or other litigation, sanctions or restrictions issued by the SEC.
Our stock is currently deemed a “penny stock,” which makes it more difficult for our investors to sell their shares
The SEC has adopted Rule 15g-9 which establishes the definition of a “penny stock,” for the purposes relevant to us, as any equity security that has a market price of less than $5.00 per share, subject to certain exceptions. For any transaction involving a penny stock, unless exempt, the rules require that a broker or dealer approve a person’s account for transactions in penny stocks, and the broker or dealer receive from the investor a written agreement to the transaction, setting forth the identity and quantity of the penny stock to be purchased.
In order to approve a person’s account for transactions in penny stocks, the broker or dealer must obtain financial information and investment experience objectives of the person and make a reasonable determination that the transactions in penny stocks are suitable for that person and the person has sufficient knowledge and experience in financial matters to be capable of evaluating the risks of transactions in penny stocks.
The broker or dealer must also deliver, prior to any transaction in a penny stock, a disclosure schedule prescribed by the SEC relating to the penny stock market, which, in highlight form sets forth the basis on which the broker or dealer made the suitability determination, and that the broker or dealer received a signed, written agreement from the investor prior to the transaction.
Generally, brokers may be less willing to execute transactions in securities subject to the “penny stock” rules. This may make it more difficult for investors to dispose of our stock and may cause a decline in the market value of its stock.
Disclosure also has to be made about the risks of investing in penny stocks in both public offerings and in secondary trading and about the commission payable to both the broker-dealer and the registered representative, current quotations for the securities and the rights and remedies available to an investor in cases of fraud in penny stock transactions. Finally, monthly statements have to be sent disclosing recent price information for the penny stock held in the account and information on the limited market in penny stock.
As an issuer of “penny stock,” the protection provided by the federal securities laws relating to forward-looking statements does not apply to us
Although federal securities laws provide a safe harbor for forward-looking statements made by a public company that files reports under the federal securities laws, this safe harbor is not available to issuers of penny stocks. As a result, we will not have the benefit of this safe harbor protection in the event of any legal action based upon a claim that the material provided by us contained a material misstatement of fact or was misleading in any material respect because of our failure to include any statements necessary to make the statements not misleading. Such an action could hurt our financial condition.
As an issuer not previously required to make reports to the SEC under the Exchange Act, holders of restricted shares may not be able to sell shares into the open market as Rule 144 exemptions may not apply
Under Rule 144 of the Securities Act, holders of restricted shares may avail themselves of certain exemption from registration if the holder and the issuer meet certain requirements. As a company that was previously not required to file reports under Section 13 or 15(d) of the Exchange Act, referred to as a non-reporting company, we do not meet the requirements for an issuer under 144 that would allow a holder to qualify for Rule 144 exemptions. As a result, holders of restricted stock would have to utilize another exemption from registration or rely on a registration statement to be filed by the Company registering the restricted stock.
Securities analysts may elect not to report on Innovest or may issue negative reports that adversely affect the stock price
At this time, no securities analysts provide research coverage of our company, and securities analysts may not elect to provide such coverage in the future. It may remain difficult for Innovest, with our small market capitalization, to attract independent financial analysts that will cover our stock. If securities analysts do not cover us, the lack of research coverage may adversely affect our stock’s actual and potential market price. The trading market for our stock may be affected in part by the research and reports that industry or financial analysts publish about our business. If one or more analysts elect to cover our company and then downgrade the stock, the stock price would likely decline rapidly. If one or more of these analysts cease coverage of our company, we could lose visibility in the market, which, in turn, could cause our stock price to decline. This could have a negative effect on the market price of our shares.
We have not paid cash dividends in the past and do not expect to pay cash dividends in the foreseeable future and any return on investment may be limited to the value of our stock
We have never paid cash dividends on our stock and do not anticipate paying cash dividends on our shares in the foreseeable future. The payment of dividends on our stock will depend on our earnings, financial condition and other business and economic factors affecting us at such time as the board of directors may consider relevant. If we do not pay dividends, our stock may be less valuable because a return on your investment will only occur if the share price appreciates.
We may be unable to maintain an effective system of internal control over financial reporting, and as a result, we may be unable to accurately report our financial results
If we fail to maintain an effective system of internal control over financial reporting, we could experience delays or inaccuracies in our reporting of financial information, or non-compliance with the SEC’s reporting and other regulatory requirements. This could subject us to regulatory scrutiny and result in a loss of public confidence in our management, which could, among other things, cause our stock price to drop.
Item 2. Financial Information.
The following management’s discussion and analysis of financial condition and results of operations should be read together with the disclosure included in “Item 1. Business” beginning on page and our consolidated financial statements and related notes and other financial information beginning on page F-1 of this Form 10. The following discussion contains forward-looking statements that involve risks, uncertainties and assumptions. For more information about forward-looking statements, please turn to “Forward Looking Statements” beginning on page of this Form 10. Our actual results could differ materially from those contained in forward-looking statements as a result of many factors, including those discussed in “Item 1A. Risk Factors” beginning on page of this Form 10.
Our consolidated financial statements and related public financial information are based on the application of generally accepted accounting principles in the United States (“GAAP”). GAAP requires the use of estimates, assumptions, judgments and subjective interpretations of accounting principles that have an impact on the assets, liabilities, revenues and expense amounts reported. These estimates can also affect supplemental information contained in our external disclosures including information regarding contingencies, risk and financial condition. We believe our use of estimates and underlying accounting assumptions adhere to GAAP and are consistently and conservatively applied. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances. Actual results may differ materially from these estimates under different assumptions or conditions. We continue to monitor significant estimates made during the preparation of our financial statements.
Critical Accounting Policies and Estimates
Basis of Presentation
Our consolidated financial statements have been prepared on the basis of GAAP. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect amounts reported in the financial statements. Actual results could differ from those estimates.
Principles of Consolidation
The financial statements include the accounts of Innovest and all of its wholly owned subsidiaries. All material intercompany accounts and transactions have been eliminated in consolidation.
Cash Equivalents
We consider all investments with an original maturity of three months or less when purchased to be cash equivalents. We maintain cash in bank deposit accounts, which at times may exceed federally insured limits. We have not experienced any losses in such accounts. Management believes the Company is not exposed to any significant credit risk related to cash.
Trade Accounts Receivable
Accounts receivable are stated at net invoice amounts. As of December 31, 2018, $2.8 million of the outstanding accounts receivable balance is from a single customer in the Commercial Solutions segment. Based on management’s review of outstanding receivable balances and historical collection information, management’s best estimate is that all balances will be collected. Accordingly, we have not established an allowance for doubtful accounts.
Investments
Investments in equity securities without readily determinable fair value are recorded at cost less impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for identical or similar investments in the same issuer. Impairment loses are recognized for declines in value that are other than temporary. No impairment losses were recognized for 2018 and 2017.
Inventory
Inventory is stated at the lower of cost or net realizable value, with cost determined on the weighted average method. Inventory only consists of finished goods. Management has reviewed inventory quantities and determined that no allowance for obsolete and excess inventory is necessary. Throughout the year, inventory identified as obsolete or excess is written off. Innovest will continue its policy of regularly reviewing inventory quantities on hand based on related service levels and functionality. The carrying cost will be reduced to estimated net realizable value for inventories in which their cost exceeds their utility due to changes in marketing and sales strategies, obsolescence, changes in price levels, or other causes.
Property and Equipment
Property and equipment are recorded at cost. Assets are depreciated over their estimated useful lives using the straight-line method. The cost of leasehold improvements is depreciated over the lesser of the length of the related leases or the estimated useful lives of the assets. Costs of maintenance and repairs are charged to expense when incurred.
Goodwill
The recorded amounts of goodwill from business combinations are based on management’s best estimates of the fair values of assets acquired and liabilities assumed at the date of acquisition. Goodwill is not amortized, but rather is assessed at least on an annual basis for impairment. It is at least reasonably possible that management’s estimates about the fair value of goodwill could change in the near term and that such changes could materially affect amounts reported in the financial statements.
During 2018, management determined that the carrying amount of Midwest Curtain Walls and HP Technologies exceeded their fair value, which was estimated based on the present value of expected future cash inflows. Accordingly, we recognized a goodwill impairment loss in 2018 of $357,691 for Midwest Curtainwalls and $45,073 for HP Technologies.
Intangible Assets
Acquired intangible assets subject to amortization are stated at cost and are amortized using the straight-line method over the estimated useful lives of the assets. Intangible assets that are subject to amortization are reviewed for potential impairment whenever events or circumstances indicate that carrying amounts may not be recoverable. Assets not subject to amortization are tested for impairment at least annually. Intangible assets consist of trade names and customer lists and are amortized over 15 years.
Revenue Recognition
Our revenue is derived primarily from part sales, services, and the design and manufacture of custom products. These revenue streams are described below relative to each operating component. Transaction prices are specified in each contract and are not typically variable. If the consideration agreed to in a contract includes a variable amount, we will estimate the amount of consideration we expect to be entitled to in exchange for transferring the promised goods or services to the customer.
Management’s Discussion and Analysis of Results of Operations
The following is management’s discussion of the relevant items affecting results of operations for 2017 and 2018 and for the nine-months ended September 30, 2019.
For 2017, Chagrin Safety was the only entity consolidated in the financial results and this acquisition occurred on October 32, 2017. For 2018, the operating results included financial results from the following acquisitions: Shepherd Energy (acquisition date January 1, 2018), Contact Source Solutions (acquisition date January 15, 2018), HP Technologies (acquisition date March 22, 2018), Authority National Supply (acquisition date November 8, 2018) and Midwest Curtainwalls (acquisition date December 1, 2018) as well as corporate spending in the business to support the operations.
We reported our 2017 and 2018 financial results in the following segments:
|
● |
Commercial Solutions — Provides products and services, including energy, building materials, call center services and safety supplies, to companies within various commercial markets including manufacturing, municipalities and construction. This segment includes the Innovest Energy Group, Midwest Curtainwalls, Contact Source Solutions and Chagrin Safety. |
|
● |
Wholesale Purchasing — Our Wholesale Purchasing segment includes a national distributor of roofing, windows, fasteners and associated tools and materials. This segment includes the financials from the Authority National Supply. There are no reported activities in this segment for 2017. |
Net Sales
During 2018, net sales were $6,545,702, as compared to $49,756, for 2017. The increase in sales on a year over year basis is related to our acquisitions of additional operating businesses. For the nine-month period ended September 30, 2019, net sales were $47,423,657 as compared to $2,874,323 for the nine-month period ended September 30, 2018. The growth in the sales over the nine-month comparable period from 2018 to 2019 was primarily due to the inclusion of the Midwest Curtainwalls and Authority National Supply financial results 2019 but not 2018 due to the timing of these acquisitions.
Cost of Sales and Operating Expenses
Our significant general and administrative expenses principally consisted of research and development costs, sales, general and administrative costs, non-recurring items and other expenses.
During 2018, our cost of sales were $4,359,960, as compared to $143,825 the 2017. Cost of sales for the nine-month period ended September 30, 2019 were $44,516,698 as compared to $1,512,362 for the nine-month period ended September 30, 2018. As noted above, the increase in cost of sales was largely due to the acquisitions that occurred in 2018.
Operating expenses for 2018 were $1,713,289 as compared to $23,634 in 2017 due to the growth of the business from acquisition and corporate overhead to support the newly formed businesses. Operating expenses for the nine-month period ended September 30, 2019 were $5,086,633 as compared to $1,993,443 for the nine-month period ended September 30, 2018. The growth in operating expenses in the nine-month comparable period was due to acquisitions as well as growth in the corporate overhead and back office functions to support the larger Company base.
Non-Operating Income (Expense)
During 2018, we recognized total expense of $2,252,715 primarily as a result of the fair value adjustment for the stock guarantee liability related to the acquisition of Shepherd Energy which represented $2,230,000 of this amount. The remaining expense was due to interest expense for lines of credit and short-term debt offset by other income items. For 2017, the total non-operating expense was $4,094 as a result of the small amount of interest expense from Chagrin Safety which was the only operating company during this period.
Non-operating income for the nine-month period ended September 30, 2019 was $2,153,407 as compared to $31,950 for the nine-month period ended September 30, 2018. The non-operating income for the 2019 included the fair value adjustment for the stock guarantee liability credit of $2,470,000 related to the release of the stock price guarantee on the Shepherd Energy acquisition and $384,755 in losses on the sale of assets.
Net Income
As a result of the factors described above, our net loss for the year ended December 31, 2018 increased to $4,899,386 from $124,285 in the year ended December 31, 2017. For the nine-month period ended September 30, 2019, the consolidated net loss was $26,267 as compared to $599,532 for the nine-month period ended September 30, 2018.
Liquidity and Capital Resources
Our liquidity is principally used to meet our working capital needs and invest in organic growth capital needs. Since inception, we have financed our operations through a combination of commercial and shareholder loans and public equity (including the private placement of our common stock). We hold our cash reserves in a major United States bank.
Going Concern
Innovest has a history of recurring losses that has resulted in a stockholders’ deficit of $(1,573,037) as of December 31, 2018 and $(2,487) as of December 31, 2017. During 2018, the we recognized a net loss of $(4,899,386) and used net cash of $(1,706,875) in operating activities. During 2017, we recognized a net loss of $(124,285) and used net cash of $(58,815) in operating activities.
As of September 30, 2019, Innovest had a stockholders’ deficit of $873,194 and as of September 30, 2018 the deficit was $1,280,230. For the nine-month period ended September 30, 2019, we had a loss of $26,267 and used net cash of $7,412,957 in operating activities. The Company was able to obtain $7,239,042 from financing activities largely through a bond payable. For the nine-month period ended September 30, 2018, we recognized a net loss of $599,532 and used net cash of $609,647 in operating activities.
Our consolidated financial statements are prepared assuming that Innovest will continue as a concern. This assumes that the Company will be able to realize its assets and discharge its liabilities in the normal course of business for the foreseeable future. We anticipate future losses in the development of our business, raising substantial doubt about our ability to continue as a going concern. The ability to continue as a going concern is dependent upon Innovest generating profitable operations in the future and/or obtaining the necessary financing to meet its obligations and repay its liabilities arising from normal business operations when they come due.
Management plans to increase cash flow by acquiring and/or developing profitable businesses that will create positive income from operations, obtaining debt through loans from outside parties, and/or issuing additional common shares. In mid-2019, we also triggered mechanisms provided by the bond agreement that was executed for a Midwest Curtainwalls customer contract to fund the project working capital requirement. Management believes that by taking these actions, we will be provided with sufficient future operations and cash flow to continue as a going concern. However, we cannot guarantee that we will be successful in consummating our plans on acceptable terms, if at all. Moreover, any our plans can be expected to result in substantial dilution to the existing shareholders of Innovest.
Cash Flows from Operating Activities
For the year ended December 31, 2018, cash used in operating activities was $1,706,875 which was primarily driven by a net loss of $4,899,386. The net loss was primarily offset by non-cash charges of $24,458 in depreciation and amortization, $2,230,000 in the fair value adjustment for stock price guarantee liability, $402,764 from the goodwill and $631,575 from non-cash stock compensation. The remaining changes in operating activities was driven by a use of cash of $101,584 resulting from working capital activities as we ramped up operating activities and absorbed the activities of recently acquired entities. For the year ended December 31, 2017, cash used in operating activities was $58,815 primarily driven by the net loss of $124,285 offset by the change in working capital. The change in operating activities were the result of the Chagrin Safety acquisition which occurred in late 2017.
For the nine-month period ended September 30, 2019, cash used in operating activities was $7,412,957 which was driven by the net loss of $26,267 combined with the add back for the stock guarantee liability of $2,470,000 and $5,011,889 results from working capital activities. For the nine-month period ended September 30, 2018, cash used in operating activities was $609,647 primarily driven by the net loss of $599,532 offset by the change in working capital. The change in operating activities were the result of acquisitions that took place in 2018 and having the full nine-month effect of these acquisitions in 2019.
Cash Flows from Investing Activities
Cash provided by investing activities for the year ended December 31, 2018 was $518,123 as compared to a use of cash of $750 for the year ended December 31, 2017 due to acquisitions and cash received in excess of cash paid.
Cash used in investing activities for the nine-month period ended September 30, 2019 was $5,000 for leasehold improvements as compared to $17,500 for the nine-month period ended September 30, 2018. Cash used in investing in the nine-month period ended 2018 related to the license acquisition of the StemVax technology.
Cash Flows from Financing Activities
For the period ended December 31, 2018, we received $1,989,446 from financing activities due mostly to sale of stock in the amount of $2,035,249, which was offset by $45,803 for payment of debt. For the period ended December 31, 2017, Innovest had $63,398 in cash received primarily as a result from stock issuances.
Cash provided by financing activities for the nine-month period ended September 30, 2019 was $7,239,042, which includes $5,630,755 from the bond payable that was executed for the Midwest Curtainwalls customer contract, $644,695 from asset backed loans, $162,300 from a shareholder loan and the remaining $801,293 from stock issuances and subscriptions. The cash provided from financing activities for nine-month period ended September 30, 2018 was $1,013,500 from a private placement offering of restricted shares.
12-Month Plan of Operation
Our 12-month plan includes growth of existing businesses and growth through acquisitions. Innovest had acquired seven companies between 2017 through early 2019 and in 2019 focused on integration of those acquisitions. We are now seeking profitable, synergistic industrial companies with annual sales of $10 million and higher and positive operating profits coupled with cash generation. Acquisition candidate companies will generally have a long history and good name recognition within the industry.
In 2020, our organic growth plan includes greater leverage of the “lead-in” marketing function to obtain sales leads for our business functions into new markets and territories while growing the existing base business of customers. In addition, we plan to upgrade the existing facility space for the industrial operations located in Bedford, Ohio to allow for the cross collaboration of Innovest businesses while providing a greater space to fabricate multiple curtainwall system projects in tandem.
Item 3. Properties.
Our corporate headquarters is located at 8834 Mayfield Road in Chesterland, Ohio. The building is eight years old and is in excellent condition, with 11,000 square feet of fully furnished and equipped office space. We lease the headquarters for $11,700 a month under a lease that expires in January 2025.
Our subsidiary HP Technologies’ headquarters is located at 5505 Detroit Road in Sheffield Village, Ohio. The building is in excellent condition, with 1,289 square feet of fully furnished and equipped office space. HP Technologies leases this facility for $1,503 a month under a lease that expires in April 2023.
Our industrial operations, including Midwest Curtainwalls and the Innovest Energy Group, are located at 22209 Rockside Road in Bedford, Ohio. The building is in good condition, with 197,000 square feet industrial facilities. Midwest Curtainwalls leases this facility for $53,784 a month under a lease that expires in June 2024.
We believe our facilities are sufficient to meet our current and foreseeable future needs.
Item 4. Security Ownership of Certain Beneficial Owners and Management.
The following table summarizes information about ownership of our stock by each of our directors and senior executive officers, all of our directors and executive officers as a group, and each other person we know beneficially owns more than 5% of our stock. The information is as of April 1, 2020.
Unless otherwise noted, the address of each beneficial owner listed in the table is c/o Innovest Global, Inc., 8834 Mayfield Road, Chesterland, Ohio 44026.
We have determined beneficial ownership in accordance with the rules of the SEC. Except as indicated by the footnotes below, we believe, based on the information furnished to us, that the persons and entities named in the table below have sole voting and investment power with respect to all shares of stock that they beneficially own, subject to applicable community property laws. Applicable percentage ownership is based on 163,802,125 shares of common stock outstanding.
|
Shareholder |
Shares Held |
Percentage |
||||||
|
Daniel G. Martin, Chairman and CEO (1) |
151,466,666 | 52.4 | % | |||||
|
Timothy S. Figley, Director |
3,210,000 | 2.0 | % | |||||
|
John Klopp, Director (2) |
17,248,183 | 10.5 | % | |||||
|
Alfred T. Marciano, Director |
— | — | ||||||
|
Damon K. Mintz, Director and President |
11,205,000 | 6.8 | % | |||||
|
Jason L. Painley, Director |
5,036,364 | 3.1 | % | |||||
|
Indrani Egleston, Chief Financial Officer |
3,000,000 | 1.8 | % | |||||
|
All Directors and Executive Officers as a Group (3) |
66,166,213 | 40.4 | % | |||||
|
Ponte Investments LLC (4) 1300 Division Road, Suite 305 West Warwick, Rhode Island, 02893 |
20,000,000 | 11.5 | % | |||||
|
1. |
Mr. Martin owns 26,466,666 shares of our common stock. In addition, TN3, LLC, a company owned by Mr. Martin, owns 1,250,000 shares of our Series A preferred stock. Each share of preferred stock is convertible into 100 shares of common stock at the option of the holder. As a result, Mr. Martin has the right to acquire 125.0 million common shares upon conversion of his preferred stock, and under applicable SEC rules is considered the beneficial owner of those common shares. His percentage ownership is computed assuming the conversion of his preferred shares. There are no other preferred shares outstanding. |
|
2. |
Mr. Klopp owns 6,367,273 shares directly and 5,545,455 shares through the Klopp Investment Management Profit Sharing Plan, of which he is the sole beneficiary. The remaining 5,335,455 shares are held by members of Mr. Klopp’s immediate family. Mr. Klopp disclaims beneficial ownership of shares held by his family members to the extent that he does not have a pecuniary interest in those shares. |
|
3. |
Does not include shares issuable upon conversion of Mr. Martin’s preferred stock. Please see note one above for more information. |
|
4. |
Ponte Investments owns 10,000,000 shares of our stock. The amount reported includes an additional 10,000,000 shares issuable upon exercise of a warrant held by Ponte Investments. The warrant is currently exercisable and expires in January 2030. The warrant exercise price is $0.16 a share. Ponte Investments’ percentage ownership is computed assuming the exercise of these warrants. |
Item 5. Directors and Executive Officers.
Board of Directors
Each member of our board of directors is elected and holds office until a successor is elected and qualified. The following table lists our board members. Our board has determined that each of the directors identified as independent qualify as an “independent director” as defined in the OTX Markets’ OTCQX Rules for U.S. Companies.
|
Name |
|
Positions Held |
|
Age |
|
Director Since |
|
Daniel G. Martin |
|
Chairman of the Board and CEO |
|
46 |
|
August 2016 |
|
Timothy S. Figley |
|
Director and Management Advisor |
|
65 |
|
October 2019 |
|
John Klopp |
|
Independent Director |
|
57 |
|
January 2018 |
|
Alfred T. Marciano |
|
Independent Director |
|
65 |
|
January 2020 |
|
Damon K. Mintz |
|
Director and President |
|
45 |
|
October 2019 |
|
Jason L. Painley |
|
Independent Director |
|
42 |
|
January 2018 |
Daniel G. Martin, Chairman of the Board and Chief Executive Officer. Mr. Martin is a life-long entrepreneur. Since launching Innovest in August 2016, he has led the Company through eight acquisitions, transforming Innovest into a diversified industrial company. Mr. Martin credits his business tenacity to growing up in his father’s drugstore which required managing very low margins and critically important services. From December 2014 to January 2016, Mr. Martin served as the chief financial officer of global operations of Momentis International, where he was instrumental in stabilizing the company post-acquisition. In November 2015, he established TN3, LLC to pursue diverse investment opportunities, including the acquisition of preferred stock of Innovest. Mr. Martin has a Bachelor of Business Administration from John Carrol University. Mr. Martin filed for bankruptcy as a result of his personal guarantee of the obligations of an unrelated company, but the bankruptcy was discharged in May 2015.
Tim S. Figley, Director and Management Advisor. Mr. Figley joined Innovest as our a seasoned advisor to our management team in in February 2019 and as a board member in October 2019. He works daily with our management team to achieve our short and long-term strategic objectives. From 2014 to February 2019, he served as the director of operations of the Flynn Auto Group, where he oversaw operations of six auto dealerships with over 400 employees and was responsible for growing the organization from startup to $200 million in sales. Mr. Figley has extensive experience growing businesses and has built dozens of commercial properties, owned an eight-figure semiconductor distributorship, a residential real estate development, oil and gas partnerships and a youth center. Mr. Figley attended Kent State University.
John Klopp, Independent Director. Mr. Klopp is chief executive officer of the second-generation firm Klopp Investment Management headquartered in Cleveland, Ohio. The firm is a large-cap, blue chip platform fund, which is available to Klopp clients and trust accounts directly, and others through their financial advisors and investment platforms. Their balanced blue-chip strategy of investing in large companies, has averaged over 14% growth per year from 2009–2019. Prior to joining Klopp Investment Management in 1996, Mr. Klopp worked at Dean Witter Reynolds’ where he was responsible for inter broker-dealer transactions, compliance, trading, research, asset allocation, and portfolio management. Mr. Klopp has a Master of Business Administration from Baldwin Wallace College and a Bachelor of Art from Ohio Wesleyan. He is a member of the Cleveland Society of Security Analysts and is active in the Chartered Financial Analysts program. Mr. Klopp also serves on the board of Rose-Mary Center, a non-profit organization in Cleveland, Ohio.
Alfred T. Marciano, Independent Director. Mr. Marciano is the managing partner of Charland, Marciano & Company, CPAs, LLP, a full-service Rhode Island accounting firm with clients in a diverse range of industries throughout the country. The accounting firm has a concentration in corporate and personal tax planning, management consulting, corporate audits and estate tax planning. Mr. Marciano’s focuses in these same areas, particularly estate tax planning. Mr. Marciano also brings his expertise in financial and retirement planning to his position as the Chairman of the City of Warwick Municipal Retirement Board. He is an expert witness for the Rhode Island Family Court and Rhode Island Superior Court. Mr. Marciano has a Bachelor of Science Degree in Business Administration from Bryant University and is a Certified Public Accountant. He also serves on the board of directors for the Hope Academy Charter School, and on the boards of various other civic and religious organizations. In January 2020, Ponte Investments, LLC purchased 10.0 million shares of common stock from Innovest. In connection with the investment, we agreed to add Mr. Marciano to the board of directors.
Damon K. Mintz, Director and President. Mr. Mintz joined Innovest’s management team in January 2018 as president of what has become the Innovest Energy Group and has served as president of Innovest since January 2019. He joined our board in October 2019. During his tenure at Innovest, he has successfully completed four acquisitions while at the same time establishing the foundation for our future growth. Mr. Mintz has an extensive track record of successfully growing businesses in multiple industries including industrials and advanced technologies. His career has been defined by leadership and sales achievements, first acquiring approximately 50,000 residential, and small commercial energy customers which generated over $30 million per year in revenues for a national energy procurement company. As an operator he has managed and consulted for commercial and industrial companies ranging from mid-sized, to a multi-billion-dollar public company, and most recently from 2015 to January 2018 conceived and grew Shepherd Energy, a single source procurement, management, and energy efficiency company which is now the foundation of the Innovest Energy Group. Prior to this time, from 2012 to 2015, he was the co-founder and president of Legacy Network Holdings (Livio International) which was the parent company to a cosmetic retailer selling through a direct sales model. Mr. Mintz attended John Carroll University and is a licensed insurance broker in the State of Ohio.
Jason L. Painley, Independent Director. Mr. Painley is the treasurer of Mechanics Financial Corporation and the chief financial officer of Mechanics Bank, a $550 million bank headquartered in Mansfield, Ohio. Prior to Mechanics Bank, Mr. Painley was senior vice president and chief risk officer of Park National Corporation (NYSE: PRK), where he developed and administered the organization’s independent enterprise-wide risk management programs. Mr. Painley started his career at the Federal Reserve Bank of Cleveland where he was an examiner and accounting policy specialist, contributing to several strategic initiatives throughout the Federal Reserve System. While there, he provided supervisory oversight to large regional financial institutions, helping to ensure they were operating in a safe and sound manner, and in compliance with laws and regulations. Mr. Painley has a Master of Business Administration from John Carroll University and a Bachelor of Business Administration from Kent State University. He is a Certified Public Accountant and Certified Enterprise Risk Professional. Mr. Painley also serves on several non-profit boards in central Ohio and his community.
The members of the audit committee of the board of directors are Messrs. Martin, Klopp and Painley. Our board does not currently have any other standing committees.
Executive Officers
Our senior executive officers are Daniel G. Martin, chairman of the board and chief executive officer, Indrani Egleston, executive vice president and chief financial officer, and Damon K. Mintz, director and president. Biographical information for Messrs. Martin and Mintz is included above under “Board of Directors.”
Indrani Egleston, age 44, Chief Financial Officer. Ms. Egleston has served as executive vice president and chief financial officer since October 2019. Ms. Egleston brings strong financial and professional public company experience to Innovest and oversees our finance, accounting, internal control and investor relations functions. Prior to joining Innovest, Ms. Egleston was at Covia Holdings Corp. (NYSE:CVIA, formerly Fairmount Santrol NYSE:FMSA) from 2015 to 2019 where she served as vice president of financial planning and analysis and director of investor relations and FP&A. Prior to Covia, she held various roles in internal audit, controls and mergers and acquisitions at Nordson Corporation (Nasdaq:NDSN) from 2007 to 2015, and prior to this time was at PWC LLP. Ms. Egleston holds an Executive Master of Business Administration from Case Western Reserve University and a Bachelor of Business Administration from the University of Michigan.
Item 6. Executive Compensation.
Executive Officers
The compensation of our senior executive officers is reviewed annually and takes into consideration various relevant factors, including the expected nature and quantity of duties and responsibilities, past performance, comparison with compensation paid by other companies of comparable size and nature, and the availability of financial resources. The following table summarizes the compensation of our senior executive officers.
|
Officer |
Year |
Salary |
Bonus |
Stock |
Other |
Total |
||||||||||||||||
|
Daniel G. Martin Chairman of the Board and Chief Executive Officer |
2019 |
$ | 324,615 | — | — | — | $ | 324,615 | ||||||||||||||
|
2018 |
377,725 | $ | 18,000 | — | — | 395,725 | ||||||||||||||||
|
2017 |
75,000 | — | — | — | 75,000 | |||||||||||||||||
|
Indrani Egleston (1) Chief Financial Officer |
2019 |
83,846 | — | — | — | 83,846 | ||||||||||||||||
|
Damon K. Mintz (2) President |
2019 |
313,877 | 4,000 | — | — | 317,877 | ||||||||||||||||
|
2018 |
136,296 | 7,000 | $ | 1,348,500 | — | 1,491,796 | ||||||||||||||||
|
L. Michael Yukich (3) Prior Chief Financial Officer |
2019 |
135,212 | 3,000 | — | $ | 3,250 | 141,462 | |||||||||||||||
|
2018 |
93,553 | — | 49,500 | — | 143,053 | |||||||||||||||||
|
(1) |
Ms. Egleston joined us in August 2019 as executive vice president of finance and controls and was appointed our chief financial officer on October 8, 2019. |
|
(2) |
Mr. Mintz joined our management team in January 2018 and has served as president of Innovest since January 2019. In December 2018, we issued 3.0 million shares to Mr. Mintz for his service as president of the Innovest Energy Group. The stock compensation in 2018 represents the 3.0 million shares multiplied by $0.4495, the closing market price of our stock on the date of issuance. These shares were not registered under the Securities Act and may not be sold unless they are registered or held for an appropriate time period (typically two years). |
|
(3) |
Mr. Yukich served as our chief financial officer from August 2018 to October 8, 2019, when he retired. The other compensation in 2019 represents a car allowance provided to Mr. Yukich for business purposes. In January 2018, we issued 2.5 million shares to Mr. Yukich for his service as our chief financial officer. The stock compensation in 2018 represents the 2.5 million shares multiplied by $0.0198, the closing market price of our stock on the date of issuance. These shares were not registered under the Securities Act and may not be sold unless they are registered or held for an appropriate time period (typically two years). |
Employment Agreements
We do not have formal employment agreements with any of our senior executive officers. The offer letter we provided to Indrani Egleston, our chief financial officer, states that if Ms. Egleston is terminated either with or without cause during her first year of employment, she will receive six months’ salary as severance and all of her unvested stock grants, if any, will immediately vest. There are no other agreements that provide for severance compensation for any of our directors or executive officers.
Benefit Plans
We provide competitive health care benefits, including medical, dental and vision coverage, to our senior executive officers as an element of their compensation packages.
Equity Compensation Plan Information
In December 2019, our board and shareholders adopted the Innovest Global, Inc. 2019 Equity Incentive Plan to provide for stock-based compensation to attract and retain employees, consultants and directors who will contribute to our long-term success. Our board can issue various types of equity grants under the plan, including incentive and non-qualified stock options and restricted stock grants, to participants eligible under the plan. We have not issued any grants under the plan to our senior executive officers or board members.
Outstanding Equity Awards
We have not issued any options to our senior executive officers. The shares of stock that we issued to two of our senior executives in 2018 were immediately vested.
Board of Directors
Our directors do not receive compensation for attending or preparing for board meetings but may be reimbursed for reasonable expenses they incur in connection with performing their services as board members.
Item 7. Certain Relationships and Related Transactions, and Director Independence.
Transactions with Related Parties
Our board of directors reviews and approves all proposed transactions between Innovest and any of our officers, directors or significant shareholders. We have summarized below significant related party transactions required to be disclosed under applicable SEC rules.
TN3, LLC, a company owned by our chief executive officer Daniel Martin, advanced to Innovest $34,608 in 2017 and $28,115 in 2018 for general working capital needs. We repaid these advances to TN3 in 2018 without interest. During 2019, TN3 advanced a total of $364,800 to Innovest and we repaid without interest $30,250. At December 31, 2019 we owed TN3 $337,050. During the first quarter of 2020, TN3 advanced a total of $239,000 to Innovest and we repaid without interest $221,000. At March 31, 2020 we owed TN3 $355,050.
In January 2018, we acquired Shepherd Energy Solutions pursuant to a share exchange agreement and issued 5,790,000 shares to the three owners of Shepherd Energy in consideration for our purchase of the company. Damon Mintz and his father Steve Mintz were both owners of Shepherd Energy and each received 1,930,000 of these shares. Mr. Mintz joined the Company to lead the Energy Group in January 2018 and has served as Innovest’s president since January 2019. Steve Mintz joined the Company in January 2018 as the sales director for the Energy Group. The Shepherd Energy share exchange agreement included a stock price guarantee that would have required Innovest to issue additional shares of stock to the owners of Shepherd Energy if our common stock was not trading for at least $1.00 on the second anniversary of closing the acquisition. In March 2019, we entered into an amendment to the share exchange agreement and issued 1.5 million shares to the prior owners of Shepherd Energy in exchange for the termination of the stock price guarantee. Each of Damon Mintz and Steve Mintz received 500,000 of these shares.
Damon Mintz’s father, Steve Mintz, joined us in January 2018 as the sales director for the Energy Group. Damon Mintz’s brother, Judd Mintz, joined us in January 2019 as the director of business development for the Energy Group. We did not pay either of them more than $100,00 in any year.
In January 2020, Ponte Investments, LLC purchased 10.0 million shares of common stock from Innovest, representing approximately 6.3% of our outstanding common shares.
On January 30, 2020, Ponte Investments loaned Innovest $150,000 pursuant to a secured promissory note. The loan was secured by a pledge of our assets pursuant to a security agreement and personally guaranteed by our chief executive officer Daniel Martin. The note was due on February 6, 2020. We repaid the loan in full after the due for $180,000, including late fees and interest.
On February 21, 2020, Ponte Investments entered into a business line of credit agreement with Innovest. Pursuant to the agreement, Ponte Investments provided Innovest with a $500,000 revolving line of credit secured by a pledge of our assets. We are required to pay a loan fee each month equal to 6% of the outstanding principal balance for that month. We cannot draw more that 75% of the line without the approval of Ponte Investments. The line of credit matures on February 23, 2021. On March 31, 2020, we had drawn $375,000 on the line of credit. Our chief executive officer Daniel Martin personally guaranteed the loan.
Director Independence
Our board of directors has determined that each of John Klopp, Alfred Marciano and Jason Painley qualify as an “independent director” as defined in the OTX Markets’ OTCQX Rules for U.S. Companies. Because he serves as our CEO, Daniel Martin is not considered an independent director. However, our board has determined that he should serve as a member of our audit committee due to the wealth of knowledge that he possesses concerning our company and operations.
Item 8. Legal Proceedings.
Innovest and its subsidiaries are currently engaged in ordinary routine litigation incidental to our business. We do not believe that any of these cases will have a material adverse impact on the company or our business.
Item 9. Market Price of and Dividends on the Registrant’s Common Equity and Related Stockholder Matters.
Our shares of common stock are traded on the OTC Markets under the symbol “IVST.” The following table lists the high and low market sales prices per share for our common stock for each completed quarter of 2020, 2019 and 2018 as reported by the OTC Markets. The bid quotations in the over-the-counter market represent prices between securities dealers, do not include retail markups, markdowns, or commissions, and may not represent actual transactions.
|
Quarter Ended |
High |
Low |
||||||
|
March 31, 2020 |
$ | 0.20 | $ | 0.11 | ||||
|
December 31, 2019 |
0.22 | 0.16 | ||||||
|
September 30, 2019 |
0.32 | 0.15 | ||||||
|
June 30, 2019 |
0.38 | 0.22 | ||||||
|
March 31, 2019 |
0.46 | 0.26 | ||||||
|
December 31, 2018 |
0.54 | 0.27 | ||||||
|
September 30, 2018 |
0.30 | 0.14 | ||||||
|
June 30, 2018 |
0.31 | 0.16 | ||||||
|
March 31, 2018 |
0.23 | 0.04 | ||||||
Stockholders
There were approximately 392 holders of record of our common stock as of April 1, 2020. However, many of our stockholders hold their stock in “street name” in brokerage accounts and do not appear on the stockholder list maintained by our transfer agent.
Dividends
We have not declared or paid any cash dividends, and do not anticipate paying cash dividends in the near future.
Securities Authorized for Issuance Under Equity Compensation Plans
The Innovest Global, Inc. 2019 Equity Incentive Plan provides for the issuance of equity awards covering up to 25.0 million shares to our employees, consultants and directors. The 2019 equity plan was approved by our shareholders. We do not have any other equity compensation plans. The following table summarizes options that have been granted under the 2019 equity plan and shares available for grant under the plan in the future.
|
Equity Compensation Plan Category |
Number of Shares to be Issued Upon Exercise of Outstanding Options |
Weighted-Average Exercise Price of Outstanding Options |
Number of Additional Shares Remaining Available for Future Issuance Under Plans |
|||||||||
|
Plans approved by shareholders |
4,515,000 | $ | 0.15 | 16,735,000 | ||||||||
|
Plans not approved by shareholders |
— | — | — | |||||||||
|
Total |
4,515,000 | 16,735,000 | ||||||||||
Item 10. Recent Sales of Unregistered Securities.
The following summarizes all issuances by Innovest during the past three years of common stock and options to purchase common stock which were not registered under the Securities Act. We did not issue any other securities during that time. We did not sell any unregistered shares in 2017.
In January 2018, we issued 50.0 million common shares to our CEO Daniel Martin upon the conversion of 500,000 shares of our preferred stock held by Mr. Martin pursuant to the terms of the preferred stock. The issuance was exempt pursuant to Section 3(a)(9) of the Securities Act.
In January 2018, we issued 1.0 million shares to director John Klopp for his service as a board member. The issuance was exempt pursuant to Section 4(a)(2) of the Securities Act.
In January 2018, we issued 4,545,455 shares to director John Klopp for $0.02 a share for general working capital needs. The issuance was exempt pursuant to Section 4(a)(2) of the Securities Act.
In January 2018, we issued 2.5 million shares to L. Michael Yukich for his service as our chief financial officer. The issuance was exempt pursuant to Section 4(a)(2) of the Securities Act.
In the first quarter of 2018, we issued 5.9 million shares to three parties for consulting services. The issuance was exempt pursuant to Section 4(a)(2) of the Securities Act.
In the first quarter of 2018, we issued 1.0 million shares to the owners of Chagrin Safety Supply in consideration for our purchase of that company. The issuance was exempt pursuant to Section 4(a)(2) of the Securities Act.
In March 2018, we issued 5,790,000 shares to the owners of Shepherd Energy in consideration for our purchase of that company. Our president Damon Mintz was an owner of Shepherd Energy and received 1,930,000 of these shares. The issuance was exempt pursuant to Section 4(a)(2) of the Securities Act.
In March 2018, we issued 2,975,000 shares to the owners of Call Center Resources in consideration for our purchase of that company. The issuance was exempt pursuant to Section 4(a)(2) of the Securities Act.
From March 2018 to November 2018, we issued 8,272,730 shares to nine accredited investors for $0.011 a share for general working capital needs. Director John Klopp purchased 727,273 of these shares, and three of his immediate family members purchased 1,545,555 shares. The issuance was exempt pursuant to Section 4(a)(2) of the Securities Act.
In April 2018, we issued 1.0 million shares to director Jason Painley for his service as a board member. The issuance was exempt pursuant to Section 4(a)(2) of the Securities Act.
In April 2018, we issued 3,636,364 shares to director Jason Painley for $0.02 a share for general working capital needs. The issuance was exempt pursuant to Section 4(a)(2) of the Securities Act.
In April 2018, we issued 600,000 shares to two parties for consulting services. The issuance was exempt pursuant to Section 4(a)(2) of the Securities Act.
In the second quarter of 2018, we issued 13,590,000 shares to a total of 59 accredited investors for $0.05 a share for general working capital needs. The issuance was exempt pursuant to Rule 506(b) under the Securities Act.
From November 2018 to November 2019, we issued 8,516,997 shares to a total of 48 accredited investors for $0.15 a share for general working capital needs. The issuance was exempt pursuant to Rule 506(b) under the Securities Act.
In November 2018, we issued 1,550,000 shares to four parties for consulting services. The issuance was exempt pursuant to Section 4(a)(2) of the Securities Act.
In November 2018, we issued 155,500 shares to a vendor in exchange for office equipment. The issuance was exempt pursuant to Section 4(a)(2) of the Securities Act.
In November 2018, we issued 5,625,000 shares to director John Klopp for $0.008 a share for general working capital needs. The issuance was exempt pursuant to Section 4(a)(2) of the Securities Act.
In November 2018, we issued 1.5 million shares to the owner of HP Technologies in consideration for our purchase of that company. The issuance was exempt pursuant to Section 4(a)(2) of the Securities Act.
In December 2018, we issued 2.0 million shares to the owner of Midwest Curtainwalls in consideration for our purchase of that company. The issuance was exempt pursuant to Section 4(a)(2) of the Securities Act.
In December 2018, we issued 3.0 million shares to Damon Mintz, president of Innovest, and 2.5 million shares to Dwain Irwin, president of our biotech division, for their services to the Company. The issuances were exempt pursuant to Section 4(a)(2) of the Securities Act.
In February 2019, we issued 1.0 million shares to the owner of Primary Metering Systems in consideration for our purchase of that company. The issuance was exempt pursuant to Section 4(a)(2) of the Securities Act.
In April 2019, we issued 3,695,000 shares to the members of Authority National Supply in consideration for our purchase of that company. The issuances were exempt pursuant to Section 4(a)(2) of the Securities Act.
In May 2019, we issued 1.5 million shares to the prior owners of Shepherd Energy in exchange for the termination of a stock price guarantee. Our president Damon Mintz was an owner of Shepherd Energy and received 500,000 of these shares. The issuances were exempt pursuant to Section 4(a)(2) of the Securities Act.
In December 2019, we issued 610,000 stock options with an exercise price of $0.18 a share pursuant to the Innovest Global Equity Incentive Plan to 39 of our employees as part of their compensation. The issuances were exempt pursuant to Rule 701 under the Securities Act.
In January 2020, we issued 3,905,000 stock options with an exercise price of $0.15 a share and 650,000 restricted shares to employees pursuant to the Innovest Global Equity Incentive Plan to 21 of our employees as part of their compensation. The issuances were exempt pursuant to Rule 701 under the Securities Act.
In January 2020, we issued 10.0 million shares to an accredited investor for services. The issuance was exempt pursuant to Section 4(a)(2) of the Securities Act.
In February 2020, we issued 500,000 shares to an accredited investor for consulting services. The issuance was exempt pursuant to Section 4(a)(2) of the Securities Act.
In February 2020, we issued 854,833 shares to a customer of Authority National Supply as part of a customer purchasing program. The issuance was exempt pursuant to Section 4(a)(2) of the Securities Act.
In March 2020, we issued 3.0 million unregistered shares to Indrani Egleston for her services as our chief financial officer and 100,000 shares to a prior employee as part of his compensation. The issuances were exempt pursuant to Rule 701 under the Securities Act.
Item 11. Description of Registrant’s Securities to be Registered.
Our articles of incorporation authorize 510.0 million shares of capital stock, consisting of 500.0 million shares of common stock, $0.001 par value per share, and 10.0 million shares of preferred stock, $0.001 par value per share. There are 163,802,125 shares of common stock outstanding. Although our board of directors has the right to designate up to ten classes of preferred stock with rights and preferences determined by the board, there is only one class currently outstanding, Series A preferred. There are 1,250,000 shares of Series A preferred outstanding, all of which are held by our chairman and CEO, Daniel Martin. The following briefly outlines rights associated with our outstanding shares of common and preferred stock.
Common Stock
Voting
Holders of shares of our common stock are entitled to one vote for each share held on all matters submitted to a vote of our shareholders. Any action at a meeting at which a quorum is present will be decided by a majority of the votes cast, subject to the rights of our shares of preferred stock described below. Our board of directors is not divided into classes and cumulative voting for the election of directors is not permitted.
Dividends
Holders of shares of our common stock are entitled to receive dividends when, as and if declared by our board of directors out of funds legally available for payment, subject to the rights of holders, if any, of our preferred stock. Any decision to pay dividends on our stock will be at the discretion of our board. We intend to retain earnings for use in our operations and to finance our business and do not anticipate paying any cash dividends in the near future. Any change in our dividend policy is within the discretion of our board and will depend, among other things, on our earnings, debt service and capital requirements, restrictions in financing agreements, if any, business conditions, legal restrictions and other factors that our directors consider relevant.
Liquidation Rights
In the event of a voluntary or involuntary liquidation, dissolution or winding up of our company, the holders of our shares of common stock will be entitled to share ratably on the basis of the number of shares held in any of the assets available for distribution after we have paid in full all of our debts and after the holders of all outstanding preferred stock, if any, have received their liquidation preferences in full.
Series A Preferred Stock
Voting
The holder of shares of our Series A preferred stock is entitled to 1,000 votes for each share held on all matters submitted to a vote of our shareholders. This is ten times the number of shares of common stock issuable upon conversion of a share of Series A preferred stock.
Conversion
The holder of shares of our Series A preferred stock may convert each share of preferred stock into 100 shares of our common stock.
Dividends
The holder of shares of our Series A preferred stock is entitled to receive dividends when declared on our common stock as if the preferred shares had been converted to common (100 times the common stock dividend for each share of preferred).
Liquidation
Upon any liquidation or dissolution of Innovest, before any distribution or payment may be made to any of the holders of our common stock, the holders of our Series A preferred stock are entitled to receive an amount equal to $0.001 per share of preferred stock, plus any declared and unpaid dividends.
Item 12. Indemnification of Directors and Officers.
Our directors and officers are entitled to indemnification from Innovest under Nevada law (where we are incorporated) as well as our articles of incorporation. In this section we have summarized the indemnification provisions applicable to Innovest. This is a summary, and the applicable statutes and articles of incorporation contain additional details and qualifications.
Section 78.7502 of the Nevada Revised Statutes (“NRS) permits Innovest to indemnify any person who is a party or is threatened to be made a party to any suit or proceeding, except an action by Innovest, because that the person is a director, officer or employee of Innovest, for expenses, including attorneys’ fees, judgments, fines and amounts paid in settlement, actually and reasonably incurred by the person in connection with the suit or proceeding. To qualify for indemnification, the person must have acted in good faith and in a manner which he or she reasonably believed to be in or not opposed to the best interests of Innovest, and, with respect to any criminal action or proceeding, had no reasonable reason to believe the conduct was unlawful.
NRS Section 78.7502 also permits Innovest to indemnify an officer, director or employee who is a party or is threatened to be made a party to any suit by Innovest (or brought on our behalf by a third party). To qualify for indemnification, the person must not be liable under NRS Section 78.138 and have acted in good faith and in a manner which he or she reasonably believed to be in or not opposed to the best interests of Innovest. In addition, indemnification under NRS Section 78.7502 may not be made for any matter for which the person has been adjudged by a court to be liable to Innovest or for amounts paid in settlement to Innovest, unless the court determines that the person is fairly and reasonably entitled to indemnification.
Generally, discretionary indemnification under NRS Section 78.7502 only applies if authorized by a majority of the disinterested directors.
NRS Section 78.751 requires Innovest to indemnify any director, officer or employee who is successful in defending any suit or proceeding, whether civil, criminal, administrative or investigative, including an action by Innovest, for expenses, including attorney’s fees, incurred by the person in connection with defending the suit or proceeding
NRS Section 78.751 further provides that, unless otherwise restricted by our articles of incorporation, bylaws or other agreement, Innovest may pay the expenses of its officers and directors incurred in defending a civil or criminal suit or proceeding as they are incurred and in advance of the final disposition of the suit or proceeding. The director or officer must agree to repay the amounts advanced if it is ultimately determined by a court that the director or officer is not entitled to be indemnified by Innovest.
Indemnification under NVS Sections 78.751 and 78.7502 and advancement of expenses under Section 78.751 does not generally exclude any other rights to which a person seeking indemnification or advancement of expenses may be entitled under our articles of incorporation or bylaws, by agreement, or otherwise. However, unless ordered by a court, we cannot indemnify or advance expenses to any director or officer finally adjudged by a court to be liable for intentional misconduct, fraud or a knowing violation of law.
Our articles of incorporation provide that we must indemnify to the fullest extent permitted by law any person made a party to or otherwise involved in any suit or proceeding because he or she is a director or officer of Innovest, or is serving at our request as a director or officer of another company, against all expenses and liabilities (including attorneys’ fees, judgments, fines and amounts paid in settlement), reasonably incurred or suffered by him or her in connection with the suit or proceeding. Our articles require us to pay the expenses of officers and directors incurred in defending a civil or criminal suit or proceeding as they are incurred and in advance of the final disposition of the suit or proceeding, upon receipt of an undertaking by the director or officer to repay the amount if it is ultimately determined by a court that he or she is not entitled to be indemnified.
NRS Section 78.752 authorizes Innovest to maintain insurance covering any of our directors, officers or employees for any liability asserted against the person and liability and expenses incurred by the person in his or her capacity as a director, officer or employee, whether or not Innovest has the authority to indemnify such a person against such liability and expenses. We have obtained insurance coverage for our directors, officers and employees.
Item 13. Financial Statements and Supplementary Data.
Our financial statements listed below are included in this Form 10 beginning on page F-1.
Report of Independent Registered Public Accounting Firm
Consolidated Balance Sheets as of December 31, 2018 and 2017
Consolidated Statements of Operations for the Years Ended December 31, 2018 and 2017
Consolidated Statements of Stockholders’ Equity (Deficit) for the Years Ended December 31, 2018 and 2017
Consolidated Statements of Cash Flows for the Years Ended December 31, 2018 and 2017
Notes to Consolidated Financial Statements for the Years Ended December 31, 2018 and 2017
Consolidated Balance Sheets as of September 30, 2019 and September 30, 2018
Consolidated Statements of Operations for the Period Ended September 30, 2019 and 2018
Consolidated Statements of Stockholders’ Equity (Deficit) for the Period Ended September 30, 2019 and December 31, 2018
Consolidated Statements of Cash Flows for the Period Ended September 30, 2019 and 2018
Notes to Consolidated Financial Statements for the Period Ended September 30, 2019 and 2018
Item 14. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.
NMS Inc., Certified Public Accountants, audited our 2017 and 2018 financial statements included with this Form 10 and continues to serve as our principal independent accountant. There have been no changes in our principal independent accountant or any other events relating to our accountants reportable under applicable SEC regulations.
Item 15. Financial Statements and Exhibits.
Financial Statements
Our financial statements listed under “Item 13. Financial Statements and Supplementary Data” on page are filed as part of this Form 10.
Exhibit Index
The exhibits listed in the following table are furnished with this Form 10.
|
Exhibit |
|
Description of Exhibit |
|
Filed |
|
2.1 |
|
|
(1) |
|
|
2.2 |
|
|
(1) |
|
|
2.3 |
|
|
(1) |
|
|
2.4 |
|
|
(1) |
|
|
2.5 |
|
|
(1) |
|
|
2.6 |
|
|
(1) |
|
|
2.7 |
|
|
(1) |
|
|
2.8 |
(1) |
|||
|
2.9 |
Sale of LLC Interest Agreement dated July 17, 2018 between Innovest Global, Inc. and Dr. Dwain Irwin |
(1) |
||
|
2.10 |
Interest Purchase Agreement dated February 1, 2020 between Innovest Global, Inc. and Dr. Dwain Irwin |
(1) |
||
|
3.1 |
|
|
(1) |
|
|
3.2 |
|
Certificate of Amendment (name change to Cal Alta Auto Glass) |
|
(1) |
|
3.3 |
|
|
(1) |
|
|
3.4 |
|
|
(1) |
|
|
3.5 |
|
|
(1) |
|
|
3.6 |
|
|
(1) |
|
|
3.7 |
|
|
(1) |
|
|
3.8 |
|
|
(1) |
|
|
3.9 |
|
|
(1) |
|
|
3.10 |
|
|
(1) |
|
|
3.11 |
|
|
(1) |
|
|
3.12 |
|
|
(1) |
|
|
10.1 |
(1) |
|||
|
10.2 |
Lease and Option to Purchase dated September 1, 2018 between Innovest Global, Inc. and ICI-OH, LLC for the Corporate Headquarters |
(2) |
|
Exhibit |
Description of Exhibit |
||||
|
10.3 |
Lease Agreement dated May 6, 2019 between Bedford Rockside LLC and Midwest Curtainwalls, Inc. |
(2) |
|||
|
10.4 |
Lease Agreement dated November 29. 2017 between H.P. Technologies, Inc. and the Trust of Billy S. Rowland |
(2) |
|||
|
10.5 |
|
Exclusive License Agreement dated July 23, 2018 between Cedar-Sinai Medical Center and StemVax LLC |
|
(1) |
|
|
10.6 |
Secured Term Promissory Note dated February 6, 2020 between Innovest Global, Inc. and Ponte Investments, LLC |
(2) |
|||
|
10.7 |
Business Line of Credit Agreement dated February 21, 2020 between Innovest Global, Inc. and Ponte Investments, LLC |
(2) |
|||
|
10.8 |
Stock Purchase and Subscription Agreement dated January 9, 2020 between Innovest Global, Inc. and Ponte Investments, LLC |
(2) |
|||
|
10.9 |
Security Agreement dated October 28, 2014 between Midwest Curtainwalls, Inc. and Citizens Bank, N.A. |
(2) |
|||
|
10.10 |
Funds Control Agreement dated August 14, 2019 between Midwest Curtainwalls, Inc. and Zurich American Insurance Company |
(2) |
|||
|
21.1 |
(1) |
||||
1. Included with this filing.
2. To be filed by amendment.
Signatures
Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized.
|
|
Innovest Global, Inc. |
|
|
|
|
|
|
|
|
|
|
|
|
|
Date: April 17, 2020 |
By: |
/s/ Daniel G. Martin |
|
|
|
|
Daniel G. Martin |
|
|
|
|
Chairman of the Board and Chief Executive Officer |
|
Innovest Global, Inc.
Consolidated Financial Report
December 31, 2018 & 2017
Innovest Global, Inc.
Contents
|
Consolidated Financial Statements |
|
|
Report of Independent Registered Public Accounting Firm |
F-3 |
|
Balance Sheet |
F-4 - F-5 |
|
Statement of Operations |
F-6 |
|
Statement of Stockholders' Equity (Deficit) |
F-7 |
|
Statement of Cash Flows |
F-8 |
|
Notes to Consolidated Financial Statements |
F-9 - F-35 |
Innovest Global, Inc.
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
To the Board of Directors and Stockholders
Innovest Global, Inc.
Opinion on the Financial Statements
We have audited the accompanying consolidated balance sheets of Innovest Global Inc. and Subsidiaries (the “Company”), a Nevada corporation, as of December 31, 2018 and 2017, and the related consolidated statements of operations, shareholders’ equity, and cash flows for each of the years in the two-year period ended December 31, 2018 and December 31, 2017, and the related notes (collectively referred to as the “financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the consolidated financial position of the Company as of December 31, 2018 and 2017, and the consolidated results of its operations and its cash flows for each of the years in the two-year period ended December 31, 2018 and December 31, 2017, in conformity with accounting principles generally accepted in the United States of America.
Emphasis of Matter - Going Concern
The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the financial statements, the Company has a history of operating losses resulting in a significant accumulated deficit of $5,148,306 and negative cash flows from operations of $1,706,875 as of December 31, 2018. These factors raise substantial doubt about the Company’s ability to continue as a going concern. Management’s plans in regard to these matters are also described in Note 2. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.
Basis for Opinion
These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.
Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.
/s/ NMS, Inc.
Certified Public Accountants
We have served as the Company’s auditor since 2018.
Mentor, Ohio
December 31, 2019
Innovest Global, Inc.
Consolidated Balance Sheet
December 31, 2018 and 2017
|
2018 |
2017 |
|||||||
|
Assets |
||||||||
|
Current Assets |
||||||||
|
Cash and cash equivalents |
$ | 804,527 | $ | 3,833 | ||||
|
Accounts receivable - Net |
5,446,065 | 23,448 | ||||||
|
Inventory |
30,371 | 5,894 | ||||||
|
Subscription receivable |
- | 100,000 | ||||||
|
Prepaid expenses and other current assets |
126,183 | - | ||||||
|
Total current assets |
6,407,146 | 133,175 | ||||||
|
Property and Equipment - Net |
369,606 | - | ||||||
|
Goodwill |
5,453,551 | 82,381 | ||||||
|
Intangible Assets - Net |
352,450 | - | ||||||
|
Other Assets |
||||||||
|
Investment |
141,742 | - | ||||||
|
Other noncurrent assets |
29,172 | - | ||||||
|
Total other assets |
170,914 | - | ||||||
|
Total assets |
$ | 12,753,667 | $ | 215,556 | ||||
See notes to consolidated financial statements.
Innovest Global, Inc.
Consolidated Balance Sheet (Continued)
December 31, 2018 and 2017
|
2018 |
2017 |
|||||||
|
Liabilities and Stockholders' Equity (Deficit) |
||||||||
|
Current Liabilities |
||||||||
|
Accounts payable |
$ | 3,568,526 | $ | 61,847 | ||||
|
Bank line of credit |
348,640 | - | ||||||
|
Notes payable |
138,584 | 41,600 | ||||||
|
Billings in excess of cost and estimated earnings |
1,523,824 | - | ||||||
|
Accrued and other current liabilities: |
||||||||
|
Accrued compensation |
189,299 | - | ||||||
|
Customer rebates |
680,110 | - | ||||||
|
Deferred compensation |
48,750 | - | ||||||
|
Other accrued liabilities |
159,971 | 114,596 | ||||||
|
Total current liabilities |
6,657,704 | 218,043 | ||||||
|
Stock Guarantee Liability |
6,919,000 | - | ||||||
|
Share Issuance Liability |
750,000 | - | ||||||
|
Total liabilities |
14,326,704 | 218,043 | ||||||
|
Stockholders' Equity (Deficit) |
||||||||
|
Common stock, par value $0.001 per share:
|
141,050 | 62,339 | ||||||
|
Preferred stock, par value $0.001 per share:
|
1,250 | 1,750 | ||||||
|
Stock subscriptions, common shares: 0 at December 31, 2018 and 16,193,183 at December 31, 2017 |
- | 150,000 | ||||||
|
Additional paid-in capital |
3,432,969 | 32,344 | ||||||
|
Retained deficit |
(5,148,306 |
) |
(248,920 |
) |
||||
|
Total stockholders' equity (deficit) |
(1,573,037 |
) |
(2,487 |
) |
||||
|
Total liabilities and stockholders' equity (deficit) |
$ | 12,753,667 | $ | 215,556 | ||||
See notes to consolidated financial statements.
Innovest Global, Inc.
Consolidated Statement of Operations
Years Ended December 31, 2018 and 2017
|
2018 |
2017 |
|||||||
|
Net Sales |
$ | 6,545,702 | $ | 49,756 | ||||
|
Cost of Sales |
4,832,413 | 26,122 | ||||||
|
Gross Profit |
1,713,289 | 23,634 | ||||||
|
Operating Expenses |
4,359,960 | 143,825 | ||||||
|
Operating Loss |
(2,646,671 |
) |
(120,191 |
) |
||||
|
Non-operating Income (Expenses) |
||||||||
|
Interest income |
1,635 | - | ||||||
|
Other income |
1,346 | 56 | ||||||
|
Interest expense |
(25,696 |
) |
(4,150 |
) |
||||
|
Fair value adjustment for stock guarantee liability |
(2,230,000 |
) |
- | |||||
|
Total non-operating income |
(2,252,715 |
) |
(4,094 |
) |
||||
|
Consolidated Net Loss |
$ | (4,899,386 |
) |
$ | (124,285 |
) |
||
|
Net Loss Per Share - Basic and Diluted |
$ | (0.03 |
) |
$ | 0.00 | |||
|
Weighted-average Common Shares Outstanding - Basic and Diluted |
141,050,291 | 62,338,524 | ||||||
See notes to consolidated financial statements.
Innovest Global, Inc.
Consolidated Statement of Stockholders' Equity (Deficit)
Years Ended December 31, 2018 and 2017
|
Common Stock |
Preferred Stock |
Stock Subscriptions |
Additional Paid-in Capital |
Accumulated Deficit |
Total |
|||||||||||||||||||
|
Balance - January 1, 2017 |
$ | 62,339 | $ | 1,750 | $ | - | $ | 32,344 | $ | (124,635 |
) |
$ | (28,202 |
) |
||||||||||
|
Consolidated net loss |
- | - | - | - | (124,285 |
) |
(124,285 |
) |
||||||||||||||||
|
Stock subscriptions issued |
- | - | 150,000 | - | - | 150,000 | ||||||||||||||||||
|
Balance - December 31, 2017 |
62,339 | 1,750 | 150,000 | 32,344 | (248,920 |
) |
(2,487 |
) |
||||||||||||||||
|
Consolidated net loss |
- | - | - | - | (4,899,386 |
) |
(4,899,386 |
) |
||||||||||||||||
|
Issuance of common shares |
46,153 | - | - | 2,651,108 | - | 2,697,261 | ||||||||||||||||||
|
Conversion of preferred shares to common shares |
50,000 | (500 |
) |
- | (49,500 |
) |
- | - | ||||||||||||||||
|
Cancellation of common shares |
(50,000 |
) |
- | - | 50,000 | - | - | |||||||||||||||||
|
Issuance of common shares for services |
16,365 | - | - | 615,210 | - | 631,575 | ||||||||||||||||||
|
Stock subscriptions collected |
16,193 | - | (150,000 |
) |
133,807 | - | - | |||||||||||||||||
|
Balance - December 31, 2018 |
$ | 141,050 | $ | 1,250 | $ | - | $ | 3,432,969 | $ | (5,148,306 |
) |
$ | (1,573,037 |
) |
||||||||||
See notes to consolidated financial statements.
Innovest Global, Inc.
Consolidated Statement of Cash Flows
Years Ended December 31, 2018 and 2017
|
2018 |
2017 |
|||||||
|
Cash Flows from Operating Activities |
||||||||
|
Net loss |
$ | (4,899,386 |
) |
$ | (124,285 |
) |
||
|
Adjustments to reconcile net loss to net cash and cash equivalents from operating activities: |
||||||||
|
Depreciation and amortization |
24,458 | - | ||||||
|
Fair value adjustment for stock guarantee liability |
2,230,000 | - | ||||||
|
Impairment of goodwill |
402,764 | - | ||||||
|
Stock compensation |
631,575 | - | ||||||
|
Loss on disposals |
5,298 | - | ||||||
|
Changes in operating assets and liabilities that (used) provided cash and cash equivalents: |
||||||||
|
Accounts receivable |
(679,869 |
) |
752 | |||||
|
Inventory |
529 | 3,282 | ||||||
|
Prepaid expenses and other assets |
(80,407 |
) |
- | |||||
|
Accounts payable |
(497,196 |
) |
(3,540 |
) |
||||
|
Accrued and other liabilities |
747,301 | 64,976 | ||||||
|
Billings in excess of costs and estimated earnings |
408,058 | - | ||||||
|
Net cash used in operating activities |
(1,706,875 |
) |
(58,815 |
) |
||||
|
Cash Flows from Investing Activities |
||||||||
|
Acquisition of investment |
(16,742 |
) |
- | |||||
|
Acquisition of business (cash received in excess of cash paid) |
534,865 | (750 |
) |
|||||
|
Net cash provided by (used in) investing activities |
518,123 | (750 |
) |
|||||
|
Cash Flows from Financing Activities |
||||||||
|
Proceeds from debt |
- | 13,398 | ||||||
|
Payments on debt |
(45,803 |
) |
- | |||||
|
Stock issuance |
2,035,249 | 50,000 | ||||||
|
Net cash provided by financing activities |
1,989,446 | 63,398 | ||||||
|
Net Increase in Cash and Cash Equivalents |
800,694 | 3,833 | ||||||
|
Cash and Cash Equivalents - Beginning of year |
3,833 | - | ||||||
|
Cash and Cash Equivalents - End of year |
$ | 804,527 | $ | 3,833 | ||||
|
Supplemental Cash Flow Information |
||||||||
|
Restricted common shares issued in connection with acquisitions (Note 4) |
$ | 1,309,155 | $ | - | ||||
|
Unissued shares in connection with Authority National Supply acquisition (Note 14) |
750,000 | - | ||||||
|
Restricted common shares issued for investment (Note 5) |
125,000 | - | ||||||
|
Unpaid stock subscriptions |
- | 100,000 | ||||||
|
Furniture and fixtures acquired through obligation and issuance of restricted common shares |
52,333 | - | ||||||
|
Interest paid |
(25,696 |
) |
(4,150 |
) |
||||
See notes to consolidated financial statements.
Innovest Global, Inc.
Notes to Consolidated Financial Statements
December 31, 2018 and 2017
Note 1 - Nature of Business
Innovest Global, Inc. (the “Company” or IVST) was formed in 1999 as International Sports Marketing Group, Inc. In August 2016, after a series of transactions, the Company’s ownership, name, and business plan was changed to operate as a diversified holding company, or conglomerate.
The Company’s business plan includes the focus on acquisition of privately held businesses whose owners are willing to consider merging their businesses in order to establish a public trading market for their common stock and whose management teams are willing to operate the acquired businesses as divisions or subsidiaries of the Company.
The current business units operate within the following segments:
Commercial Solutions - The Commercial Solutions segment provides products and services, including energy, building materials, call center services and safety supplies, to companies within various commercial markets including manufacturing, municipalities and construction. This segment includes the following operating divisions further described below: Innovest Energy Group, Midwest Curtainwalls, Contact Source Solutions and Chagrin Safety Supply.
|
|
● |
Innovest Energy Group creates solutions which are custom-tailored to drastically reduce customers energy spend, protect infrastructure investment, and provide sources of project funding. The energy services business also includes energy broker services for both residential and commercial businesses throughout Ohio. |
|
|
● |
Midwest Curtainwalls provides building material solutions in the commercial industry. For nearly 50 years, the company has designed, engineered and manufactured non-structural curtainwall solutions for large commercial building development. |
|
|
● |
This segment also includes two other operating companies, Contact Source Solutions, LLC and Chagrin Safety Supply, LLC. Contact Source Solutions provides inbound and outbound call center services to commercial and industrial clients. Chagrin Safety Supply is a leading supplier of personal protection equipment, apparel and safety supplies serving the medical, dental, industrial and construction industries. |
Wholesale Purchasing - The Wholesale Purchasing segment is composed of Authority National Supply, which is a national distributor of roofing, windows, fasteners and associated tools and accessories. Authority National Supply was established to create purchasing power amongst a group of independent building material providers by obtaining discounts from suppliers based on the collective buying power of its members.
Note 2 - Significant Accounting Policies
Basis of Presentation
The consolidated financial statements of the Company have been prepared on the basis of generally accepted accounting principles (GAAP). The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect amounts reported in the financial statements. Actual results could differ from those estimates.
Going Concern
The Company has a history of recurring losses that has resulted in a stockholders' deficit of $(1,573,037) as of December 31, 2018 and $(2,487) as of December 31, 2017. During the year ended December 31, 2018, the Company recognized a net loss of $(4,899,386) and used net cash of $(1,706,875) in operating activities. During the year ended December 31, 2017, the Company recognized a net loss of $(124,285) and used net cash of $(58,815) in operating activities.
Innovest Global, Inc.
Notes to Consolidated Financial Statements
December 31, 2018 and 2017
Note 2 - Significant Accounting Policies (Continued)
The Company's consolidated financial statements are prepared assuming that the Company will continue as a concern. This assumes that the Company will be able to realize its assets and discharge its liabilities in the normal course of business for the foreseeable future. The Company anticipates future losses in the development of its business, raising substantial doubt about the Company’s ability to continue as a going concern. The ability to continue as a going concern is dependent upon the Company generating profitable operations in the future and/or obtaining the necessary financing to meet its obligations and repay its liabilities arising from normal business operations when they come due.
Management plans to additionally increase cash flow by acquiring and/or developing profitable businesses that will create positive income from operations, obtaining debt through loans from outside parties, and/or issuing common shares. In mid-2019, the company also triggered mechanisms provided by the bond agreement to fund the project working capital requirement. Management believes that by taking these actions, the Company will be provided with sufficient future operations and cash flow to continue as a going concern. However, there can be no assurances or guarantees whatsoever that the Company will be successful in consummating such actions on acceptable terms, if at all. Moreover, any such actions can be expected to result in substantial dilution to the existing shareholders of the Company.
Principles of Consolidation
The financial statements include the accounts of the Company and all of its wholly owned subsidiaries. All material intercompany accounts and transactions have been eliminated in consolidation.
Cash Equivalents
The Company considers all investments with an original maturity of three months or less when purchased to be cash equivalents.
Concentration of Cash
The Company maintains its cash in bank deposit accounts, which at times may exceed federally insured limits. The Company has not experienced any losses in such accounts. Management believes the Company is not exposed to any significant credit risk related to cash.
Trade Accounts Receivable
Accounts receivable are stated at net invoice amounts. As of December 31, 2018, $2.8 million of the outstanding accounts receivable balance is from a single customer in the Construction and Building Materials segment. Based on management's review of outstanding receivable balances and historical collection information, management's best estimate is that all balances will be collected. Accordingly, the Company has not established an allowance for doubtful accounts.
Investments
Investments in equity securities without readily determinable fair value are recorded at cost less impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for identical or similar investments in the same issuer. Impairment loses are recognized for declines in value that are other than temporary. No impairment losses were recognized for 2018 and 2017.
Innovest Global, Inc.
Notes to Consolidated Financial Statements
December 31, 2018 and 2017
Note 2 - Significant Accounting Policies (Continued)
Inventory
Inventory is stated at the lower of cost or net realizable value, with cost determined on the weighted-average method. Inventory only consists of finished goods.
Management has reviewed inventory quantities and determined that no allowance for obsolete and excess inventory is necessary. Throughout the year, inventory identified as obsolete or excess is written off. The Company will continue its policy of regularly reviewing inventory quantities on hand based on related service levels and functionality. The carrying cost will be reduced to estimated net realizable value for inventories in which their cost exceeds their utility due to changes in marketing and sales strategies, obsolescence, changes in price levels, or other causes.
Property and Equipment
Property and equipment are recorded at cost. Assets are depreciated over their estimated useful lives using the straight-line method. The cost of leasehold improvements is depreciated over the lesser of the length of the related leases or the estimated useful lives of the assets. Costs of maintenance and repairs are charged to expense when incurred.
Goodwill
The recorded amounts of goodwill from business combinations are based on management's best estimates of the fair values of assets acquired and liabilities assumed at the date of acquisition. Goodwill is not amortized, but rather is assessed at least on an annual basis for impairment. It is at least reasonably possible that management’s estimates about the fair value of goodwill could change in the near term and that such changes could materially affect amounts reported in the financial statements.
During 2018, management determined that the carrying amount of Midwest Curtain Walls and H.P. Technologies exceeded their fair value, which was estimated based on the present value of expected future cash inflows. Accordingly, a goodwill impairment loss of $357,691 and $45,073, respectively, was recognized in 2018.
Intangible Assets
Acquired intangible assets subject to amortization are stated at cost and are amortized using the straight-line method over the estimated useful lives of the assets. Intangible assets that are subject to amortization are reviewed for potential impairment whenever events or circumstances indicate that carrying amounts may not be recoverable. Assets not subject to amortization are tested for impairment at least annually. Intangible assets consist of trade names and customer lists and are amortized over 15 years.
Revenue Recognition
The Company's revenue is derived primarily from part sales, services, and the design and manufacture of custom products. These revenue streams are described below relative to each operating component. Transaction prices are specified in each contract and are not typically variable. If the consideration agreed to in a contract includes a variable amount, the Company will estimate the amount of consideration it expects to be entitled to in exchange for transferring the promised goods or services to the customer.
Innovest Global, Inc.
Notes to Consolidated Financial Statements
December 31, 2018 and 2017
Note 2 - Significant Accounting Policies (Continued)
Commercial Solutions
For the construction of custom commercial window solutions within Midwest Curtainwalls, the Company has performance obligations for the window solution that are recognized over time based on the contract terms. The Company recognizes revenue as costs are incurred (the input method), which best measures progress and results in a right to payment. The production cycle for customer contracts is generally less than 12 months. The Company uses standard, generally accepted payment terms; customers either pay at delivery of the product or are billed upon milestones achieved. A portion of amounts billed are held back as retainage and are generally paid upon project completion. Warranty terms cover the product workmanship and guarantee the product work as intended.
In some situations, the Company bills customers and collects cash prior to the satisfaction of the performance obligation, which results in the Company recognizing contract liabilities. For some contracts, the Company recognizes revenue before its right to some or all consideration becomes unconditional which results in the Company recording contract assets.
For energy services, the Company has performance obligations for providing lighting and installation services. The Company recognizes revenue as costs are incurred (the input method), which best measures progress and results in a right to payment. The production cycle for customer contracts is generally less than three months. The Company uses standard, generally accepted payment terms; customers typically pay upon completion of the service or are billed. There are no significant obligations for warranties, refunds, or similar obligations.
In some situations, the Company bills customers and collects cash prior to the satisfaction of the performance obligation, which results in the Company recognizing contract liabilities.
The Company also acts as an energy broker connecting residential and commercial businesses with the lowest cost provider. This revenue is recorded as earned each month based on the commission schedule agreed to with each energy (gas or electric) distributor.
For call center services, the Company has performance obligations for providing staffing resources and recognizes revenue on a monthly basis based on staff hours spent. The customer is invoiced monthly and has 30-day payment terms.
For distributed part sales, the Company has a performance obligation to deliver goods in accordance with the terms and conditions of the contract. Revenue is recognized at a point in time when the Company transfers control to customers, either evidenced by shipment or delivery to customer when title and risk of loss pass. The Company uses standard, generally accepted payment terms, which require payment upon delivery or within 30 days. There are no significant obligations for refunds, warranties, or similar obligations.
Wholesale Purchasing
The Company connects purchasers of building supplies to vendors and leverages the purchasing power of the group to those participating. Revenue is recognized at a point in time based on when the products are shipped. As the Company is primarily responsible for fulfilling the obligation with the ability to establish the price and inventory risk, the Company is determined to be the principal in the transaction.
Income Taxes
A current tax liability or asset is recognized for the estimated taxes payable or refundable on tax returns for the year. Deferred tax liabilities or assets are recognized for the estimated future tax effects of temporary differences between financial reporting and tax accounting.
Innovest Global, Inc.
Notes to Consolidated Financial Statements
December 31, 2018 and 2017
Note 2 - Significant Accounting Policies (Continued)
Advertising Expense
Advertising expense is charged to income during the year in which it is incurred. Advertising expense for 2018 and 2017 was $283,291 and $248, respectively.
Stock Subscriptions
Stock subscriptions that are paid subsequent to year end but before the date the financial statements are issued for each respective year are treated as receivables in the current assets section on the consolidated balance sheet rather than a deduction from equity.
Earnings per Share
Basic loss per share is based on the weighted-average number of common shares outstanding during the year. Diluted loss per share is computed giving effect to all potentially dilutive common shares. Potentially dilutive common shares may consist of incremental shares issuable upon the exercise of stock options and warrants and the conversion of notes payable to common stock, if applicable. In periods in which a net loss has been incurred, all potentially dilutive common shares are considered antidilutive and, thus, are excluded from the calculation.
Restricted Stock Awards
Stock issued to employees and to nonemployees for services consumed by the company are recognized compensation expense or as applicable operating expenses based on the fair value of the stock on the grant date of the shares issued. See Note 14 for more information.
Shipping and Handling Costs
Shipping and handling costs are recorded as costs of sales as they are incurred.
Use of Estimates
The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.
Upcoming Accounting Pronouncements
In February 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2016-02, Leases, which supersedes the current lease accounting requirements. This standard requires a lessee to record on the balance sheet the assets and liabilities for the rights and obligations created by leases with lease terms of more than 12 months. In addition, this standard requires lessees to disclose certain key information about lease transactions. Upon implementation, an entity’s lease payment obligations will be recognized at their estimated present value along with a corresponding right-of-use asset. Lease expense recognition will be generally consistent with current practice. In July 2018, the FASB issued ASU No. 2018-11, Leases (Topic 842): Targeted Improvements, which simplifies adoption of the new lease accounting requirements by allowing an additional transition method that will not require restatement of prior periods and providing a new practical expedient for lessors to avoid separating lease and non-lease components within a contract if certain requirements are met. The provisions of this guidance must be elected upon adoption of the new lease accounting requirements, which will be effective for interim and annual periods beginning after December 15, 2018.
Innovest Global, Inc.
Notes to Consolidated Financial Statements
December 31, 2018 and 2017
Note 2 - Significant Accounting Policies (Continued)
We will adopt the standard as required on January 1, 2019 and use that date as our date of initial application of the guidance. Consequently, we will not update previously reported financial information, and the disclosures under the new standard will not be provided for dates and periods prior to January 1, 2019. We will elect all of the practical expedients available under the transition guidance. The new standard also provides practical expedients for ongoing accounting. We will elect the short-term lease recognition exemption for all leases that qualify. This means we will not recognize right-of-use assets or lease liabilities for those leases. We will also elect the practical expedient to not separate lease and non-lease components for all of our leases.
We expect that this standard will have a material impact on our financial statements. While we continue to assess all of the effects of adoption, we currently believe the most significant effects relate to the recognition of new right-of-use assets and lease liabilities on our consolidated balance sheet for our real estate operating leases and the significant new required disclosures regarding our leasing activities. Upon adoption, we expect to recognize additional operating lease liabilities of approximately $700,000, with corresponding right-of-use assets for the same amount based on the present value of the remaining minimum rental payments under current leasing standards for existing operating leases.
In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments. The ASU includes changes to the accounting and measurement of financial assets, including the Company's accounts receivable, by requiring the Company to recognize an allowance for all expected losses over the life of the financial asset at origination. This is different from the current practice where an allowance is not recognized until the losses are considered probable. The new guidance will be effective for the Company's year ending December 31, 2020. Upon adoption, the ASU will be applied using a modified retrospective transition method to the beginning of the earliest period presented. Early adoption is permitted for fiscal years beginning after December 15, 2018. The Company is currently evaluating the impact this standard will have on the financial statements.
Subsequent Events
The consolidated financial statements and related disclosures include evaluation of events up through and including December 31, 2019, which is the date the consolidated financial statements have been issued.
Note 3 - New Accounting Principles
ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606)
In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606), which amends the guidance for revenue recognition. This amendment contains principles that require an entity to recognize revenue to depict the transfer of promised goods and services to customers at an amount an entity expects to be entitled to in exchange for those promised goods or services. The Company adopted this amendment on January 1, 2018, using the modified retrospective method for all contracts for which performance was not completed as of January 1, 2018. There was no adjustment to opening equity as a result of the adoption of ASC 606, as there was no change to recognizing revenue from current practice. See also Note 10 for additional details on revenue recognition.
Innovest Global, Inc.
Notes to Consolidated Financial Statements
December 31, 2018 and 2017
Note 3 - New Accounting Principles (Continued)
ASU No. 2016-01, Financial Instruments (Topic 825)
In January 2016, the FASB issued ASU No. 2016-01, Recognition and Measurement of Financial Assets and Financial Liabilities. The ASU covers various changes to the accounting, measurement, and disclosures related to certain financial instruments, including requiring equity investments to be accounted for at fair value with changes recorded through earnings, the use of the exit price when measuring fair value, and disaggregation of financial assets and liabilities by category for disclosure purposes. The ASU also provides guidance on the accounting treatment for measurement of equity investments that do not have a readily determinable fair value. This new guidance is effective for the Company's year ended December 31, 2018. See Note 5 for the impact this standard has on the financial statements.
ASU No. 2017-04, Intangibles - Goodwill (Topic 350)
In January 2017, the FASB issued ASU No. 2017-04, Intangibles - Goodwill and Other (Topic 350), Simplifying the Test for Goodwill Impairment. The standard simplifies the subsequent measurement of goodwill, requiring only a single-step quantitative test to identify and measure impairment based on the excess of a reporting unit's carrying amount over its fair value, instead of the current two-step test. A qualitative assessment may still be completed first to determine if a quantitative impairment test is required. While this standard is effective on a prospective basis for fiscal years beginning after December 15, 2019 for public business entities, the Company has decided to early adopt the standard as of December 31, 2018 in assessing goodwill impairment. See Note 7 for the impact this standard has on the financial statements.
ASU No. 2018-07, Compensation - Stock Compensation (Topic 718)
In June 2018, the FASB issued ASU No. 2018-07, Compensation - Stock Based Payment Accounting (Topic 718), Improvements to Nonemployee Share-Based Payment Accounting. This amendment expands the scope of Topic 718 to include nonemployee awards for acquiring goods and services from nonemployees. This amendment treats employee and nonemployee stock-based awards the same, which is to measure the transaction at the grant-date fair value of the equity instruments that the entity is obligated to issue when the good has been delivered or the service has been rendered. While the standard is effective for fiscal years beginning after December 15, 2018, the Company has decided to early adopt the standard to account for its stock-based awards in order to simplify measurement processes as of January 1, 2018. See Note 14 for the impact this standard has on the financial statements.
Note 4 - Business Combinations and Acquisitions
The Company has determined we are unable to supply supplemental pro forma information for the year to date reporting period ending December 31, 2017. After making every reasonable effort, the Company has deemed it impracticable to apply the requirements of ASC 805-10-50 which requires the revenues and earnings of the combined entities for the prior year to date reporting be reported as though the asset or stock purchase had been completed as of the beginning of the annual reporting period and the prior period.
Innovest Global, Inc.
Notes to Consolidated Financial Statements
December 31, 2018 and 2017
Note 4 - Business Combinations and Acquisitions (Continued)
Chagrin Safety Supply
On October 23, 2017, the Company entered into an asset purchase agreement with Chagrin Safety Supply, pursuant to which the Company purchased substantially all the assets and assumed certain liabilities of Chagrin Safety Supply. The complementary strength of certain company businesses are expected to create product and distribution synergies. The Company is expected to gain entry into new product categories by the association with other commercial companies acquired. The purchase price consisted of cash, shares of the Company's restricted common stock, and a stock guarantee.
|
Cash |
$ | 750 | ||
|
Equity instruments (750,000 common shares of the Company) |
5,774 | |||
|
Stock guarantee liability |
139,000 | |||
|
Fair value of total consideration transferred |
$ | 145,524 |
The fair value of the 750,000 shares issued as part of the consideration transferred for Chagrin Safety Supply was determined on the basis of the value of shares trading near the time of acquisition.
Under the terms of the acquisition agreement, the former stockholders of Chagrin Safety Supply are guaranteed that the value of the 750,000 shares issued will be trading at $1 per share by the fourth anniversary of the acquisition, or October 23, 2021. The value of this guarantee was determined to be $139,000 at the time of acquisition. See Note 16 regarding the valuation methodology and key assumptions made in the determination of this liability at date of acquisition and at year end.
The following table summarizes the acquisition date fair values of the assets acquired and liabilities assumed:
|
Cash |
$ | 453 | ||
|
Accounts receivable |
24,200 | |||
|
Inventories |
9,176 | |||
|
Accounts payable |
(45,882 |
) |
||
|
Accrued liabilities |
(63,804 |
) |
||
|
Total identifiable net assets |
(75,857 |
) |
||
|
Goodwill |
221,381 | |||
|
Total |
$ | 145,524 |
The fair value of financial assets includes accounts receivable with a contractual amount due of $24,200, which is expected to be collected in the full amount. The goodwill arising from the acquisition consists primarily of the going-concern element of the existing business (the higher rate of return on the assembled collection of net assets versus if the Company had acquired all of the net assets separately). There were no acquisition costs related to this transaction.
The $139,000 stock guarantee represents a measurement period adjustment that was made in 2018. This amount has been included in the total consideration transferred and the goodwill recognized.
The amounts of Chagrin Safety Supply's revenue and earnings included in the accompanying consolidated statement of operations for the year ended December 31, 2018 totaled $339,042 and $(114,256), respectively.
Innovest Global, Inc.
Notes to Consolidated Financial Statements
December 31, 2018 and 2017
Note 4 - Business Combinations and Acquisitions (Continued)
Shepherd Energy
Effective on January 1, 2018, the Company acquired 100 percent of the equity of Shepherd Energy, LLC (Shepherd Energy). The primary reason for the acquisition was to launch a commercial energy division and further diversify the Company's portfolio. The purchase price consisted of shares of the Company's restricted common stock and a stock guarantee.
The following table summarizes the fair value of the consideration transferred as part of the acquisition of Shepherd Energy:
|
Equity instruments (5,790,000 common shares of the Company) |
$ | 185,280 | ||
|
Stock guarantee liability |
1,000,000 | |||
|
Fair value of total consideration transferred |
$ | 1,185,280 |
The fair value of the 5,790,000 shares issued as part of the consideration transferred for Shepherd Energy was determined on the basis of the value of shares trading near the time of acquisition.
Under the terms of the acquisition agreement, the former stockholders of Shepherd Energy are guaranteed that the issued shares will be worth $1 per share and $5,790,000 in the aggregate at December 28, 2019. The value of this guarantee was determined to be $1,000,000 at the time of acquisition. See Note 16 regarding the valuation methodology and key assumptions made in the determination of this liability at date of acquisition and at year end. One of the former stockholders of Shepherd Energy is the President of Innovest.
The following table summarizes the acquisition date fair values of the assets acquired and liabilities assumed:
|
Cash |
$ | 13,859 | ||
|
Accounts receivable |
7,152 | |||
|
Other current assets |
41,749 | |||
|
Accounts payable |
(56,826 |
) |
||
|
Total identifiable net assets |
5,934 | |||
|
Goodwill |
1,179,346 | |||
|
Total |
$ | 1,185,280 |
The fair value of financial assets includes accounts receivable with a contractual amount due of $7,152, which is expected to be collected in the full amount. The goodwill arising from the acquisition consists primarily of the going-concern element of the existing business (the higher rate of return on the assembled collection of net assets versus if the Company had acquired all of the net assets separately). There were no acquisition-related costs related to this transaction.
The amounts of Shepherd Energy's revenue and loss included in the accompanying consolidated statement of operations for the year ended December 31, 2018 totaled $697,237 and $(1,691,163), respectively.
Innovest Global, Inc.
Notes to Consolidated Financial Statements
December 31, 2018 and 2017
Note 4 - Business Combinations and Acquisitions (Continued)
Contact Source Solutions
On January 15, 2018, the Company acquired 100 percent of the equity interest of Contact Source Solutions. The primary reason for the acquisition was to increase revenue stream, as well as obtain a business unit that can provide marketing solutions for the other business units. The purchase price consisted of shares of the Company's restricted common stock and a stock guarantee.
The following table summarizes the fair value of the consideration transferred as part of the acquisition of Contact Source Solutions:
|
Equity instruments (2,500,000 common shares of the Company) |
$ | 43,875 | ||
|
Stock guarantee liability |
500,000 | |||
|
Fair value of total consideration transferred |
$ | 543,875 |
The fair value of the 2,500,000 shares issued as part of the consideration transferred for Contact Source Solutions was determined on the basis of the value of shares trading near the time of acquisition.
Under the terms of the acquisition agreement, the former stockholders of Contact Source Solutions are guaranteed that the issued shares will be worth $1 per share and $2,500,000 in the aggregate at March 22, 2020. The value of this guarantee was determined to be $500,000 at the time of acquisition. See Note 16 regarding the valuation methodology and key assumptions made in the determination of this liability at date of acquisition and at year end.
The following table summarizes the acquisition date fair values of the assets acquired and liabilities assumed:
|
Cash |
$ | 4,718 | ||
|
Accounts receivable |
32,806 | |||
|
Accounts payable |
(21,670 |
) |
||
|
Accrued liabilities |
(72,769 |
) |
||
|
Total identifiable net assets |
(56,915 |
) |
||
|
Goodwill |
600,790 | |||
|
Total |
$ | 543,875 |
The fair value of financial assets includes accounts receivable with a contractual amount due of $32,806, which is expected to be collected in the full amount. The goodwill arising from the acquisition consists primarily of the going-concern element of the existing business (the higher rate of return on the assembled collection of net assets versus if the Company had acquired all of the net assets separately). There were no acquisition-related costs related to this transaction.
The amounts of Contact Source Solutions' revenue and loss included in the accompanying consolidated statement of operations for the year ended December 31, 2018 totaled $1,266,071 and $(386,375), respectively, from the date of acquisition. The following pro forma information for 2018 is based on the assumption that the acquisition of Contact Source Solutions occurred on January 1, 2018:
|
December 31, 2018 |
||||
|
Revenue |
$ | 1,298,239 | ||
|
Net income |
(413,699 |
) |
||
Innovest Global, Inc.
Notes to Consolidated Financial Statements
December 31, 2018 and 2017
Note 4 - Business Combinations and Acquisitions (Continued)
H.P. Technologies
On March 22, 2018, the Company acquired 100 percent of the outstanding common shares of H.P. Technologies. The primary reason for the acquisition was to strengthen the commercial energy division and further diversify the Company's portfolio. The purchase price consisted of shares of the Company's restricted common stock and a stock guarantee.
The following table summarizes the fair value of the consideration transferred as part of the acquisition of H.P. Technologies:
|
Equity instruments (1,500,000 common shares of the Company) |
$ | 30,000 | ||
|
Stock guarantee liability |
600,000 | |||
|
Fair value of total consideration transferred |
$ | 630,000 |
The fair value of the 1,500,000 shares issued as part of the consideration transferred for H.P. Technologies was determined on the basis of the value of shares trading near the time of acquisition.
Under the terms of the acquisition agreement, the former stockholders of H.P. Technologies are guaranteed that the issued shares will be worth $1 per share and $1,500,000 in the aggregate at March 22, 2020. The value of this guarantee was determined to be $600,000 at the time of acquisition. See Note 16 regarding the valuation methodology and key assumptions made in the determination of this liability at date of acquisition and at year end.
The following table summarizes the acquisition date fair values of the assets acquired and liabilities assumed:
|
Cash |
$ | 76,132 | ||
|
Intangible asset - Trade names |
131,000 | |||
|
Intangible asset - Customer contracts |
240,000 | |||
|
Accrued liabilities |
(130,095 |
) |
||
|
Total identifiable net assets |
317,037 | |||
|
Goodwill |
312,963 | |||
|
Total |
$ | 630,000 |
The goodwill arising from the acquisition consists primarily of the going-concern element of the existing business (the higher rate of return on the assembled collection of net assets versus if the Company had acquired all of the net assets separately) and an assembled workforce. There were no acquisition-related costs related to this transaction.
The amounts of H.P. Technologies's revenue and loss included in the accompanying consolidated statement of operations for the year ended December 31, 2018 totaled $1,000,303 and $(30,000), respectively, from the date of acquisition. The following pro forma information for 2018 is based on the assumption that the acquisition of H.P. Technologies occurred on January 1, 2018:
|
December 31, 2018 |
||||
|
Revenue |
$ | 1,469,104 | ||
|
Net income |
43,266 | |||
Innovest Global, Inc.
Notes to Consolidated Financial Statements
December 31, 2018 and 2017
Note 4 - Business Combinations and Acquisitions (Continued)
Authority National Supply
On November 5, 2018, the Company acquired 100 percent of the member units of Authority National Supply. The primary reason for the acquisition was to strategically expand within the building supply distribution industry. The purchase price consisted of cash, shares of the Company's restricted common stock, and a stock guarantee.
The following table summarizes the fair value of the consideration transferred as part of the acquisition of Authority National Supply:
|
Cash |
$ | 55,000 | ||
|
Equity instruments (5,000,000 common shares of the Company) |
750,000 | |||
|
Stock guarantee liability |
1,700,000 | |||
|
Fair value of total consideration transferred |
$ | 2,505,000 |
The fair value of the 5,000,000 shares to be issued as part of the consideration transferred for Authority National Supply was determined on the basis of the value of other restricted shares issued at the date of the transaction. These shares were not issued until 2019; consequently, the Company has recorded the commitment to issue the shares as a liability as of December 31, 2018. This fair value of this share issuance liability has been measured based on the value of other restricted shares issued at the date of the transaction.
Under the terms of the acquisition agreement, the former members of Authority National Supply are guaranteed that the issued shares will be worth $1 per share and $5,000,000 in the aggregate at November 5, 2020. The value of this guarantee was determined to be $1,700,000 at the time of acquisition. See Note 16 regarding the valuation methodology and key assumptions made in the determination of this liability at date of acquisition and at year end.
The following table summarizes the acquisition date fair values of the assets acquired and liabilities assumed:
|
Cash |
$ | 361,808 | ||
|
Accounts receivable |
2,108,986 | |||
|
Property, plant, and equipment |
19,709 | |||
|
Other assets |
14,096 | |||
|
Accounts payable |
(2,409,625 |
) |
||
|
Accrued liabilities |
(66,043 |
) |
||
|
Total identifiable net assets |
28,931 | |||
|
Goodwill |
2,476,069 | |||
|
Total |
$ | 2,505,000 |
The fair value of financial assets includes accounts receivable with a contractual amount due of $2,108,986, which is expected to be collected in the full amount. The goodwill arising from the acquisition consists primarily of future business growth and the going-concern element of the existing business (the higher rate of return on the assembled collection of net assets versus if the Company had acquired all of the net assets separately). Acquisition-related costs, which include legal, accounting, and valuation fees, totaled $68,261 and have been included in operating expenses in the accompanying consolidated statement of operations.
Innovest Global, Inc.
Notes to Consolidated Financial Statements
December 31, 2018 and 2017
Note 4 - Business Combinations and Acquisitions (Continued)
The amounts of Authority National Supply's revenue and loss included in the accompanying statement of operations for the year ended December 31, 2018 totaled $2,599,576 and $160,223, respectively, from the date of acquisition. The following pro forma information for 2018 is based on the assumption that the acquisition of Authority National Supply occurred on January 1, 2018:
|
December 31, 2018 |
||||
|
Revenue |
$ | 28,577,541 | ||
|
Net loss |
(19,386 |
) |
||
Midwest Curtain Walls
On December 1, 2018, the Company acquired 100 percent of the outstanding common shares of Midwest Curtain Walls. The primary reason for the acquisition was to expand its penetration in the building materials segment, as well as geographic reach. At the time of purchase, the Midwest Curtain Walls shares were held in an estate that was not in a position to continue to manage the operations. The purchase price consisted of shares of the Company's restricted common stock, contingent consideration, and a stock guarantee.
The following table summarizes the fair value of the consideration transferred as part of the acquisition of Midwest Curtain Walls:
|
Equity instruments (2,000,000 common shares of the Company) |
$ | 300,000 | ||
|
Stock guarantee liability |
750,000 | |||
|
Total |
$ | 1,050,000 |
The fair value of the 2,000,000 shares issued as part of the consideration transferred for Midwest Curtain Walls was determined on the basis of the value of other restricted shares issued at the time of acquisition.
All of the 2,000,000 shares issued in connection with this agreement are subject to a stock guarantee as follows. Under the terms of the acquisition agreement, the former members of Midwest Curtain Walls are guaranteed that 1,600,000 of issued shares will be worth $1.25 per share and $2,000,000 in the aggregate at December 1, 2020. The value of this guarantee was determined to be $600,000 at the time of acquisition. In addition, 400,000 shares issued to settle a shareholder loan are guaranteed to be trading at $1.00 per share or $400,000 in the aggregate at December 1, 2020. The value of this guarantee was determined to be $150,000 at the time of acquisition.
See Note 16 regarding the valuation methodology and key assumptions made in the determination of this liability at the date of acquisition and at year end.
Innovest Global, Inc.
Notes to Consolidated Financial Statements
December 31, 2018 and 2017
Note 4 - Business Combinations and Acquisitions (Continued)
The following table summarizes the acquisition date fair values of the assets acquired and liabilities assumed:
|
Cash |
$ | 133,348 | ||
|
Accounts receivable |
2,593,804 | |||
|
Inventory |
25,006 | |||
|
Property, plant, and equipment |
308,770 | |||
|
Other assets |
19,103 | |||
|
Accounts payable |
(1,450,245 |
) |
||
|
Accrued liabilities |
(38,359 |
) |
||
|
Billings in excess of costs and estimated earnings |
(1,115,766 |
) |
||
|
Debt |
(491,427 |
) |
||
|
Total identifiable net assets |
(15,766 |
) |
||
|
Goodwill |
1,065,766 | |||
|
Total |
$ | 1,050,000 |
The fair value of financial assets includes accounts receivable with a contractual amount due of $2,593,804, which is expected to be collected in the full amount. The goodwill arising from the acquisition consists primarily of future business growth and the going-concern element of the existing business (the higher rate of return on the assembled collection of net assets versus if the Company had acquired all of the net assets separately). Acquisition-related costs, which include legal, accounting, and valuation fees, totaled $21,800 and have been included in operating expenses in the accompanying consolidated statement of operations.
The amounts of Midwest Curtain Walls's revenue and loss included in the accompanying consolidated statement of operations for the year ended December 31, 2018 totaled $639,764 and $(300,000), respectively, from the date of acquisition. The following pro forma information for 2018 is based on the assumption that the acquisition of Midwest Curtain Walls occurred on January 1, 2018:
|
December 31, 2018 |
||||
|
Revenue |
$ | 5,717,053 | ||
|
Net loss |
(562,672 |
) |
||
Summary of 2018 and 2017 Activity
The table below summarizes the fair value of the total consideration transferred for the business combinations occurring in 2018 and 2017.
|
2018 |
2017 |
|||||||
|
Cash |
$ | 55,000 | $ | 750 | ||||
|
Equity instruments |
1,309,155 | 5,774 | ||||||
|
Stock guarantee liability |
4,550,000 | 139,000 | ||||||
|
Fair value of total consideration transferred |
$ | 5,914,155 | $ | 145,524 | ||||
Innovest Global, Inc.
Notes to Consolidated Financial Statements
December 31, 2018 and 2017
Note 4 - Business Combinations and Acquisitions (Continued)
The acquisition date fair values of the assets acquired and liabilities assumed for the business combinations are summarized as follows:
|
2018 |
2017 |
|||||||
|
Cash |
$ | 589,865 | $ | 453 | ||||
|
Accounts receivable |
4,742,748 | 24,200 | ||||||
|
Inventory |
25,006 | 9,176 | ||||||
|
Property and equipment |
328,479 | - | ||||||
|
Customer contracts |
240,000 | - | ||||||
|
Trade names |
131,000 | - | ||||||
|
Other assets |
74,948 | - | ||||||
|
Accounts payable |
(4,003,875 |
) |
(45,882 |
) |
||||
|
Billings in excess of costs and estimated earnings |
(1,115,766 |
) |
- | |||||
|
Accrued liabilities |
(241,757 |
) |
(63,804 |
) |
||||
|
Debt |
(491,427 |
) |
- | |||||
|
Total identifiable net assets |
279,221 | (75,857 |
) |
|||||
|
Goodwill |
5,634,934 | 221,381 | ||||||
|
Total |
$ | 5,914,155 | $ | 145,524 | ||||
The following pro forma information for 2018 is based on the assumption that all of the acquisitions occurring above occurred on January 1, 2018:
|
December 31, 2018 |
||||
|
Revenue |
$ | 37,029,769 | ||
|
Net loss |
(987,657 |
) |
||
Innovest Global, Inc.
Notes to Consolidated Financial Statements
December 31, 2018 and 2017
Note 5 - Investment
On July 17, 2018, the Company acquired 20 percent of StemVax Therapeutics (StemVax) for 2.5 million common IVST shares and cash of $16,742 related to the anticipated requirements of pending license agreements, presently being negotiated by StemVax with Cedars-Sinai Medical Center (Cedars) in Los Angeles, California. Cedars owns intellectual property that StemVax requires to effectuate its business plan, and these license agreements would satisfy the business requirements. The license agreements were successfully executed. The investment has not been accounted for using the equity method, as the Company does not have significant influence over the entity. The investment is recorded at $141,742, which represents the cost incurred related to license agreements plus the value of IVST shares issued based on the trading value of $0.05 per share at the time of issuance or $125,000. This holding is not expected to generate revenue in the short term, but represents what the Company believes will be a substantially valuable intellectual property holding.
Note 6 - Property and Equipment
Property and equipment at December 31, 2018 are summarized as follows:
|
Amount |
Depreciable
|
||||||
|
Machinery and equipment |
$ | 289,666 | 9 | ||||
|
Transportation equipment |
8,950 | 2 | |||||
|
Furniture and fixtures |
58,113 | 3-10 | |||||
|
Computer equipment and software |
18,785 | 3-5 | |||||
|
Total cost |
375,514 | ||||||
|
Accumulated depreciation |
5,908 | ||||||
|
Net property and equipment |
$ | 369,606 | |||||
Depreciation expense for 2018 was $5,908. There was no property or equipment in 2017.
Note 7 - Acquired Intangible Assets and Goodwill
Intangible assets of the Company at December 31, 2018 are summarized as follows:
|
Gross Carrying Amount |
Accumulated Amortization |
|||||||
|
Amortized intangible assets: |
||||||||
|
Customer contracts |
$ | 240,000 | $ | 12,000 | ||||
|
Trade names |
131,000 | 6,550 | ||||||
|
Total amortized intangible assets |
$ | 371,000 | $ | 18,550 | ||||
There were no Intangible assets as of December 31, 2017. Amortization expense for 2018 totaled $18,550.
Innovest Global, Inc.
Notes to Consolidated Financial Statements
December 31, 2018 and 2017
Note 7 - Acquired Intangible Assets and Goodwill (Continued)
Anticipated amortization expense for the years ending December 31 is as follows:
|
Years Ending |
Amount |
|||
|
2019 |
$ | 25,000 | ||
|
2020 |
25,000 | |||
|
2021 |
25,000 | |||
|
2022 |
25,000 | |||
|
2023 |
25,000 | |||
|
Thereafter |
227,450 | |||
|
Total |
$ | 352,450 | ||
The changes in the carrying amount of goodwill (by reportable segment) are as follows:
|
2018 |
||||||||||||
|
Commercial Solutions |
Wholesale Purchasing |
Total |
||||||||||
|
Balance - January 1: |
||||||||||||
|
Goodwill |
82,381 | - | 82,381 | |||||||||
|
Less accumulated impairment losses |
- | - | - | |||||||||
|
Opening goodwill - Net |
$ | 82,381 | $ | - | $ | 82,381 | ||||||
|
Current year activity: |
||||||||||||
|
Goodwill as a result of business acquisition |
3,158,865 | 2,476,069 | 5,634,934 | |||||||||
|
Remeasurement adjustment |
139,000 | - | 139,000 | |||||||||
|
Impairment losses |
(402,764 |
) |
- | (402,764 |
) |
|||||||
|
Ending goodwill - Net |
$ | 2,977,482 | $ | 2,476,069 | $ | 5,453,551 | ||||||
|
Balance - December 31: |
||||||||||||
|
Goodwill |
3,380,246 | 2,476,069 | 5,856,315 | |||||||||
|
Less accumulated impairment losses |
(402,764 |
) |
- | (402,764 |
) |
|||||||
|
Ending goodwill - Net |
$ | 2,977,482 | $ | 2,476,069 | $ | 5,453,551 | ||||||
Innovest Global, Inc.
Notes to Consolidated Financial Statements
December 31, 2018 and 2017
Note 7 - Acquired Intangible Assets and Goodwill (Continued)
|
2017 |
||||||||||||
|
Commercial Solutions |
Wholesale Purchasing |
Total |
||||||||||
|
Balance - January 1: |
||||||||||||
|
Goodwill |
- | - | - | |||||||||
|
Less accumulated impairment losses |
- | - | - | |||||||||
|
Opening goodwill - Net |
$ | - | $ | - | $ | - | ||||||
|
Current year activity: |
||||||||||||
|
Goodwill as a result of business acquisition |
82,381 | - | 82,381 | |||||||||
|
Ending goodwill - Net |
$ | 82,381 | $ | - | $ | 82,381 | ||||||
|
Balance - December 31: |
||||||||||||
|
Goodwill |
82,381 | - | 82,381 | |||||||||
|
Less accumulated impairment losses |
- | - | - | |||||||||
|
Ending goodwill - Net |
$ | 82,381 | $ | - | $ | 82,381 | ||||||
Each reportable segment noted above is a specific reporting unit for goodwill impairment testing purposes. Goodwill is reviewed for possible impairment at least annually or more frequently upon the occurrence of an event or when circumstances indicate that a reporting unit's carrying amount is greater than its fair value, which was estimated based on the present value of expected future cash inflows. Accordingly, a goodwill impairment loss of $402,764 was recognized in 2018. Each reporting unit had a zero or negative carrying amount at December 31, 2018 and 2017.
Note 8 - Line of Credit
Midwest Curtain Walls has a line of credit agreement with a bank to borrow up to $1,500,000 to support working capital needs. Interest is payable monthly at the one-month LIBOR plus 2.75 percent (an effective rate of 5.25 percent at December 31, 2018). The line of credit is collateralized by all assets of Midwest Curtain Walls. The balance outstanding on this line of credit was $348,640 at December 31, 2018.
In January 2019, the Company entered into a forbearance agreement with the bank (see Note 9), which prohibited additional borrowings under the line of credit. Additionally, the line of credit which was to be repaid in monthly principal payments of $50,000 through August 2019 and a final payment of $48,640 due in September 2019. This final payment has not yet been paid and the company is currently finalizing payments for early 2020.
Innovest Global, Inc.
Notes to Consolidated Financial Statements
December 31, 2018 and 2017
Note 9 - Notes Payable
Notes payable at December 31 are as follows:
|
2018 |
2017 |
|||||||
|
Midwest Curtain Walls - Notes payable to bank with interest ranging from 4.5 and 4.85 percent and due in full in September 2019. Secured by specific equipment |
$ | 138,584 | $ | - | ||||
|
IVST - Unsecured working capital note payable to a related party (TN3, LLC) with interest of 7 percent. This note matured in July 2018 |
- | 34,608 | ||||||
|
IVST - Unsecured working capital note payable with interest at 7 percent. This note matured in July 2018 |
- | 6,992 | ||||||
|
Total |
$ | 138,584 | $ | 41,600 | ||||
Ownership transitions before the acquisition of Midwest Curtain Walls and the acquisition of Midwest Curtain Walls by IVST have caused the note payable and the line of credit to be in default, and remedied through a forbearance agreement entered into in January 2019. The note was required to be paid in full by September 2019 as a result of the conditions of the forbearance. Accordingly, the note payable has been classified as a current liability. This final payment has not yet been paid and the company is currently finalizing payments for early 2020.
Interest expense for 2018 and 2017 was $25,696 and $4,150, respectively.
Note 10 - Revenue Recognition
The following table shows revenue from contracts with customer by business segments. Predominately all revenue is derived from customers within the midwestern part of the United States. Revenue from customized goods within the Construction and Building Materials segment is derived from one customer contract.
|
2018 |
||||||||||||
|
Segments |
Commercial Solutions |
Wholesale Purchasing |
Total |
|||||||||
|
Major goods/service lines: |
||||||||||||
|
Goods |
$ | 1,673,745 | $ | 2,599,576 | $ | 4,273,321 | ||||||
|
Services & Other |
2,272,381 | 2,272,381 | ||||||||||
|
Total |
$ | 3,946,126 | $ | 2,599,576 | $ | 6,545,702 | ||||||
|
Timing of revenue recognition: |
||||||||||||
|
Point in time |
$ | 2,609,126 | $ | 2,599,576 | $ | 5,208,702 | ||||||
|
Over time |
1,337,000 | 1,337,000 | ||||||||||
|
Total |
$ | 3,946,126 | $ | 2,599,576 | $ | 6,545,702 | ||||||
Revenue for 2017 was only derived from sale of goods and was recognized at a point in time.
Innovest Global, Inc.
Notes to Consolidated Financial Statements
December 31, 2018 and 2017
Note 10 - Revenue Recognition (Continued)
Contract Liabilities
Contract liabilities consist of billings in excess of costs and estimated earnings, as presented on the consolidated balance sheet. The following table provides information on the changes in the balance of contract liabilities for the year ended December 31, 2018:
|
Opening balance |
$ | - | ||
|
Cash received |
269,382 | |||
|
Acquired in business combination |
1,115,766 | |||
|
Less revenue recognized from continuing operations (net of returns, allowances, etc.) - From satisfaction of performance obligations in the current period |
138,676 | |||
|
Closing balance |
$ | 1,523,824 |
Total contract liabilities increased by $1,523,824 during the year ended December 31, 2018. The increase was primarily due to businesses acquired during 2018.
Performance Obligations
Revenue that is expected to be recognized related to performance obligations that have not been fully satisfied as of December 31, 2018 totals $4,880,029 and is expected to be realized during 2019.
Note 11 - Business Segment Information
Innovest Global, Inc. has three two reportable segments: Commercial Solutions & Wholesale Purchasing. construction and building materials, energy services, and call center services. The construction and building materials segment designs and manufactures nonstructural window solutions for commercial building contractors and acts as an agent leveraging the combined purchasing power of its customers in securing vendor pricing for construction-related supplies. The energy segment provides energy broker services for both residential and commercial businesses throughout Ohio and designs and installs energy-efficient lighting solutions. The call center services segment provides inbound and outbound call center services to commercial and industrial clients primarily in Ohio and is currently serving the medical supplies sector. The Commercial Solutions segment provides products and services, including energy, building materials, call center services and safety supplies, to companies within various commercial markets including manufacturing, municipalities and construction. This segment includes the following operating divisions: Innovest Energy Group, Midwest Curtainwalls, Contact Source Solutions and Chagrin Safety Supply. The Wholesale Purchasing segment is composed of Authority National Supply, which is a national distributor of roofing, windows, fasteners and associated tools and accessories.
Innovest Global, Inc.'s reportable segments are strategic business units that offer different product and service offerings. They are managed separately because each business requires different technology and marketing strategies. All of the businesses were acquired individually, and the management at the time of the acquisition was retained if possible.
Innovest Global, Inc.
Notes to Consolidated Financial Statements
December 31, 2018 and 2017
Note 11 - Business Segment Information (Continued)
The following table provides selected information as of and for the year ended December 31, 2018. Reportable segments did not exist prior to 2018.
|
Commercial Solutions |
Wholesale Purchasing |
Corporate |
Eliminations |
Total |
||||||||||||||||
|
Revenue from external customers |
3,940,120 | 2,599,576 | 12,006 | (6,000 | ) | 6,545,702 | ||||||||||||||
|
Interest revenue |
- | - | 1,635 | - | 1,635 | |||||||||||||||
|
Interest expense |
25,688 | 7 | 1 | - | 25,696 | |||||||||||||||
|
Depreciation and amortization |
23,164 | 1,294 | - | - | 24,458 | |||||||||||||||
|
Operating income (loss) |
(387,452 | ) | (40,216 | ) | (2,219,002 | ) | - | (2,646,670 | ) | |||||||||||
|
Noncash charge for adjustment to fair value of stock guarantee |
2,110,000 | 120,000 | - | - | 2,230,000 | |||||||||||||||
|
Segment profit (loss) |
(2,523,140 | ) | (160,223 | ) | (2,217,368 | ) | - | (4,900,731 | ) | |||||||||||
|
Goodwill |
2,977,482 | 2,476,069 | 5,453,551 | |||||||||||||||||
|
Segment assets |
7,245,696 | 5,006,648 | 624,823 | (123,500 | ) | 12,753,667 | ||||||||||||||
Note 12 - Operating Leases
The Company is obligated under operating leases primarily for facilities, expiring at various dates through 2023. The leases require the Company to pay taxes, insurance, utilities, and maintenance costs. Total rent expense under these leases was $73,420 and $0 for 2018 and 2017, respectively.
Future minimum annual commitments under these operating leases are as follows:
|
Years Ending December 31 |
Amount |
|||
|
2019 |
$ | 206,188 | ||
|
2020 |
164,188 | |||
|
2021 |
141,046 | |||
|
2022 |
141,046 | |||
|
2023 |
141,046 | |||
|
Total |
$ | 793,514 | ||
Innovest Global, Inc.
Notes to Consolidated Financial Statements
December 31, 2018 and 2017
Note 13 - Income Taxes
The components of the income tax provision included in the consolidated statement of operations are all attributable to continuing operations and are detailed as follows:
|
2018 |
2017 |
|||||||
|
Current income tax expense (recovery) |
$ | - | $ | - | ||||
|
Deferred income tax recovery |
(1,022,045 | ) | (33,578 | ) | ||||
|
Change in valuation reserve |
1,022,045 | 33,578 | ||||||
|
Total income tax expense (recovery) |
$ | - | $ | - | ||||
|
2018 |
2017 |
|||||||
|
Income tax recovery, computed at 21 percent of pretax loss |
$ | (1,028,871 | ) | $ | (26,100 | ) | ||
|
Effect of nontaxable income |
6,826 | - | ||||||
|
Increase in valuation reserve |
1,022,045 | 33,578 | ||||||
|
Changes to statutory tax rates |
- | (14,935 | ) | |||||
|
Other |
- | 7,457 | ||||||
|
Total provision for income taxes |
$ | - | $ | - | ||||
The details of the net deferred tax asset (liability) are as follows:
|
2018 |
2017 |
|||||||
|
Deferred tax assets: |
||||||||
|
Contingent consideration - Stock guarantee liability |
$ | 625,800 | $ | - | ||||
|
Net operating loss and tax credit carryforward |
518,448 | 52,273 | ||||||
|
Other |
102.097 | - | ||||||
|
Gross deferred tax assets |
1,246,345 | 52,273 | ||||||
|
Valuation allowance recognized for deferred tax assets |
(1,225,987 | ) | (52,273 | ) | ||||
|
Net deferred tax assets |
20,358 | - | ||||||
|
Deferred tax liabilities: |
||||||||
|
Depreciation and amortization |
(20,358 | ) | - | |||||
|
Gross deferred tax liabilities |
(20,358 | ) | - | |||||
|
Net deferred tax asset (liability) |
$ | - | $ | - | ||||
The Company has approximately $2,469,000 of net operating loss carryforwards available to reduce future income taxes that have no expiration.
Realization of deferred tax assets is dependent on generating sufficient taxable income prior to the expiration of loss carryforwards. Due to uncertainty as to the realization of the net operating loss carryforwards, a valuation allowance has been recorded against the related deferred tax assets.
The valuation allowance increased by $1,022,045 from current year operating results and increased an additional $151,669 as a result of a valuation allowance established at acquisition related to Midwest Curtain Walls.
Innovest Global, Inc.
Notes to Consolidated Financial Statements
December 31, 2018 and 2017
Note 14 - Stockholders' Equity
Stock Compensation and Other Stock Awards
During 2018, the Company issued 16,365,000 shares of its restricted common stock to employees and service providers. A total of 7,975,000 shares were issued to employees, officers, or directors of the Company, and 8,390,000 shares were issued for consulting services to nonemployees. The fair value of the shares issued was determined based on actual transactions of the Company's stock occurring around the time the shares were granted and resulted in a $631,575 increase to equity and a charge to operations for the year ended December 31, 2018. All of the stock awards granted in 2018 were fully vested upon issuance. No stock-based awards were granted in 2017.
Common and Preferred Stock
During 2018, the Company converted 500,000 shares of preferred stock into 50,000,000 shares of common stock. The 50,000,000 were then canceled prior to December 31, 2018.
Note 15 - Fair Value Measurements
Accounting standards require certain assets and liabilities be reported at fair value in the financial statements and provide a framework for establishing that fair value. The framework for determining fair value is based on a hierarchy that prioritizes the inputs and valuation techniques used to measure fair value.
Fair values determined by Level 1 inputs use quoted prices in active markets for identical assets or liabilities that the Company has the ability to access.
Fair values determined by Level 2 inputs use other inputs that are observable, either directly or indirectly. These Level 2 inputs include quoted prices for similar assets and liabilities in active markets and other inputs, such as interest rates and yield curves, that are observable at commonly quoted intervals.
Level 3 inputs are unobservable inputs, including inputs that are available in situations where there is little, if any, market activity for the related asset or liability. These Level 3 fair value measurements are based primarily on management’s own estimates using pricing models, discounted cash flow methodologies, or similar techniques taking into account the characteristics of the asset or liability.
In instances whereby inputs used to measure fair value fall into different levels in the above fair value hierarchy, fair value measurements in their entirety are categorized based on the lowest level input that is significant to the valuation. The Company’s assessment of the significance of particular inputs to these fair value measurements requires judgment and considers factors specific to each asset or liability.
Innovest Global, Inc.
Notes to Consolidated Financial Statements
December 31, 2018 and 2017
Note 15 - Fair Value Measurements (Continued)
The following tables present information about the Company’s assets and liabilities measured at fair value at December 31, 2018 and 2017.
|
Quoted Prices in Active Markets for Identical
Assets
|
Significant Other Observable
Inputs
|
Significant Unobservable
Inputs
|
||||||||||
|
Assets |
||||||||||||
|
Cash and cash equivalents |
$ | 804,527 | $ | - | $ | - | ||||||
|
Accounts receivable |
5,446,065 | - | - | |||||||||
|
Total assets |
$ | 6,250,592 | $ | - | $ | - | ||||||
|
Liabilities |
||||||||||||
|
Accounts payable |
$ | 3,568,526 | $ | - | $ | - | ||||||
|
Bank line of credit |
348,640 | - | - | |||||||||
|
Note payable |
138,584 | - | - | |||||||||
|
Stock guarantee (Note 16) |
- | - | 6,919,000 | |||||||||
|
Total liabilities |
$ | 4,055,750 | $ | - | $ | 6,919,000 | ||||||
Innovest Global, Inc.
Notes to Consolidated Financial Statements
December 31, 2018 and 2017
Note 16 - Stock Guarantee Liability
In connection with business combinations (see Note 4), Innovest Global, Inc. has recorded contingent consideration in the form of a guaranteed stock price at a future date. Should the stock price not reach the guaranteed market price by the agreed-upon date, the Company has generally guaranteed the difference in the form of issuance of additional shares of stock. The maximum potential payments under these guarantees are equal to the number of shares multiplied by the guaranteed stock price. The Company has recorded a stock guarantee liability upon issuance of the guarantee and has adjusted the fair value at December 31, 2018. Adjustments to the liability are recorded in the accompanying consolidated statement of operations as nonoperating expense.
This liability is measured at fair value on a recurring basis using Level 3 fair value measurements. Specifically, the Company has estimated the fair value using a Monte Carlo simulation that is affected by the Company’s stock price, as well as assumptions regarding a number of complex and subjective variables. Changes to contingent consideration obligations can result from movements in publicly traded stock prices of IVST, adjustments to discount rates, expected stock price volatility, estimated dividend rates, estimated counterparty risk, periods, and updates in the assumed achievement or timing of exceeding any target stock price. The assumptions related to determining the value of a contingent consideration include a significant amount of judgment, and any changes in the assumptions could have a material impact in any given period. In determining the fair value, the Company used the following significant unobservable inputs:
|
● |
Expected stock price volatility - 75 percent |
|
● |
Risk-free interest rate - Ranges from 1.89 percent to 3.19 percent |
|
● |
Counterparty credit risk (discount rate) - 30 percent |
|
● |
Dividend rate - 0 percent |
The following table reconciles the opening and closing balance of the stock guarantee liability for 2018. There was no activity in 2017.
|
Acquiree |
Fair Value at January 1, 2018 |
Amounts Recognized in Business Combinations |
Fair Value Adjustments Recognized in Earnings |
Fair Value at December 31, 2018 |
||||||||||||
|
Chagrin Safety Supply |
$ | - | $ | 139,000 | $ | 90,000 | $ | 229,000 | ||||||||
|
Shepherd Energy |
- | 1,000,000 | 1,470,000 | 2,470,000 | ||||||||||||
|
Contact Source Solutions |
- | 500,000 | 560,000 | 1,060,000 | ||||||||||||
|
H.P. Technologies |
- | 600,000 | 20,000 | 620,000 | ||||||||||||
|
Authority National Supply |
- | 1,700,000 | 120,000 | 1,820,000 | ||||||||||||
|
Midwest Curtain Walls |
- | 750,000 | (30,000 | ) | 720,000 | |||||||||||
| $ | - | $ | 4,689,000 | $ | 2,230,000 | $ | 6,919,000 | |||||||||
On March 18, 2019, the Company entered an agreement to issue 1,500,000 restricted common shares in exchange for the cancellation of the stock guarantee related to the Shepherd Energy, LLC acquisition, whereby the 5,790,000 shares were guaranteed to have a trading value of $1 per share by December 2019. This share issuance settles a stock liability of $2,470,000 at December 31, 2018.
Innovest Global, Inc.
Notes to Consolidated Financial Statements
December 31, 2018 and 2017
Note 17 - Related Party Transactions
The officers and directors of the Company are involved in other business activities. They may face a conflict of interests between the Company and other business interests. The Company has not formulated a policy to address such conflicts.
One of the members that participates in the purchasing program at Authority National Supply is owned by an individual who is the CEO of Authority National Supply.
The prior owners of the business, Contact Source Solutions, are independent contractors to the Company providing business consultation services on the call center business.
TN3, LLC is a company owned and controlled by the Company's chairman and CEO, Daniel Martin. TN3, LLC is also a significant shareholder of IVST. As of December 31, 2017, there was a loan payable to TN3, LLC, which was paid off in 2018, as described in Note 9.
Note 18 - Retirement Plans
Midwest Curtain Walls sponsors a 401(k) plan for substantially all employees who meet certain age and length of service requirements. The plan allows for the Company to make a discretionary matching contribution. There were no contributions made by the Company to the plan in 2018 or 2017.
Note 19 - Subsequent Events
Subsequent to December 31, 2018 (January 1, 2019), the Company acquired certain contracts and assets from Primary Metering Solutions, LLC. The transaction was accounted for as an asset acquisition and recorded at cost of $175,000. The consideration transferred included $25,000 of cash and the issuance of 1,000,000 restricted shares of the Company's common stock. The fair value of the shares issued was determined on the basis of the value of other restricted shares issued at the time of the acquisition. The transaction was completed in order to provide additional growth opportunities for the Energy segment.
In May 2019, Midwest Curtain Walls entered into a new lease agreement for properly located in Cleveland, Ohio to serve as the Company’s new manufacturing and fabrication facility. The prior lease obligation expired in 2016 and the Company was in need of a larger space to support the anticipated growth of the business going forward.
At the time of acquisition, Midwest Curtain Walls, had entered into a sales contract for a large commercial project. In the third quarter 2019, disputes arose among Midwest, the customer, and subcontractors which involved the subcontractor performing and billing in excess of contracted amounts which resulted in the customer withholding certain accounts receivable. The Midwest sales obligation does not permit the suspension of work during such disputes which resulted in being contractually obligated to continue the project and seek remedy for these disputes only after completion. To cover the shortfalls created by the disputes, Midwest triggered mechanisms provided by the bond agreement to fund the project working capital requirement. As of September 30, 2019, the bond liability on the balance sheet is $5,630,755. Given the timing for when the sales obligation was initiated which was prior to Innovest Global’s acquisition of Midwest Curtain Walls, Midwest Curtain Walls has assumed the bond liability as it is entitled to the receivables that have been withheld in support of the associated liability.
Innovest Global, Inc.
Notes to Consolidated Financial Statements
December 31, 2018 and 2017
Note 19 - Subsequent Events (Continued)
In order to achieve the working capital required to accommodate rapid growth, Innovest Global initiated a strategy to obtain short term cash flow in exchange for a lien on the accounts receivable balances of the Company and its subsidiaries. In the second and third quarter of 2019, Innovest entered into a variety of transactions which pre-sold future accounts receivable by receiving deposits on those future receivables in exchange for a discount on them to the purchasers. The payoff timeline was approximately four months. In the fourth quarter 2019, Innovest began working with a third party to retire the outstanding balances, and subsequently terminated payments to the lien holders. This caused the agreements to default, but the company has plans to finalize payments and lien releases in early 2020.
In 2019, the Company created an Equity Incentive Plan to provide stock-based compensation to employees. The Plan allows for the issuance of Incentive Stock Options, Non-qualified Stock Options and Restricted Stock units to participants eligible under the plan. The plan was approved by the Board of Directors on December 31, 2019 and no awards had yet to be issued in 2019.
Innovest Global, Inc.
Consolidated Financial Report
September 30, 2019 & 2018
Innovest Global, Inc.
Contents
|
Consolidated Financial Statements |
|
|
Balance Sheet |
F-38 - F-39 |
|
Statement of Income (Loss) |
F-40 |
|
Statement of Stockholders' Equity (Deficit) |
F-41 |
|
Statement of Cash Flows |
F-42 |
|
Notes to Consolidated Financial Statements |
F43 - F-63 |
Innovest Global, Inc.
Consolidated Balance Sheet
|
Period Ended September 30, |
||||||||
|
2019 |
2018 |
|||||||
|
Current Assets: |
||||||||
|
Cash and cash equivalents |
$ | 614,988 | $ | 390,186 | ||||
|
Accounts receivable: |
||||||||
|
Trade |
7,840,023 | 320,863 | ||||||
|
Retentions |
843,922 | |||||||
|
Inventory |
40,925 | 4,915 | ||||||
|
Cost in excess of billings |
6,300,554 | - | ||||||
|
Backlog |
- | - | ||||||
|
Subscription Receivable |
- | - | ||||||
|
Notes Receivable |
- | 25,000 | ||||||
|
Prepaid expenses and other current assets |
8,286 | 116,271 | ||||||
|
Total current assets |
$ | 15,648,697 | $ | 857,235 | ||||
|
Property and Equipment – Net (Note 6) |
309,170 | - | ||||||
|
Goodwill (Note 7) |
5,295,770 | 82,381 | ||||||
|
Intangible Assets ‑ Net (Note 7) |
324,000 | - | ||||||
|
Other Assets: |
||||||||
|
Leasehold Improvements |
5,000 | - | ||||||
|
Investment (Note 5) |
141,742 | - | ||||||
|
Deposits |
- | - | ||||||
|
Other noncurrent assets |
12,410 | 132,000 | ||||||
|
Total other assets |
$ | 159,152 | $ | 132,000 | ||||
|
Total assets |
$ | 21,736,788 | $ | 1,071,616 | ||||
See notes to consolidated financial statements.
Innovest Global, Inc.
Consolidated Balance Sheet (Continued)
|
Period Ended September 30, |
||||||||
|
2019 |
2018 |
|||||||
|
Current Liabilities: |
||||||||
|
Accounts payable |
9,815,323 | 320,026 | ||||||
|
Billings in excess of cost and estimated earnings |
- | - | ||||||
|
Bank line of credit (Note 8) |
348,640 | - | ||||||
|
Current portion of LT Debt |
- | - | ||||||
|
Notes payable (Note 9) |
107,576 | - | ||||||
|
Bond Payable (Note 10) |
5,630,755 | - | ||||||
|
Deposit on Assets (Note 11) |
644,695 | - | ||||||
|
Accrued and other current liabilities: |
||||||||
|
Accrued Compensation |
236,184 | - | ||||||
|
Deferred Compensation |
- | - | ||||||
|
Accrued Expenses |
24,769 | 12,472 | ||||||
|
Other accrued liabilities |
395,929 | 165,779 | ||||||
|
Total current liabilities |
$ | 17,203,870 | $ | 498,277 | ||||
|
Shareholder Loan Payable (Note 15) |
162,300 | |||||||
|
Stock Guarantee Liability (Notes 4 and 14) |
4,449,000 | |||||||
|
Share Issuance Liability (Note 4) |
750,000 | |||||||
|
Other Long Term Liabilities |
44,812 | |||||||
|
Total liabilities |
$ | 22,609,982 | $ | 498,277 | ||||
|
Stockholders' Equity (Deficit): |
||||||||
|
Common stock, par value $0.001 per share: Authorized shares: 500,000,000 in 2018 and 2017 Issued and outstanding shares: 148,338,959 at September 30, 2019 and 109,188,071 at September 30, 2018 |
148,339 | 109,188 | ||||||
|
Preferred stock, par value $0.001 per share: Authorized shares: 10,000,000 in 2019 and 2018 Issued and outstanding shares: 1,250,000 at September 30, 2019 and 1,250,000 at September 30, 2018 |
1,250 | 1,250 | ||||||
|
Stock subscriptions, common shares: 0 at September 30, 2019 and 16,193,183 at September 30, 2018 |
- | 312,000 | ||||||
|
Additional paid‑in capital |
3,884,973 | 996,453 | ||||||
|
Retained deficit |
(4,907,756 | ) | (845,552 | ) | ||||
|
Total stockholders' equity (deficit) |
$ | (873,194 | ) | $ | 573,339 | |||
|
Total liabilities and stockholders' equity (deficit) |
$ | 21,736,788 | $ | 1,071,616 | ||||
See notes to consolidated financial statements.
Innovest Global, Inc.
Consolidated Statement of Income (Loss)
|
Three months ended September 30, |
Nine months ended September 30, |
||||||||||||||||
|
2019 |
2018 |
2019 |
2018 |
||||||||||||||
|
Net Sales |
$ | 17,638,128 | $ | 1,064,152 | $ | 47,423,657 | $ | 2,874,323 | |||||||||
|
Cost of Sales |
15,218,258 | 602,351 | 44,516,698 | 1,512,362 | |||||||||||||
|
Gross Profit |
$ | 2,419,870 | $ | 461,801 | $ | 2,906,959 | $ | 1,361,961 | |||||||||
|
Operating Expenses |
1,887,907 | 722,978 | 5,086,633 | 1,993,443 | |||||||||||||
|
Operating Income / (Loss) |
$ | 531,963 | $ | (261,177 | ) | $ | (2,179,674 | ) | $ | (631,482 | ) | ||||||
|
Non-operating Income (Expenses) |
|||||||||||||||||
|
Interest income |
|||||||||||||||||
|
Other income |
(2,792 | ) | 8,380 | 68,162 | 31,950 | ||||||||||||
|
Loss on Asset Sale - A/R |
(135,798 | ) | - | (384,755 | ) | ||||||||||||
|
Fair value adjustment for stock guarantee liability credit |
- | - | 2,470,000 | ||||||||||||||
|
Total nonoperating income |
(138,589 | ) | 8,380 | 2,153,407 | 31,950 | ||||||||||||
|
Consolidated Net Profit/(Loss) |
$ | 393,374 | $ | (252,797 | ) | $ | (26,267 | ) | $ | (599,532 | ) | ||||||
|
Net Gain/(Loss) Per Share ‑ Basic |
$ | 0.003 | $ | (0.002 | ) | $ | (0.000 | ) | $ | (0.005 | ) | ||||||
|
Net Gain/(Loss) Per Share ‑ Diluted |
$ | 0.001 | $ | (0.001 | ) | $ | (0.000 | ) | $ | (0.003 | ) | ||||||
|
Weighted average Common Shares Outstanding ‑ Basic |
148,338,959 | 109,188,071 | 148,338,959 | 109,188,071 | |||||||||||||
|
Weighted average Fully Diluted Common Shares |
273,338,959 | 234,188,071 | 273,338,959 | 234,188,071 | |||||||||||||
See notes to consolidated financial statements.
Innovest Global, Inc.
Consolidated Statement of Stockholders' Equity (Deficit)
|
Common Stock |
Preferred Stock |
Stock Subscriptions |
Additional Paid‑in Capital |
Accumulated Deficit |
Total |
|||||||||||||||||||
|
Balance ‑ December 31, 2018 |
$ | 141,050 | $ | 1,250 | $ | 342,000 | $ | 3,432,969 | $ | (5,197,499 | ) | $ | (1,280,230 | ) | ||||||||||
|
Consolidated net loss |
- | - | - | - | 289,743 | 289,743 | ||||||||||||||||||
|
Issuance of common shares |
7,289 | - | - | - | - | 7,289 | ||||||||||||||||||
|
Stock subscriptions issued |
- | - | (342,000 | ) | - | (342,000 | ) | |||||||||||||||||
|
Balance – September 30, 2019 |
$ | 148,339 | $ | 1,250 | $ | - | $ | 3,884,973 | $ | (4,907,756 | ) | $ | (1,325,198 | ) | ||||||||||
See notes to consolidated financial statements.
Innovest Global, Inc.
Consolidated Statement of Cash Flows
|
Nine Month Period Ended September 30, |
||||||||
|
2019 |
2018 |
|||||||
|
Net Gain/ (Loss) |
$ | (26,267 | ) | $ | (599,532 | ) | ||
|
Cash Flows from Operating Activities |
||||||||
|
Depreciation & Amortization |
78,437 | - | ||||||
|
Adjustment for stock guarantee liability |
(2,470,000 | ) | - | |||||
|
Change in non current assets |
16,762 | - | ||||||
| Changes in operating assets and liabilities that (used) provided cash and cash equivalents: | ||||||||
|
Accounts receivable |
(3,875,241 | ) | (322,415 | ) | ||||
|
Inventory |
(10,554 | ) | 979 | |||||
|
Costs and estimated earnings in excess of billings |
(6,300,554 | ) | - | |||||
|
Prepaid expenses and other assets |
117,897 | (116,271 | ) | |||||
|
Accounts payable |
6,237,644 | 363,937 | ||||||
|
Accrued expenses |
106,785 | 12,472 | ||||||
|
Billings in excess of costs and estimated earnings |
(1,523,824 | ) | - | |||||
|
Accrued and other liabilities |
235,958 | 51,183 | ||||||
|
Net cash used in operating activities |
(7,412,957 | ) | (609,647 | ) | ||||
|
Cash Flows from Investing Activities |
||||||||
|
Leasehold Improvements |
(5,000 | ) | - | |||||
|
Investment in StemVax |
(17,500 | ) | ||||||
|
Net cash provided by (used in) investing activities |
(5,000 | ) | (17,500 | ) | ||||
|
Cash Flows from Financing Activities |
||||||||
|
Proceeds on stock subscriptions |
342,000 | 1,013,500 | ||||||
|
Proceeds from bond payable (Note 10) |
5,630,755 | - | ||||||
|
Proceeds from cash advances (deposit on assets) (Note 11) |
644,695 | - | ||||||
|
Proceeds from shareholder loan (Note 15) |
162,300 | - | ||||||
|
Proceeds from stock issuances |
459,293 | |||||||
|
Net cash provided by financing activities |
7,239,042 | 1,013,500 | ||||||
|
Net Increase in Cash and Cash Equivalents |
$ | (178,915 | ) | $ | 386,353 | |||
|
Cash and Cash Equivalents – Beginning of Period |
$ | 793,903 | $ | 3,833 | ||||
|
Cash and Cash Equivalents – End of Period |
$ | 614,988 | $ | 390,186 | ||||
See notes to consolidated financial statements.
Innovest Global, Inc.
Notes to Consolidated Financial Statements
September 30, 2019 and 2018
Note 1 - Nature of Business
Innovest Global, Inc. (the “Company” or “IVST”) was formed in 1999 as International Sports Marketing Group, Inc. In August 2016, after a series of transactions, the Company’s ownership, name, and business plan was changed to operate as a diversified industrials company with biotechnology holdings.
Innovest Global is a diversified industrial company providing value-added solutions across multiple business sectors. The Company is reported into two segments, Commercial Solutions and Wholesale Purchasing. The Company’s Commercial Solutions segment is a fabricator of large curtainwall systems and provides energy consumption solutions for high-use commercial and industrial customers to lower demand, improve utilization and drastically reduce spending. The Wholesale Purchasing segment includes a distributor of building supplies to independent building materials providers.
Commercial Solutions
The Commercial Solutions segment provides products and services, including energy, building materials, call center services and safety supplies, to companies within various commercial markets including manufacturing, municipalities and construction. This segment includes the following operating divisions further described below: Innovest Energy Group, Midwest Curtainwalls, Contact Source Solutions and Chagrin Safety Supply.
Innovest Energy Group creates solutions which are custom-tailored to drastically reduce customers energy spend, protect infrastructure investment, and provide sources of project funding. The energy services business also includes energy broker services for both residential and commercial businesses throughout Ohio.
Midwest Curtainwalls provides building material solutions in the commercial industry. For nearly 50 years, the company has designed, engineered and manufactured non-structural curtainwall solutions for large commercial building development.
This segment also includes two other operating companies, Contact Source Solutions, LLC and Chagrin Safety Supply, LLC. Contact Source Solutions provides inbound and outbound call center services to commercial and industrial clients. Chagrin Safety Supply is a leading supplier of personal protection equipment, apparel and safety supplies serving the medical, dental, industrial and construction industries.
Wholesale Purchasing
The Wholesale Purchasing segment is composed of Authority National Supply, which is a national distributor of roofing, windows, fasteners and associated tools and accessories. Authority National Supply was established to create purchasing power amongst a group of independent building material providers by obtaining discounts from suppliers based on the collective buying power of its members.
Innovest Global, Inc.
Notes to Consolidated Financial Statements
September 30, 2019 and 2018
Note 2 - Significant Accounting Policies
Basis of Presentation
The consolidated financial statements of the Company have been prepared on the basis of generally accepted accounting principles (GAAP). The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect amounts reported in the financial statements. Actual results could differ from those estimates.
Going Concern
The Company has a history of recurring losses that has resulted in a stockholders' deficit of $873,194 as of September 30, 2019 and $1,280,230 as of September 30, 2018. For the nine month period ended September 30, 2019, the Company had a loss of $26,267 and used net cash of $7,412,957 in operating activities. The Company was able to obtain $7,239,042 from financing activities largely through a Bond Payable (see Note 10). For the nine month period ended September 30, 2018, the Company recognized a net loss of $599,532 and used net cash of $609,647 in operating activities.
The Company's consolidated financial statements are prepared assuming that the Company will continue as a concern. This assumes that the Company will be able to realize its assets and discharge its liabilities in the normal course of business for the foreseeable future. The Company anticipates future losses in the development of its business, raising substantial doubt about the Company’s ability to continue as a going concern. The ability to continue as a going concern is dependent upon the Company generating profitable operations in the future and/or obtaining the necessary financing to meet its obligations and repay its liabilities arising from normal business operations when they come due.
Management plans to additionally increase cash flow by acquiring and/or developing profitable businesses that will create positive income from operations, obtaining debt through loans from directors, and/or issuing common shares. Management believes that by taking these actions, the Company will be provided with sufficient future operations and cash flow to continue as a going concern. However, there can be no assurances or guarantees whatsoever that the Company will be successful in consummating such actions on acceptable terms, if at all. Moreover, any such actions can be expected to result in substantial dilution to the existing shareholders of the Company.
Principles of Consolidation
The financial statements include the accounts of the Company and all of its wholly owned subsidiaries. All material intercompany accounts and transactions have been eliminated in consolidation.
Cash Equivalents
The Company considers all investments with an original maturity of three months or less when purchased to be cash equivalents.
Innovest Global, Inc.
Notes to Consolidated Financial Statements
September 30, 2019 and 2018
Note 2 - Significant Accounting Policies (Continued)
Concentration of Cash
The company maintains its cash in bank deposit accounts, which at times may exceed federally insured limits. The Company has not experienced any losses in such accounts. Management believes the Company is not exposed to any significant credit risk related to cash.
Trade Accounts Receivable
Accounts receivable are stated at net invoice amounts. Based on management's review of outstanding receivable balances and historical collection information, management's best estimate is that all balances will be collected. Accordingly, the Company has not established an allowance for doubtful accounts.
Inventory
Inventory is stated at the lower of cost or net realizable value, with cost determined on the weighted-average method. Inventory only consists of finished goods.
Management has reviewed inventory quantities and determined that no allowance for obsolete and excess inventory is necessary. Throughout the year, inventory identified as obsolete or excess is written off. The Company will continue its policy of regularly reviewing inventory quantities on hand based on related service levels and functionality. The carrying cost will be reduced to estimated net realizable value for inventories in which their cost exceeds their utility due to changes in marketing and sales strategies, obsolescence, changes in price levels, or other causes.
Property and Equipment
Property and equipment are recorded at cost. Assets are depreciated over their estimated useful lives using the straight-line method. The cost of leasehold improvements is depreciated over the lesser of the length of the related leases or the estimated useful lives of the assets. Costs of maintenance and repairs are charged to expense when incurred.
Goodwill
The recorded amounts of goodwill from business combinations are based on management's best estimates of the fair values of assets acquired and liabilities assumed at the date of acquisition. Goodwill is not amortized, but rather is assessed at least on an annual basis for impairment. It is at least reasonably possible that management’s estimates about the fair value of goodwill could change in the near term and that such changes could materially affect amounts reported in the financial statements.
During 2018, management determined that the carrying amount of the H.P. Technologies exceeded its fair value, which was estimated based on the present value of expected future cash inflows. Accordingly, a goodwill impairment loss of $25,169 was recognized in 2018.
Intangible Assets
Acquired intangible assets subject to amortization are stated at cost and are amortized using the straight-line method over the estimated useful lives of the assets. Intangible assets that are subject to amortization are reviewed for potential impairment whenever events or circumstances indicate that carrying amounts may not be recoverable. Assets not subject to amortization are tested for impairment at least annually. Intangible assets consist of trade names and customer lists and are amortized over 15 years.
Innovest Global, Inc.
Notes to Consolidated Financial Statements
September 30, 2019 and 2018
Note 2 - Significant Accounting Policies (Continued)
Revenue Recognition
The Company's revenue is derived primarily from part sales, services, and the design and manufacture of custom products. These revenue streams are described below relative to each operating component. Transaction prices are specified in each contract and are not typically variable. If the consideration agreed to in a contract includes a variable amount, the Company will estimate the amount of consideration it expects to be entitled to in exchange for transferring the promised goods or services to the customer.
Commercial Solutions
Within the Commercial Solutions segment, the Company has performance obligations for providing lighting, curtainwall design and installation services. The Company recognizes revenue as costs are incurred (the input method), which best measures progress and results in a right to payment. The production cycle for customer contracts in the Energy space is generally less than three months. The Company uses standard, generally accepted payment terms; customers typically pay upon completion of the service or are billed. There are no significant obligations for warranties, refunds, or similar obligations. In some situations, the Company bills customers and collects cash prior to the satisfaction of the performance obligation, which results in the Company recognizing contract liabilities.
For the manufacturing of custom commercial curtainwall solutions, the Company has performance obligations for the window solution that are recognized over time based on the contract terms. The Company recognizes revenue as costs are incurred (the input method), which best measures progress and results in a right to payment. The production cycle for customer contracts is generally less than 12 months. The Company uses standard, generally accepted payment terms; customers either pay at delivery of the product or are billed upon milestones achieved. A portion of amounts billed are held back as retainage and are generally paid upon project completion. Warranty terms cover the product workmanship and guarantee the product work as intended.
The Company also acts as an energy broker connecting residential and commercial businesses with the lowest cost provider. This revenue is recorded as earned each month based on the commission schedule agreed to with each energy (gas or electric) distributor.
For distributed part sales, the Company has a performance obligation to deliver goods in accordance with the terms and conditions of the contract. Revenue is recognized at a point in time when the Company transfers control to customers, either evidenced by shipment or delivery to customer when title and risk of loss pass. The Company uses standard, generally accepted payment terms, which require payment upon delivery or within 30 days. There are no significant obligations for refunds, warranties, or similar obligations.
For call center services, the Company has performance obligations for providing staffing resources and recognizes revenue on a monthly basis based on staff hours spent. The customer is invoiced monthly and has 30-day payment terms.
Wholesale Purchasing
The Company distributes building supplies to vendors and leverages the purchasing power of the group to those participating. Revenue is recognized at a point in time based on when the products are shipped. As the Company is primarily responsible for fulfilling the obligation with the ability to establish the price and inventory risk, the Company is determined to be the principal in the transaction.
Innovest Global, Inc.
Notes to Consolidated Financial Statements
September 30, 2019 and 2018
Note 2 - Significant Accounting Policies (Continued)
Income Taxes
A current tax liability or asset is recognized for the estimated taxes payable or refundable on tax returns for the year. Deferred tax liabilities or assets are recognized for the estimated future tax effects of temporary differences between financial reporting and tax accounting.
Stock Subscriptions
Stock subscriptions that are paid subsequent to year end but before the date the financial statements are issued for each respective year are treated as receivables in the current assets section on the consolidated balance sheet rather than a deduction from equity.
Earnings per Share
Basic loss per share is based on the weighted-average number of common shares outstanding during the year. Diluted loss per share is computed giving effect to all potentially dilutive common shares. Potentially dilutive common shares may consist of incremental shares issuable upon the exercise of stock options and warrants and the conversion of notes payable to common stock, if applicable. In periods in which a net loss has been incurred, all potentially dilutive common shares are considered antidilutive and, thus, are excluded from the calculation.
Restricted Stock Awards
Stock issued to employees and to nonemployees for services consumed by the company are recognized compensation expense or as applicable operating expenses based on the fair value of the stock on the grant date of the shares issued. See Note 14 for more information.
Shipping and Handling Costs
Shipping and handling costs are recorded as costs of sales as they are incurred.
Use of Estimates
The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.
Innovest Global, Inc.
Notes to Consolidated Financial Statements
September 30, 2019 and 2018
Note 2 - Significant Accounting Policies (Continued)
Upcoming Accounting Pronouncements
In February 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2016-02, Leases, which supersedes the current lease accounting requirements. This standard requires a lessee to record on the balance sheet the assets and liabilities for the rights and obligations created by leases with lease terms of more than 12 months. In addition, this standard requires lessees to disclose certain key information about lease transactions. Upon implementation, an entity’s lease payment obligations will be recognized at their estimated present value along with a corresponding right-of-use asset. Lease expense recognition will be generally consistent with current practice. In July 2018, the FASB issued ASU No. 2018-11, Leases (Topic 842): Targeted Improvements, which simplifies adoption of the new lease accounting requirements by allowing an additional transition method that will not require restatement of prior periods and providing a new practical expedient for lessors to avoid separating lease and non-lease components within a contract if certain requirements are met. The provisions of this guidance must be elected upon adoption of the new lease accounting requirements, which will be effective for interim and annual periods beginning after December 15, 2018.
We will adopt the standard as required on January 1, 2019 and use that date as our date of initial application of the guidance. Consequently, we will not update previously reported financial information, and the disclosures under the new standard will not be provided for dates and periods prior to January 1, 2019. We will elect all of the practical expedients available under the transition guidance. The new standard also provides practical expedients for ongoing accounting. We will elect the short-term lease recognition exemption for all leases that qualify. This means we will not recognize right-of-use assets or lease liabilities for those leases. We will also elect the practical expedient to not separate lease and non- lease components for all of our leases.
We expect that this standard will have a material impact on our financial statements. While we continue to assess all of the effects of adoption, we currently believe the most significant effects relate to the recognition of new right-of-use assets and lease liabilities on our consolidated balance sheet for our real estate operating leases and the significant new required disclosures regarding our leasing activities. Upon adoption, we expect to recognize additional operating lease liabilities of approximately $700,000, with corresponding right-of-use assets for the same amount based on the present value of the remaining minimum rental payments under current leasing standards for existing operating leases.
In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments. The ASU includes changes to the accounting and measurement of financial assets, including the Company's accounts receivable, by requiring the Company to recognize an allowance for all expected losses over the life of the financial asset at origination. This is different from the current practice where an allowance is not recognized until the losses are considered probable. The new guidance will be effective for the Company's year ending December 31, 2020. Upon adoption, the ASU will be applied using a modified retrospective transition method to the beginning of the earliest period presented. Early adoption is permitted for fiscal years beginning after December 15, 2018. The Company is currently evaluating the impact this standard will have on the financial statements.
Innovest Global, Inc.
Notes to Consolidated Financial Statements
September 30, 2019 and 2018
Note 3 - New Accounting Principles
ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606)
In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606), which amends the guidance for revenue recognition. This amendment contains principles that require an entity to recognize revenue to depict the transfer of promised goods and services to customers at an amount an entity expects to be entitled to in exchange for those promised goods or services. The Company adopted this amendment on January 1, 2018, using the modified retrospective method for all contracts for which performance was not completed as of January 1, 2018. There was no adjustment to opening equity as a result of the adoption of ASC 606, as there was no change to recognizing revenue from current practice. See also Note 10 for additional details on revenue recognition.
ASU No. 2016-01, Financial Instruments (Topic 825)
In January 2016, the FASB issued ASU No. 2016-01, Recognition and Measurement of Financial Assets and Financial Liabilities. The ASU covers various changes to the accounting, measurement, and disclosures related to certain financial instruments, including requiring equity investments to be accounted for at fair value with changes recorded through earnings, the use of the exit price when measuring fair value, and disaggregation of financial assets and liabilities by category for disclosure purposes. The ASU also provides guidance on the accounting treatment for measurement of equity investments that do not have a readily determinable fair value. This new guidance is effective for the Company's year ended December 31, 2018. See Note 5 for the impact this standard has on the financial statements.
ASU No. 2017-04, Intangibles - Goodwill (Topic 350)
In January 2017, the FASB issued ASU No. 2017-04, Intangibles - Goodwill and Other (Topic 350), Simplifying the Test for Goodwill Impairment. The standard simplifies the subsequent measurement of goodwill, requiring only a single-step quantitative test to identify and measure impairment based on the excess of a reporting unit's carrying amount over its fair value, instead of the current two-step test. A qualitative assessment may still be completed first to determine if a quantitative impairment test is required. While this standard is effective on a prospective basis for fiscal years beginning after December 15, 2019 for public business entities, the Company has decided to early adopt the standard as of December 31, 2018 in assessing goodwill impairment. See Note 7 for the impact this standard has on the financial statements.
ASU No. 2018-07, Compensation - Stock Compensation (Topic 718)
In June 2018, the FASB issued ASU No. 2018-07, Compensation - Stock Based Payment Accounting (Topic 718), Improvements to Nonemployee Share-Based Payment Accounting. This amendment expands the scope of Topic 718 to include nonemployee awards for acquiring goods and services from nonemployees. This amendment treats employee and nonemployee stock-based awards the same, which is to measure the transaction at the grant-date fair value of the equity instruments that the entity is obligated to issue when the good has been delivered or the service has been rendered. While the standard is effective for fiscal years beginning after December 15, 2018, the Company has decided to early adopt the standard to account for its stock-based awards in order to simplify measurement processes as of January 1, 2018. See Note 14 for the impact this standard has on the financial statements.
Innovest Global, Inc.
Notes to Consolidated Financial Statements
September 30, 2019 and 2018
Note 4 - Business Combinations
Chagrin Safety Supply
On October 23, 2017, the Company entered into an asset purchase agreement with Chagrin Safety Supply, pursuant to which the Company purchased substantially all the assets and assumed certain liabilities of Chagrin Safety Supply. The complementary strength of certain company businesses are expected to create product and distribution synergies. The Company is expected to gain entry into new product categories by the association with other commercial companies acquired. The purchase price consisted of cash, shares of the Company's restricted common stock, and a stock guarantee.
|
Cash |
$ | 750 | ||
|
Equity instruments (750,000 common shares of the Company) |
5,774 | |||
|
Stock guarantee liability |
139,000 | |||
|
Fair value of total consideration transferred |
$ | 145,524 |
The fair value of the 750,000 shares issued as part of the consideration transferred for Chagrin Safety Supply was determined on the basis of the value of shares trading near the time of acquisition.
Under the terms of the acquisition agreement, the former stockholders of Chagrin Safety Supply are guaranteed that the value of the 750,000 shares issued will be trading at $1 per share by the fourth anniversary of the acquisition, or October 23, 2021. The value of this guarantee was determined to be $139,000 at the time of acquisition. This amount has been included in the total consideration transferred and the goodwill recognized. See Note 14 regarding the valuation methodology and key assumptions made in the determination of this liability at date of acquisition and at year end.
The following table summarizes the acquisition date fair values of the assets acquired and liabilities assumed:
|
Cash |
$ | 453 | ||
|
Accounts receivable |
24,200 | |||
|
Inventories |
9,176 | |||
|
Accounts payable |
(45,882 | ) | ||
|
Accrued liabilities |
(63,804 | ) | ||
|
Total identifiable net assets |
(75,857 | ) | ||
|
Goodwill |
221,381 | |||
|
Total |
$ | 145,524 |
The fair value of financial assets includes accounts receivable with a contractual amount due of $24,200, which is expected to be collected in the full amount. The goodwill arising from the acquisition consists primarily of the going-concern element of the existing business (the higher rate of return on the assembled collection of net assets versus if the Company had acquired all of the net assets separately). There were no acquisition costs related to this transaction.
Innovest Global, Inc.
Notes to Consolidated Financial Statements
September 30, 2019 and 2018
Note 4 - Business Combinations (Continued)
Shepherd Energy
Effective on January 1, 2018, the Company acquired 100 percent of the equity of Shepherd Energy, LLC (Shepherd Energy). The primary reason for the acquisition was to launch a commercial energy division and further diversify the Company's portfolio. The purchase price consisted of shares of the Company's restricted common stock and a stock guarantee.
The following table summarizes the fair value of the consideration transferred as part of the acquisition of Shepherd Energy:
|
Equity instruments (5,790,000 common shares of the Company) |
$ | 185,280 | ||
|
Stock guarantee liability |
1,000,000 | |||
|
Fair value of total consideration transferred |
$ | 1,185,280 |
The fair value of the 5,790,000 shares issued as part of the consideration transferred for Shepherd Energy was determined on the basis of the value of shares trading near the time of acquisition.
Under the terms of the acquisition agreement, the former stockholders of Shepherd Energy had been guaranteed that the issued stocks will be worth $1 per share and $5,790,000 in the aggregate at December 28, 2019. The value of this guarantee was determined to be $1,000,000 at the time of acquisition. See Note 14 regarding the valuation methodology and key assumptions made in the determination of this liability at date of acquisition and at year end.
In the first quarter 2019, negotiations with the former principals of Shepherd resulted in the execution of an agreement terminating the Administrative Agreement and the Guarantee. This termination resulted in a non-operating gain to Innovest of $2.47 million and consideration for the termination agreement was 1.5 million shares paid equally to the three former principals (one of which is Damon Mintz, Innovest’s president). Prior to the termination, principal Jeffrey Simler had been running Shephard. Subsequent to the termination agreement Mr. Simler declined an employment agreement offer and left the Company unexpectedly, resulting in a management void. This void left two support personnel and no leadership, resulting in the elimination of the Shepherd initiative.
As Shepherd had incurred losses, the remaining personnel were reassigned to the “Innovest Energy Group”, which is now representative of a combined initiative of procurement (see H.P. Technologies below), efficiency solutions (see Primary Metering Solutions below), and branded lighting products being sold under the Innovest Energy Group brand.
The following table summarizes the acquisition date fair values of the assets acquired and liabilities assumed:
|
Cash |
$ | 13,859 | ||
|
Accounts receivable |
7,152 | |||
|
Other current assets |
41,749 | |||
|
Accounts payable |
(56,826 | ) | ||
|
Total identifiable net assets |
5,934 | |||
|
Goodwill |
1,179,346 | |||
|
Total |
$ | 1,185,280 |
The fair value of financial assets includes accounts receivable with a contractual amount due of $7,152, which is expected to be collected in the full amount. The goodwill arising from the acquisition consists primarily of the going-concern element of the existing business (the higher rate of return on the assembled collection of net assets versus if the Company had acquired all of the net assets separately). There were no acquisition-related costs related to this transaction.
Innovest Global, Inc.
Notes to Consolidated Financial Statements
September 30, 2019 and 2018
Note 4 - Business Combinations (Continued)
Primary Metering Solutions
On January 1, 2019, the Company acquired 100 percent of the assets of Primary Metering Solutions, LLC (Primary Metering Solutions), an Ohio-based company. The primary reason for the acquisition was to allow the energy group the ability to directly provide procurement solutions to clients, as this subsidiary is fully licensed in all energy-deregulated states for commercial and industrial energy brokerage. The purchase price consisted of shares of the Company's restricted common stock, cash, and a stock guarantee.
The following table summarizes the fair value of the consideration transferred as part of the acquisition.
|
Cash |
$ | 25,000 | ||
|
Equity instruments (1,000,000 common shares of the Company) |
150,000 | |||
|
Fair value of total consideration transferred |
$ | 175,000 |
The fair value of the 1,000,000 shares issued as part of the consideration transferred for Primary Metering Solutions was determined on the basis of the value of other restricted shares issued at the time of acquisition.
Primary Metering Solutions is a startup company whereby the company purchased the assets and contracts for the business.
Innovest Global, Inc.
Notes to Consolidated Financial Statements
September 30, 2019 and 2018
Note 4 - Business Combinations (Continued)
Contact Source Solutions
On January 15, 2018, the Company acquired 100 percent of the equity interest of Contact Source Solutions. The primary reason for the acquisition was to increase revenue stream, as well as establish a business unit that can provide marketing solutions for the other business units. The purchase price consisted of shares of the Company's restricted common stock and a stock guarantee.
The following table summarizes the fair value of the consideration transferred as part of the acquisition of Contact Source Solutions:
|
Equity instruments (2,500,000 common shares of the Company) |
$ | 43,875 | ||
|
Stock guarantee liability |
500,000 | |||
|
Fair value of total consideration transferred |
$ | 543,875 |
The fair value of the 2,500,000 shares issued as part of the consideration transferred for Contact Source Solutions was determined on the basis of the value of shares trading near the time of acquisition.
Under the terms of the acquisition agreement, the former stockholders of Contact Source Solutions are guaranteed that the issued stocks will be worth $1 per share and $2,500,000 in the aggregate at March 22, 2020. The value of this guarantee was determined to be $500,000 at the time of acquisition. See Note 14 regarding the valuation methodology and key assumptions made in the determination of this liability at date of acquisition and at year end.
The following table summarizes the acquisition date fair values of the assets acquired and liabilities assumed:
|
Cash |
$ | 12,375 | ||
|
Accounts receivable |
103,087 | |||
|
Accounts payable |
(21,670 | ) | ||
|
Accrued liabilities |
(56,769 | ) | ||
|
Total identifiable net assets |
37,023 | |||
|
Goodwill |
506,852 | |||
|
Total |
$ | 543,875 |
The fair value of financial assets includes accounts receivable with a contractual amount due of $103,087, which is expected to be collected in the full amount. The goodwill arising from the acquisition consists primarily of the going-concern element of the existing business (the higher rate of return on the assembled collection of net assets versus if the Company had acquired all of the net assets separately). There were no acquisition-related costs related to this transaction.
Innovest Global, Inc.
Notes to Consolidated Financial Statements
September 30, 2019 and 2018
Note 4 - Business Combinations (Continued)
H.P. Technologies
On March 22, 2018, the Company acquired 100 percent of the outstanding common shares of H.P. Technologies. The primary reason for the acquisition was to strengthen the commercial energy division and further diversify the Company's portfolio. The purchase price consisted of shares of the Company's restricted common stock and a stock guarantee.
The following table summarizes the fair value of the consideration transferred as part of the acquisition of H.P. Technologies:
|
Equity instruments (1,500,000 common shares of the Company) |
$ | 30,000 | ||
|
Stock guarantee liability |
600,000 | |||
|
Fair value of total consideration transferred |
$ | 630,000 |
The fair value of the 1,500,000 shares issued as part of the consideration transferred for H.P. Technologies was determined on the basis of the value of shares trading near the time of acquisition.
Under the terms of the acquisition agreement, the former stockholders of Contact Source Solutions are guaranteed that the issued stocks will be worth $1 per share and $1,500,000 in the aggregate at March 22, 2020. The value of this guarantee was determined to be $600,000 at the time of acquisition. See Note 14 regarding the valuation methodology and key assumptions made in the determination of this liability at date of acquisition and at year end.
The following table summarizes the acquisition date fair values of the assets acquired and liabilities assumed:
|
Cash |
$ | 65,508 | ||
|
Accounts receivable |
128,469 | |||
|
Intangible asset - Trade names |
131,000 | |||
|
Intangible asset - Customer contracts |
229,000 | |||
|
Commissions payable |
(64,586 | ) | ||
|
Accrued liabilities |
(65,509 | ) | ||
|
Total identifiable net assets |
423,882 | |||
|
Goodwill |
206,118 | |||
|
Total |
$ | 630,000 |
The fair value of financial assets includes accounts receivable with a contractual amount due of $128,469, which is expected to be collected in the full amount. The goodwill arising from the acquisition consists primarily of the going-concern element of the existing business (the higher rate of return on the assembled collection of net assets versus if the Company had acquired all of the net assets separately) and an assembled workforce. There were no acquisition-related costs related to this transaction.
Innovest Global, Inc.
Notes to Consolidated Financial Statements
September 30, 2019 and 2018
Note 4 - Business Combinations (Continued)
Authority National Supply
On November 5, 2018, the Company acquired 100 percent of the member units of Authority National Supply. The primary reason for the acquisition was to strategically expand within the building supply distribution industry. The purchase price consisted of cash, shares of the Company's restricted common stock, and a stock guarantee.
The following table summarizes the fair value of the consideration transferred as part of the acquisition of Authority National Supply:
|
Cash |
$ | 55,000 | ||
|
Equity instruments (5,000,000 common shares of the Company) |
750,000 | |||
|
Stock guarantee liability |
1,700,000 | |||
|
Fair value of total consideration transferred |
$ | 2,505,000 |
The fair value of the 5,000,000 shares to be issued as part of the consideration transferred for Authority National Supply was determined on the basis of the value of other restricted shares issued at the date of the transaction. These shares were not issued until 2019; consequently, the Company has recorded the commitment to issue the shares as a liability as of December 31, 2018. This fair value of this share issuance liability has been measured based on the value of other restricted shares issued at the date of the transaction.
Under the terms of the acquisition agreement, the former members of Authority National Supply are guaranteed that the issued stocks will be worth $1 per share and $5,000,000 in the aggregate at November 5, 2020. The value of this guarantee was determined to be $1,700,000 at the time of acquisition. See Note 14 regarding the valuation methodology and key assumptions made in the determination of this liability at date of acquisition and at year end.
The following table summarizes the acquisition date fair values of the assets acquired and liabilities assumed:
|
Cash |
$ | 88,224 | ||
|
Accounts receivable |
2,054,311 | |||
|
Property, plant, and equipment |
19,709 | |||
|
Other assets |
14,096 | |||
|
Accounts payable |
(2,104,464 | ) | ||
|
Accrued liabilities |
(66,043 | ) | ||
|
Total identifiable net assets |
5,833 | |||
|
Goodwill |
2,499,167 | |||
|
Total |
$ | 2,505,000 |
The fair value of financial assets includes accounts receivable with a contractual amount due of $2,054,311, which is expected to be collected in the full amount. The goodwill arising from the acquisition consists primarily of future business growth and the going-concern element of the existing business (the higher rate of return on the assembled collection of net assets versus if the Company had acquired all of the net assets separately). Acquisition-related costs, which include legal, accounting, and valuation fees, totaled $68,261 and have been included in operating expenses in the accompanying consolidated statement of operations.
Innovest Global, Inc.
Notes to Consolidated Financial Statements
September 30, 2019 and 2018
Note 4 - Business Combinations (Continued)
Midwest Curtainwalls
On December 1, 2018, the Company acquired 100 percent of the outstanding common shares of Midwest Curtainwalls. The primary reason for the acquisition was to expand its penetration in the building materials segment, as well as geographic reach. At the time of purchase, the Midwest Curtainwalls shares were held in an estate that was not in a position to continue to manage the operations. The estate needed to sell the company by a certain date and did not have time to properly market it to other potential buyers. The purchase price consisted of shares of the Company's restricted common stock, contingent consideration, and a stock guarantee.
The following table summarizes the fair value of the consideration transferred as part of the acquisition of Midwest Curtainwalls:
|
Equity instruments (2,000,000 common shares of the Company) |
$ | 300,000 | ||
|
Contingent consideration |
32,000 | |||
|
Stock guarantee liability |
750,000 | |||
|
Total |
$ | 1,082,000 |
The fair value of the 2,000,000 shares issued as part of the consideration transferred for Midwest Curtainwalls was determined on the basis of the value of other restricted shares issued at the time of acquisition.
Contingent consideration consists of a success fee based on the profitability of current jobs in progress.
All of the 2,000,000 shares issued in connection with this agreement are subject to a stock guarantee as follows. Under the terms of the acquisition agreement, the former members of Midwest Curtainwalls are guaranteed that the 1,600,000 of issued stocks will be worth $1.25 per share and $2,000,000 in the aggregate at December 1, 2020. The value of this guarantee was determined to be $600,000 at the time of acquisition. In addition, the 400,000 shares issued to settle a shareholder loan are guaranteed to be trading at $1.00 per share or $400,000 in the aggregate at December 1, 2020. The value of this guarantee was determined to be $150,000 at the time of acquisition.
See Note 14 regarding the valuation methodology and key assumptions made in the determination of this liability at the date of acquisition and at year end.
The following table summarizes the acquisition date fair values of the assets acquired and liabilities assumed:
|
Cash |
$ | 133,348 | ||
|
Accounts receivable |
2,711,384 | |||
|
Inventory |
25,006 | |||
|
Property, plant, and equipment |
308,770 | |||
|
Intangible asset - Backlog |
333,000 | |||
|
Other assets |
19,103 | |||
|
Accounts payable |
(1,450,245 | ) | ||
|
Accrued liabilities |
(62,339 | ) | ||
|
Debt |
(491,427 | ) | ||
|
Total identifiable net assets |
1,526,600 | |||
|
Goodwill |
713,122 | |||
|
Total |
$ | 2,239,722 |
Innovest Global, Inc.
Notes to Consolidated Financial Statements
September 30, 2019 and 2018
Note 4 - Business Combinations (Continued)
Midwest Curtainwalls (continued)
The fair value of financial assets includes accounts receivable with a contractual amount due of $2,711,384, which is expected to be collected in the full amount. Liabilities arising from contingencies consist of stock guarantee liability and have been recognized at fair value. Acquisition-related costs, which include legal, accounting, and valuation fees, totaled $21,800 and have been included in operating expenses in the accompanying consolidated statement of operations.
Innovest Global, Inc.
Notes to Consolidated Financial Statements
September 30, 2019 and 2018
Note 5 - Investment
On July 17, 2018, the Company acquired 20 percent of StemVax Therapeutics (StemVax) for 2.5 million common IVST shares and cash of $16,742 related to the anticipated requirements of pending license agreements, presently being negotiated by StemVax with Cedars-Sinai Medical Center (Cedars) in Los Angeles, California. Cedars owns intellectual property that StemVax requires to effectuate its business plan, and these license agreements would satisfy the business requirements. The license agreements were successfully executed. The investment has not been accounted for using the equity method, as the Company does not have significant influence over the issuer. The investment is recorded at $141,742, which represents the cost incurred related to license agreements plus the value of IVST shares issued based on the trading value of $0.05 per share at the time of issuance or $125,000. This holding is not expected to generate revenue in the short term, but represents what the Company believes will be a substantially valuable intellectual property holding.
Note 6 - Property and Equipment
Property and equipment at September 30, 2019 are summarized as follows:
|
Balance at Sept. 30, 2019 |
Depreciable Life - Years |
||||||
|
Machinery and equipment |
305,347 | 9 | |||||
|
Transportation equipment |
8,950 | 2 | |||||
|
Furniture and fixtures |
5,780 | 3-10 | |||||
|
Computer equipment and software |
27,670 | 3-5 | |||||
|
Total cost |
$ | 347,747 | |||||
|
Accumulated depreciation |
38,927 | ||||||
|
Net property and equipment |
$ | 308,820 | |||||
Depreciation expense for three months ended September 30, 2019 was $16,467 and for the nine months ended September 30, 2019 was $49,400.
Note 7 - Acquired Intangible Assets and Goodwill
Intangible assets of the Company at September 30, 2019 are summarized as follows:
|
Balance at Sept. 30, 2019 |
Accumulated Amortization |
|||||||
|
Amortized intangible assets: |
||||||||
|
Customer contracts |
229,000 | 22,900 | ||||||
|
Trade names |
131,000 | 13,100 | ||||||
|
Total amortized intangible assets |
$ | 360,000 | $ | 36,000 | ||||
Innovest Global, Inc.
Notes to Consolidated Financial Statements
September 30, 2019 and 2018
Each reportable segment noted above is a specific reporting unit for goodwill impairment testing purposes. Goodwill is reviewed for possible impairment at least annually or more frequently upon the occurrence of an event or when circumstances indicate that a reporting unit's carrying amount is greater than its fair value, which was estimated based on the present value of expected future cash inflows.
|
Segment |
Balance at Sept. 30, 2019 |
Balance at Sept. 30, 2018 |
||||||
|
Commercial Solutions |
2,796,603 | 82,381 | ||||||
|
Wholesale Purchasing |
2,499,167 | |||||||
|
Total Goodwill |
$ | 5,295,770 | $ | 82,381 | ||||
Note 8 - Line of Credit
Midwest Curtainwalls has a line of credit agreement with a bank to borrow up to $1,500,000 to support working capital needs. Interest is payable monthly at the one-month LIBOR plus 2.75 percent. The line of credit is collateralized by all assets of Midwest Curtainwalls. The balance outstanding on this line of credit was $348,640 at September 30, 2019.
In January 2019, the Company entered into a forbearance agreement with the bank, which prohibited additional borrowings under the line of credit.
Note 9 - Notes Payable
Notes payable at September 30 are as follows:
|
2019 |
2018 |
|||||||
|
Midwest Curtainwalls - Note payable to bank with interest of 4.85 percent. Secured by specific equipment |
$ | 138,584 | ||||||
|
Total |
$ | 138,584 | ||||||
Ownership transitions before the acquisition of Midwest Curtainwalls and the acquisition of Midwest Curtainwalls by IVST have caused the note payable and the line of credit to be in default, and remedied through a forbearance agreement entered into in January 2019.
Note 10 – Bond Payable
At the time of acquisition, Midwest Curtainwalls, had entered into a sales contract for a large commercial project. In July 2019, disputes arose among Midwest, the customer, and subcontractors which involved the subcontractor performing and billing in excess of contracted amounts which resulted the customer withholding certain accounts receivable. The Midwest sales obligation does not permit the suspension of work during such disputes which resulted in being contractually obligated to continue the project and seek remedy for these disputes only after completion. To cover the shortfalls created by the disputes, Midwest triggered mechanisms provided by the bond agreement to fund the project working capital requirement. As of September 30, 2019, the bond liability on the balance sheet is $5,630,755. This amount may increase, and is subject to offsets based on revenue and future remedies. Given the timing for when the Midwest sales obligation was initiated being prior to Innovest Global’s acquisition of Midwest Curtainwalls, Innovest Global Inc. is not a direct party to the bond liability or a guarantor of the facility.
Innovest Global, Inc.
Notes to Consolidated Financial Statements
September 30, 2019 and 2018
Note 11 – Deposit on Assets
In order to achieve the working capital required to accommodate rapid growth, Innovest Global initiated a strategy to obtain short term cash flow in exchange for a lien on the accounts receivable balances of the Company and its subsidiaries. Innovest entered into a variety of transactions which pre-sold future accounts receivable by receiving deposits on those future receivables in exchange for a discount on them to the purchasers. The payoff timeline was approximately four months. As of September 30, 2019, the balance on these deposits is $644,695. The cost of these transactions is booked to the account Loss on Sale (A/R) and for the three month and nine month period ended September 30, 2019, these amounts represent $135,798 and $384,755 respectively.
Note 12 - Revenue Recognition
The following table shows revenue from contracts with customer by business segments. Predominately all revenue is derived from customers within the midwestern part of the United States.
|
Three Months Ended September 30, 2019 |
Three Months Ended September 30, 2018 |
|||||||||||||||||||||||
|
Commercial Solutions |
Wholesale Purchasing |
Total |
Commercial Solutions |
Wholesale Purchasing |
Total |
|||||||||||||||||||
|
Major Goods & Services |
||||||||||||||||||||||||
|
Goods |
7,556,116 | 9,472,010 | 17,028,126 | 651,653 | - | 651,653 | ||||||||||||||||||
|
Services |
610,002 | - | 610,002 | 412,500 | - | 412,500 | ||||||||||||||||||
|
Total Revenues |
$ | 8,166,118 | $ | 9,472,010 | $ | 17,638,128 | $ | 1,064,152 | $ | - | $ | 1,064,152 | ||||||||||||
|
Timing of Revenue Recognition |
||||||||||||||||||||||||
|
Point in Time |
2,082,518 | 9,472,010 | 11,554,528 | 1,064,152 | - | 1,064,152 | ||||||||||||||||||
|
Over Time |
6,083,600 | - | 6,083,600 | - | - | - | ||||||||||||||||||
|
Total Revenues |
$ | 8,166,118 | $ | 9,472,010 | $ | 17,638,128 | $ | 1,064,152 | $ | - | $ | 1,064,152 | ||||||||||||
|
Nine Months Ended September 30, 2019 |
Nine Months Ended September 30, 2018 |
|||||||||||||||||||||||
|
Commercial Solutions |
Wholesale Purchasing |
Total |
Commercial Solutions |
Wholesale Purchasing |
Total |
|||||||||||||||||||
|
Major Goods & Services |
||||||||||||||||||||||||
|
Goods |
14,779,981 | 31,117,803 | 45,897,784 | 1,836,683 | - | 1,836,683 | ||||||||||||||||||
|
Services |
1,525,873 | - | 1,525,873 | 1,037,640 | - | 1,037,640 | ||||||||||||||||||
|
Total Revenues |
$ | 16,305,854 | $ | 31,117,803 | $ | 47,423,657 | $ | 2,874,323 | $ | - | $ | 2,874,323 | ||||||||||||
|
Timing of Revenue Recognition |
||||||||||||||||||||||||
|
Point in Time |
5,378,467 | 31,117,803 | 36,496,270 | 2,874,323 | - | 2,874,323 | ||||||||||||||||||
|
Over Time |
10,927,388 | - | 10,927,388 | - | - | - | ||||||||||||||||||
|
Total Revenues |
$ | 16,305,854 | $ | 31,117,803 | $ | 47,423,657 | $ | 2,874,323 | $ | - | $ | 2,874,323 | ||||||||||||
Innovest Global, Inc.
Notes to Consolidated Financial Statements
September 30, 2019 and 2018
Note 13 - Operating Leases
The Company is obligated under operating leases primarily for facilities, expiring at various dates through 2023. The leases require the Company to pay taxes, insurance, utilities, and maintenance costs. Total rent expense under these leases was $110,617 and $65,600 for the three month periods ended September 30, 2019 and 2018, respectively and $403,602 and $234,800 for the nine month periods ended September 30, 2019 and 2018, respectively.
Note 14 - Stock Guarantee Liability
In connection with business combinations (see Note 4), Innovest Global, Inc. has recorded contingent consideration in the form of a guaranteed stock price at a future date. Should the stock price not reach the guaranteed market price by the agreed-upon date, the Company has guaranteed the difference in the form of issuance of additional shares of stock. The maximum potential payments under these guarantees are equal to the number of shares multiplied by the guaranteed stock price. The Company has recorded a stock guarantee liability upon issuance of the guarantee and has adjusted the fair value at December 31, 2018 of $4,449,000. Adjustments to the liability are recorded in the accompanying consolidated statement of operations as nonoperating expense.
This liability is measured at fair value on an annual basis using Level 3 fair value measurements. Specifically, the Company has estimated the fair value using a Monte Carlo simulation that is affected by the Company’s stock price, as well as assumptions regarding a number of complex and subjective variables. Changes to contingent consideration obligations can result from movements in publicly traded stock prices of Innovest Global, adjustments to discount rates, expected stock price volatility, estimated dividend rates, estimated counterparty risk, periods, and updates in the assumed achievement or timing of exceeding any target stock price. The assumptions related to determining the value of a contingent consideration include a significant amount of judgment, and any changes in the assumptions could have a material impact in any given period. In determining the fair value, the Company used the following significant unobservable inputs:
|
● |
Expected stock price volatility - 75 percent |
|
● |
Risk-free interest rate - Ranges from 1.89 percent to 3.19 percent |
|
● |
Counterparty credit risk (discount rate) - 30 percent |
|
● |
Dividend rate - 0 percent |
Innovest Global, Inc.
Notes to Consolidated Financial Statements
September 30, 2019 and 2018
Note 14 - Stock Guarantee Liability (Continued)
The following table reconciles the opening and closing balance of the stock guarantee liability for September 30, 2019.
|
Acquiree |
Fair Value at January 1, 2019 |
Adjustment for Contract Modification |
Fair Value at September 30, 2019 |
|||||||||
|
Chagrin Safety Supply |
$ | 229,000 | $ | 0 | $ | 229,000 | ||||||
|
Shepherd Energy |
2,470,000 | (2,470,000 | ) | 0 | ||||||||
|
Contact Source Solutions |
1,060,000 | 0 | 1,060,000 | |||||||||
|
H.P. Technologies |
620,000 | 0 | 620,000 | |||||||||
|
Authority National Supply |
1,820,000 | 0 | 1,820,000 | |||||||||
|
Midwest Curtainwalls |
570,000 | 0 | 570,000 | |||||||||
|
Midwest Curtainwalls |
150,000 | 0 | 150,000 | |||||||||
| $ | 6,919,000 | $ | (2,470,000 | ) | $ | 4,449,000 | ||||||
On March 18, 2019, the Company entered an agreement to issue 1,500,000 restricted common shares in exchange for the cancellation of the stock guarantee related to the Shepherd Energy, LLC acquisition, whereby the 5,790,000 shares were guaranteed to have a trading value of $1 per share by December 2019. This share issuance settles a stock liability of $2,470,000 at December 31, 2018.
Note 15 - Related Party Transactions
The officers and directors of the Company are involved in other business activities. They may face a conflict of interests between the Company and other business interests. The Company has not formulated a policy to address such conflicts.
One of the members that participates in the purchasing program at Authority National Supply is owned by an individual who is the CEO of Authority National Supply.
TN3, LLC is a company owned and controlled by the Company's chairman and CEO, Daniel Martin. TN3, LLC is also a significant shareholder of Innovest Global. As of September 30, 2019, there was a loan payable to TN3, LLC of $162,300.
Note 16 - Retirement Plans
Midwest Curtainwalls sponsors a 401(k) plan for substantially all employees who meet certain age and length of service requirements. The plan allows for the Company to make a discretionary matching contribution. There were no contributions made by the Company to the plan in 2019 or 2018.
Note 17 – Business Segment Information
Innovest Global, Inc. has two reportable segments: Commercial Solutions & Wholesale Purchasing. The Commercial Solutions segment provides products and services, including energy, building materials, call center services and safety supplies, to companies within various commercial markets including manufacturing, municipalities and construction. This segment includes the following operating divisions: Innovest Energy Group, Midwest Curtainwalls, Contact Source Solutions and Chagrin Safety Supply. The Wholesale Purchasing segment is composed of Authority National Supply, which is a national distributor of roofing, windows, fasteners and associated tools and accessories.
Innovest Global, Inc.
Notes to Consolidated Financial Statements
September 30, 2019 and 2018
Note 17 – Business Segment Information (Continued)
Innovest Global, Inc.’s reportable segments are strategic business units that offer different product and service offerings. They are managed separately because each business requires different technology and marketing strategies. All of the businesses were acquired individually, and the management at the time of the acquisition was retained if possible.
The following table provides selected information as of and for the nine month period ended September 30, 2019.
|
Commercial Solutions |
Wholesale Purchasing |
Corporate |
Eliminations |
Total |
||||||||||||||||
|
Revenue from external customers |
16,305,854 | 31,117,803 | 47,423,657 | |||||||||||||||||
|
Depreciation and amortization |
39,056 | 4,194 | 43,250 | |||||||||||||||||
|
Other Non-Operating (Income) / Expense |
58,497 | 9,665 | 68,162 | |||||||||||||||||
|
Operating income (loss) |
562,694 | 74,855 | (2,817,223 | ) | (2,179,674 | ) | ||||||||||||||
|
Fair value adjustment for stock guarantee liability credit |
2,470,000 | 2,470,000 | ||||||||||||||||||
|
(Loss) on Asset Sale - A/R |
(384,755 | ) | (384,755 | ) | ||||||||||||||||
|
Segment profit (loss) |
3,032,694 | 74,855 | (3,201,978 | ) | - | (94,429 | ) | |||||||||||||
| - | ||||||||||||||||||||
|
Goodwill |
2,796,603 | 2,499,167 | 5,295,770 | |||||||||||||||||
|
Segment assets |
11,906,112 | 10,460,321 | (659,249 | ) | 29,605 | 21,736,788 | ||||||||||||||
Exhibit 2.1
AGREEMENT AND SHARE EXCHANGE
THIS AGREEMENT AND SHARE EXCHANGE (hereinafter referred to as the "Agreement"), is entered into as of December 28 2017 by and among, Innovest Global, INC., a publicly-owned Nevada corporation ("IVST"), and Shepherd Energy, LLC an Ohio LLC ("SEL") sometimes hereinafter collectively referred to as the "Parties" and individually as a "Party.")
WITNESSETH
A) WHEREAS, IVST is a publicly-owned Nevada corporation and is quoted on the Over the Counter Bulletin Board under the symbol ("IVST").
B) WHEREAS, the ("SEL") Shareholders listed on Schedule I hereto own all of the issued and outstanding Members Units of ("SEL") (the "("SEL") Member Units").
C) WHEREAS, SEL owns and operations a lighting business Operating under the name "Shepherd".
D) WHEREAS, Shepherd has a contract for procurement services from "Blue Flame Energy".
E) WHEREAS, the Parties desire that IVST acquire all of the ("SEL") Members Units from the ("SEL") Members solely in exchange for an aggregate of 5,790,000 newly issued shares of restricted common stock of IVST (the "Exchange Shares") pursuant to the terms and conditions set forth in this Agreement.
F) WHEREAS, immediately upon consummation of the Closing (as hereinafter defined), the Exchange Shares will be issued to the ("SEL") Members on a pro rata basis, in proportion to the ratio of each Members Units of ("SEL") held by such ("SEL") Member, bears to the Membership Units of ("SEL") held by all the ("SEL") Members as of the date of the Closing.
G) WHEREAS, following the Closing, ("SEL") will become a wholly-owned subsidiary of IVST.
H) WHEREAS, the Parties intend that the transaction contemplated herein (the "Transaction") qualify as a reorganization and tax-free exchange under Section 368(a) of the Internal Revenue Code of 1986, as amended.
I) NOW THEREFORE, on the stated premises and for and in consideration of the foregoing recitals which are hereby incorporated by reference, the mutual covenants and agreements hereinafter set forth and the mutual benefits to the Parties to be derived here from and for other good and valuable consideration, the sufficiency and receipt of which are hereby acknowledged, the Parties hereto agree as follows:
ARTICLE I
PLAN OF EXCHANGE
1.1 The Exchange. At the Closing (as hereinafter defined), one hundred percent (100%) of the Member Units of ("SEL") shall be exchanged for 5,790,000 shares of IVST Restricted Common Stock. From and after the Closing Date, the ("SEL") Members shall no longer own any Membership Units of ("SEL") and the certificates formerly representing Members Ownership Units of ("SEL") shall represent the pro rata portion of the Exchange Shares issuable in exchange therefor pursuant to this Agreement. Any fractional shares that would result from such exchange will be rounded up to the next highest whole number.
1.2 Guarantee. IVST shall guarantee the Exchange Shares to be worth $1 per share by the second (2nd) anniversary of the issuance. In the event that the price is not $1 per share by the second anniversary, on the second anniversary IVST shall issue SEL the number of additional shares necessary to achieving an aggregate value of
$5,790,000 for the Exchange Shares. This guarantee is in full force and effect unless there is a "Guarantee Disqualifying Event", which would be any one of the following: A) Liquidation of more than 15% of the Exchange Shares prior to the second anniversary of the issuance, B) Failure of SEL to achieve an aggregate revenue growth rate of 5% year over year for the two years, C) Material misrepresentations.
1.3 Closing. The closing ("Closing") of the transactions contemplated by this Agreement shall occur immediately on the execution of this Agreement (the "Closing Date").
1.4 Closing Events. At the Closing, SEL shall execute, acknowledge, and deliver (or shall cause to be executed, acknowledged, and delivered) any and all stock certificates, officers' certificates, opinions, financial statements, schedules, agreements, resolutions, rulings, or other instruments required by this Agreement to be so delivered at or prior to the Closing, and the documents and certificates provided in Sections 5.2, 5.4, 6.2, 6.4 and 6.5, together with such other items as may be reasonably requested by the parties hereto and their respective legal counsel in order to effectuate or evidence the transactions contemplated hereby. If agreed to by the parties, the Closing may take place through the exchange of documents (other than the exchange of stock certificates) by efax, fax, email and/or express courier. At the Closing, the Exchange Shares shall be issued in the names and denominations provided by ("SEL").
ARTICLE II
REPRESENTATIONS, COVENANTS, AND WARRANTIES OF ("SEL")
As an inducement to, and to obtain the reliance of lVST, ("SEL") represents and warrants as follows:
2.1 Organization. ("SEL") is an LLC duly organized, validly existing, and in good standing under the laws of the State of Ohio. ("SEL") has the power and is duly authorized, qualified, franchised, and licensed under all applicable laws, regulations, ordinances, and orders of public authorities to own all of its properties and assets and to carry on its business in all material respects as it is now being conducted, including
qualification to do business as a foreign corporation in jurisdictions in which the character and location of the assets owned by it or the nature of the business transacted by it requires qualification. The execution and delivery of this Agreement does not, and the consummation of the transactions contemplated by this Agreement in accordance with the terms hereof will not, violate any provision of ("SEL")'s organizational documents. ("SEL") has taken all action required by laws, its certificate of incorporation, certificate of business registration, or otherwise to authorize the execution and delivery of this Agreement. ("SEL") has full power, authority, and legal right and has taken or will take all action required by law, its Certificate of Incorporation, and otherwise to consummate the transactions herein contemplated.
2.2 Capitalization. All issued and outstanding members units of ("SEL") are legally issued, fully paid, and non-assessable and were not issued in violation of the pre-emptive or other rights of any person. ("SEL") has no outstanding options, warrants, or other convertible securities.
2.3 Financial Statements.
(a)("SEL") has filed all local income tax returns required to be filed by it from its inception to the date hereof. All such returns are complete and accurate in all material respects.
(b)("SEL") has no liabilities with respect to the payment of federal, county, local, or other taxes (including any deficiencies, interest, or penalties), except for taxes accrued but not yet due and payable, for which ("SEL") may be liable in its own right or as a transferee of the assets of, or as a successor to, any other corporation or entity.
(c) No deficiency for any taxes has been proposed, asserted or assessed against ("SEL"). There has been no tax audit, nor has there been any notice to ("SEL") by any taxing authority regarding any such tax audit, or, to the knowledge of ("SEL"), is any such tax audit threatened with regard to any taxes or ("SEL") tax returns. ("SEL") does not expect the assessment of any additional taxes of ("SEL") for any period prior to the date hereof and has no knowledge of any unresolved questions concerning the liability for taxes of ("SEL'').
(d) The books and records, financial and otherwise, of ("SEL") are in all material respects complete and correct and have been maintained in accordance with good business and accounting practices.
2.4 Information. The information concerning ("SEL") set forth in this Agreement and the ("SEL") Schedules (as that term is defined herein) are and will be complete and accurate in all material respects and does not contain any untrue statement of a material fact or omit to state a material fact required to make the statements made, in light of the circumstances under which they were made, not misleading as of the date hereof and as of the Closing Date.
2.5 Membership Units Equivalents. There are no existing options, warrants, calls, commitments of any character or other Membership equivalents relating to the authorized and unissued ("SEL") Common Stock. Qualification to do business as a foreign corporation in jurisdictions in which the character and location of the assets owned by it or the nature of the business transacted by it requires qualification. The execution and delivery of this Agreement does not, and the consummation of the transactions contemplated by this Agreement in accordance with the terms hereof will not, violate any provision of ("SEL")'s organizational documents. ("SEL") has taken all action required by laws, its certificate of incorporation, certificate of business registration, or otherwise to authorize the execution and delivery of this Agreement. ("SEL") has full power, authority, and legal right and has taken or will take all action required by law, its Certificate of Incorporation, and otherwise to consummate the transactions herein contemplated.
2.6 Absence of Certain Changes or Events. Except as set forth in this Agreement or the ("SEL") Schedules (as that term is defined herein):
(a)except in the normal course of business, there has not been (i) any material adverse change in the business, operations, properties, assets, or condition of ("SEL"); or (ii) any damage, destruction, or loss to ("SEL") (whether or not covered by insurance) materially and adversely affecting the business, operations, properties, assets, or condition of ("SEL");
(b)("SEL") has not (i) borrowed or agreed to borrow any funds or incurred, or become subject to, any material obligation or liability (absolute or contingent) not otherwise in the ordinary course of business, and except for capital raised by issuance of debt or equity in a private placement or other capital raising transaction deemed advisable by ("SEL''); (ii) paid any material obligation or liability not otherwise in the ordinary course of business (absolute or contingent) other than current liabilities reflected in or shown on the most recent ("SEL") consolidated balance sheet, and current liabilities incurred since that date in the ordinary course of business; (iii) sold or transferred, or agreed to sell or transfer, any of its assets, properties, or rights not otherwise in the ordinary course of business; (iv) made or permitted any amendment or termination of any contract, agreement, or license to which they are a party not otherwise in the ordinary course of business if such amendment or termination is material, considering the business of ("SEL"); or (v) issued, delivered, or agreed to issue or deliver any Membership Units (whether authorized and unissued or held as treasury stock).
2.7 Litigation and Proceedings. There are no actions, suits, proceedings, or investigations pending or, to the knowledge of ("SEL"), threatened by or against ("SEL"), or affecting ("SEL''), or its properties, at law or in equity, before any court or other governmental agency or instrumentality, domestic or foreign, or before any arbitrator of any kind.
2.8 No Conflict With Other Instruments. The execution of this Agreement and the consummation of the transactions contemplated by this Agreement will not result in the breach of any term or provision of, or constitute an event of default under, any material indenture, mortgage, deed of trust, or other material contract, agreement, or instrument to which ("SEL") is a party or to which any of its properties or operations are subject.
2.9 Contracts. ("SEL") has provided, or will provide IVST, copies of all material contracts, agreements, franchises, license agreements, or other commitments to which ("SEL") is a party or by which it or any of its assets, products, technology, or properties are bound.
2.10 Compliance With Laws and Regulations. ("SEL") has complied with all applicable statutes and regulations of any national, county, or other governmental entity or agency thereof, except to the extent that noncompliance would not materially and adversely affect the business, operations, properties, assets, or condition of ("SEL").
2.11 Approval of Agreement. The Members of ("SEL") (the "("SEL") Board") and the ("SEL") Membership Owners have authorized the execution and delivery of this Agreement by ("SEL") and have approved the transactions contemplated hereby.
2.12 ("SEL") Schedules. ("SEL'') will deliver, as soon as practicable, the following schedules, which are collectively referred to as the "("SEL") Schedules" and which consist of separate schedules dated as of the date of execution of this Agreement and instruments and data as of such date, all certified by the chief executive officer of ("SEL'') as complete, true and correct:
(a) a schedule containing complete and correct copies of the organizational documents, as amended, of ("SEL") in effect as of the date of this Agreement; and
(b) a schedule as requested by IVST, containing true and correct copies of all material contracts, agreements, or other instruments to which ("SEL") is a party or by which it or its properties are bound, specifically including all contracts, agreements, or arrangements referred to in Section 2.9.
2.13 Title and Related Matters. ("SEL") has good and marketable title to all of its properties, interest in properties, and assets, real and personal, which are reflected in the ("SEL") balance sheet or acquired after that date (except properties, interest in properties, and assets sold or otherwise disposed of since such date in the ordinary course of business), free and clear of all liens, pledges, charges, or encumbrances except:
(a) statutory liens or claims not yet delinquent; and (b)as described in the ("SEL") Schedules.
2.14 Governmental Authorizations. ("SEL") has all licenses, franchises, permits, and other government authorizations, that are legally required to enable it to conduct its business operations in all material respects as conducted on the date hereof. Except for compliance with federal and state securities or corporation laws, as hereinafter provided, no authorization, approval, consent, or order of, or registration, declaration, or filing with, any court or other governmental body is required in connection with the execution and delivery by ("SEL") of this Agreement and the consummation by ("SEL") of the transactions contemplated hereby.
2.15 Continuity of Business Enterprises. ("SEL") has no commitment or present intention to liquidate ("SEL") or sell or otherwise dispose of a material portion of its business or assets following the consummation of the transactions contemplated hereby.
2.16 Ownership of ("SEL") Shares. The ("SEL'') Members are the legal and beneficial owners of 100% of ("SEL") which members are set forth on Schedule I, free and clear of any claims, charges, equities, liens, security interests, and encumbrances whatsoever, and the ("SEL") Members have full right, power, and authority to transfer, assign, convey, and deliver their respective ("SEL") Membership Units and delivery of such Membership Units at the Closing will convey to IVST good and marketable title to such units free and clear of any claims, charges, equities, liens, security interests, and encumbrances except for any such claims, charges, equities, liens, security interests, and encumbrances arising out of such shares being held by IVST.
2.17 Brokers. ("SEL") has not entered into any contract with any person, firm or other entity that would obligate ("SEL") or IVST to pay any commission, brokerage or finders' fee in connection with the transactions contemplated herein.
2.18 Nominees. The nominees of ("SEL") to serve as IVST's directors and officers following the Closing (the "Nominees"), whose names and signatures appear on Schedule II hereto, represent that no event listed in Sub-paragraphs (1) through (4) of Subparagraph (d) of Item 40I of Regulation S-B has occurred with respect to any of the Nominees during the past five years which is material to an evaluation of the ability or integrity of such Nominee.
2.19 Subsidiaries and Predecessor Corporations. ("SEL") does not have any subsidiaries and does not own, beneficially or of record, any shares or other equity interests of any other corporation or entity.
ARTICLE III
REPRESENTATIONS, COVENANTS, AND WARRANTIES OF IVST
As an inducement to, and to obtain the reliance of ("SEL"), IVST represents and warrants as follows:
3.1 Organization. IVST is a corporation duly organized, validly existing, and in good standing under the laws of the State of Nevada, and has the corporate power and is duly authorized, qualified, franchised, and licensed under all applicable laws, regulations, ordinances, and orders of public authorities to own all of its properties and assets and to carry on its business in all material respects as it is now being conducted, and there is no jurisdiction in which it is not qualified in which the character and location of the assets owned by it or the nature of the business transacted by it requires qualification. Included in the IVST Schedules (as hereinafter defined) are complete and correct copies of the Articles of incorporation and bylaws of IVST, and all amendments thereto, as in effect on the date hereof. The execution and delivery of this Agreement does not, and the consummation of the transactions contemplated hereby will not, violate any provision of IVST's Articles of incorporation or bylaws. IVST has taken all action required by law, its Certificate of Incorporation, its bylaws, or otherwise to authorize the execution and delivery of this Agreement, and IVST has full power, authority, and legal right and has taken all action required by law, its Certificate of Incorporation, By-Laws, or otherwise to consummate the transactions herein contemplated.
3.2 Capitalization. IVST's presently issued and outstanding shares are legally issued, fully paid, and non-assessable and not issued in violation of the pre-emptive or other rights of any person. The Exchange Shares will be legally issued, fully paid and non- assessable and shall not be issued in violation of the pre-emptive or other rights of any other person.
3.3 Financial Statements. Except as set forth within its filing of reports with the OTC Markets (the "OTC Reports"):
(a) IVST has no liabilities with respect to the payment of any federal, state, county, local, or other taxes (including any deficiencies, interest, or penalties), except for taxes accrued but not yet due and payable, for which IVST may be liable in its own right, or as a transferee of the assets of, or as a successor to, any other corporation or entity.
(b) The books and records, financial and otherwise, of IVST are in all material respects complete and correct and have been maintained in accordance with good business and accounting practices.
(c) No deficiency for any taxes has been proposed, asserted or assessed against IVST. There has been no tax audit, nor has there been any notice to IVST by any taxing authority regarding any such tax audit, or, to the knowledge of IVST, is any such tax audit threatened with regard to any taxes or IVST tax returns. IVST does not expect the assessment of any additional taxes of IVST for any period prior to the date hereof and has no knowledge of any unresolved questions concerning the liability for taxes of IVST.
(d) IVST has good and marketable title to its assets and, except as set forth in the IVST Schedules, has no material contingent liabilities, direct or indirect, matured or unmatured.
3.4 Information. The information concerning IVST set forth in this Agreement and the IVST Schedules are and will be complete and accurate in all material respects and does not contain any untrue statement of a material fact or omit to state a material fact required to make the statements made, in light of the circumstances under which they were made, not misleading as of the date hereof and as of the Closing Date.
3.5 Absence of Certain Changes or Events. Except as described herein or in the IVST Schedules:
(a) There has not been (i) any material adverse change, financial or otherwise, in the business, operations, properties, assets, or condition of IVST (whether or not covered by insurance) materially and adversely affecting the business, operations, properties, assets, or condition of IVST;
(b) To the best knowledge of IVST, it has not become subject to any law or regulation which materially and adversely affects, or in the future may adversely affect, the business, operations, properties, assets, or condition of lVST.
3.6 Litigation and Proceedings. There are no actions, suits, or proceedings pending or, to the knowledge of IVST, threatened by or against or affecting JVST, at law or in equity, before any court or other governmental agency or instrumentality, domestic or foreign, or before any arbitrator of any kind.
3.7 No Conflict With Other Instruments. The execution of this Agreement and the consummation of the transactions contemplated by this Agreement will not result in the breach of any term or provision of, or constitute a default under, any indenture, mortgage, deed of trust, or other material agreement or instrument to which IVST is a party or to which it or any of its assets or operations are subject.
3.8 Governmental Authorizations. IVST is not required to have any licenses, franchises, permits, and other government authorizations, that are legally required to enable it to conduct its business operations in all material respects as conducted on the date hereof. Except for compliance with federal and state securities or corporation laws, as hereinafter provided, no authorization, approval, consent, or order of, or registration, declaration, or filing with, any court or other governmental body is required in connection with the execution and delivery by IVST of this Agreement and the consummation by IVST of the transactions contemplated hereby.
3.9 Compliance With Laws and Regulations. To the best of its knowledge, IVST has complied with all applicable statutes and regulations of any federal, state, or other applicable governmental entity or agency thereof, except to the extent that noncompliance would not materially and adversely affect the business, operations, properties, assets, or conditions of IVST or except to the extent that noncompliance would not result in the incurrence of any material liability.
3.10 Insurance. IVST owns no insurable properties and carries no casualty or liability insurance.
3.11 Approval of Agreement. The board of directors of IVST (the "IVST Board") has authorized the execution and delivery of this Agreement by IVST and has approved this Agreement and the transactions contemplated hereby.
3.12 Brokers. IVST has not entered into any contract with any person, firm or other entity that would obligate ("SEL") or IVST to pay any commission, brokerage or finders' fee in connection with the transactions contemplated herein.
ARTICLE IV
SPECIAL COVENANTS
4.7 Indemnification.
(a)("SEL") hereby agrees to indemnify IVST and each of the officers, agents and directors of IVST as of the date of execution of this Agreement against any loss, liability, claim, damage, or expense (including, but not limited to, any and all expense whatsoever reasonably incurred in investigating, preparing, or defending against any litigation, commenced or threatened, or any claim whatsoever), to which it or they may become subject arising out of or based on any inaccuracy appearing in or misrepresentation made in Article IL The indemnification provided
for in this paragraph shall not survive the Closing and consummation of the transactions contemplated hereby but shall survive the termination of this Agreement pursuant to Section 7.1(b) of this Agreement.
(b) IVST hereby agrees to indemnify ("SEL") and each of the officers, agents and directors of ("SEL") as of the date of execution of this Agreement against any loss, liability, claim, damage, or expense (including, but not limited to, any and all expense whatsoever reasonably incurred in investigating, preparing, or defending against an litigation, commenced or threatened, or any claim whatsoever), to which it or they may become subject arising out of or based on any inaccuracy appearing in or misrepresentation made under Article III. The indemnification provided for in this paragraph shall not survive the Closing and consummation of the transactions contemplated hereby but shall survive the termination of this Agreement pursuant to Section 7. I (c) of this Agreement.
ARTICLE V
CONDITIONS PRECEDENT TO OBLIGATIONS OF IVST
The obligations of IVST under this Agreement are subject to the satisfaction, at or before the Closing, of the following conditions:
5.1 Accuracy of Representations; Performance. The representations and warranties made by ("SEL") in this Agreement were true when made and shall be true at the Closing Date with the same force and effect as if such representations and warranties were made at and as of the Closing Date (except for changes therein permitted by this Agreement), and ("SEL") shall have performed or complied with all covenants and conditions required by this Agreement to be performed or complied with by ("SEL") prior to or at the Closing. IVST may request to be furnished with a certificate, signed by a duly authorized officer of ("SEL") and dated the Closing Date, to the foregoing effect.
5.2 Officer's Certificates. IVST shall have been furnished with a certificate dated the Closing Date and signed by a duly authorized officer of ("SEL") to the effect that no litigation, proceeding, investigation, or inquiry is pending or, to the best knowledge of ("SEL") threatened, which might result in an action to enjoin or prevent the consummation of the transactions contemplated by this Agreement, or, to the extent not disclosed in the ("SEL") Schedules, by or against ("SEL") which might result in any material adverse change in any of the assets, properties, business, or operations of ("SEL").
5.3 No Material Adverse Change. Prior to the Closing Date, there shall not have occurred any material adverse change in the financial condition, business, or operations of ("SEL"), nor shall any event have occurred which, with the lapse of time or the giving of notice, may cause or create any material adverse change in the financial condition, business, or operations.
5.4 Other Items.
(a) IVST shall have received such further documents, certificates, or instruments relating to the transactions contemplated hereby as IVST may reasonably request.
(b) Complete and satisfactory due diligence review of ("SEL") by IVST.
(c)Approval of the Transaction by the ("SEL") Board and the ("SEL") Shareholders.
(d) Any necessary third-party consents shall be obtained prior to Closing, including but not limited to consents necessary from ("SEL")' s lenders, creditors, vendors and lessors.
ARTICLE VI
CONDITIONS PRECEDENT TO OBLIGATIONS OF ("SEL")
The obligations of ("SEL") under this Agreement are subject to the satisfaction, at or before the Closing, of the following conditions:
6.1 Accuracy of Representations; Performance. The representations and warranties made by IVST in this Agreement were true when made and shall be true as of the Closing Date (except for changes therein permitted by this Agreement) with the same force and effect as if such representations and warranties were made at and as of the Closing Date, and IVST shall have performed and complied with all covenants and conditions required by this Agreement to be performed or complied with by IVST prior to or at the Closing. ("SEL") shall have been furnished with a certificate, signed by a duly authorized executive officer of IVST and dated the Closing Date, to the foregoing effect.
6.2 No Material Adverse Change. Prior to the Closing Date, there shall not have occurred any material adverse change in the financial condition, business, or operations of IVST nor shall any event have occurred which, with the lapse of time or the giving of notice, may cause or create any material adverse change in the financial condition, business, or operations of IVST.
ARTICLE VII
MISCELLANEOUS
7.1 Governing Law. This Agreement shall be governed by, enforced, and construed under and in accordance with the laws of the United States of America and, with respect to matters of state law, with the laws of Ohio. Any dispute arising under or in any way related to this Agreement will be submitted to binding arbitration before a single arbitrator by the American Arbitration Association in accordance with the Association's commercial rules then in effect. The arbitrator shall be mutually selected. The arbitration will be conducted in Cleveland, Ohio. The decision of the arbitrator will set forth in reasonable detail the basis for the decision and will be binding on the parties. The arbitration award may be confirmed by any court of competent jurisdiction.
7.2 Notices. Any notices or other communications required or permitted hereunder shall be sufficiently given if personally delivered to it or sent by registered mail or certified mail, postage prepaid, or by prepaid telegram and any such notice or communication shall be deemed to have been given as of the date so delivered, mailed, or telegraphed.
SEL
Damon Mintz, and Steve Mintz, and Jeffrey Simler
8456 Washington St.
Second Floor
Chagrin Falls, OH 44023
IVST
Innovest Global Inc.
930 S 4th St.
Suite 150
Las Vegas, NV 89101
7.3 Attorney's Fees. In the event that any party institutes any action or suit to enforce this Agreement or to secure relief from any default hereunder or breach hereof, the breaching party or parties shall reimburse the non-breaching party or parties for all costs, including reasonable attorneys' fees, incurred in connection therewith and in enforcing or collecting any judgment rendered therein.
7.4 Confidentiality. IVST, on the one hand, and ("SEL") and the ("SEL") Shareholders, on the other hand, will keep confidential all information and materials regarding the other Party designated by such Party as confidential. The provisions of this Section 7.4 shall not apply to any information which is or shall become part of the public domain through no fault of the Party subject to the obligation from a third party with a right to disclose such information free of obligation of confidentiality. IVST and ("SEL") agree that no public disclosure will be made by either Party of the existence of the Transaction or the letter of intent or any of its terms without first advising the other Party and obtaining its prior written consent to the proposed disclosure, unless such disclosure is required by law, regulation or stock exchange rule.
7.5 Expenses. Except as otherwise set forth herein, each party shall bear its own costs and expenses associated with the transactions contemplated by this Agreement. Without limiting the generality of the foregoing, all costs and expenses incurred by ("SEL") and IVST after the Closing shall be borne by the surviving entity. After the Closing, the costs and expenses of the ("SEL") Shareholders shall be borne by the ("SEL") Shareholders.
7.6 Schedules; Knowledge. Each party is presumed to have full knowledge of all information set forth in the other party's schedules delivered pursuant to this Agreement.
7.7 Third Party Beneficiaries. This contract is solely between IVST, ("SEL") and the ("SEL") Shareholders, and, except as specifically provided, no director, officer, stockholder, employee, agent, independent contractor, or any other person or entity shall be deemed to be a third party beneficiary of this Agreement.
7.8 Entire Agreement. This Agreement represents the entire agreement between the parties relating to the transaction. There are no other courses of dealing, understandings, agreements, representations, or warranties, written or oral, except as set forth herein.
7.9 Survival. The representations and warranties of the respective parties shall survive the Closing Date and the consummation of the transactions herein contemplated.
7.10 Counterparts. This Agreement may be executed in multiple counterparts, each of which shall be deemed an original and all of which taken together shall be but a single instrument.
7.11 Amendment or Waiver. Every right and remedy provided herein shall be cumulative with every other right and remedy, whether conferred herein, at law, or in equity, and may be enforced concurrently herewith, and no waiver by any party of the performance of any obligation by the other shall be construed as a waiver of the same or any other default then, theretofore, or thereafter occurring or existing. At any time prior to the Closing Date, this Agreement may be amended by a writing signed by all parties hereto, with respect to any of the terms contained herein, and any term or condition of this Agreement may be waived or the time for performance hereof may be extended by a writing signed by the party or parties for whose benefit the provision is intended.
(The rest of this page left intentionally blank.)
IN WITNESS WHEREOF, the corporate parties hereto have caused this Agreement to be executed by their respective officers, hereunto duly authorized, as of the date first above- written.
Innovest Global, Inc.
By: Daniel G. Martin, CEO
/s/ Daniel G. Martin
Shepherd Energy, LLC
By: Damon Mintz, CEO
/s/ Damon Mintz
SCHEDULE I
Dated: December 28, 2017
The following persons are the only owners of the capital stock of ("SEL"):
SCHEDULE 1
SHARES TO BE ISSUED
| DAMON MINTZ | 1,930,000 |
| STEVE MINTZ | 1,930,000 |
| JEFFREY SIMLER | 1,930,000 |
| Total | 5,790,000 |
SCHEDULE II
STOCK EXCHANGE AGREEMENT RESOLUTION
The undersigned Members of Shepherd Solutions, an LLC, duly organized under the laws of Ohio, hereby certify that a resolution was duly adopted by said Members of the LLC on December 28, 2017, and that such resolution has not been modified or rescinded as of the date hereof:
RESOLVED, that the Share Exchange Agreement attached hereto was unanimously approved and Damon Mintz approved to execute it on behalf of the Members.
Shepherd Solutions LLC - Board of Directors
Name:
Damon Mintz: /s/ Damon Mintz
Steve Mintz: /s/Steve Mintz
Jeffrey Simler: /s/Jeffrey Simler
Exhibit 2.2
SHARE ACQUISITION AGREEMENT
THIS SHARE ACQUISITION AGREEMENT (this "Agreement"), is entered into as of 5th day of November, 2018 (the "Closing Date") by and among INNOVEST GLOBAL, INC., a publicly-owned Nevada corporation ("IVST"), and AUTHORITY NATIONAL SUPPLY COMPANY, LLC, an Ohio limited liability company (referred to herein together with its successors and assigns as "ANS"). IVST and ANS are sometimes hereinafter collectively referred to as the "Parties" and individually as a "Party."
WI T N E S E T H
A) WHEREAS, IVST is a publicly-owned Nevada corporation engaged in the business of owning and operating diversified holdings in various industries including "Commercial & Industrial", "Energy" and "Biotechnology & Health services, and is quoted on the OTC Markets Group Inc. ("OTC Markets") tiered system (i.e., the OTCQX, OTCQB and Pink markets) under the symbol "IVST".
B) WHEREAS, (i) each member of ANS (individually, an "ANS Member" and collectively, the "ANS Members") is listed on Schedule I hereto; (ii) there are two thousand (2,000) issued and outstanding membership units of ANS all of which are uncertificated (the "ANS Units") and each ANS Member owns one hundred (100) such ANS Units; and (iii) ANS has filed articles of organization for Authority National Acquisition, LLC, an Ohio limited liability company (referred to herein together with its successors and assigns as "ANA") but no equity in ANA has been issued and ANA is not otherwise capitalized.
C) WHEREAS, ANS owns and operates a consolidated purchasing group for building and construction supplies and materials.
D) WHEREAS, the Parties desire that IVST acquire, pursuant to the terms and conditions set forth in this Agreement, all of the ANS Units from the ANS Members in consideration for Three Hundred Fifty Thousand Dollars ($350,000) comprised of, and payable with, the following (the "Purchase Price"), and as such Purchase Price may be adjusted by any "Additional Purchase Price" (as defined in Section 1.5 below):
(i) Two Hundred Ninety Five Thousand Dollars ($295,000) payable in the form of five million (5,000,000) (as such number is adjusted in accordance with the terms of this Agreement including, without limitation, Section 1.1 as to fractional shares) newly issued shares of "restricted" (as defined below) "Common Stock" (as defined below) (the 5,000,000 shares of restricted Common Stock, as adjusted, being referred to as the "IVST Shares"), as such IVST Shares may be adjusted in accordance with the terms Section 1.2 as to the "Guaranty Shares" (as defined below); and
(ii) Fifty-Five Thousand Dollars ($55,000) (the "Cash Payment").
The term "Common Stock" means common stock of IVST having a par value of $0.00 l.
The term " restricted " is in conformance with Rule 504 of Regulation D of the Securities Act of 1933, but in any event, the restriction period shall not exceed a period equal to twelve (12) months from the date of issuance of such Common Stock. IVST shall not restrict the Common Stock in any additional manner.
E) WHEREAS, following the "Closing" (as hereinafter defined), ANS will become a wholly-owned subsidiary of IVST.
F) Now THEREFORE, on the stated premises and for and in consideration of the foregoing recitals which are hereby incorporated by reference, the mutual covenants and agreements hereinafter set forth and the mutual benefits to the Parties to be derived here from and for other good and valuable consideration, the sufficiency and receipt of which are hereby acknowledged , the Parties hereto agree as follows:
ARTICLE I PLAN OF AQUISITION
1.1 The Acquisition. At the Closing (except as otherwise set forth in Section 1.l(ii)(b) below) the following shall occur:
(i) Purchase and Sale of ANS Units. The ANS Members shall sell the ANS Units to IVST for the Purchase Price and free and clear of all “Encumbrances” (as defined below), and IVST shall purchase and accept the ANS Units from Seller in exchange for the Purchase Price.
(ii) Payment. The Purchase Price (other than any Guaranty Shares otherwise payable hereunder or any Additional Purchase Price which may be due under Section 1.5 below) shall be payable by IVST to the ANS Members as follows:
(a) the IVST Shares free and clear of all Encumbrances, and with each ANS Member receiving its pro rata share of the IVST Shares (based on ANS Unit ownership), and with such pro rata share being 250,000 IVST Shares assuming 20 ANS Members at Closing; provided however, that any fractional IVST Shares that would result from such issuance will be rounded up to the next highest whole number , and
(b) the Cash Payment, and with each ANS Member receiving its pro rata share of the Cash Payment (based on ANS Unit ownership), and with such pro rata share being Two Thousand Seven Hundred Fifty Dollars ($2,750) assuming 20 ANS Members at Closing; provided however, that the Cash Payment owed to a particular ANS Member shall only be paid to said ANS Member at Closing to the extent that said ANS Member executes and delivers to IVST at Closing a waiver of its rights under Section 3.3(E) of the "Participation Agreement" (as defined in Section 1.2 of this Agreement) in the form attached hereto as Exhibit A; otherwise, the Cash Payment owed to said ANS Member shall be paid to it on the 31st day after Closing , and if applicable, as such amount is adjusted in accordance with Section 3.3.(E) of the Participation Agreement.
From and after the Closing Date, the ANS Members shall no longer own the ANS Units and IVST shall no longer own the IVST Shares.
1.2 Guarantee. IVST guarantees to ANS and the ANS Members that the IVST Shares (as the same are adjusted for any reorganization, recapitalization, re-classification, stock split, stock dividend, combination of shares, reverse stock split or other change in the capital structure of IVST, as such adjustments are referred to collectively herein as an " IVST Share Adjustment") shall be worth at least $5,000,000 in the aggregate (the "Guaranty Amount") on the second (2nd anniversary of the Closing Date (the "Guaranty Date"), as determined by using the capital structure and the closing price of IVST's Common Stock on the Guaranty Date. If the Guaranty Amount is less than $5,000,000 on the Guaranty Date, then within 60 days following the Guaranty Date IVST shall: (i) issue to each ANS Member which, on the Guaranty Date, remains a "Participant" (as defined below in this Section 1.2) of ANS and owns at least eighty five percent (85%) of the IVST Shares paid to it at Closing as part of the Purchase Price (as such number of IVST Shares is adjusted for any IVST Share Adjustment), its pro rata share (based on ANS Unit ownership Closing, i.e. 5% assuming 20 ANS Members at Closing) of the number of
additional shares of Common Stock necessary to achieve an aggregate value of $5,000,000 for the IVST Shares (i.e. $250,000 of value per ANS Member assuming 20 ANS Members at Closing) based on the capital structure and the closing price of the Common Stock on the Guaranty Date (the "Guaranty Shares"); or (ii) at the option of each applicable ANS Member , make a cash payment to such ANS Member in an amount equal to the dollar value of its pro rata share of the Guaranty Shares as of the Guaranty Date, said option to be exercised by any applicable ANS Member by written notice of the same delivered to IVST by such ANS Member within 30 days following the Guaranty Date. If IVST is required to issue the Guaranty Shares, and/or make a cash payment in lieu of Guaranty Shares, and fails to do so within 60 days of the Guaranty Date, then for an additional 60 days after the expiration of the initial 60 day period (the "Option Period ") the ANS Members shall have the option, to be exercised in accordance with the terms and conditions of Section 3.4 of a certain Participation Agreement of even date herewith by and among IVST, ANS the "Participants " and the "Owners", as the same may be amended from time to time (the "Participation Agreement" , with the terms " Participants " and "Owners" being as defined therein) , to reacquire the ANS Units from IVST by returning the IVST Shares to IVST for cancelation and in exchange for the ANS Units (the "Reacquisition Option"). In the event that a Reacquisition Option has been exercised in accordance with the terms and conditions of Section 3.4 of the Participation Agreement, then the "CEO" (as defined in the Participation Agreement) shall notify IVST of such exercise on behalf of the ANS Members (and any applicable Participants) and within the Option Period. Upon any such election, the ANS Members (and any applicable Participants) shall provide IVST with the "Reacquisition Shares" (as defined in Section 3.4 of the Participation Agreement), free and clear of any Encumbrance , and IVST shall provide each ANS Member (and any applicable Participant) with its pro rata share of the ANS Units (as based on the total number ANS Members and any applicable Participants), free and clear of any Encumbrance, in any event, in accordance with the terms and conditions of Section 3.4 of the Participation Agreement. Further, the Parties shall supply each other with any ancillary documents necessary to complete the Reacquisition Option as reasonably requested by the other, and before expiration of the Option Period. If the Reacquisition Option is not timely exercised before expiration of the Option Period, it will be of no further force and effect.
1.3 Closing. Upon the terms and subject to the conditions set forth herein, the closing of the Transaction contemplated by this Agreement (the "Closing" ) shall take place at the offices of IVST at 8834 Mayfield Road, Chesterland, Ohio 44122 Eastern Standard Time on the Closing Date, and assuming the last of the conditions set forth herein are fulfilled or waived in accordance with this Agreement, or at such other place or such other method (including remotely via the internet) as the Parties may mutually agree in writing.
1.4 Closing Conditions.
1.4.1 Conditions to IVST's Obligations to Affect the Closing. The obligation of IVST to consummate the Transaction provided for hereby is subject to the satisfaction, on or prior to the Closing Date, of each of the following conditions, any of which may be waived by IVST:
(a) Representations and Warranties. The representations and warranties made by ANS in this Agreement shall be true and correct in all material respects as of the Closing.
(b) Covenants. ANS shall have performed or complied with all agreements, covenants and conditions required by this Agreement to be performed or complied with by them prior to or at the Closing.
(c) ANS shall have tendered for delivery the documents and other items to be delivered at Closing pursuant to Article V each of which shall be in full force and effect.
1.4.2 Conditions to ANS's Obligations to Affect the Closing. The obligation of ANS to consummate the Transaction provided for hereby are subject to the satisfaction, on or prior to the Closing Date, of each of the following conditions, any of which may be waived by ANS.
(a) Representations and Warranties. The representations and warranties made by IVST in this Agreement shall be true and correct in all material respects as of the Closing.
(b) Covenants. IVST shall have performed or complied with all agreements, covenants and conditions required by this Agreement to be performed or complied with by them prior to or at the Closing.
(c) IVST shall have tendered for delivery the documents and other items to be delivered pursuant to Article VI each of which shall be in full force and effect.
1.5 Additional Purchase Price. The Parties hereto agree as follows:
1.5.l Each ANS Member shall be entitled to additional purchase price from IVST ("Additional Purchase Price") if the Purchase Price of $350,000 is challenged by the Internal Revenue Service or any other governmental authority (a "Purchase Price Challenge"), and as a result, such Purchase Price is increased to a new value in a final, non-appealable decision (an "Adjusted Purchase Price"). The amount of Additional Purchase Price owed to each ANS Member shall be equal to the sum of the following:
(a) its pro rata share (as such pro rata share is adjusted as a result of any adjustment in Purchase Price under Section 3.3(E) of the Participation Agreement) of an amount equal to twenty percent (20%) of the difference between the Adjusted Purchase Price and the Purchase Price (i.e., $350,000,) plus
(b) an amount equal to such ANS Member's tax liability (federal, state and local) on the amount paid to such ANS Member under Section 1.5. l(a) above (the " Additional Tax").
So for example purposes only, if there is an Adjusted Purchase Price equal to $700,000, then the Additional Purchase Price owed to each ANS Member (assuming 20 ANS Members) shall be calculated as follows:
$700,000 - $350,000 = $350,000 20% X $350,000 = $70,000
$70,0007 20 = $3,500
$3,500 + Additional Tax= the Additional Purchase Price owed to each ANS Member
1.5.2 In the event that there is a Purchase Price Challenge levied against any Party or ANS Member , then such Party or ANS Member shall give to the other Party and ANS Members prompt written notice of the same (but at a minimum, reasonably prior to the date on which a Party' s right to respond to such Purchase Price Challenge expires). The Parties and each ANS Member agree that IVST shall direct the process of demonstrating and defending the Purchase Price Challenge subject to the consent of ANS and the ANS Members (said consent not to be unreasonably withheld , delayed or withheld) ; provided however, that: (i) all Parties and ANS Members agree to work in good faith to resolve any such Purchase Price Challenge , and (ii) IVST agrees to indemnify and reimburse ANS and each ANS Member for, and hold ANS and each ANS Member harmless from, any liabilities, costs or expenses associated with or
resulting from such Purchase Price Challenge and/or its resolution (including, without limitation, reasonable attorneys and accountants fees).
ARTICLE II
REPRESENTATIONS, COVENANTS, AND WARRANTIES OF ANS
As an inducement to, and to obtain the reliance of IVST, ANS represents and warrants to IVST as of the Closing Date as follows:
2.1 Organization. ANS is a limited liability company duly organized, validly existing, and in good standing under the laws of the State of Ohio. ANS has the power and is duly authorized, qualified, franchised, and licensed under all applicable laws , regulations , ordinances, and orders of public authorities to own all of its properties and assets and to carry on its business in all material respects as it is now being conducted. Except as may be required to enforce Section 8.3(B) of ANS's Amended and Restated Operating Agreement effective March 26, 2014, by and among ANS and the ANS Members (the "Operating Agreement") including, without limitation, ANS' s drag along rights therein (the "Drag Along Rights " ): (i) the execution and delivery of this Agreement by ANS does not, and the consummation of the transactions contemplated by this Agreement in accordance with the terms hereof will not, violate any provision of ANS' s organizational documents; (ii) ANS has taken all action required by laws, its articles of organization, operating agreement, certificate of business registration , or otherwise to authorize the execution and delivery of this Agreement; and (iii) ANS has full power, authority, and legal right and has taken or will take all action required by law, its articles of organization, Operating Agreement , and otherwise to consummate the transactions herein contemplated.
2.2 Capitalization. The ANS Units constitute all of the issued and outstanding membership units of ANS and are legally issued, fully paid, and non-assessable and were not issued in violation of the pre-emptive or other rights of any person; provided however, that the ANS Units are uncertificated. Except for the ANS Units, ANS has no outstanding options, warrants, calls, commitments of any character, convertible securities or other membership equivalents relating to the authorized and unissued equity of ANS.
2.3 Taxes; Financial Statements. Except as set forth in Section 2.3(e) below:
(a) ANS has filed all local income tax returns required to be filed by it from its inception to the date hereof. All such returns are complete and accurate in all material respects.
(b) ANS has no liabilities with respect to the payment of federal, county, local, or other taxes (including any deficiencies, interest , or penalties) , except for taxes accrued but not yet due and payable, for which ANS may be liable in its own right or as a transferee of the assets of, or as a successor to, any other corporation or entity.
(c) No deficiency for any taxes has been proposed, asserted or assessed against ANS. There has been no tax audit, nor has there been any notice to ANS by any taxing authority regarding any such tax audit , or, to the knowledge of ANS, is any such tax audit threatened with regard to any taxes or ANS tax returns. ANS does not expect the assessment of any additional taxes of ANS for any period prior to the date hereof and has no knowledge of any unresolved questions concerning the liability for taxes of ANS.
(d) The books and records, financial and otherwise, of ANS are in all material respects complete and correct and have been maintained in accordance with good business and accounting
practices consistent with the past practices of ANS. Correct and complete copies of the internally prepared: (i) balance sheets of ANS as of December 31, 2016 and 2017, and the related statements of income of ANS for the years then ended, and (ii) the balance sheet of ANS as of September 30, 2018, and the related statement of income of ANS for the period then ended, are available to. IVST upon request (collectively, the "ANS Financial Statements" it being agreed that the September 30, 2018 ANS Financial Statements shall be referred to herein as the " Most Recent ANS Financial Statement”). The ANS Financial Statements: (y) are accurate and complete in all material respects and are consistent with the books and records of ANS (which are accurate and complete in all material respects) , as the case may be; and (z) fully and fairly present the financial position and results of operation of ANS in all material respects at the respective dates thereof and for the periods therein indicated.
(e) ANS has been filing and withholding Barberton tax on its employees, and Barberton income tax returns for ANS, but ANS's office is located in Clinton, Ohio.
2.4 Information. The information concerning ANS set forth in this Agreement is complete and accurate in all material respects and does not contain any untrue statement of a material fact or omit to state a material fact required to make the statements made, in light of the circumstances under which they were made, not misleading as of the date hereof and as of the Closing Date.
2.5 Absence of Certain Changes or Events. Except as set forth in this Agreement and/or the ANS Financial Statements including, without limitation, the possible enforcement of the Drag Along Rights:
(a) since the date of the Most Recent ANS Financial Statement, and except in the ordinary course of business , there has not been (i) any material adverse change in the business, operations , properties, assets, or condition of ANS; or (ii) any damage, destruction , or loss to ANS (whether or not covered by insurance) materially and adversely affecting the business , operations, properties, assets, or condition of ANS;
(b) since the date of the Most Recent ANS Financial Statement, and except in the ordinary course of business, ANS has not (i) borrowed or agreed to borrow any funds or incurred, or become subject to, any material obligation or liability (absolute or contingent) not otherwise in the ordinary course of business; (ii) paid any material obligation or liability not otherwise in the ordinary course of business absolute or contingent); (iii) sold or transferred, or agreed to sell or transfer, any of its assets, properties, or rights not otherwise in the ordinary course of business; (iv) made or permitted any amendment or termination of any contract, agreement, or license to which they are a party not otherwise in the ordinary course of business if such amendment or termination is material, considering the business of ANS; or (v) issued , delivered , or agreed to issue or deliver any ANS Units (whether authorized and unissued or held in treasury).
2.6 Litigation and Proceedings. Except for the possible enforcement of the Drag Along Rights, there are no action s, suits , proceedings , or investigations pending or, to the knowledge of ANS threatened, by or against ANS, or its properties, at law or in equity, before any court or other governmental agency or instrumentality, domestic or foreign, or before any arbitrator of any kind .
2.7 No Conflict With Other Instruments. Except for the possible enforcement of the Drag Along Rights, the execution of this Agreement and the consummation of the transactions contemplated by this Agreement will not result in the breach of any term or provision of, or constitute an event of default under , any material indenture , mortgage, deed of trust, or other material contract, agreement, or instrument to which ANS is a party or to which any of its properties or operations are subject.
2.8 Contracts. Copies of all material contracts, agreements, franchises, license agreements, or other commitments to which ANS is a party, or by which it or any of its assets, products, technology, or properties are bound, have been made available to IVST by ANS.
2.9 Compliance with Laws and Regulations. ANS has complied with all applicable statutes and regulations of any national, count y, or other governmental entity or agency thereof, except to the extent that noncompliance would not materially and adversely affect the business, operations, properties, assets, or condition of ANS.
2.10 Approval of Agreement. Except for the possible enforcement of the Drag Along Rights, the Members of ANS and the manager of ANS have authorized the execution and deliver y of this Agreement by ANS and have approved the transactions contemplated hereby including, without limitation , in accordance with Section 3.4(F) and Section 8.3(B) of ANS ' s Amended and Restated Operating Agreement effective March 26, 2014 by and among ANS and the ANS Members.
2.11 Title and Related Matters. Except for liens for taxes, assessments, or other governmental charges or levies not yet due and payable, ANS has good and marketable title to all of its properties, interest in properties, and assets, real and personal , which are reflected in the ANS Financial Statements or acquired since the date of the Most Recent ANS Financial Statement (except properties, interest in properties, and assets sold or otherwise disposed of since such date in the ordinary course of business), free and clear of all lien s, pledges , charges or encumbrances .
2.12 Governmental Authorizations. ANS has all licenses, franchises, permits, and other government authorizations, that are legally required to enable it to conduct its business operations in all material respects as conducted on the date hereof. No authorization , approval, con sent, or order of, or registration, declaration, or filing with, any court or other governmental body is required in connection with the execution and delivery by ANS of this Agreement and the consummation by ANS of the transactions contemplated hereby.
2.13 Continuity of Business Enterprises. ANS has no commitment or present intention to liquidate ANS or sell or otherwise dispose of a material portion of its business or assets.
2.14 Ownership of ANS Units. The ANS Members are the legal and beneficial owners of 100% of the ANS Units.
2.15 Brokers. ANS has not entered into any contract with any person, firm or other entity that would obligate ANS or IVST to pay any commission, brokerage or finders' fee in connection with the transactions contemplated herein.
2.16 Subsidiaries and Predecessor Entities. ANS does not have any subsidiaries and does not own, beneficially or of record, any shares or other equity interests of any other corporation or entity; provided however, that while ANS is the organizer of ANA no equity in ANA has been issued and ANA is not otherwise capitalized.
ARTICLE III
REPRESENTATIONS, COVENANTS, AND WARRANTIES OF IVST
As an inducement to, and to obtain the reliance of ANS and the ANS Members, IVST represents and warrants to both ANS and the ANS Members as of the Closing Date as follows:
3.1 Organization. IVST is a corporation duly organized, validly existing, and in good standing under the laws of the State of Nevada, and has the corporate power and is duly authorized, qualified, franchised, and licensed under all applicable laws, regulations, ordinances, and orders of public authorities to own all of its properties and assets and to carry on its business in all material respects as it is now being conducted, and there is no jurisdiction in which it is not qualified in which the character and location of the assets owned by it or the nature of the business transacted by it requires qualification. Complete and correct copies of IVST's articles of incorporation , bylaws, regulations, shareholders agreements and any other governance document of IVST, and all amendments thereto, as in effect on the Closing Date, have been provided to ANS and the ANS Members, , and furthermore, complete and correct copies of all such items are also available at www.otcmarke ts.com under the ticker symbol IVST (collectively , the "IVST Governance Documents"). The execution and delivery of this Agreement does not, and the consummation of the transactions contemplated hereby will not, violate any provision of the IVST Governance Documents. IVST has taken all action required by law, the IVST Governance Documents, or otherwise to authorize the execution and delivery of this Agreement, and IVST has full power, authority, and legal right and has taken all action required by law, the IVST Governance Documents, or otherwise to consummate the transactions herein contemplated.
3.2 Capitalization. IVST's presently issued and outstanding shares are legally issued, fully paid, and non-assessable and are not issued in violation of the pre-emptive or other rights of any person. The IVST Shares are, and any Guaranty Shares will be as of the time of their issuance, legally issued, fully paid and non-assessable and are not (and shall not be) issued in violation of the pre-emptive or other rights of any other person.
3.3 Taxes; Financial Statements.
(a) IVST has filed all federal, state and local income tax returns required to be filed by it from its inception to the date hereof. All such returns are complete and accurate in all material respects.
(b) IVST has no liabilities with respect to the payment of any federal, state, county, loc al, or other taxes (including any deficiencies, interest , or penalties) , except for taxes accrued but not yet due and payable, for which IVST may be liable in its own right, or as a transferee of the assets of, or as a successor to, any other corporation or entity.
(c) The books and records, financial and otherwise, of IVST are in all material respects complete and correct and have been maintained in accordance with good business and accounting practices. Correct and complete copies of: (i) the balance sheets of IVST as of December 31, 2016 and 2017, and the related statements of income and cash flow of ANS for the years then ended, and (ii) the balance sheet of IVST as of September 30, 2018, and the related statement of income of ANS for the period then ended, are all are available at www.otcmarkets.com under the ticker symbol IVST (collectively, the "IVST Financial Statements" it being agreed that the September 30, 2018 IVST Financial Statements shall be referred to herein as the " Most Recent IVST Financial Statement"). The IVST Financial Statements : (x) are accurate and complete in all material respects and are consistent with the books and records of IVST (which are accurate and complete in all material respects) , as the case may be; (y) have been prepared in accordance with GAAP applied consistently throughout periods indicated ; and (z) fully and fairly present the financial position and results of operation of IVST in all material respects at the respective dates thereof and for the periods therein indicated .
(d) No deficiency for any taxes has been proposed, asserted or assessed against IVST. There has been no tax audit, nor has there been any notice to IVST by any taxing authority regarding any such tax audit, or, to the knowledge of IVST, is any such tax audit threatened with regard to any taxes or IVST tax returns. IVST does not expect the assessment of any additional taxes of IVST for any period prior to the date hereof and has no knowledge of any unresolved questions concerning the liability for taxes of IVST.
3.4 Information. The information concerning IVST set forth in this Agreement is and will be complete and accurate in all material respects and does not contain any untrue statement of a material fact or omit to state a material fact required to make the statements made, in light of the circumstances under which they were made, not misleading as of the date hereof and as of the Closing Date.
3.5 Absence of Certain Changes or Events.
(a) There has not been (i) any material adverse change, financial or otherwise, in the business , operations, properties, assets, or condition of IVST; or (ii) any damage , destruction, or loss to IVST (whether or not covered by insurance) materially and adversely affecting the business , operations, properties, assets, or condition of IVST;
(b) it has not become subject to any law or regulation which materially and adversely affects, or in the future may adversely affect, the business, operations, properties, assets, or condition of IVST;
(c) IVST has not: (i) borrowed or agreed to borrow any funds or incurred, or become subject to, any material obligation or liability (absolute or contingent) not otherwise in the ordinary course of business; (ii) paid any material obligation or liability not otherwise in the ordinary course of business (absolute or contingent); (iii) sold or transferred, or agreed to sell or transfer, any of its assets, properties, or rights not otherwise in the ordinary course of business ; or (iv) made or permitted any amendment or termination of any contract, agreement , or license to which they are a party not otherwise in the ordinary course of business if such amendment or termination is material, considering the business of IVST.
3.6 Litigation and Proceedings. There are no actions, suits, or proceedings pending or, to the knowledge of IVST threatened, by or against IVST, at law or in equity, before any court or other governmental agency or instrumentality, domestic or foreign, or before any arbitrator of any kind.
3.7 No Conflict With Other Instruments. The execution of this Agreement and the consummation of the transactions contemplated by this Agreement will not result in the breach of any term or provision of, or constitute a default under, any indenture, mortgage, deed of trust, or other material agreement or instrument to which IVST is a party or to which it or any of its assets or operations are subject including, without limitation, any IVST Governance Document.
3.8 Governmental Authorizations. IVST is not required to have any licenses, franchises, permits, and other government authorizations, that are legally required to enable it to conduct its business operations in all material respects as conducted on the date hereof. No authorization, approval, consent, or order of, or registration, declaration, or filing with, any court or other governmental body is required in connection with the execution and delivery by IVST of this Agreement and the consummation by IVST of the transactions contemplated hereby.
3.9 Compliance With Laws and Regulations. IVST has complied with all applicable statutes and regulations of any federal, state, or other applicable governmental entity or agency thereof, except to the extent that noncompliance would not materially and adversely affect the business, operations, properties,
assets, or conditions of IVST or except to the extent that noncompliance would not result in the incurrence of any material liability.
3.10 Approval of Agreement. The board of directors of IVST has authorized the execution and delivery of this Agreement by IVST and has approved this Agreement and the transactions contemplated hereby, and no other approval on behalf of IVST is needed or required.
3.11 Brokers. IVST has not entered into any contract with any person, firm or other entity that would obligate ANS or IVST to pay any commission, brokerage or finders' fee in connection with the transactions contemplated herein.
3.12 Title and Related Matters. Except for liens for taxes, assessments, or other governmental charges or levies not yet due and payable, IVST has good and marketable title to all of its properties, interest in properties, and assets, real and personal , which are reflected in the IVST Financial Statements or acquired since the date of the Most Recent IVST Financial Statement (except properties, interest in properties, and assets sold or otherwise disposed of since such date in the ordinary course of business) , free and clear of all lien s, pledges, charges or encumbrances.
3.13 Continuity of Business Enterprises. IVST has no commitment or present intention to liquidate IVST or sell or otherwise dispose of a material portion of its business or assets.
3.14 Ownership of IVST. The legal and beneficial owners of 100% of IVST are as listed at www.otcmarkets.com under the ticker symbol IVST.
3.15 Subsidiaries and Predecessor Entities. Except as set forth at www.otcmarkets.com under the ticker symbol IVST, IVST does not have any subsidiaries and does not own, beneficially or of record, any shares or other equity interests of any other corporation or entity.
3.16 Due Diligence. IVST has been given access to full and complete information regarding ANS, and has utilized such access to its satisfaction for the purpose of obtaining information and otherwise conducting due diligence with respect to ANS. IVST has had the opportunity to discuss the business, management and financial affairs of ANS with ANS' s management.
ARTICLE IV
SPECIAL COVENANTS
4.1 Indemnification.
(a) ANS hereby agrees to indemnify IVST, and each of the officers, agents , employees and directors of IVST, from and against any loss, liability, claim , damage , or expense (including, but not limited to, any and all expense whatsoever reasonably incurred in investigating, preparing, or defending against any litigation , commenced or threatened, or any claim whatsoever), to which it or they may become subject arising out of, or based on, the breach of any representation or warranty of ANS contained in Article II of this Agreement.
(b) IVST hereby agrees to indemnify ANS, the ANS Members and the Participants, and each of the officers, agents, employees and directors of ANS and/or of the ANS Members and Participants , from and against any loss, liability, claim, damage , or expense (including, but not limited to, any and all expense whatsoever reasonably incurred in investigating, preparing, or defending against any litigation,
commenced or threatened, or any claim whatsoever) , to which it or they may become subject arising out of, or based on, the breach of any representation or warranty of IVST contained in Article III of this Agreement.
4.2 Reservation of Stock. IVST shall reserve for issuance a minimum of 10,000,000 shares of Common Stock to attract and retain Participants and to supplement ANS rebates in compliance with applicable federal and state securities laws.
4.3 No Other Representations and Warranties. Except as set forth herein and in each "Unit Power" (as defined below), the ANS Units are transferred by each ANS Member to IVST "AS-IS," " WHERE-IS" and " WITH ALL FAULTS." IVST acknowledges that neither ANS nor any of the ANS Members have made, and are not making, any representations or warranties whatsoever regarding the subject matter of this Agreement, the Participation Agreement or any Unit Power, express or implied, except as set forth herein , in the Participation Agreement or in any Unit Power respectively , and that it is not relying on, and has not relied on, any representations or warranties whatsoever regarding the subject matter of this Agreement, the Participation Agreement or any Unit Power, express or implied, except as set forth here in, in the Participation Agreement or in any Unit Power respectively.
ARTICLE V
DELIVERIES OF ANS
5.1 Deliveries by ANS. ANS shall use good faith efforts to deliver , or cause to be delivered, to IVST the following items to IVST by Closing or at some point thereafter, it being understood and agreed by IVST however , that: (a) ANS may not be able to deliver all such items whether by Closing or otherwise ; and furthermore : (b) IVST hereby waives as a Closing condition, and assumes the risk with respect to, any such item that is not delivered by ANS to IVST at Closing:
(a) a unit power and third-party beneficiary agreement in the form attached hereto as Exhibit B signed by each ANS Member as to its respective ANS Units (each a "Unit Power”).
(b) the Participation Agreement, as fully entered into by each ANS Member.
(c) a certificate of ANS dated as of the Closing Date and duly executed by a duly elected, qualified and acting officer or Manager of ANS as to the fulfillment of each of the conditions set forth in Section 1.4.1 of this Agreement by ANS; and
(d) such other documents and instruments as may be necessary or desirable to effect or evidence the transaction contemplated hereby that IVST may reasonably request.
ARTICLE VI
CLOSING DELIVERIES OF IVST
6.1 Closing Deliveries by IVST. At the Closing (unless otherwise set forth in Section 1.l(ii)(b) of this Agreement), IVST shall deliver, or shall cause to be delivered, the following:
(a) the Purchase Price as follows:
(i) book entries (and any and all other appropriate or applicable actions or documents) evidencing the ANS Members ' ownership of the IVST Shares; provided however , that certificates representing such IVST shares shall be delivered by IVST ' s transfer agent directly to each ANS Member via Federal Express, and within twenty (20) business days of the date of this Agreement , and all of the same shall be accompanied by duly executed assignments separate from certificates and/or other instruments of conveyance which are necessary or desirable to effect the transfer of the IVST Shares to the ANS Members, and
(ii) the Cash Payment by wire transfer or otherwise immediately available funds acceptable to ANS with each ANS Member ' s pro rata share (as may be adjusted consistent with any adjustments under Section 3.3(E) of the Participation Agreement) to be delivered directly to it.
(b) the Unit Power for each ANS Member as signed by IVST.
(c) the Participation Agreement, as fully entered into by IVST.
(d) a certificate of IVST dated as of the Closing Date, and duly executed by a duly elected, qualified and acting officer of IVST, as to the fulfillment of each of the conditions set forth in Section 1.4.2 of this Agreement by IVST; and
(e) such other documents and instruments as may be necessary or desirable to effect or evidence the transactions contemplated hereby that ANS may reasonably request.
ARTICLE VII
MISCELLANEOUS
7.1 Governing Law; Venue; JURY WAIVER. This Agreement shall be governed by, enforced, and construed under and in accordance with the laws of the United States of America and, with respect to matters of state law, with the laws of Ohio (exclusive of the conflict of law’s provisions thereof). Venue for all disputed matters shall be in the federal and state courts located in Cuyahoga County, Ohio. EACH PARTY HEREBY IRREVOCABLY AND UNCONDITIONALLY WAIVES ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY LITIGATION DIRECTLY OR INDIRECTLY ARISING OUT OF OR RELATING TO THIS AGREEMENT OR OTHER AGREEMENTS ENTERED INTO IN CONNECTION HEREWITH OR THE TRANSACTIONS CONTEMPLATED HEREBY OR THEREBY. EACH PARTY CERTIFIES AND ACKNOWLEDGES THAT: (i) IT UNDERSTANDS AND HAS CONSIDERED THE IMPLICATIONS OF SUCH WAIVERS, (ii) IT MAKES SUCH WAIVERS VOLUNTARILY , AND (iii) IT HAS BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS SECTION 7.1.
7.2 Notices. Any notices or other communications required or permitted hereunder shall be in writing and shall be deemed to be sufficiently given : (i) when received if personally delivered; (ii) three (3) business days after mailing if delivered by certified mail, return receipt requested; or (iii) one (1) business
day after being sent by nationally-recognized, overnight-delivery service; and in each case addressed as follows:
ANS:
2809 Crookston Lane Clinton, Ohio 44216
Attn: Chief Executive Officer
If to an ANS Member, then at the address for such ANS Member as set forth in its Unit Power.
IVST:
lnnovest Global, Inc.
8834 Mayfield Road
Chesterland, OH 44122
Attn: Damon Mintz - President - Commercial & Industrial Division
Any Party by written notice to the other Party may change the address or the persons to whom notices thereof shall be directed.
7.3 Confidentiality. In addition to the obligations under the Confidentiality and Non- Disclosure Agreement by and between ANS and IVST dated January 11, 2018 (the "NDA" ), IVST on the one hand, and ANS on the other hand, will keep confidential all information and materials regarding the other Party designated by such Party as confidential. The provisions of this Section 7.3 shall not apply to any information which is or shall become part of the public domain through no fault of the Party subject to the obligation from a third party with a right to disclose such information free of obligation of confidentiality. The Parties agree that no public disclosure will be made by any Party of the existence of the Transaction or the letter of intent or any of its terms without first advising the other Parties and obtaining their prior written consent to the proposed disclosure, unless such disclosure is required by law , regulation or stock exchange rule.
7.4 Schedules; Knowledge. Each Party is presumed to have full knowledge of all information set forth in the other Party' s schedules (if any) delivered pursuant to this Agreement.
7.6 Third Party Beneficiaries.
7.6.1 This Agreement is between IVST and ANS but the Parties specifically agree that the ANS Members are third party beneficiaries of this Agreement, and as such, except as specifically provided herein with respect to the ANS Members including, without limitation as provided in Section 7.6.2 below with respect to ANS Members, no director , officer, stockholder, employee, agent, independent contractor, or any other person or entity shall be deemed to be a third party beneficiary of this Agreement.
7.6.2 Notwithstanding anything in this Agreement to the contrary, IVST and ANS hereby represent, warrant, covenant and agree that: (i) each ANS Member is a third party beneficiary of this Agreement, (ii) as such, and in addition to any and all other rights and remedies afforded to a third party beneficiary whether at law or equity, each ANS Member is entitled to enforce this Agreement against IVST, ANS and/or any other applicable party with respect to any and all rights, remedies, benefits and obligations afforded to and/or owed to such ANS Member under this Agreement including, without limitation: (a) the right of such ANS Member to receive its
applicable portion of the Purchase Price, any Additional Purchase Price, any Guaranty Shares and any and all other amounts owed to such ANS Member by IVST (or other party) under this Agreement ; (b) the right to file a law suit against IVST (or other party) for any breach of the Agreement by IVST (or such other party); and/or, (c) the right to pursue any other legal remedies available to the ANS Member against IVST (or other party); and (iii) because ANS will be owned by IVST immediately after Closing, any and all rights and remedies which ANS has under this Agreement including, without limitation, the right to enforce this Agreement against IVST, are hereby assigned by ANS to the ANS Members effective as of the Closing.
7.7 Entire Agreement. This Agreement, together with the Participant Agreement, the Unit Powers and the NDA, and their respective Exhibits and Schedules (if any), represents the entire agreement between the parties relating to the transactions contemplated herein and therein. There are no other courses of dealing, understandings, agreements, representations, or warranties, written or oral, except as set forth herein. No Party may assign this Agreement without the prior written consent of the other which consent shall not unreasonably withheld or delayed. Each and all of the covenants, terms, provisions and agreements contained in this Agreement shall be binding upon and inure to the benefit of the parties hereto and their respective heirs, legal representatives, successors and permitted assigns.
7.8 Survival. The representations and warranties of the respective parties shall survive the Closing Date and the consummation of the transactions herein contemplated.
7.9 Counterparts. This Agreement may be executed in multiple counterparts, each of which shall be deemed an original and all of which taken together shall be but a single instrument.
7.10 Amendment or Waiver. Every right and remedy provided herein shall be cumulative with every other right and remedy , whether conferred herein, at law, or in equity, and may be enforced concurrently herewith , and no waiver by any party of the performance of any obligation by the other shall be construed as a waiver of the same or any other default then, theretofore, or thereafter occurring or existing. This Agreement may only be amended by a writing signed by all parties hereto and sixty seven percent (67%) of the ANS Members, with respect to any of the terms contained herein , and any term or condition of this Agreement may be waived or the time for performance hereof may be extended by a writing signed by the party or parties for whose benefit the provision is intended ; provided however , that if such party signing is ANS then it must also be signed by sixty seven percent (67%) of the of the ANS Members.
(the rest of this page left intentionally blank)
IN WITNESS WHEREOF, the Parties hereto have caused this Agreement to be executed by their respective officers, hereunto duly authorized, as of the date first above-written.
Innovest Global, Inc.
Daniel G. Martin, Chief Executive Officer
/s/Daniel G. Martin
Authority National Supply Company, LLC
Tony Crookston, Manager
/s/Tony Crookston
Schedule I
ANS Members
l. Sunrise Building Supply Inc.
2. Benson' s Building Supply Corp
3. SIBCO Building Supply Inc.
4. Old Reliable Wholesale Company dba C.C. Supply Company
5. R.J. Wholesale, Inc.
6. Badger Building Supply, Inc.
7. Adler Warehouse & Sales Inc.
8. Complete Supply, Inc.
9. Trinity Wholesale Distributors, Inc.
10. S.G. Williams & Bros Co., Inc.
11. Quality Building Supply
12. Building Material Products Inc. / Kan-Am Product Inc.
13. Armor Building Supply, Inc.
14. Apollo Siding Supply Inc.
15. Midwest Wholesale Materials Co. Inc.
16. Greater Niagara Building Center Inc.
17. North Country Distributors Inc. 18. Builders Loft Inc.
19. PAL Aluminum Inc. dba PAL Industries / PAL Building Supplies, Inc.
20. Dina Lumber & Building Materials, Inc.
EXHIBIT A
Waiver
The undersigned ANS Member by its signature below, as of the Closing Date, hereby unconditionally waives any and all right it has to make an "Elect ion" (as such term is defined in Section 3.3(E) of the Participation Agreement) and in so doing hereby agrees that it forfeits any right to make an Election under Section 3.3(E) of the Participation Agreement.
[Print name of Participant]
Signature : ________________________________________________________________________
Printed Name: ________________________________________________________________________
Title: ________________________________________________________________________
Date: ________________________________________________________________________
Address: ________________________________________________________________________
Email: ________________________________________________________________________
EXHIBIT B
Form of Unit Power
see attached form
CLOSING CERTIFICATE OF
AUTHORITY NATIONAL SUPPLY COMPANY, LLC
Pursuant to Section 5. l(c) of the Share Acquisition Agreement (the "Agreement" ) dated November 5, 2018, by and among Innovest Global, Inc., a publicly-owned Nevada corporation, and Authority National Supply Company, LLC (" ANS" ), the undersigned does hereby certify as follows as of November 5, 2018:
1. The representations and warranties made by ANS in the Agreement are true and correct in all material respects as of the "Closing" (as defined in the Agreement).
2. ANS has performed or complied with all agreements, covenants and conditions required by this Agreement to be performed or complied with by it prior to or at the Closing.
3. ANS has tendered for delivery the documents and other items to be delivered pursuant to Article V of the Agreement each of which shall be in full force and effect.
Authority National Supply Company, LLC
Tony Crookston, Manager
/s/Tony Crookston
CLOSING CERTIFICATE OF
INNOVEST GLOBAL, INC.
Pursuant to Section 6. l(d) of the Share Acquisition Agreement (the "Agreement") dated November 5, 2018, by and among Innovest Global, Inc., a publicly-owned Nevada corporation ("IVST"), and Authority National Supply Company , LLC, the undersigned does hereby certify as follows as of November 5, 2018:
1. The representations and warranties made by IVST in the Agreement are true and correct in all material respects as of the "Closing" (as defined in the Agreement).
2. IVST has performed or complied with all agreements, covenants and conditions required by this Agreement to be performed or complied with by it prior to or at the Closing.
3. IVST has tendered for delivery the documents and other items to be delivered pursuant to Article VI of the Agreement each of which shall be in full force and effect.
Innovest Global, Inc.
Daniel G. Martin, Chief Executive Officer
/s/Daniel G. Martin
Exhibit 2.3
ASSET PURCHASE AGREEMENT
This Agreement entered into this the 23rd day of October 2017 by and among Chagrin Safety Supply, Inc, (hereinafter "Seller"), and Innovest Global Inc. (hereinafter "Buyer").
WHEREAS, Seller operates a business primarily engaged in the safety supply industry, as broadly defined; and
WHEREAS, Seller owns telephone numbers, intellectual property, websites, marketing materials, equipment, inventory, and miscellaneous assets used in connection with the operations of its business; and
WHEREAS, Buyer desires to acquire substantially all of the assets used or useful or intended to be used in the operation of Sellers business and Seller desires to sell such assets to Buyer.
NOW, THEREFORE, in consideration of mutual covenants contained herein and other good and valuable consideration the receipt and sufficiency of which is hereby acknowledged, the parties agree as follows:
SECTION 1. ASSETS PURCHASED; LIABILITIES ASSUMED
1.1 ASSETS PURCHASED. Seller agrees to sell to Buyer and Buyer agrees to purchase from Seller, on the terms and conditions set forth in this Agreement, the following assets.
1.1.1 All equipment including computers, fixtures, marketing materials, miscellaneous inventory, together with any replacements or additions to the equipment, etc. made prior to the closing date.
1.1.2 All inventories and supplies owned by Seller together with any replacements or additions to the inventories made prior to the closing date, but excluding inventory disposed of in the ordinary course of Seller's business.
1.1.3 Seller's goodwill and customer lists.
1.1.4 The name "Chagrin Safety Supply" And websites, telephone numbers, etc.
1.1.5 The accounts receivable as of the date of Closing.
1.1.6 All bank and merchant accounts.
1.2 ASSUMPTION OF LIABILITIES
Buyer shall be responsible for any current liabilities from vendors of Seller a list of which is to be provided to Buyer at Closing.
SECTION 2. EXCLUDED ASSETS
Excluded from this sale and purchase are Seller's:
a. Vehicles and Personal Property listed on Schedule " A" hereto.
SECTION 3. PURCHASE PRICE FOR ASSETS
The purchase price for the assets shall be $750.
SECTION 4. PAYMENT OF PURCHASE PRICE
The price for the Assets shall be paid as follows:
4.1 At closing, Buyer shall cause to be delivered to Seller 750,000 Common restricted Shares in Innovest Global Inc.
4.2 Buyer will guarantee the Shares be unrestricted and in aggregate, worth $750,000.00 by the 4th year anniversary of the Closing.
SECTION 6. SELLER'S AND SELLER'S MEMBERS' REPRESENTATIONS AND WARRANTIES
Seller and Seller's Members each represent and warrant to Buyer as follows:
6.1 EXISTENCE OF CORPORATION. Seller is now and on the date of closing will be a Corporation duly organized and validly existing and in good standing under the laws of the State of Ohio. Seller has all requisite power and authority to own, operate and/or lease the assets , as the case may be, and to carry on its business as now being conducted.
6.2 AUTHORIZATION. The execution, delivery and performance of this Agreement have been duly authorized and approved by Seller, and this Agreement constitutes a valid and binding agreement of Seller in accordance with its terms.
6.3 TITLE TO ASSETS. Except as described in the Agreement, Seller holds good and marketable title to the assets, free and clear of restrictions on or conditions to transfer or assignment, and free and clear of lien s, pledges, charges or encumbrances.
6.4 TRANSFER NOT SUBJECT TO ENCUMBRANCES OR THIRD-PARTY APPROVAL. The execution and delivery of this Agreement by Seller and Seller's Members , and the consummation of the contemplated transact ions, will not result in the creation or imposition of any valid lien, charge or encumbrance on any of the assets , and will not require the authorization, consent, or approval of any third party, including any governmental division or regulatory agency.
6.5 LABOR AGREEMENTS AND DISPUTES. Seller is neither a party to, nor otherwise subject to any collective bargaining or other agreement governing the wages, hours, in terms of employment of Seller's employees. Neither Seller nor Seller's Members is aware of any labor dispute or labor trouble involving employees of Seller.
6.6 NONCANCELLABLE CONTRACTS. At the time of closing, there will be no material leases , employment contracts, contracts for services, or maintenance, or other similar contacts, existing or related to or connected with the operation of Seller's business not cancelable within ninety (90) days.
6.7 LITIGATION. Seller has no knowledge of any claim, litigation, proceeding, or investigation pending or threatened against Seller that might result in any material adverse change in the business or condition of the assets being conveyed under this Agreement.
6.8 ACCURACY OF REPRESENTATIONS AND WARRANTIES. None of the representations or warranties of Seller or Seller's Members contain or will contain any untrue statements of a material fact or omit or will omit or misstate a material fact necessary in order to make statements in this Agreement not misleading. Seller and Seller's Members know of no fact that has resulted, or that in the reasonable judgment of Seller ' s Members will result in material change in the business , operations, or assets of Seller that has not been set forth in this Agreement or otherwise disclosed to Buyer.
SECTION 7. REPRESENTATIONS OF BUYER
Buyer represents and warrants as follows:
7.1 CORPORATE EXISTENCE. Buyer is a corporation duly organized, validly existing, and in good standing under the laws of the State of Ohio. Buyer has all requisite corporate power and authority to enter into this Agreement and perform its obligations hereunder.
7.2 AUTHORIZATION. The execution, delivery and performance of this Agreement have been duly authorized and approved by the Board of Directors and shareholders of Buyer, and this Agreement constitutes a valid and binding agreement of Buyer in accordance with its terms.
7.3 ACCURACY OF REPRESENTATIONS AND WARRANTIES. None of the representations or warranties of Buyer contain or will contain any untrue statement of a material fact or omit or will omit or misstate a material fact necessary in order to make the misstatements contained herein not misleading.
SECTION 8. COVENANTS OF SELLER AND SELLER'S MEMBERS
8.1 SELLER'S OPERATION OF BUSINESS PRIOR TO CLOSING. Seller and Seller's Members agree that between the date of this Agreement and the date of closing, Seller will:
8.1.1 Use its best efforts to preserve its business organization and preserve the continued operation of its business with its customers, suppliers, and others having business relations with Seller.
8.1.2 Not assign, sell, lease or otherwise transfer or dispose of any of the assets listed on the balance sheet, except to Buyer.
8.1.3 Maintain all of its assets other than inventories in their present conditions, reasonable wear and tear and ordinary usage accepted and maintain the inventories at levels normally maintained.
8.2 ACCESS TO PREMISES AND INFORMATION. At reasonable times prior to the closing date, Seller will provide Buyer and its representatives with reasonable access during business hours to the assets, titles, contracts and records of Seller and furnish such additional information concerning Seller's businesses Buyer may from time to time reasonably request.
8.3 EMPLOYEE MATTERS.
8.3.1 Prior to closing, Seller will deliver to Buyer a list of the names of all persons on the payroll of Seller, together with a statement of amounts paid to each during Seller's most recent fiscal year and amounts paid for services from the beginning of the current fiscal year to the closing date. Seller will also provide Buyer with a schedule of all employee bonus arrangements and a schedule of other material compensation including commission structure and personnel benefits or policies in effect.
8.3.2 Prior to the closing date, Seller will not, without Buyer's prior written consent, enter into any material agreements with its employees, increase the rate of compensation or bonus payable to or to become payable to any employee or effect any change in the management , personnel policies, or employee benefits, except in accordance with existing employment practices.
8.3.3 As of or prior to the closing date , Seller will retain all of its employees, except Seller's Members, not having employee agreements transferable to Buyer and will pay each employee all wages, comm1ss1ons, and accrued vacation pay earned up to the time of termination, including ove1time pay.
8.4 CONDITIONS AND BEST EFFORTS. Seller will use its best efforts to effectuate the transactions contemplated by this Agreement and to fulfill all the conditions of the obligations of Seller under this Agreement, and will do all acts and things as may be required to carry out its respective obligations under this Agreement and to consummate and complete this agreement. Seller will be required to provide all financial and other company information required to close this transaction within a timely manner as set forth per the Lender.
SECTION 9. COVENANTS OF BUYER
9.1 CONDITIONS AND BEST EFFORTS. Buyer will use its best efforts to effectuate the transaction contemplated by this Agreement and to fulfill all the conditions of Buyer's obligations under this Agreement, and shall do all acts and things as may be required to carry out Buyer's obligations and to consummate this Agreement.
9.2 CONFIDENTIAL INFORMATION. If for any reason the sale of Assets is not closed, Buyer will not disclose to third parties any confidential information received from Seller or Selling Shareholder in the course of investigating, negotiating, and performing the transactions contemplated by this Agreement.
SECTION 10. CONDITIONS PRECEDENT TO BUYER'S OBLIGATIONS
The obligation of Buyer to purchase the Assets is subject to the fulfillment, prior to or at the closing date, of each of the following conditions, any one or portion of which may be waived in writing by Seller:
10.1 REPRESENTATIONS, WARRANTIES AND COVENANTS AND SELLING SHAREHOLDER. All representations and warranties made in this Agreement by Seller and Seller's Members shall be true as of the closing date as fully as those such representations and warranties had been made on or as of the closing date, and, as of the closing date, neither Seller nor Seller's Members shall have violated or shall have failed to perform in accordance with any covenant contained in this Agreement.
10.2 LICENSES AND PERMITS. Buyer shall be responsible for obtaining all licenses and permits from public authorities necessary to authorize the ownership and operation of the business of Seller.
10.3 CONDITIONS OF THE BUSINESS. There shall have been no material adverse change in the manner of the operation of Seller's business prior to the closing date.
10.4 NO SUITS OR ACTIONS. At the closing date, no suit, action or other proceeding shall have been threatened or instituted to restrain, enjoin or otherwise prevent the consummation of this Agreement or the contemplated transactions.
SECTION 11. CONDITIONS PRECEDENT TO OBLIGATIONS OF SELLER
The obligations of Seller to consummate the transactions contemplated by this Agreement are subject to the fulfillment, prior to or at the closing date, of the following condition, which may be waived in writing by Buyer:
All representations and warranties made in this Agreement by Seller shall be true as of the closing date as fully as though such representations and warranties have been made on and as of the closing date, and Seller shall not have violated or shall not have failed to perform in accordance with any covenant contained in this Agreement.
SECTION 12. BUYER'S ACCEPTANCE
Buyer represents and acknowledges that it has entered into this Agreement on the basis of its own examination, personal knowledge, and opinion of the value of the business. Buyer has not relied on any representations made by Seller other than those specified in this Agreement. Buyer further acknowledges that Seller has made no agreement or promise to repair or improve any equipment, rolling stock (inventory) or other personal property being sold to Buyer under this Agreement, and that Buyer takes all such property in the condition existing on the date of this Agreement , except as otherwise provided in this Agreement.
SECTION 13. INDEMNIFICATION AND SURVIVAL
13.1 SURVIVAL OF REPRESENTATIONS AND WARRANTIES. All representations and warranties made in this Agreement shall survive the closing of this Agreement, except that any party to whom a representation of warranty has been made in this Agreement shall be deemed to have waived any misrepresentation or breach of representation or warranty which such party had knowledge of prior to closing. Any party learning of a misrepresentation or breach of representation or warranty under this Agreement shall immediately give notice thereof to all other patties to this Agreement. The representations and warranties in this Agreement shall terminate three (3) years from the closing date , and such representations or warranties shall thereafter be without force or effect, except any claim with respect to which notice has been given to the party to be charged prior to such expiration date.
13.2 SELLERS AND SELLER'S MEMBERS INDEMNIFICATION.
13.2.1 Seller and Seller's Members each hereby agree to indemnify and hold Buyer, its successors and assigns harmless from and against:
(1) Any and all claims, liabilities and obligations of every kind and description, contingent or otherwise, arising out of or related to the operation of Seller's business prior to the close of business on the day before the closing date, except for claims, liabilities and obligations of Seller expressly assumed by Buyer under this agreement or paid by insurance maintained by Seller or Buyer.
(2) Any and all damage or deficiency resulting from any material misrepresentation or breach of warranty or covenant, or nonfulfillment of any agreement on the part of Seller or Seller's Members under this agreement.
13.2.2 Sellers and Seller's Members indemnity obligations under 14.2.1 shall be subject to the following:
(1) If any claim is asserted against Buyer that would give rise to a claim by Buyer against Seller and Seller's Members for indemnification under the provisions of this paragraph, the Buyer shall promptly give written notice to Seller concerning such claim and Seller shall, at no expense to Buyer, defend the claim.
(2) Seller shall not be required to indemnify Buyer for any amount that exceeds the total purchase price paid by Buyer under Section 3 of this Agreement.
13.3 BUYERS INDEMNIFICATION. Buyer agrees to defend, indemnify and hold harmless Seller and Seller's Members from and against:
13.3.1 Any all claims, liabilities and obligations of every kind and description arising out of or related to the operation of the business following closing or arising out of Buyer's failure to perform obligations of Seller assumed by Buyer pursuant to this agreement.
13.3.2 Any and all damage or deficiency resulting from any material misrepresentation, breach of warranty or covenant, or nonfulfillment of any agreement on the part of Buyer under this agreement.
SECTION 14. CLOSING
14.1 TIME AND PLACE. This agreement shall be closed at a location to be agreed upon by the parties on the 1st day of October 2017, or such other time as the parties may agree in writing. If the
closing has not occurred on or before Oct 30, 2017, then either party may elect to terminate this agreement. If, however, the closing has not occurred because of a breach of contract by one or more of the pa1iies, the breaching party or parties shall remain liable for breach of contract.
15.2 OBLIGATIONS OF SELLER AT CLOSING. At the closing, Seller and Seller's Members shall deliver to Buyer the following:
15.2.1 Bills of Sale, Assignments, properly endorsed Certificates of Title, and other instruments of transfer, in a form and substance reasonably satisfactory to counsel for Buyer, necessary to transfer and convey all of the assets to Buyer.
15.2.3 Such other ce1iificates and documents as may be called for by the provisions of this Agreement.
15.3 OBLIGATIONS OF BUYER AT CLOSING. At the closing Buyer shall deliver to Seller the following:
15.3.1 Note in the amount specified in Section 4.1. plus, Buyer's share of any closing costs.
15.3.2 Such other certificates and documents as may be called for by the provisions of this Agreement.
SECTION 16. RIGHTS AND OBLIGATIONS SUBSEQUENT TO CLOSING
16.1 BOOKS AND RECORDS. This sale does include the books of account and records of Seller's business. Buyer will exercise reasonable care in the safekeeping of such records.
16.2 SELLER'S RIGHT TO PAY. In the event Buyer fails to make any payment of taxes, assessments, insurance premiums, or other charges that Buyer is required to pay to third parties under this Agreement, Seller shall have the right, but not the obligation, to pay the same. Buyer will reimburse Seller for any such payment immediately upon Seller’s demand, together with interest at the same rate provided in the Note from the date of Seller's payment until Buyer reimburses Seller. Any such payment by Seller shall not constitute a waiver by Seller of any remedy available by reason of Buyer's default for failure to make the payments.
SECTION 17. BULK SALES LAW. Buyer waives compliance by Seller with the Bulk Transfer Act. In the event any creditor of Seller claims the benefit of the Bulk Transfer Law as against Buyer or any of the assets being conveyed to Buyer under this Agreement, Seller shall immediately pay or otherwise satisfy such claim or undertake its defense. Seller shall indemnify and hold Buyer harmless from and against any and all loss, expense, or damage resulting from the failure to comply with the Bulk Transfer law. If Seller fails to comply with the provision of this Section 17 and Buyer is required to pay any creditor of Seller in order to protect the property purchased under this agreement from claims or liens of Seller's creditors, except those assumed by Buyer, the Buyer may offset the amount it pays against the balance due Seller by furnishing to the Seller proof of such payment in the form of a receipt from the creditor involved.
SECTION 18. TERMINATION OF AGREEMENT
18.1 BY MUTUAL CONSENT. This Agreement may be terminated by mutual written consent of Buyer and Seller.
18.2 BREACH OF REPRESENTATIONS AND WARRANTIES; FAILURE OF CONDITIONS. Buyer may elect by notice to Seller, and Seller may elect by notice to Buyer, to terminate this Agreement if.
18.2.1 The terminating party shall have discovered a material error, misstatement, or omission in the representations and warranties made in this Agreement by the other party which shall not have been cured by such other party within fifteen (15) days after written notice to such other party specifying in detail such asserted error, misstatement, or omission, or by the closing date, whichever first occurs.
18.2.2 All of the conditions precedent of the terminating party's obligations under this Agreement as set forth in either Section 11 or 12, as the case may be, have not occurred and have not been waived by the terminating part-y on or prior to the closing date.
18.3 CLOSING NOTWITHSTANDING THE RIGHT TO TERMINATE. The party with a right to terminate this Agreement pursuant to Section 18.2.1 or 18.2.2 shall not be bound to exercise such right, and its failure to exercise such right shall not constitute a waiver of any other right it may have under this Agreement, including but not limited to remedies for breach of a representation, warranty, or covenant.
SECTION 19. MISCELLANEOUS
19.1 The provisions of this Agreement shall be binding upon and inure to the benefit of the heirs, personal representatives, successors, and assigns of the parties.
19.2 Any notice or other communication required or permitted to be given under this Agreement shall be in writing and shall be mailed by certified mail, return receipt requested, postage prepaid, addressed to the parties as follows:
All notices and other communications shall be deemed to be given at the expiration of three (3) days after the date of mailing. The addresses to which notices or other communications shall be mailed may be changed from time to time by giving written notice to the other parties as provided above.
19.3 In the event of a default under this Agreement, the defaulting party shall reimburse the nondefaulting party or parties for all costs and expenses reasonably incurred by the nondefaulting party or parties in connection with the default, including without limitation attorney fees. Additionally, in the event a suit or action is filed to enforce this Agreement or with respect to this Agreement, the prevailing party or patties shall be reimbursed by the other party for all costs and expenses incurred in connection with the suit or action, including without limitation reasonable attorney fees at the trial level and on appeal.
19.4 No waiver of any provision of this Agreement shall be deemed, or shall constitute, a waiver of any other provision, whether or not similar, nor shall any waiver constitute a continuing waiver. No waiver shall be binding unless executed in writing by the party making the waiver.
19.5 This Agreement shall be governed by and shall be construed in accordance with the laws of the State of Ohio.
19.6 This Agreement constitutes the entire agreement between the parties pertaining to its subject matter and it supersedes all prior contemporaneous agreements, representations, and understandings of the parties. No supplement, modification, or amendment of this Agreement shall be binding unless executed in writing by all parties.
The remainder of this page is intentionally blank
Witness the signatures of the parties this 23 day of October 2017
SELLER:
Chagrin Safety Supply, Inc.
BY: /s/William Oler
TITLE: President & CEO
BUYER:
Innovest Global, Inc.
BY: /s/Daniel G. Martin
TITLE: Chairman & Chief Executive Officer
Exhibit 2.4
AGREEMENT AND SHARE EXCHANGE
THIS AGREEMENT AND SHARE EXCHANGE (hereinafter referred to as the "Agreement"), is entered into as of March 22, 2018 by and among, Innovest Global, INC., a publicly-owned Nevada corporation ("IVST"), and H.P. Technologies Inc., an Ohio Corporation ("I-IPT") sometimes hereinafter collectively referred to as the "Parties" and individually as a "Party.")
WITNESSETH
A) WHEREAS, IVST is a publicly-owned Nevada corporation and is quoted on the Over the Counter Bulletin Board under the symbol (IVST).
B) WHEREAS, the (HPT) Shareholders listed on Schedule I hereto own all of the issued and outstanding Shares.
C) WHEREAS, HPT owns and operates an energy procurement business.
E) WHEREAS, the Parties desire that IVST acquire all of the (HPT) Members Units from the (HPT) Members solely in exchange for an aggregate of 1,500,000 newly issued shares of restricted common stock of IVST (the "Exchange Shares") pursuant to the terms and conditions set forth in this Agreement.
F) WHEREAS, immediately upon consummation of the Closing (as hereinafter defined), the Exchange Shares will be issued to the (HPT) Shareholders on a pro rata basis, as of the date of the Closing.
G) WHEREAS, following the Closing, (HPT) will become a wholly-owned subsidiary of IVST.
H) WHEREAS, the Parties intend that the transaction contemplated herein (the "Transaction") qualify as a reorganization and tax-free exchange under Section 368(a) of the Internal Revenue Code of 1986, as amended.
I) NOW THEREFORE, on the stated premises and for and in consideration of the foregoing recitals which are hereby incorporated by reference, the mutual covenants and agreements hereinafter set forth and the mutual benefits to the Parties to be derived here from and for other good and valuable consideration, the sufficiency and receipt of which are hereby acknowledged, the Parties hereto agree as follows:
ARTICLE I
PLAN OF EXCHANGE
1.1 The Exchange. At the Closing (as hereinafter defined), one hundred percent (100%) of the Shares of (HPT) shall be exchanged for 1,500,000 shares of IVST Restricted Common Stock. From and after the Closing Date, the (HPT) Shareholders shall no longer own any Membership Units of (I-IPT) and the certificates formerly representing Shares of (HPT) shall represent the pro rata portion of the Exchange Shares issuable in exchange therefor pursuant to this Agreement. Any fractional shares that would result from such exchange will be rounded up to the next highest whole number.
1.2 Guarantee. IVST shall guarantee the Exchange Shares to be worth $1 per share (at closing price) by the second (2nd) anniversary of the issuance. In the event that the price is not $1 per share by the second anniversary, on the second anniversary IVST shall issue HPT the number of additional shares necessary to achieving an aggregate value of $1,500,000 for the Exchange Shares. This guarantee is in full force and effect unless there is a "Guarantee Disqualifying Event", which would be any one of the following: A) Liquidation of more than 15% of the Exchange Shares prior to the second anniversary of
the issuance, B) Failure of HPT to achieve an aggregate revenue growth rate of 5% year over year for the two years, C) Material misrepresentations.
1.3 Closing. The closing ("Closing") of the transactions contemplated by this Agreement shall occur immediately on the execution of this Agreement (the "Closing Date").
1.4 Closing Events. At the Closing, HPT shall execute, acknowledge, and deliver (or shall cause to be executed, acknowledged, and delivered) any and all stock certificates, officers' certificates, opinions, financial statements, schedules, agreements, resolutions, rulings, or other instruments required by this Agreement to be so delivered at or prior to the Closing, and the documents and certificates provided in Sections 5.2, 5.4, 6.2, 6.4 and 6.5, together with such other items as may be reasonably requested by the parties hereto and their respective legal counsel in order to effectuate or evidence the transactions contemplated hereby . If agreed to by the parties, the Closing may take place through the exchange of documents (other than the exchange of stock certificates) by efax, fax, email and/or express courier. At the Closing, the Exchange Shares shall be issued in the names and denominations provided by (HPT).
ARTICLE II
REPRESENTATIONS, COVENANTS, AND WARRANTIES OF (HPT)
As an inducement to, and to obtain the reliance of IVST, (HPT) represents and warrants as follows:
2. 1 Organization. (HPT) is a Corporation duly organized, validly existing, and in good standing under the laws of the State of Ohio. (HPT) has the power and is duly authorized, qualified, franchised, and licensed under all applicable laws, regulations, ordinances, and orders of public authorities to own all of its properties and assets and to carry on its business in all material respects as it is now being conducted, including qualification to do business as a foreign corporation in jurisdictions in which the character and location of the assets owned by it or the nature of the business transacted by it requires qualification. The execution and delivery of this Agreement does not, and the consummation of the transactions contemplated by this Agreement in accordance with the terms hereof will not, violate any provision of (HPT)'s organizational documents. (HPT) has taken all action required by laws, its certificate of incorporation, certificate of business registration, or otherwise to authorize the execution and delivery of this Agreement. (HPT) has full power, authority, and legal right and has taken or will take all action required by law, its Certificate of Incorporation, and otherwise to consummate the transactions herein contemplated.
2.2 Capitalization. All issued and outstanding members units of (HPT) are legally issued, fully paid, and non-assessable and were not issued in violation of the pre-emptive or other rights of any person. (HPT) has no outstanding options, warrants, or other convertible securities.
2.3 Financial Statements.
(a) (HPT) has filed all local income tax returns required to be filed by it from its inception to the date hereof. All such returns are complete and accurate in all material respects.
(b) (HPT) has no liabilities with respect to the payment of federal, county, local, or other taxes (including any deficiencies, interest, or penalties), except for taxes accrued but not yet due and payable , for which (HPT) may be liable in its own right or as a transferee of the assets of, or as a successor to, any other corporation or entity.
(c) No deficiency for any taxes has been proposed, asserted or assessed against (HPT). There has been no tax audit, nor has there been any notice to (HPT) by any taxing authority regarding any such tax audit, or, to the knowledge of (HPT), is any such tax audit threatened with regard to any taxes or (HPT)
tax returns. (HPT) does not expect the assessment of any additional taxes of (HPT) for any period prior to the date hereof and has no knowledge of any unresolved questions concerning the liability for taxes of (HPT).
(d) The books and records, financial and otherwise, of (HPT) are in all material respects complete and correct and have been maintained in accordance with good business and accounting practices.
2.4 Information. The information concerning (HPT) set forth in this Agreement and the (HPT) Schedules (as that tern1 is defined herein) are and will be complete and accurate in all material respects and does not contain any untrue statement of a material fact or omit to state a material fact required to make the statements made, in light of the circumstances under which they were made, not misleading as of the date hereof and as of the Closing Date.
2.5 Membership Units Equivalents. There are no existing options, warrants, calls, commitments of any character or other Membership equivalents relating to the authorized and unissued (HPT) Common Stock.
2.6 Absence of Certain Changes or Events. Except as set forth in this Agreement or the (HPT) Schedules (as that term is defined herein):
(a) except in the normal course of business, there has not been (i) any material adverse change in the business, operations, properties, assets, or condition of (HPT); or (ii) any damage, destruction, or loss to (HPT) (whether or not covered by insurance) materially and adversely affecting the business, operations, properties, assets, or condition of (HPT);
(b) (HPT) has not (i) borrowed or agreed to borrow any funds or incurred, or become subject to, any material obligation or liability (absolute or contingent) not otherwise in the ordinary course of business, and except for capital raised by issuance of debt or equity in a private placement or other capital raising transaction deemed advisable by (HPT); (ii) paid any material obligation or liability not otherwise in the ordinary course of business (absolute or contingent) other than current liabilities reflected in or shown on the most recent (HPT) consolidated balance sheet, and current liabilities incurred since that date in the ordinary course of business; (iii) sold or transferred, or agreed to sell or transfer, any of its assets, properties, or rights not otherwise in the ordinary course of business; (iv) made or permitted any amendment or termination of any contract, agreement, or license to which they are a party not otherwise in the ordinary course of business if such amendment or termination is material, considering the business of (HPT); or (v) issued, delivered, or agreed to issue or deliver any Membership Units (whether authorized and unissued or held as treasury stock).
2.7 Litigation and Proceedings. There are no actions, suits, proceedings, or investigations pending or, to the knowledge of (HPT), threatened by or against (HPT), or affecting (HPT), or its properties, at law or in equity, before any court or other governmental agency or instrumentality, domestic or foreign, or before any arbitrator of any kind.
2.8 No Conflict with Other Instruments. The execution of this Agreement and the consummation of the transactions contemplated by this Agreement will not result in the breach of any term or provision of, or constitute an event of default under, any material indenture, mortgage, deed of trust, or other material contract, agreement, or instrument to which (HPT) is a party or to which any of its properties or operations are subject.
2.9 Contracts. (HPT) has provided, or will provide IVST, copies of all material contracts, agreements, franchises, license agreements, or other commitments to which (HPT) is a party or by which it or any of its assets, products, technology, or properties are bound.
2.10 Compliance with Laws and Regulations. (HPT) has complied with all applicable statutes and regulations of any national, county, or other governmental entity or agency thereof, except to the extent that noncompliance would not materially and adversely affect the business, operations, properties, assets, or condition of (HPT).
2.11 Approval of Agreement. The Members of (HPT) (the "(HPT) Board”) and the (HPT) Membership Owners have authorized the execution and delivery of this Agreement by ("HPT") and have approved the transactions contemplated hereby.
2.12 (HPT) Schedules. (HPT) will deliver, as soon as practicable, the following schedules, which are collectively referred to as the (HPT) Schedules" and which consist of separate schedules dated as of the date of execution of this Agreement and instruments and data as of such date, all certified by the chief executive officer of (HPT) as complete, true and correct:
(a) a schedule containing complete and correct copies of the organizational documents, as amended, of (HPT) in effect as of the date of this Agreement; and
(b) a schedule as requested by IVST , containing true and correct copies of all material contracts, agreements, or other instruments to which (HPT) is a party or by which it or its properties are bound, specifically including all contracts, agreements, or arrangements referred to in Section 2.9.
2.13 Title and Related Matters. (HPT) has good and marketable title to all of its properties, interest in properties, and assets, real and persona l, which are reflected in the (HPT) balance sheet or acquired after that date (except properties, interest in properties, and assets sold or otherwise disposed of since such date in the ordinary course of business), free and clear of all liens, pledges, charges, or encumbrances except:
(a) statutory liens or claims not yet delinquent; and (b)as described in the (HPT) Schedules.
2.14 Governmental Authorizations. (HPT) has all licenses, franchises, permits, and other government authorizations, that are legally required to enable it to conduct its business operations in all material respects as conducted on the date hereof. Except for compliance with federal and state securities or corporation laws, as hereinafter provided, no authorization, approval, consent, or order of, or registration, declaration, or filing with, any court or other governmental body is required in connection with the execution and delivery by (HPT) of this Agreement and the consummation by (HPT) of the transactions contemplated hereby.
2.15 Continuity of Business Enterprises. (HPT) has no commitment or present intention to liquidate (HPT) or sell or otherwise dispose of a material portion of its business or assets following the consummation of the transactions contemplated hereby.
2.16 Ownership of (HPT) Shares. The (HPT) Shareholders are the legal and beneficial owners of 100% of (HPT) which members are set forth on Schedule I, free and clear of any claims, charges, equities, liens , security interests, and encumbrances whatsoever , and the (HPT) Shareholders have full right, power, and authority to transfer, assign, convey, and deliver their respective (HPT) Membership Units and delivery of such Membership Units at the Closing will convey to IVST good and marketable title to such units free and clear of any claims, charges, equities , liens, security interests, and encumbrances except for any such claims, charges, equities, liens, security interests, and encumbrances arising out of such shares being held by IVST.
2.17 Brokers. (HPT) has not entered into any contract with any person, firm or other entity that would obligate (HPT) or IVST to pay any commission, brokerage or finders' fee in connection with the transactions contemplated herein.
2.18 Subsidiaries and Predecessor Corporations. (HPT) does not have any subsidiaries and does not own, beneficially or of record, any shares or other equity interests of any other corporation or entity. This transaction excludes Energy Deals LLC.
2.19 Shareholder understands that the issuance of the Exchange Shares is intended to be exempt from registration under the Securities Act of 1933 , as amended (the "Securities Act"), by virtue of Sections 3(b) and 4(2) of the Securities Act, and Shareholder represents and warrants that: (a) Shareholder has been advised that the Exchange Shares have not been registered under the Securities Act and, therefore , cannot be resold unless they are registered under the Securities Act or unless an exemption from registration is available and the certificates representing the Exchange Shares will be legended accordingly; (b) Shareholder is aware that Shareholder may be required to hold the Exchange Shares for an extended period; (c) Shareholder is purchasing the Exchange Shares for his own account for investment and not with a view to, or for resale in connection with, the distribution thereof , and Shareholder has no present intention of distributing or reselling the Exchange Shares ; (d) Shareholder represents and warrants that he has such knowledge and experience in financial and business matters that he is capable of evaluating the merits and risks of investing in the Exchange Shares and is able to bear the economic risk of such investment; and (e) Shareholder is an "accredited Shareholder" as such term is defined in Rule 501(a) of Regulation D.
ARTICLE III
REPRESENTATIONS, COVENANTS, AND WARRANTIES OF IVST
As an inducement to, and to obtain the reliance of (HPT), IVST represents and warrants as follows:
3.1 Organization. IVST is a corporation duly organized, validly existing , and in good standing under the laws of the State of Nevada, and has the corporate power and is duly authorized, qualified, franchised, and licensed under all applicable laws, regulations, ordinances, and orders of public authorities to own all of its properties and assets and to carry on its business in all material respects as it is now being conducted , and there is no jurisdiction in which it is not qualified in which the character and location of the assets owned by it or the nature of the business transacted by it requires qualification. Included in the IVST Schedules (as hereinafter defined) are complete and correct copies of the Articles of Incorporation and bylaws of IVST, and all amendments thereto, as in effect on the date hereof. The execution and delivery of this Agreement does not, and the consummation of the transactions contemplated hereby will not, violate any provision of IVST ' s Articles of Incorporation or bylaws. IVST has taken all action required by law, its Certificate of Incorporation, its bylaws, or otherwise to authorize the execution and delivery of this Agreement , and IVST has full power, authority, and legal right and has taken all action required by law, its Certificate of Incorporation, By-Laws, or otherwise to consummate the transactions herein contemplated.
3.2 Capitalization. IVST's presently issued and outstanding shares are legally issued, fully paid, and non-assessable and not issued in violation of the pre-emptive or other rights of any person. The Exchange Shares will be legally issued, fully paid and non-- assessable and shall not be issued in violation of the pre-emptive or other rights of any other person.
3.3 Financial Statements. Except as set forth within its filing of reports with the OTC Markets (the "OTC Reports"):
(a) IVST has no liabilities with respect to the payment of any federal, state, county, local, or other taxes (including any deficiencies, interest, or penalties), except for taxes accrued but not yet due and
payable, for which IVST may be liable in its own right, or as a transferee of the assets of, or as a successor to, any other corporation or entity.
(b) The books and records, financial and otherwise, of IVST are in all material respects complete and correct and have been maintained in accordance with good business and accounting practices.
(c) No deficiency for any taxes has been proposed, asserted or assessed against IVST. There has been no tax audit, nor has there been any notice to IVST by any taxing authority regarding any such tax audit, or, to the knowledge of IVST, is any such tax audit threatened with regard to any taxes or IVST tax returns. IVST does not expect the assessment of any additional taxes of IVST for any period prior to the date hereof and has no knowledge of any unresolved questions concerning the liability for taxes of IVST.
(d) IVST has good and marketable title to its assets and, except as set forth in the IVST Schedules, has no material contingent liabilities, direct or indirect, matured or unmatured.
3.4 Information. The information concerning IVST set forth in this Agreement and the IVST Schedules are and will be complete and accurate in all material respects and does not contain any untrue statement of a material fact or omit to state a material fact required to make the statements made, in light of the circumstances under which they were made, not misleading as of the date hereof and as of the Closing Date.
3.5 Absence of Certain Changes or Events. Except as described herein or in the IVST Schedules:
(a) There has not been (i) any material adverse change, financial or otherwise, in the business, operations, properties, assets, or condition of IVST (whether or not covered by insurance) materially and adversely affecting the business, operations, properties, assets, or condition of IVST;
(b) To the best knowledge of IVST, it has not become subject to any law or regulation which materially and adversely affects, or in the future may adversely affect, the business, operations, properties, assets, or condition of IVST.
3.6 Litigation and Proceedings. There are no actions, suits, or proceedings pending or, to the knowledge of IVST, threatened by or against or affecting IVST, at law or in equity, before any court or other governmental agency or instrumentality, domestic or foreign, or before any arbitrator of any kind .
3.7 No Conflict With Other Instruments. The execution of this Agreement and the consummation of the transactions contemplated by this Agreement will not result in the breach of any term or provision of, or constitute a default under , any indenture, mortgage, deed of trust, or other material agreement or instrument to which IVST is a party or to which it or any of its assets or operations are subject.
3.8 Governmental Authorizations. IVST is not required to have any licenses, franchises, permits, and other government authorizations, that are legally required to enable it to conduct its business operations in all material respects as conducted on the date hereof. Except for compliance with federal and state securities or corporation laws, as hereinafter provided, no authorization, approval, consent, or order of, or registration, declaration, or filing with, any court or other governmental body is required in connection with the execution and delivery by IVST of this Agreement and the consummation by IVST of the transactions contemplated hereby.
3.9 Compliance With Laws and Regulations. To the best of its knowledge, IVST has complied with all applicable statutes and regulations of any federal, state, or other applicable governmental entity or agency thereof, except to the extent that noncompliance would not materially and adversely affect the business, operations, properties, assets, or conditions of IVST or except to the extent that noncompliance would not result in the incurrence of any material liability.
3.10 Insurance. IVST owns no insurable properties and carries no casualty or liability insurance.
3.11 Approval of Agreement. The board of directors of IVST (the "l VST Board") has authorized the execution and delivery of this Agreement by IVST and has approved this Agreement and the transact ions contemplated hereby.
3.12 Brokers. IVST has not entered into any contract with any person, firm or other entity that would obligate (HPT) or IVST to pay any commission, brokerage or finders' fee in connection with the transactions contemplated herein.
ARTICLE IV
SPECIAL COVENANTS
4.7 Indemnification.
(a)(HPT) hereby agrees to indemnify IVST and each of the officers, agents and directors of IVST as of the date of execution of this Agreement against any loss , liability, claim, damage , or expense (including, but not limited to, any and all expense whatsoever reasonably incurred in investigating, preparing , or defending against any litigation, commenced or threatened, or any claim whatsoever), to which it or they may become subject arising out of or based on any inaccuracy appearing in or misrepresentation made in Article II. The indemnification provided for in this paragraph shall not survive the Closing and consummation of the transactions contemplated hereby but shall survive the termination of this Agreement pursuant to Section 7.1(b) of this Agreement.
(b)IVST hereby agrees to indemnify (HPT) and each of the officers, agents and directors of ("HPT") as of the date of execution of this Agreement against any loss, liability , claim, damage, or expense (including, but not limited to, any and all expense whatsoever reasonably incurred in investigating, preparing, or defending against any litigation, commenced or threatened, or any claim whatsoever), to which it or they may become subject arising out of or based on any inaccuracy appearing in or misrepresentation made under Article III. The indemnification provided for in this paragraph shall not survive the Closing and consummation of the transactions contemplated hereby but shall survive the termination of this Agreement pursuant to Section 7. l(c) of this Agreement.
ARTICLE V
CONDITIONS PRECEDENT TO OBLIGATIONS OF IVST
The obligations of IVST under this Agreement are subject to the satisfaction, at or before the Closing, of the following conditions:
5.1 Accuracy of Representations; Performance. The representations and warranties made by (HPT) in this Agreement were true when made and shall be true at the Closing Date with the same force and effect as if such representations and warranties were made at and as of the Closing Date (except for changes therein permitted by this Agreement), and (HPT) shall have performed or complied with all covenants and conditions required by this Agreement to be performed or complied with by (HPT) prior to or at the Closing. IVST may request to be furnished with a certificate, signed by a duly authorized officer of (HPT) and dated the Closing Date, to the foregoing effect.
5.2 Officer's Certificates. IVST shall have been furnished with a certificate dated the Closing Date and signed by a duly authorized officer of (HPT) to the effect that no litigation, proceeding, investigation, or inquiry is pending or, to the best knowledge of (HPT" ) threatened, which might result in an action to enjoin or prevent the consummation of the transactions contemplated by this Agreement, or, to the extent not disclosed in the (HPT) Schedules, by or against (HPT) which might result in any material adverse change in any of the assets, properties, business, or operations of (HPT).
5.3 No Material Adverse Change. Prior to the Closing Date, there shall not have occurred any material adverse change in the financial condition, business, or operations of (HPT), nor shall any event have occurred which , with the lapse of time or the giving of notice , may cause or create any material adverse change in the financial condition, business, or operations.
5.4 Other Items.
(a) IVST shall have received such further documents, certificates, or instruments relating to the transactions contemplated hereby as IVST may reasonably request.
(b) Complete and satisfactory due diligence review of (HPT) by IVST. (c)Approval of the Transaction by the (HPT) Board and the (HPT) Shareholders.
(d)Any necessary third-party consents shall be obtained prior to Closing, including but not limited to consents necessary from (HPT)'s lenders, creditors, vendors and lessors.
ARTICLE VI
CONDITIONS PRECEDENT TO OBLIGATIONS OF (HPT)
The obligations of (HPT) under this Agreement are subject to the satisfaction, at or before the Closing, of the following conditions:
6.1 Accuracy of Representations; Performance. The representations and warranties made by IVST in this Agreement were true when made and shall be true as of the Closing Date (except for changes therein permitted by this Agreement) with the same force and effect as if such representations and warranties were made at and as of the Closing Date, and IVST shall have performed and complied with all covenants and conditions required by this Agreement to be performed or complied with by IVST prior to or at the Closing. (HPT) shall have been furnished with a certificate, signed by a duly authorized executive officer of IVST and dated the Closing Date, to the foregoing effect.
6.2 No Material Adverse Change. Prior to the Closing Date, there shall not have occurred any material adverse change in the financial condition, business, or operations of IVST nor shall any event have occurred which, with the lapse of time or the giving of notice, may cause or create any material adverse change in the financial condition, business, or operations of IVST.
ARTICLE VII
MISCELLANEOUS
7.1 Governing Law. This Agreement shall be governed by, enforced, and construed under and in accordance with the laws of the United States of America and, with respect to matters of state law, with the laws of Ohio. Any dispute arising under or in any way related to this Agreement will be submitted to binding arbitration before a single arbitrator by the American Arbitration Association in accordance with the Association's commercial rules then in effect. The arbitrator shall be mutually selected. The arbitration will be conducted in Cleveland, Ohio. The decision of the arbitrator will set forth in reasonable detail the basis for the decision and will be binding on the parties. The arbitration award may be confirmed by any court of competent jurisdiction.
7.2 Notices. Any notices or other communications required or permitted hereunder shall be sufficiently given if personally delivered to it or sent by registered mail or certified mail, postage prepaid, or by prepaid telegram and any such notice or communication shall be deemed to have been given as of the date so delivered, mailed, or telegraphed.
HPT:
Dennis Giancola
33648 St Francis Drive
Avon, OH 44011
IVST:
lnnovest Global Inc.
8456 E Washington St.
Chagrin Falls, OH 44023
7.3 Attorney's Fees. In the event that any party institutes any action or suit to enforce this Agreement or to secure relief from any default hereunder or breach hereof, the breaching party or parties shall reimburse the non-breaching party or parties for all costs, including reasonable attorneys ' fees, incurred in connection therewith and in enforcing or collecting any judgment rendered therein.
7.4 Confidentiality. IVST, on the one hand, and (HPT) and the (HPT) Shareholders, on the other hand, will keep confidential all information and materials regarding the other Party designated by such Party as confidential. The provisions of this Section 7.4 shall not apply to any information which is or shall become part of the public domain through no fault of the Party subject to the obligation from a third party with a right to disclose such information free of obligation of confidentiality. IVST and (HPT) agree that no public disclosure will be made by either Party of the existence of the Transaction or the letter of intent or any of its terms without first advising the other Party and obtaining its prior written consent to the proposed disclosure, unless such disclosure is required by law, regulation or stock exchange rule.
7.5 Expenses. Except as otherwise set forth herein, each party shall bear its own costs and expenses associated with the transactions contemplated by this Agreement. Without limiting the generality of the foregoing, all costs and expenses incurred by (HPT) and IVST after the Closing shall be borne by the surviving entity. After the Closing, the costs and expenses of the (HPT) Shareholders shall be borne by the (HPT) Shareholders.
7.6 Schedules; Knowledge. Each party is presumed to have full knowledge of all information set forth in the other party's schedules delivered pursuant to this Agreement.
7.7 Third Party Beneficiaries. This contract is solely between IVST, (HPT) and the (HPT) Shareholders, and, except as specifically provided, no director, officer, stockholder, employee, agent, independent contractor, or any other person or entity shall be deemed to be a third party beneficiary of this Agreement.
7.8 Entire Agreement. This Agreement represents the entire agreement between the parties relating to the transaction. There are no other courses of dealing, understandings, agreements, representations, or warranties, written or oral, except as set forth herein.
7.9 Survival. The representations and warranties of the respective parties shall survive the Closing Date and the consummation of the transactions herein contemplated.
7.10 Counterparts. This Agreement may be executed in multiple counterparts, each of which shall be deemed an original and all of which taken together shall be but a single instrument.
7.11 Amendment or Waiver. Every right and remedy provided herein shall be cumulative with every other right and remedy, whether conferred herein, at law, or in equity, and may be enforced concurrently herewith, and no waiver by any party of the performance of any obligation by the other shall be construed as a waiver of the same or any other default then, theretofore, or thereafter occurring or existing. At any time prior to the Closing Date, this Agreement may be amended by a writing signed by all parties hereto, with respect to any of the terms contained herein, and any term or condition of this Agreement may be waived or the time for performance hereof may be extended by a writing signed by the party or parties for whose benefit the provision is intended.
(The rest of this page left intentionally blank.)
IN WITNESS WHEREOF, the corporate parties hereto have caused this Agreement to be executed by their respective officers, hereunto duly authorized, as of the date first above- written.
INNOVEST GLOBAL, INC.
By: Damon Mintz, President, Innovest Energy Group
/s/Damon Mintz
H.P. Technologies, Inc
By: Dennis Giancola, CEO
/s/Dennis Giancola
SCHEDULE I
Dated: March 22, 2018
The following persons are the only owners of the capital stock of (HPT):
SCHEDULE 1
SHARES TO BE ISSUED
DENNIS GIANCOLA 1,500,000
SCHEDULE II
STOCK EXCHANGE AGREEMENT RESOLUTION
The undersigned Shareholder of H.P. Technologies Inc., duly organized under the laws of Ohio, hereby certify that a resolution was duly adopted by said Shareholder on March 22, 2018, and that such resolution has not been modified or rescinded as of the date hereof:
RESOLVED, that the Share Exchange Agreement attached hereto was unanimously approved. Dennis Giancola has been approved to execute it.
H.P. Technologies, Inc
By: Dennis Giancola, CEO
/s/Dennis Giancola
Exhibit 2.5
ASSET PURCHASE AGREEMENT
This Agreement entered into this the 1st day of January,2019 by and among Primary Metering Solutions LLC, (hereinafter "Seller"), and Innovest Global Inc. (hereinafter "Buyer").
WHEREAS, Seller operates a business primarily engaged in the manufacture of energy efficiency products, as broadly defined; and
WHEREAS, Seller owns telephone numbers, designs, builds, intellectual property, websites, marketing materials, equipment, inventory, sales contracts, and miscellaneous assets used in connection with the operations of its business; and
WHEREAS, Buyer desires to acquire substantially all of the assets used or useful or intended to be used in the operation of Sellers business and Seller desires to sell such assets to Buyer.
NOW, THEREFORE, in consideration of mutual covenants contained herein and other good and valuable consideration the receipt and sufficiency of which is hereby acknowledged, the parties agree as follows:
SECTION 1. ASSETS PURCHASED
1.1 ASSETS PURCHASED. Seller agrees to sell to Buyer and Buyer agrees to purchase from Seller, on the terms and conditions set forth in this Agreement, the following assets.
1.1.1 All equipment including computers, fixtures, marketing materials, miscellaneous inventory, together with any replacements or additions to the equipment, etc. made prior to the closing date.
1.1.2 All inventories and supplies owned by Seller together with any replacements or additions to the inventories made prior to the closing date, but excluding inventory disposed of in the ordinary course of Seller's business.
1.1.3 Seller's goodwill and customer lists.
1.1.4 The name "Primary Metering Solutions" And websites, telephone numbers, etc.
1.1.5 The accounts receivable as of the date of Closing.
1.1.6 All bank and merchant accounts.
1.1.7 All contracts for sales, estimated at $275,000 currently, but unlimited and all- inclusive.
1.1.6 All intellectual property, designs, and builds.
1.2 ASSUMPTION OF LIABILITIES
Buyer shall not be responsible for any current liabilities of Seller, except for those intrinsic to the contracts which have yet to be performed.
SECTION 2. EXCLUDED ASSETS
Excluded from this sale and purchase are Seller's:
a. Personal Property listed on Schedule "A" hereto.
SECTION 3. PURCHASE PRICE FOR ASSETS
The purchase price for the assets shall be $175,000.
SECTION 4. PAYMENT OF PURCHASE PRICE
The price for the Assets shall be paid as follows:
4.1 1,000,000 (one-million) restricted Shares of IVST stock at $0.15 per share. Seller understands that the issuance of the Shares is intended to be exempt from registration under the Securities Act of 1933, as amended (the "Securities Act"), by virtue of Sections 3(6) and 4(2) of the Securities Act, and Seller represents and warrants that: (a) Seller has been advised that the Exchange Shares have not been registered under the Securities Act and, therefore, cannot be resold unless they are registered under the Securities Act or unless an exemption from registration is available and the certificates representing the Exchange Shares will be legended accordingly; (b) Seller is aware that Seller may be required to hold the Exchange Shares for an extended period; (c) Seller is purchasing the Exchange Shares for his own account for investment and not with a view to, or for resale in connection with, the distribution thereof, and Seller has no present intention of distributing or reselling the Exchange Shares; (d) Seller represents and warrants that he has such knowledge and experience in financial and business matters that he is capable of evaluating the merits and risks of investing in the Exchange Shares and is able to bear the economic risk of such investment; and (e) Seller is an "accredited Stockholder" as such term is defined in Rule 50l(a) of Regulation D.
4.2 $25,000 to be paid in cash on or before April 1, 2019.
SECTION 6. SELLER'S AND SELLER'S MEMBERS' REPRESENTATIONS AND WARRANTIES
Seller and Seller's Members each represent and warrant to Buyer as follows:
6.1 EXISTENCE OF CORPORATION. Seller is now and on the date of closing will be a Corporation duly organized and validly existing and in good standing under the laws of the State of Ohio. Seller has all requisite power and authority to own, operate and/or lease the assets, as the case may be, and to carry on its business as now being conducted.
6.2 AUTHORIZATION. The execution, delivery and performance of this Agreement have been duly authorized and approved by Seller, and this Agreement constitutes a valid and binding agreement of Seller in accordance with its terms.
6.3 TITLE TO ASSETS. Except as described in the Agreement, Seller holds good and marketable title to the assets, free and clear of restrictions on or conditions to transfer or assignment, and free and clear of liens, pledges, charges or encumbrances.
6.4 TRANSFER NOT SUBJECT TO ENCUMBRANCES OR THIRD-PARTY APPROVAL. The execution and delivery of this Agreement by Seller and Seller's Members, and the consummation of the contemplated transactions, will not result in the creation or imposition of any valid lien, charge or encumbrance on any of the assets, and will not require the authorization, consent, or approval of any third party, including any governmental division or regulatory agency.
6.5 LABOR AGREEMENTS AND DISPUTES. Seller is neither a party to, nor otherwise subject to any collective bargaining or other agreement governing the wages, hours, in terms of employment of Seller's employees. Neither Seller nor Seller's Members is aware of any labor dispute or labor trouble involving employees of Seller.
6.6 NONCANCELLABLE CONTRACTS. At the time of closing, there will be no material leases, employment contracts, contracts for services, or maintenance, or other similar contacts, existing or related to or connected with the operation of Seller's business not cancelable within ninety (90) days.
6.7 LITIGATION. Seller has no knowledge of any claim, litigation, proceeding, or investigation pending or threatened against Seller that might result in any material adverse change in the business or condition of the assets being conveyed under this Agreement.
6.8 ACCURACY OF REPRESENTATIONS AND WARRANTIES. None of the representations or warranties of Seller or Seller's Members contain or will contain any untrue statements of a material fact or omit or will omit or misstate a material fact necessary in order to make statements in this Agreement not misleading. Seller and Seller's Members know of no fact that has resulted, or that in the reasonable judgment of Seller's Members will result in material change in the business, operations, or assets of Seller that has not been set forth in this Agreement or otherwise disclosed to Buyer.
SECTION 7. REPRESENTATIONS OF BUYER
Buyer represents and warrants as follows:
7.1 CORPORATE EXISTENCE. Buyer is a corporation duly organized, validly existing, and in good standing under the laws of the State of Ohio. Buyer has all requisite corporate power and authority to enter into this Agreement and perform its obligations hereunder.
7.2 AUTHORIZATION. The execution, delivery and performance of this Agreement have been duly authorized and approved by the Board of Directors and shareholders of Buyer, and this Agreement constitutes a valid and binding agreement of Buyer in accordance with its terms.
7.3 ACCURACY OF REPRESENTATIONS AND WARRANTIES. None of the representations or warranties of Buyer contain or will contain any untrue statement of a material fact or omit or will omit or misstate a material fact necessary in order to make the misstatements contained herein not misleading.
SECTION 8. COVENANTS OF SELLER AND SELLER'S MEMBERS
8.1 SELLER'S OPERATION OF BUSINESS PRIOR TO CLOSING. Seller- and Seller's Members agree that between the date of this Agreement and the date of closing, Seller will:
8.1.1 Use its best efforts to preserve its business organization and preserve the continued operation of its business with its customers, suppliers, and others having business relations with Seller.
8.1.2 Not assign, sell, lease or otherwise transfer or dispose of any of the assets listed on the balance sheet, except to Buyer.
8.1.3 Maintain all of its assets other than inventories in their present conditions, reasonable wear and tear and ordinary usage accepted and maintain the inventories at levels normally maintained.
8.2 ACCESS TO PREMISES AND INFORMATION. At reasonable times prior to the closing date, Seller will provide Buyer and its representatives with reasonable access during business hours to the assets, titles, contracts and records of Seller and furnish such additional information concerning Seller's businesses Buyer may from time to time reasonably request.
8.3 EMPLOYEE MATTERS.
8.3.1 Prior to closing, Seller will deliver to Buyer a list of the names of all persons on the payroll of Seller, together with a statement of amounts paid to each during Seller's most recent fiscal year and amounts paid for services from the beginning of the current fiscal year to the closing date. Seller will also provide Buyer with a schedule of all employee bonus arrangements and a schedule of other material compensation including commission structure and personnel benefits or policies in effect.
8.3.2 Prior to the closing date, Seller will not, without Buyer's prior written consent, enter into any material agreements with its employees, increase the rate of compensation or bonus payable to or to become payable to any employee or effect any change in the management, personnel policies, or employee benefits, except in accordance with existing employment practices.
8.3.3 As of or prior to the closing date, Seller will retain all of its employees, except Seller's Members, not having employee agreements transferable to Buyer and will pay each employee all wages, commissions, and accrued vacation pay earned up to the time of termination, including overtime pay.
8.4 CONDITIONS AND BEST EFFORTS. Seller will use its best efforts to effectuate the transactions contemplated by this Agreement and to fulfill all the conditions of the obligations of Seller under this Agreement, and will do all acts and things as may be required to carry out its respective obligations under this Agreement and to consummate and complete this agreement. Seller will be required to provide all financial and other company information required to close this transaction within a timely manner as set forth per the Lender.
SECTION 9. COVENANTS OF BUYER
9.1 CONDITIONS AND BEST EFFORTS. Buyer will use its best efforts to effectuate the transaction contemplated by this Agreement and to fulfill all the conditions of Buyer's obligations under this Agreement, and shall do all acts and things as may be required to carry out Buyer's obligations and to consummate this Agreement.
9.2 CONFIDENTIAL INFORMATION. If for any reason the sale of Assets is not closed, Buyer will not disclose to third parties any confidential information received from Seller or Selling Shareholder in the course of investigating, negotiating, and performing the transactions contemplated by this Agreement.
SECTION 10. CONDITIONS PRECEDENT TO BUYER'S OBLIGATIONS
The obligation of Buyer to purchase the Assets is subject to the fulfillment, prior to or at the closing date, of each of the following conditions, any one or portion of which may be waived in writing by Seller:
10.1 REPRESENTATIONS, WARRANTIES AND COVENANTS AND SELLING SHAREHOLDER. All representations and warranties made in this Agreement by Seller and Seller's Members shall be true as of the closing date as fully as those such representations and warranties had been made on or as of the closing date, and, as of the closing date, neither Seller nor Seller's Members shall have violated or shall have failed to perform in accordance with any covenant contained in this Agreement.
10.2 LICENSES AND PERMITS. Buyer shall be responsible for obtaining all licenses and permits from public authorities necessary to authorize the ownership and operation of the business of Seller.
10.3 CONDITIONS OF THE BUSINESS. There shall have been no material adverse change in the manner of the operation of Seller's business prior to the closing date.
10.4 NO SUITS OR ACTIONS. At the closing date, no suit, action or other proceeding shall have been threatened or instituted to restrain, enjoin or otherwise prevent the consummation of this Agreement or the contemplated transactions.
SECTION 11. CONDITIONS PRECEDENT TO OBLIGATIONS OF SELLER
The obligations of Seller to consummate the transactions contemplated by this Agreement are subject to the fulfillment, prior to or at the closing date, of the following condition, which may be waived in writing by Buyer:
All representations and warranties made in this Agreement by Seller shall be true as of the closing date as fully as though such representations and warranties have been made on and as of the closing date, and Seller shall not have violated or shall not have failed to perform in accordance with any covenant contained in this Agreement.
SECTION 12. BUYER'S ACCEPTANCE
Buyer represents and acknowledges that it has entered into this Agreement on the basis of its own examination, personal knowledge, and opinion of the value of the business. Buyer has not relied on any representations made by Seller other than those specified in this Agreement. Buyer further acknowledges that Seller has made no agreement or promise to repair or improve any equipment, rolling stock (inventory) or other personal property being sold to Buyer under this Agreement, and that Buyer takes all such property in the condition existing on the date of this Agreement, except as otherwise provided in this Agreement.
SECTION 13. INDEMNIFICATION AND SURVIVAL
13.1 SURVIVAL OF REPRESENTATIONS AND WARRANTIES. All representations and warranties made in this Agreement shall survive the closing of this Agreement, except that any party to whom a representation of warranty has been made in this Agreement shall be deemed to have waived any misrepresentation or breach of representation or warranty which such party had knowledge of prior to closing. Any party learning of a misrepresentation or breach of representation or warranty under this Agreement shall immediately give notice thereof to all other parties to this Agreement. The representations and warranties in this Agreement shall terminate three (3) years from the closing date, and such representations or warranties shall thereafter be without force or effect, except any claim with respect to which notice has been given to the party to be charged prior to such expiration date.
13.2 SELLERS AND SELLER'S MEMBERS INDEMNIFICATION.
13.2.1 Seller and Seller's Members each hereby agree to indemnify and hold Buyer, its successors and assigns harmless from and against:
(1) Any and all claims, liabilities and obligations of every kind and description, contingent or otherwise, arising out of or related to the operation of Seller's business prior to the close of business on the day before the closing date, except for claims, liabilities and obligations of Seller expressly assumed by Buyer under this agreement or paid by insurance maintained by Seller or Buyer.
(2) Any and all damage or deficiency resulting from any material misrepresentation or breach of warranty or covenant, or nonfulfillment of any agreement on the part of Seller or Seller's Members under this agreement.
13.2.2 Sellers and Seller's Members indemnity obligations under 14.2.1 shall be subject to the following:
(1) If any claim is asserted against Buyer that would give rise to a claim by Buyer against Seller and Seller's Members for indemnification under the provisions of this paragraph, the Buyer shall promptly give written notice to Seller concerning such claim and Seller shall, at no expense to Buyer, defend the claim.
(2) Seller shall not be required to indemnify Buyer for any amount that exceeds the total purchase price paid by Buyer under Section 3 of this Agreement.
13.3 BUYERS INDEMNIFICATION. Buyer agrees to defend, indemnify and hold harmless Seller and Seller's Members from and against:
13.3.1 Any all claims, liabilities and obligations of every kind and description arising out of or related to the operation of the business following closing or arising out of Buyer's failure to perform obligations of Seller assumed by Buyer pursuant to this agreement.
13.3.2 Any and all damage or deficiency resulting from any material misrepresentation, breach of warranty or covenant, or nonfulfillment of any agreement on the part of Buyer under this agreement.
SECTION 14. CLOSING
14.1 TIME AND PLACE. This agreement shall be closed at a location to be agreed upon by the party’s effective 1st day of January 2019, or such other time as the parties may agree in writing. If the closing has not occurred on or before January 15, 2019, then either party may elect to terminate this agreement. If, however, the closing has not occurred because of a breach of contract by one or more of the parties, the breaching party or parties shall remain liable for breach of contract.
15.2 OBLIGATIONS OF SELLER AT CLOSING. At the closing, Seller and Seller's Members shall deliver to Buyer the following:
15.2.1 Bills of Sale, Assignments, properly endorsed Certificates of Title, and other instruments of transfer, in a form and substance reasonably satisfactory to counsel for Buyer, necessary to transfer and convey all of the assets to Buyer.
15.2.3 Such other certificates and documents as may be called for by the provisions of this Agreement.
15.3 OBLIGATIONS OF BUYER AT CLOSING. At the closing Buyer shall deliver to Seller the following:
15.3.1 Note in the amount specified in Section 4.1. plus, Buyer's share of any closing costs.
15.3.2 Such other certificates and documents as may be called for by the provisions of this Agreement.
SECTION 16. RIGHTS AND OBLIGATIONS SUBSEQUENT TO CLOSING
16.1 BOOKS AND RECORDS. This sale does include the books of account and records of Seller's business. Buyer will exercise reasonable care in the safekeeping of such records.
16.2 SELLER'S RIGHT TO PAY. In the event Buyer fails to make any payment of taxes, assessments, insurance premiums, or other charges that Buyer is required to pay to third parties under this Agreement, Seller shall have the right, but not the obligation, to pay the same. Buyer will reimburse Seller for any such payment immediately upon Seller's demand, together with interest at the same rate provided in the Note from the date of Seller's payment until Buyer reimburses Seller. Any such payment by Seller shall not constitute a waiver by Seller of any remedy available by reason of Buyer's default for failure to make the payments.
SECTION 17. BULK SALES LAW. Buyer waives compliance by Seller with the Bulk Transfer Act. In the event any creditor of Seller claims the benefit of the Bulk Transfer Law as against Buyer or
any of the assets being conveyed to Buyer under this Agreement, Seller shall immediately pay or otherwise satisfy such claim or undertake its defense. Seller shall indemnify and hold Buyer harmless from and against any and all loss, expense, or damage resulting from the failure to comply with the Bulk Transfer law. If Seller fails to comply with the provision of this Section 17 and Buyer is required to pay any creditor of Seller in order to protect the property purchased under this agreement from claims or liens of Seller's creditors, except those assumed by Buyer, the Buyer may offset the amount it pays against the balance due Seller by furnishing to the Seller proof of such payment in the form of a receipt from the creditor involved.
SECTION 18. TERMINATION OF AGREEMENT
18.1 BY MUTUAL CONSENT. This Agreement may be terminated by mutual written consent of Buyer and Seller.
18.2 BREACH OF REPRESENTATIONS AND WARRANTIES; FAILURE OF CONDITIONS. Buyer may elect by notice to Seller, and Seller may elect by notice to Buyer, to terminate this Agreement if.
18.2.1 The terminating party shall have discovered a material error, misstatement, or omission in the representations and warranties made in this Agreement by the other party which shall not have been cured by such other party within fifteen (15) days after written notice to such other party specifying in detail such asserted error, misstatement, or omission, or by the closing date, whichever first occurs.
18.2.2 All of the conditions precedent of the terminating party's obligations under this Agreement as set forth in either Section 11 or 12, as the case may be, have not occurred and have not been waived by the terminating party on or prior to the closing date.
18.3 CLOSING NOTWITHSTANDING THE RIGHT TO TERMINATE. The party with a right to terminate this Agreement pursuant to Section 18.2.1 or 18.2.2 shall not be bound to exercise such right, and its failure to exercise such right shall not constitute a waiver of any other right it may have under this Agreement, including but not limited to remedies for breach of a representation, warranty, or covenant.
18.4 CONTINGENT UPON OTHER AGREEMENT. Closing is contingent upon, and shall not occur in the absence of, Buyer entering into an employment agreement with Tom Eichele simultaneous to Closing.
SECTION 19. MISCELLANEOUS
19.1 The provisions of this Agreement shall be binding upon and inure to the benefit of the heirs, personal representatives, successors, and assigns of the parties.
19.2 Any notice or other communication required or permitted to be given under this Agreement shall be in writing and shall be mailed by certified mail, return receipt requested, postage prepaid, addressed to the parties as follows:
All notices and other communications shall be deemed to be given at the expiration of three (3) days after the date of mailing. The addresses to which notices or other communications shall be mailed may be changed from time to time by giving written notice to the other parties as provided above.
19.3 In the event of a default under this Agreement, the defaulting party shall reimburse the non-defaulting party or parties for all costs and expenses reasonably incurred by the non-defaulting party or parties in connection with the default, including without limitation attorney fees. Additionally, in the event a suit or action is filed to enforce this Agreement or with respect to this Agreement, the prevailing party or parties shall be reimbursed by the other party for all costs and expenses incurred in connection with the suit or action, including without limitation reasonable attorney fees at the trial level and on appeal.
19.4 No waiver of any provision of this Agreement shall be deemed, or shall constitute, a waiver of any other provision, whether or not similar, nor shall any waiver constitute a continuing waiver. No waiver shall be binding unless executed in writing by the party making the waiver.
19.5 This Agreement shall be governed by and shall be construed in accordance with the laws of the State of Ohio.
19.6 This Agreement constitutes the entire agreement between the parties pertaining to its subject matter and it supersedes all prior contemporaneous agreements, representations, and understandings of the parties. No supplement, modification, or amendment of this Agreement shall be binding unless executed in writing by all parties.
The remainder of this page is intentionally blank
Witness the signatures of the parties this 3rd day of January 2019.
SELLER:
Primary Metering Solutions LLC
By: Tom Eichele, President
/s/Tom Eichele
BUYER:
Innovest Global Inc.
By: Damon Mintz, Presdient
/s/Damon Mintz
Exhibit 2.6
Midwest Draft
December 18, 2018
SHARE EXCHANGE AGREEMENT
AND
PLAN OF REORGANIZATION
THIS SHARE EXCHANGE AGREEMENT AND PLAN OF REORGANIZATION (this "Agreement"), is entered into on the date of the last execution of this Agreement (the "Signature Date"), to be effective as of December I, 2018 (the "Effective Date") by and between Innovest Global, Inc., a publicly-owned Nevada corporation ("IVST"), and Michael S. Kelly, as Executor of the Estate of Donald F. Kelly, Jr. ("Kelly, as Executor"). IVST, Kelly, as Executor, and Midwest Curtainwalls, Inc., where applicable, are sometimes hereinafter collectively referred to as the “Parties” and individually as a "Party."
WITNESSETH
A) WHEREAS, IVST is a publicly-owned Nevada corporation and is quoted on the Over the Counter Bulletin Board under the symbol (IVST).
B) WHEREAS, Kelly, as Executor, is the duly-appointed Executor of the Estate of Donald F. Kelly, Jr., Cuyahoga County Probate Court No. 2018-EST-236072 (the "Estate").
C) WHEREAS, prior to his death, Donald F. Kelly, Jr. ("Don Kelly") owned and operated Midwest Curtainwalls, Inc., an Ohio corporation ("Midwest"), which designs and fabricates custom building envelope and curtainwall systems for construction projects throughout the United States and the world.
D) WHEREAS, the Estate owns, and Kelly, as Executor, has the authority to sell 402 fully-paid and nonassessable shares of common stock of Midwest which constitute all of the issued and outstanding shares of stock of Midwest (the "Midwest Stock").
E) WHEREAS, the Parties desire that IVST acquire all of the Midwest Stock from Kelly, as Executor, in exchange for an aggregate of 1,600,000 newly-issued shares of Restricted Common Stock of IVST (the "Exchange Shares") pursuant to the terms and conditions set forth in this Agreement.
F) WHEREAS, following the Closing, Midwest will be a wholly-owned subsidiary of IVST.
G) WHEREAS, the Parties intend that the share exchange transaction contemplated by this Agreement (the "Transaction") qualify as a reorganization and tax-free exchange under Section 368(a) of the Internal Revenue Code of 1986, as amended (the "IRC").
NOW THEREFORE, on the basis of the premises stated above and for and in consideration of (i) the foregoing recitals, which are hereby incorporated by reference, (ii) the mutual covenants and agreements hereinafter set forth, and (iii) the mutual benefits to the Parties to be derived here from, and for other good and valuable consideration, the sufficiency and receipt of which are hereby acknowledged, the Parties hereto agree as follows:
ARTICLE I
PLAN OF EXCHANGE
1.1 The Plan of Exchange. The plan of reorganization embodied in this Agreement shall be a reorganization within the meaning of Section 368(a)(l)(B) of the IRC. IVST shall acquire all of the outstanding Midwest Stock in exchange solely for a part of lVST's voting common stock.
1.2 The Exchange. Upon the Closing (as hereinafter defined), Kelly, as Executor, shall deliver to IVST a certificate for one hundred percent (100%) of the Midwest Stock in exchange for one or more certificates for the Exchange Shares. The certificate for the Midwest Stock shall be accompanied by a stock power duly endorsed in blank by Kelly, as Executor. The certificate(s) for the Exchange Shares shall be accompanied by duly-executed stock powers in blank with signatures guaranteed by a recognized securities guarantee program.
1.3 Guarantee of Future Value of the Exchange Shares. IVST hereby agrees and guarantees that the market price of the Exchange Shares, as reported by OTC Markets, Inc. or another nationally-recognized financial reporting service, will be at least $L25 per share (at closing price) by the second anniversary of the Effective Date or any 10-day average closing price of the stock (the "Determination Date"). In the event that such market price is less than $1.25 per share on the Determination Date, IVST shall issue to Kelly, as Executor, or in the name of no more than four (4) nominees, the number of additional shares necessary to achieve an aggregate value of $2,000,000 for the Exchange Shares plus the newly-issued shares as of the Determination Date, using the per-share market price on the Determination Date. Such issuance shall occur within thirty (30) days of the Determination Date and shall be in the form of one or more additional certificate(s) accompanied by duly-executed stock powers in blank with signatures guaranteed by a recognized securities guarantee program.
1.4 Repayment of Don Kelly's Shareholder Loan. The Parties acknowledge and agree that on March 21, 2018 Don Kelly made a personal loan to Midwest in the original principal amount of $400,000, which loan bears simple interest at the rate of 6% per annum (the "Shareholder Loan"), as evidenced by a written Promissory Note Agreement (the "Note"). Upon the Closing, IVST shall purchase the Note from the Estate for the issuance and delivery to Kelly, as Executor, of 400,000 additional shares of IVST Restricted Common Stock (the "Loan Purchase Shares"). Upon the Closing, IVST shall deliver to Kelly, as Executor, one or more certificates representing the Loan Purchase Shares, accompanied by duly-executed stock powers in blank with signatures guaranteed by a recognized securities guarantee program. Upon the Closing, Kelly, as Executor, will endorse the Note payable to the order of IVST, without recourse, and deliver the original endorsed Note to IVST.
1.5 Guarantee of Future Value of the Loan Purchase Shares. IVST hereby agrees and guarantees that the market price of the Loan Purchase Shares, as reported by OTC Markets, Inc. or another nationally-recognized financial reporting service, will be at least $1.00 per share (at closing price) on the Determination Date. In the event that such market price is less than $1.00 per share on the Determination Date, IVST shall issue to Kelly, as Executor, or in the name of no more than four (4) nominees, the number of additional shares necessary to achieve an aggregate value of $400,000 for the Loan Purchase Shares plus the newly-issued shares as of the Determination Date, using the per-share market price on the Determination Date. Such issuance shall occur within thirty (30) days of the Determination Date and shall be issue by IVST’s transfer agent to a specific party.
1.6 Success Fee. Within thirty (30) days of substantial completion of the installation of Midwest's curtainwall units by Midwest's subcontractor, PSL, at the 400 South Broadway project in Los Angeles, California (the "Project"), IVST shall pay Kelly, as Executor, or his designated nominee(s), a sum of money equal to 10% of the net income earned from the Project, if any. For purposes hereof, "net income earned from the Project" shall mean the total revenue actually received by Midwest from the Project, minus (a) all direct costs paid in cash (such as subcontractor and third-party fees, freight costs, and project insurance and bonding) and costs of goods sold, (b) the proportionate share of cash operating expenses (such as salaries, benefits, facility rent, utilities , and insurance), interest expense and taxes attributable to the Project taking into account other pending Midwest projects, if any, but excluding all non-cash items such as depreciation or amortization, and (c) $125,000, representing the agreed allocation to the Project of the debt service for the Citizens Bank loans identified in Section 1.7(a).
1.7. Releases of Liability under Performance/Payment Bond and Bank Loans.
(a) Immediately upon IVST closing its books for the first fiscal quarter of 2019, which ends March 31, 2019, IVST shall formally request and use its best efforts to obtain a complete and unconditional release of the Estate from any claim of or liability or obligation to Zurich American Insurance Company and Zurich Insurance Group Ltd., and their respective subsidiaries, affiliates and associated companies (collectively , "Zurich") including but not limited all liability of the Estate, actual or contingent, arising out of that written General Indemnity Agreement, dated April 3, 2018, entered into by Midwest and Don Kelly individually for the benefit of Zurich (collectively , the "Zurich Liabilities").
(b) On or before June 30, 2019, IVST shall pay in full or otherwise obtain a complete and unconditional release of the Estate from any claim by or liability or obligation to Citizens Bank, N.A. ("Citizens"), including but not limited all liability of the Estate, actual or contingent, arising out of that written Unlimited Guaranty dated October 28, 2014, entered into by Don Kelly and which secures the repayment by Midwest of loans by Citizens Bank, N.A., including "$500,000 Term Note Non-Revolving Line of Credit", dated October 28, 2014, which has been drawn upon by Midwest and is known as "Equipment Loan I" with a balance as of the Effective Date of $________ ,and "Equipment Loan II" with a balance as of the Effective Date of $____________; and "$1,500,000 Revolving Line of Credit", dated October 28, 2014, with a balance as of the Effective Date of $__________ (collectively, the "Citizens Liabilities").
1.8. Security Interest in Midwest's Assets. In order to secure the full and timely payment and performance of each of IVST’s obligations under this Agreement at Closing, Midwest shall grant to Kelly, as Executor, a security interest in all of its tangible and intangible assets, including but not limited to equipment, inventory and accounts receivable pursuant to a written Security Agreement in form and substance reasonably acceptable to Kelly, as Executor for the specific purposes of actual liabilities incurred from the Zurich liabilities, Citizen liabilities, and shareholder loan. Kelly, as Executor, acknowledges and agrees that such security interests will be subordinate to the security interests of Citizens in the assets of Midwest to secure the Citizens Liabilities. IVST authorizes Kelly, as Executor, to act as Midwest's attorney-in-fact, to file financing statements signed only by Kelly, as Executor, representing the Estate as secured party, to perfect the security interest to be granted hereunder.
ARTICLE II
REPRESENTATIONS AND WARRANTIES OF KELLY, AS EXECUTOR
Limitations on Representations, Warranties and Liability of Kelly, whether Individually or as Executor. IVST acknowledges and agrees that (a) Michael Kelly was neither a shareholder, officer, director, employee, or contractor of or for Midwest, nor was Michael Kelly knowledgeable about or involved in Midwest's business and affairs prior to his being appointed to serve as Executor of the Estate on July 20, 2018 (the "Appointment Date"), and (b) as a result, any knowledge or information that Michael Kelly has concerning Midwest's business and affairs, including the Project, was obtained since the Appointment Date and then only by virtue of (i) his limited involvement as interim President of Midwest, (ii) information provided by Midwest's employees, and (iii) his limited review of Midwest's documents. Therefore, all representations of Michael Kelly, individually or as Executor, set forth in this Agreement are qualified by the foregoing limitation and are limited to information that is within Michael Kelly's actual knowledge, without any duty of investigation or inquiry, at the time that such representation is made. Furthermore, notwithstanding any other provision of this Agreement to the contrary, express or implied, Michael Kelly shall have no personal liability whatsoever, either individually or as Executor of the Estate, for any breach of any representation or warranty, or any breach of any covenant for any reason beyond his reasonable control, IVST's sole remedy in any such event being a right to assert a claim therefor against the Estate.
Subject to and as qualified by the foregoing, Kelly, as Executor, represents and warrants as follows:
2.1. Ownership of the Midwest Stock; Authority to Exchange. Subject to and as qualified by the disclosures set forth in Schedule 2.1, Kelly, as Executor, has been appointed as fiduciary of the Estate with the power conferred by law to fully administer Estate and in such capacity is the record owner and holder of the Midwest Stock as of the Effective Date, free and clear of all liens, encumbrances, charges and assessments of every nature and subject to no restrictions with respect to transferability. Kelly, as Executor, will on the Closing Date have full power and authority to exchange the Midwest Stock in accordance with the terms of this Agreement.
2.2. Options on Stock. Except for this Agreement, neither Kelly, as Executor, nor Midwest have issued and neither has outstanding any option, warrant or convertible securities or other right to purchase or convert any obligation into Midwest's securities, and neither of them have agreed to issue or sell any additional securities.
2.3. No Additional Issuances. Since July 24, 2018, Midwest has not issued any additional shares of stock or other securities.
2.4. No Conflict. The execution and delivery of this Agreement does not and the consummation of the Transaction will not violate any provision of Midwest's Articles of Incorporation or Code of Regulations, or any provisions of, or result in the acceleration of any obligation under, any mortgage, lien, lease, agreement, instrument, court order, arbitration award, judgment or decree to which Midwest is a party or by which it is bound, except as may be provided in any of the documents that have been uploaded prior to the Signature Date to the Midwest Curtainwalls Due Diligence files on the ShareFile database maintained by Nicola, Gudbranson & Cooper LLC (the "ShareFile Documents").
2.5. No Brokers. All negotiations regarding the Transaction and this Agreement have been carried on directly by Kelly, as Executor, and his counsel with IVST, without the intervention of any broker or third party. Neither Midwest nor Kelly, as Executor, has engaged, consented to or authorized any broker, investment banker or other agent or third party to act on their behalf as broker or finder in connection with the Transaction in any respect that would obligate Midwest, Kelly, as Executor, or IVST to pay any commission, brokerage or finders' fee in connection with the Transaction.
2.6. ShareFile Documents. Each of the ShareFile Documents is a true and complete copy of the original of such document.
2.7. Securities Matters. Kelly, as Executor, understands that the issuance of the Exchange Shares is intended to be exempt from registration under the Securities Act of 1933, as amended (the "Securities Act"), by virtue of Sections 3(b) and 4(2) of the Securities Act, and Kelly, as Executor, represents and warrants that: (a) Kelly, as Executor, has been advised that the Exchange Shares have not been registered under the Securities Act and, therefore, cannot be resold unless they are registered under the Securities Act or unless an exemption from registration is available and the certificates representing the Exchange Shares will be legended accordingly; (b) Kelly, as Executor, is aware that he may be required to hold the Exchange Shares for a period of twelve (12) months from the date of issuance; (c) Kelly, as Executor, is acquiring the Exchange Shares solely as fiduciary for the beneficiaries of the Estate and not with a view to, or for resale in connection with, the distribution thereof, and Kelly, as Executor, has no present intention of distributing or reselling the Exchange Shares; (d) Kelly, as Executor, represents and warrants that he has such knowledge and experience in financial and business matters that he is capable of evaluating the merits and risks of investing in the Exchange Shares and that the Estate is able to bear the economic risk of such investment; and (e) Michael S. Kelly, individually, is an "accredited investor" as such term is defined in Rule 50l(a) of Regulation D.
ARTICLE III
ACKNOWLEDGEMENTS, REPRESENTATIONS AND WARRANTIES OF IVST
IVST acknowledges, represents and warrants as follows:
3.1. Access for Due Diligence. IVST acknowledges and agrees that on or about October 22, 2018, John Yenges was appointed to the office of Executive Vice President/Chief Operating Officer of Midwest at the request of IVST in order to exercise primary operational control over the management of Midwest's business, including the Project, and to perform due diligence on behalf of IVST concerning Midwest and its business, assets, employees, operations and affairs. Mr. Yenges continues to serve in that capacity as of the Signature Date. Since early September, 2018, IVST and its authorized representatives have had full access to all employees, properties, books, records, contracts and documents of Midwest, including all documents that have been uploaded to the ShareFile Documents, and Midwest has furnished or caused to be furnished to IVST and its authorized representatives all information with respect to the assets, affairs and business of Midwest that IVST has reasonably requested.
3.2 Organization and Good Standing. IVST is a corporation duly organized, validly existing, and in good standing under the laws of the State of Nevada, and has the corporate power and is duly authorized, qualified, franchised, and licensed under all applicable laws, regulations, ordinances, and orders of public authorities to own all of its properties and assets and to carry on its business in all material respects as it is now being conducted, and there is no jurisdiction in which it is not qualified in which the character and location of the assets owned by it or the nature of the business transacted by it requires qualification. Attached hereto as Schedule 3.2 are complete and correct copies of the Articles of Incorporation and bylaws of IVST, and all amendments thereto, as in effect on the Effective Date. The execution and delivery of this Agreement does not, and the consummation of the transactions contemplated hereby will not, violate any provision of IVST's Articles of Incorporation or bylaws. IVST has taken all action required by law, its Certificate of Incorporation, its bylaws, or otherwise to authorize the execution and delivery of this Agreement, and IVST has full power, authority, and legal right and has taken all action required by law, its Certificate of Incorporation, By-Laws, or otherwise to consummate the transactions herein contemplated.
3.3 Capitalization. IVST's presently issued and outstanding shares are legally issued, fully paid, and non-assessable and not issued in violation of the pre-emptive or other rights of any person. As of the Closing Date, the Exchange Shares will be legally issued, fully paid and non-assessable and shall not be issued in violation of the pre-emptive or other rights of any other person.
3.4 Financial Matters. Except as set forth within its filing of reports with the OTC Markets:
(a) Neither IVST nor any of its subsidiaries has any liabilities with respect to the payment of any federal, state, county, local, or other taxes (including any deficiencies, interest, or penalties), except for taxes accrued but not yet due and payable, for which IVST or such subsidiary may be liable in its own right, or as a transferee of the assets of, or as a successor to, any other corporation or entity.
(b) The books and records, financial and otherwise, of IVST and all of its subsidiaries are in all material respects complete and correct and have been maintained in accordance with good business and accounting practices.
(c) No deficiency for any taxes has been proposed, asserted or assessed against IVST or any of its subsidiaries. There has been no tax audit, nor has there been any notice to IVST or any of its subsidiaries by any taxing authority regarding any such tax audit, or, to the knowledge of IVST, is any such tax audit threatened with regard to any taxes or IVST or such subsidiary tax returns. IVST does not expect the assessment of any additional taxes upon IVST or any of its subsidiaries for any period prior to the date hereof and has no knowledge of any unresolved questions concerning the liability for taxes of IVST or any of its subsidiaries.
(d) IVST and each of its subsidiaries has good and marketable title to its assets and, except as set forth in Schedule 3.4(d), has no material contingent liabilities, direct or indirect, matured or unmatured.
3.5 Information. The information concerning IVST and its subsidiaries set forth in this Agreement and the Schedules are and will be complete and accurate in all material respects and does not contain any untrue statement of a material fact or omit to state a material fact required to make the statements made, in light of the circumstances under which they were made, not misleading as of the Signature Date and as of the Closing Date.
3.6 Absence of Certain Changes or Events. Except as described herein or in Schedule 3.6:
(a) There has not been (i) any material adverse change, financial or otherwise, in the business, operations, properties, assets, or condition of IVST or any of its subsidiaries (whether or not covered by insurance) materially and adversely affecting the business, operations, properties, assets, or condition of IVST as a whole; and
(b) To the best knowledge of IVST, neither it nor any of its subsidiaries has become subject to any law or regulation which materially and adversely affects, or in the future may adversely affect, the business, operations, properties, assets, or condition of such subsidiary or IVST as a whole.
3.7 Litigation and Proceedings. There are no actions, suits, or proceedings pending or, to the knowledge of IVST, threatened by or against or affecting IVST or any of its subsidiaries, at law or in equity, before any court or other governmental agency or instrumentality, domestic or foreign, or before any arbitrator of any kind.
3.8 No Conflict with Other Instruments. The execution of this Agreement and the consummation of the transactions contemplated by this Agreement will not result in the breach of any term or provision of, or constitute a default under, any indenture, mortgage, deed of trust, or other material agreement or instrument to which IVST or any of its subsidiaries is a party or to which it or any of its assets, operations or subsidiaries are subject.
3.9 Governmental Authorizations. Neither IVST nor any of its subsidiaries is required to have any licenses, franchises, permits, or other government authorizations, that are legally required to enable it or them to conduct its or their business operations in all material respects as conducted on the Signature Date and as of the Closing Date. Except for compliance with federal and state securities or corporation laws, as hereinafter provided, no authorization, approval, consent, or order of, or registration, declaration, or filing with, any court or other governmental body is required in connection with the execution and delivery by IVST of this Agreement and the consummation by IVST of the transactions contemplated hereby.
3.10 Compliance with Laws and Regulations. To the best of its knowledge, IVST and each of its subsidiaries has complied with all applicable statutes and regulations of any federal, state, or other applicable governmental entity or agency thereof, except to the extent that noncompliance would not materially and adversely affect the business, operations, properties, assets, or conditions of any such subsidiary or IVST as a whole, except to the extent that noncompliance would not result in the incurrence of any material liability.
3.11 Approval of Agreement. The board of directors of IVST has authorized the execution, delivery and performance of this Agreement by IVST and has approved the issuance of the Exchange Shares contemplated by this Agreement and the Transaction.
3.12. No Brokers. All negotiations regarding the Transaction and this Agreement have been carried on directly by IVST with Kelly, as Executor, and his counsel, without the intervention of any broker or third party. IVST has not engaged, consented to or authorized any broker, investment banker or other agent or third party to act on its behalf as broker or finder in connection with the transactions contemplated by this Agreement in any respect that would obligate Midwest, Kelly, as Executor, or IVST to pay any commission, brokerage or finders' fee in connection with such transactions.
3.13. The Exchange Shares. The Exchange Shares will not have been registered pursuant to the Securities Act of 1933, as amended, as of the Closing Date, and, therefore, under current interpretations and applicable rules, such shares will be required to be retained for a period of twelve (12) months.
ARTICLE IV
COVENANTS OF MIDWEST AND KELLY, AS EXECUTOR
4.1. Actions Prior to Closing. From and after the Signature Date and until the Closing Date, Midwest and/or Kelly, as Executor, as the case may be, covenants and agrees as follows:
(a) Without the prior written consent of IVST, Midwest will not grant any general or uniform increase in the rates of pay of its employees, nor grant any general or uniform increase in the benefits under any pension plan or other contract or commitment, nor increase the compensation payable or to become payable to officers or key salaried employees, insurance, pension or other benefit plan, payment or arrangement made to, for or with any of the officers, key salaried employees or agents.
(b) Midwest shall not enter into any contract or commitment or engage in any transaction not in the usual and ordinary course of business and consistent with Midwest's business practices without the prior written consent of IVST.
(c) Midwest shall not create any indebtedness other than that incurred in the usual and ordinary course of business, that incurred pursuant to existing contracts disclosed in the ShareFile Documents, and that reasonably incurred in doing the acts and things contemplated by this Agreement.
(d) Midwest shall not declare or pay any dividend or make any distribution in respect of the Midwest Stock, shall not directly or indirectly redeem, purchase or otherwise acquire any of the Midwest Stock, shall not grant any stock options, and shall not issue or in any way dispose of any of the Midwest Stock.
(e) Midwest shall not amend its Articles of Incorporation or Code of Regulations or make any changes in its authorized or issued capital stock without the prior written consent of IVST.
(f) Midwest shall maintain current insurance and any additional insurance in effect as may be reasonably required by increased business and risks; and all property shall be used, operated, maintained and repaired in a normal business manner.
(g) Midwest shall not do any act or omit to do any act, or permit any act or omission to act, which will cause a material breach of any material contract, commitment or obligation of Midwest.
(h) Midwest shall not sell or dispose of any property or assets except products sold in the ordinary course of business.
(i) Midwest shall promptly notify IVST of any lawsuits, claims, proceedings or investigations that may be threatened, brought, asserted or commenced against Midwest, or its officers or directors involving in any way the business, properties or assets of Midwest.
ARTICLEV
CONDITIONS PRECEDENT TO IVST'S OBLIGATIONS
Each and every obligation of IVST to be performed on the Closing Date shall be subject to the prior satisfaction of the following conditions:
5.1. Accuracy of Representations and Warranties. The representations and warranties made by Kelly, as Executor, in this Agreement shall be substantially accurate in all material respects on and as of the Closing Date with the same force and effect as though the representations and warranties had been made or given on and as of the Closing Date (except for changes therein permitted by this Agreement). Kelly, as Executor, shall furnish IVST with a certificate, signed and dated as of the Closing Date, to the foregoing effect.
5.2. Compliance with Covenants. Midwest and Kelly, as Executor, shall have performed and complied with all their respective obligations under this Agreement which are to be performed or complied with prior to or on the Closing Date, including the delivery of the closing documents specified in Section 11.2.
5.3. Absence of Suit. No suit or proceeding shall be threatened or pending in which it will be or it is sought, by anyone, to restrain, prohibit, challenge or obtain damages or other relief in connection with this Agreement or the consummation of the transactions contemplated by this Agreement, or in connection with any material claim against Midwest not disclosed in the ShareFile Documents.
5.4. No Material Adverse Changes. Prior to the Closing Date, there shall not have occurred any material adverse change in the financial condition, business, assets or operations of Midwest.
5.5. Resignations. IVST shall have received the resignations required to be delivered by Kelly, as Executor, in Section 1l.2(c).
5.6. Consents. Citizens Bank and Zurich shall have consented in writing to the transactions contemplated by this Agreement.
ARTICLE VI
CONDITIONS PRECEDENT TO KELLY, AS EXECUTOR'S OBLIGATIONS
Each and every obligation of Kelly, as Executor, to be performed on the Closing Date shall be subject to the prior satisfaction of the following conditions:
6.1. Accuracy of Representations and Warranties. The representations and warranties made by IVST in this Agreement shall be substantially accurate in all material respects on and as of the Closing Date with the same force and effect as though the representations and warranties had been made or given on and as of the Closing Date (except for changes therein permitted by this Agreement). IVST shall furnish Kelly, as Executor, with a certificate, signed by a duly authorized signatory of IVST and dated the Closing Date, to the foregoing effect.
6.2. Compliance with Covenants. IVST shall have performed and complied with all its obligations under this Agreement which are to be performed or complied with prior to or on the Closing Date, including the delivery of the closing documents specified in Section 11.3.
6.3. Attorneys', Accountant's and Professionals' Fees Incurred by Kelly, as Executor. At the Closing, IVST shall pay directly to the providers all reasonable attorneys', accountants' and other professionals' fees for services actually performed for Kelly, as Executor, the Estate and/or Midwest relating to the sale of the Midwest Stock generally and the transactions contemplated by this Agreement in particular, based upon statements therefor presented by Kelly, as Executor, or Midwest prior to the Closing Date, up to a maximum aggregate amount of $60,000. The services covered by this payment obligation shall include, without limitation, the collection and online posting of the ShareFile Documents, negotiations regarding the letter of intent between the parties, the preparation and negotiation of this Agreement, counseling Kelly, as Executor, concerning securities laws and the restriction upon re-sale of the Exchange Shares and the tax-free aspects of this transaction, counseling Kelly, as Executor, concerning employee benefit plans, the preparation of closing documents and closing the transactions, and anticipated customary post-closing tasks. IVST hereby stipulates that the rate of $265 per hour for such professional fees is reasonable.
6.4. No Material Adverse Change. Prior to the Closing Date, there shall not have occurred any material adverse change in the financial condition, business, or operations of IVST nor shall any event have occurred which, with the lapse of time or the giving of notice, may cause or create any material adverse change in the financial condition, business, or operations of IVST.
ARTICLE VII TERMINATION OF OBLIGATIONS.
SURVIVAL OF REPRESENTATIONS AND COVENANTS
7.1 Termination Events. By notice given in accordance with Section 12.4 prior to the Closing, this Agreement may be terminated as follows:
(a) By IVST, if a material breach of any provision of this Agreement has been committed by Kelly, as Executor, or Midwest and either such breach has not been cured within twenty (20) business days of Kelly, as Executor's receipt of written notice of such breach from IVST, such breach is incapable of being cured or such breach has not been waived by IVST as of March 31, 2019 (the "Termination Date");
(b) By Kelly, as Executor, if a material breach of any provision of this Agreement has been committed by IVST and such breach has not been cured within twenty (20) business days of IVST's receipt of written notice of such breach from Kelly, as Executor, such breach is incapable of being cured or such breach has not been waived by Kelly, as Executor, as of the Termination Date;
(c) By IVST, if any condition in Article V has not been satisfied as of the Termination Date or if satisfaction of such a condition by such date is or becomes impossible (other than through the failure of IVST to comply with its obligations under this Agreement) and IVST has not waived such condition on or before such date;
(d) By Kelly, as Executor, if any condition in Article VI has not been satisfied as of the Termination Date or if satisfaction of such condition by such date is or becomes impossible (other than through the failure of Kelly, as Executor, to comply with his obligations under this Agreement) and Kelly, as Executor, has not waived such condition on or before such date; or
(e) By mutual consent in writing between IVST and Kelly, as Executor.
7.2. Effect of Termination; Survival. If this Agreement is terminated pursuant to Section 7.1, all obligations and rights of the parties under this Agreement will terminate except for such obligations and rights of the parties under Sections 12.4 and 12.5, which shall survive indefinitely.
7.3. Post-Closing Survival of Covenants, Representations and Warranties. The representations and warranties of Kelly, as Executor, contained herein or in any instrument or other document delivered pursuant to this Agreement or in connection with the transactions contemplated hereby shall survive the Closing for a period of twelve (12) months. The representations and warranties of IVST contained herein or in any instrument or other document delivered pursuant to this Agreement or in connection with the transactions contemplated hereby shall survive the Closing for a period of thirty-six (36) months; provided, however, that the representations and warranties contained in Section 3.3 (Capitalization), Section 3.11 (Approval of Agreement) and Section 3.13 (The Exchange Shares) shall survive indefinitely. In the event notice of any claim for indemnification under Article VIII hereof shall have been given within the applicable survival period, the representations and warranties that are the subject of such indemnification claim shall survive until such time as such claim is finally resolved. The covenants and agreements of the parties set forth in this Agreement, and the indemnification obligations of the parties hereunder shall survive indefinitely, subject to the applicable statutes of limitation.
ARTICLE VIII
INDEMNIFICATION
8.1. Obligations of Kelly, as Executor. Subject in any event to the qualifications and limitations set forth in Article II, Kelly, as Executor, agrees to indemnify and hold harmless IVST from and against any and all damages, liabilities, losses, costs or expenses (collectively, "Losses") sustained or incurred directly or indirectly by it to the extent resulting from, based upon or arising from:
(a) any inaccuracy in or breach or nonperformance of any of the representations, warranties, covenants or agreements made by Kelly, as Executor, or Midwest in or pursuant to this Agreement, including in the Certificate of Kelly, as Executor, to be delivered at the Closing; or
(b) any fraud or intentional wrongful or illegal conduct by Kelly, as Executor.
8.2. Obligations of IVST and Midwest. IVST and Midwest agree to release and discharge, and to indemnify and hold harmless (a) the Estate, (b) Kelly, as Executor, (c) the beneficiaries of the Estate, and (d) each person who served as a director, officer, employee, agent, representative, independent contractor, or professional service provider of Midwest prior to and from and after the death of Don Kelly on July 10, 2018 to and including the date of the Closing, from and against any and all Losses incurred directly or indirectly by any such party to the extent resulting from, based upon or arising from:
(a) any inaccuracy in or breach or nonperformance of any of the representations, warranties, covenants or agreements made by IVST in or pursuant to this Agreement, including in the Certificate of IVST to be delivered at the Closing.
(b) any alleged or actual fraud or intentional wrongful or illegal conduct by IVST.
(c) the Zurich Liabilities and the Citizens Liabilities.
(d) the ownership or operation by IVST and/or Midwest of the business, assets or affairs of Midwest after the Closing, except as otherwise expressly provided in Section l.7(a) with respect to the Zurich Liabilities and in Section l.7(b) with respect to the Citizens Liabilities; and
(e) all claims, civil actions or Losses asserted by any shareholder of IVST relating to any of the foregoing.
8.3 Procedure.
(a) Notice. If any party becomes aware of any threatened or pending claim, demand or Loss (including any action asserted by a third party or any request to waive any applicable statute of limitations) for or against which such party is entitled to indemnification under this Agreement (an "Indemnifiable Claim") or that might reasonably be expected to result in an Indemnifiable Claim with respect to that party (an "Indemnified Party"), such Indemnified Party shall give prompt written notice to each party that would be required to provide indemnification hereunder (each, an "Indemnifying Party") of the nature of the fact, circumstance or event and the amount believed to be involved. Notwithstanding the foregoing, the rights of any Indemnified Party to be indemnified in respect of any Indemnifiable Claim resulting from the assertion of liability by any third party shall not be adversely affected by the Indemnified Party's failure to give or delay in giving notice unless (and then only to the extent that) the Indemnifying Party is materially prejudiced thereby.
(b) Defense. If any civil or administrative action that might reasonably be expected to result in an Indemnifiable Claim (an "Action") is asserted or threatened by a third party against any Indemnified Party, the Indemnifying Party may elect to control the defense thereof with experienced counsel reasonably satisfactory to the Indemnified Party. Notwithstanding the foregoing, if the Indemnifying Party, within fifteen (15) days after receipt of a notice of such Action, fails to give written notice to the Indemnified Party that the Indemnifying Party is undertaking the defense thereof or thereafter fails to timely assume such defense, then the Indemnified Party shall have the right to defend, compromise or settle the Action for the account of the Indemnifying Party. An assertion by the Indemnifying Party of a reservation of rights with respect to such Action shall not constitute a failure to give written notice that it shall undertake such defense. If the Indemnifying Party assumes control of the defense in an Action, it will take all steps necessary in the defense, prosecution, or settlement of such claim or litigation and will hold the Indemnified Party harmless from and against all Losses caused by or arising out of such Action. The Indemnifying Party will not consent to the entry of any judgment or enter into any settlement except with the written consent of the Indemnified Party; provided, however, that the consent of the Indemnified Party shall not be required if all of the following conditions are met: (i) the terms of the judgment or proposed settlement include as an unconditional term thereof the giving to the Indemnified Party by the third party of a release of the Indemnified Party from all liability in respect of such Action; (ii) there is no finding or admission of (A) any violation of law by the Indemnified Party (or any affiliate thereof), and (B) any violation of the rights of any other person; (iii) the judgment or settlement will have no effect on any other Action or claims of a similar nature that may be made against the Indemnified Party (or any affiliate thereof); and (iv) the sole form of relief is monetary damages which are paid in full by the Indemnifying Party. The Indemnifying Party shall conduct the defense of the Action actively and diligently, and the Indemnified Party will provide reasonable cooperation in the defense of the Action. In all cases, the party that is not assigned the right to control the defense shall have the right to participate in the defense of the Action at its own expense, subject to the reasonable direction of the other party. Each of the Indemnifying Party and the Indemnified Party shall give all reasonable assistance to the other party in connection therewith. In any case, the Indemnified Party shall, subject to Section 12.5, make available to the Indemnifying Party and its attorneys, accountants, employees, agents, advisors and consultants, at reasonable times during normal business hours, all books, records, documents, employees, agents, advisors and consultants under its control and relating to such Action or such other matter as to which the Indemnified Party is or was required to give notice. The party having control of the defense of an Action shall notify the other party of every proposal, oral or written, for settlement, which it receives or makes.
(c) Settlement Limitations. Notwithstanding anything in this Article VIII to the contrary, the Indemnifying Party shall not, without the prior written consent of the Indemnified Party, settle or compromise any threatened or pending Action on behalf of the Indemnified Party or permit a default or consent to entry of any judgment in respect thereof unless such settlement, compromise or consent includes as an unconditional term thereof the giving by the claimant to the Indemnified Party of a full, complete and irrevocable general release from all liability in respect of such Action. If a claim is solely for monetary damages and a settlement offer is made by the applicable third party claimant and the Indemnifying Party notifies the Indemnified Party in writing of the Indemnifying Party's willingness to unconditionally accept the settlement offer and pay the amount called for by such offer, and the Indemnified Party declines to accept such offer, the Indemnified Party may continue to contest such Action, free of any participation by the Indemnifying Party, and the amount of any ultimate liability with respect to any Indemnifiable Claim arising therefrom that the Indemnifying Party has an obligation to pay hereunder shall be limited to the amount of the settlement offer that the Indemnified Party declined to accept plus the fees and expenses, including legal, accounting and other professional fees and expenses, of the
Indemnified Party relating to such Indemnifiable Claim incurred through the date of its rejection of the settlement offer and to which the Indemnified Party would otherwise be entitled hereunder. If a settlement offer solely for money damages is made by the applicable third party claimant and the Indemnified Party notifies the Indemnifying Party in writing of its willingness to unconditionally accept the settlement offer and the Indemnifying Party has not reserved its rights to assert that any Loss of the Indemnified Party resulting from such Action is not an Indemnifiable Claim, and the Indemnifying Party declines to accept and pay the amount called for by such offer, the Indemnifying Party may continue to contest such Action, at its own expense. The provisions of this Article VIII are subject to the rights of any Indemnified Party's insurer that may be defending any such claim; provided however, such rights may not diminish the rights of an Indemnified Party hereunder. If the Indemnifying Party makes any payment hereunder, the Indemnifying Party shall be subrogated, to the extent of such payment, to all rights and remedies of the Indemnified Party to any insurance benefits or other claims of the Indemnified Party with respect to such claim. Nothing in this Article VIII shall be deemed to obligate any person to maintain any insurance or to pursue any claim against any insurer or third party.
8.4. Exclusive Remedy. After the Closing, the indemnification provided in this Article VIII shall constitute the exclusive remedy of the parties hereto and their respective directors, officers, employees, affiliates, agents, representatives, independent contractors or professional service providers, from and against any and all Losses asserted by third parties against, resulting, imposed upon or incurred or suffered by, any of them, directly or indirectly, as a result of, or based upon or arising from, the breach of any representation or warranty or the non-fulfillment of any agreement or covenant in or pursuant to this Agreement or any other agreement, document or instrument required hereunder or pursuant to any applicable statute, rule or regulation.
8.5 Limits on Indemnification. Regardless of the nature of the claim, unless arising out of or related to the fraud or intentional wrongful or illegal conduct of the Indemnifying Party, no Indemnifying Party shall be liable to another party nor entitled to indemnification hereunder for punitive or consequential damages, including damages for business interruption or lost profits.
8.6 Effect of Knowledge. No fact, event, misrepresentation or occurrence that, in the absence of this Section 8.6, would constitute a breach or breaches of any representation or warranty of Kelly, as Executor, or IVST under this Agreement shall be deemed to constitute a breach or breaches by Kelly, as Executor, or IVST of their representations or warranties under this Agreement for which the Indemnified Party would be entitled to be indemnified pursuant to this Article VIII if the Indemnified Party, or any of its officers, directors, employees, agents or attorneys, had actual knowledge of such breach or breaches as of the Closing Date.
ARTICLE IX
SECURITIES ACT PROVISIONS
9.1. Restrictions on Disposition of Shares. Kelly, as Executor, is aware that the Exchange Shares will not have been registered pursuant to the Securities Act of 1933, as amended; and, therefore, under current interpretations and applicable rules, he will be required to retain the Exchange Shares for a period of twelve (12) months after the Closing.
9.2. Piggyback Rights. In the event IVST files a registration statement under the Securities Act with respect to shares of its common stock prior to December 31, 2020, on a form appropriate for registering the Exchange Shares, IVST shall give written notice to Kelly, as Executor, prior to filing, and Kelly, as Executor, shall have the right to request to have included such shares of the Exchange Shares as shall be specified in the request; provided, however, that the inclusion of the Exchange Shares shall not interfere with IVST's registration of its shares and that in no event shall IVST be obligated to keep the prospectus with respect to the stock current for more than 30 days after the effective date of the registration statement; and provided, further, that all sales of shares sold pursuant to the registration statement are effected within the 30 day period. If Kelly, as Executor, does not make a request for registration within twenty (20) days after receipt of notice from IVST, IVST shall have no obligation to include any of the Exchange Shares in the registration statement. In the event of a registration of any of the Exchange Shares under this Section 9.2, Kelly, as Executor, shall pay and bear the direct selling fees, disbursements and expenses relating thereto, including without limitation all underwriters' discounts, commissions and expenses, but none of the other costs of registration.
ARTICLE X
PROFIT SHARING PLAN AND OTHER EMPLOYEE BENEFIT PLANS
10.1. IVST shall before and after the Closing take all actions which may be necessary, convenient or appropriate in the opinion of IVST to transfer to IVST all the rights and to cause IVST to assume all the liabilities of Midwest under its profit sharing plan and trust (the "Plan") (including the adoption of amendments to the plan and trust and such action as may be necessary to secure approvals of the Internal Revenue Service which may be required or deemed advisable), to the end that the Plan may be maintained after the Closing so that those of Midwest's employees that were participants in the Plan prior to the Closing may continue as participants or may be integrated into any profit sharing plan maintained by IVST or any of its subsidiaries, treating employment with Midwest as employment with IVST or such subsidiary under its plan and preserving the benefits previously accrued to Midwest's employees. All other employee benefit plans of Midwest, including but not limited to health and accident insurance, major medical insurance, sick pay plans, noninsured maternity benefits, group life insurance, and other employee fringe benefits, shall be continued by IVST subject to the same rights of termination available to Midwest.
ARTICLE XI
CLOSING
11.1. Time and Place. The Closing of the Transaction (the "Closing") shall take place at the offices of Nicola, Gudbranson & Cooper, LLC, 25 W. Prospect Avenue, Suite 1400 Republic Building, Cleveland, Ohio at 10:00 a.m. on January 15, 2019 (the "Closing Date"), or at such other time and place as the Parties shall agree upon.
11.2. Documents to be Delivered by Kelly, as Executor. At the closing, Kelly, as Executor, shall deliver to IVST the following documents:
(a) A certificate for the Midwest Stock in the form required by Section 1.2;
(b) The minute book and stock transfer book, and any other record or document relating to Midwest in the possession of Kelly, as Executor, as IVST may in writing request;
(c) Written resignations effective on the Closing Date of all directors and officers of Midwest except those designated by IVST;
(d) A certificate signed by Kelly, as Executor, that the representations and warranties made by Kelly, as Executor, in this Agreement are substantially accurate in all material respects on and as of the Closing Date with the same effect as though the representations and warranties had been made on or given on and as of the Closing Date;
(e) The Security Agreement signed by Midwest as required by Section 1.8; and
(f) Any other documents of transfer as IVST may reasonably request.
11.3. Documents to be Delivered by IVST. At the Closing, IVST shall deliver to Kelly, as Executor, the following documents:
(a) A certificate for the Exchange Shares in the form required by Section 1.2;
(b) A certified copy of the duly-adopted resolutions of IVST's board of directors authorizing the execution, delivery and performance of this Agreement, and authorizing or ratifying the issuance of the Exchange Shares and the other acts of its officers and employees in carrying out the other terms and provisions of this Agreement;
(c) A certificate signed by an authorized officer of IVST that the representations and warranties made by IVST in this Agreement are substantially accurate in all material respects on and as of the Closing Date with the same effect as though the representations and warranties had been made on or given on and as of the Closing Date; and
(d) Any other documents of transfer as Kelly, as Executor, may reasonably request.
ARTICLE XII
MISCELLANEOUS
12.1. Governing Law. This Agreement shall be governed by, enforced, construed, and interpreted under and in accordance with the laws of the United States of America and, with respect to matters of state law, with the laws of the State of Ohio.
12.2. Assignment. This Agreement shall not be assigned by any Party without the prior written consent of all other Parties.
12.3. Rights Cumulative; Waiver; Amendment. Every right and remedy provided herein shall be cumulative with every other right and remedy, whether conferred herein, at law, or in equity, and may be enforced concurrently herewith, and no waiver by any Party of the performance of any obligation by any other party shall be construed as a waiver of the same or any other default then, theretofore, or thereafter occurring or existing. At any time prior to the Closing Date, this Agreement may be amended by a writing signed by all Parties, with respect to any of the terms contained herein, and any term or condition of this Agreement may be waived or the time for performance thereof may be extended by a writing signed by the Party or Parties for whose benefit the provision is intended.
12.4. Notices. Any notice or other communication hereunder must be given in writing and either (a) delivered in person, (b) transmitted by electronic mail , provided that any notice so given is also sent as provided in clause (c) or (d), (c) sent by postage-paid United States Mail, certified and return-receipt requested, or (d) sent by a national commercial overnight courier as follows:
If to Kelly, as Executor:
Michael S. Kelly
13921 Triskett Road
Cleveland, Ohio 44111
E-mail: kellyglass@aol.com
With a copy to (which shall not constitute notice):
Bruce L. Waterhouse, Jr., Esq.
Nicola, Gudbranson & Cooper, LLC
25 West Prospect Avenue, Suite 1400
Cleveland, Ohio 44115-1043
Email: waterhouse@nicola.com
If to IVST:
Innovest Global Inc.
8834 Mayfield Road
Chesterland, Ohio 44026
With a copy to (which shall not constitute notice):
or to such other address or to such other person as any Party shall have last designated by such notice to the other Parties. Each such notice or other communication shall be effective (x) if given by electronic mail, when transmitted to the applicable e-mail address and a "read receipt" is received back, and the sender has completed the other required delivery method, (y) if given by overnight courier, the next business day after such communication is deposited pre-paid with the overnight courier addressed as aforesaid, or (z) if given by any other means, when actually received.
12.4. Costs of Asserting a Claim. In the event that any Party commences a civil action to seek redress for a breach of this Agreement, then the prevailing Party in such action will be entitled to an award of reasonable attorney's fees and costs for trial and appellate proceedings, accountant's fees and costs, and any expert's fees and costs incurred therein and in enforcing or collecting any judgment or relief provided therein.
12.5. Confidentiality. IVST, on the one hand, and Kelly, as Executor, on the other hand, will keep confidential all information and materials regarding the other Party identified or designated by such Party as "confidential". The provisions of this Section 12.5 shall not apply to any information which is or shall become part of the public domain through no fault of the Party subject to the obligation of confidentiality. Notwithstanding the foregoing, IVST shall have the right to make all public disclosures regarding the transaction required by applicable securities law s.
12.6. Expenses. Except as otherwise set forth herein, each Party shall bear its own costs and expenses associated with the transactions contemplated by this Agreement.
12.7. Third Party Beneficiaries. This Agreement is solely among IVST, Midwest and Kelly, as Executor, and, except as otherwise specifically provided herein, no director, officer, stockholder, employee, agent, independent contractor, or any other person or entity shall be deemed to be a third party beneficiary of this Agreement.
12.8. Entire Agreement. This Agreement embodies the entire agreement among the Parties with respect to the contemplated transactions, and there are no other courses of dealing, understandings, agreements, representations, or warranties, written or oral, except as set forth herein; provided, however, that all previous confidentiality and non-disclosure agreements by the Parties or any of their representatives shall remain in full force and effect until the Closing. Effective upon the execution of this Agreement by the Parties, the previous the letter of intent between IVST and Kelly, as Executor, dated October 22, 2018, shall be terminated in its entirety.
12.9. Representation by Counsel: Interpretation. The Parties acknowledge that they each have been represented by counsel in connection with this Agreement and the transactions contemplated by this Agreement. Accordingly, any rule of Law, or any legal decision that would require interpretation of any claimed ambiguities in this Agreement against a drafting Party has no application and is expressly waived.
12.10. Counterparts. This Agreement and any other agreement or document delivered pursuant hereto may be executed in one or more counterparts and by different Parties in separate counterparts. All of such counterparts shall constitute one and the same agreement or other document and shall become effective when one or more counterparts thereof have been signed by a Party and delivered to the other Party or Parties. The signature page of this Agreement, and any document executed in connection with this Agreement, shall be deemed executed and delivered if executed and transmitted to the other Party or Parties by attachment to an electronic-mail message, with the same effect as delivery of the original.
12.11. Headings. The Section and Article headings in this Agreement are for convenience only and shall not have independent effect in the interpretation of this Agreement.
12.12. Business Days. As used in this Agreement, the term "business day" means any day except Saturday, Sunday or any day on which banks in the State of Ohio are permitted to be closed.
12.13. Further Assurances and Documents. IVST and Kelly, as Executor, agree to execute any other document, and to take any other action or corporate proceedings, both before and after the Closing, which may be reasonably requested as necessary or desirable to carry out the terms of this Agreement. Each Party will use commercially-reasonable efforts to cause all conditions to its obligations hereunder to be timely satisfied and to perform and fulfill all other obligations on its part to be performed and fulfilled under this Agreement, to the end that the transactions contemplated by this Agreement shall be effectuated in accordance with its terms. As used in this Agreement, the term "commercially reasonable efforts" shall not include efforts that require the performing Party (a) to do any act that is unreasonable under the circumstances, (b) to amend or waive any rights under this Agreement, or (c) to incur or expend any funds other than reasonable out-of-pocket expenses incurred in satisfying its obligations hereunder, including the fees, expenses and disbursements of its accountants, counsel and other professionals.
[Signatures on following page.]
[Signature page of Share Exchange Agreement and Plan of Reorganization.]
IN WITNESS WHEREOF, the Parties have caused this Agreement to be duly executed on the dates set forth below but as of the Effective Date, except as otherwise expressly stated herein.
INNOVEST GLOBAL INC.
By: Daniel G. Martin, Chief Executive Officer
/s/Daniel G. Martin
Date: 12/21/18
MIDWEST CURTAINWALLS, INC.
By: Michael S. Kelly, President
/s/Michael S. Kelly
Date: 12/21/18
MIDWEST CURTAINWALLS, INC.
By: Michael S. Kelly, as Executor of the Estate of Donald F. Kelly, Jr.
/s/Michael S. Kelly
Date: 12/21/18
SCHEDULE 2.1
Ownership of Midwest Stock
After the death of Don Kelly, and despite diligence search, Kelly, as Executor, did not locate the two original share Certificates evidencing Don Kelly's ownership of the Midwest Stock. Therefore, such Certificates were deemed to have been lost, misplaced, stolen or inadvertently destroyed. Those Certificates, in any event, were cancelled in connection with the issuance of a Certificate for the Midwest Stock in the name of Kelly, as Executor. Copies of the July 24, 2018 Director's Action authorizing such steps, the replacement Certificate in the name of Kelly, as Executor, and Midwest's current Share Ledgers are attached.
On July 20, 2018, pursuant to Letters of Authority issued by the Probate Court of Cuyahoga County, Ohio, a copy of which is attached, Michael Kelly was appointed to serve as fiduciary of the Estate, with the power conferred by law to fully administer the Estate. A true copy of a certified copy of the Last Will and Testament of Donald F. Kelly, Jr. is attached hereto.
SCHEDULE 3.2
IVST's Certificate of Incorporation and By-Laws
SCHEDULE 3.4(d)
Material Contingent Liabilities
SCHEDULE 3.6
Certain Changes or Events
Exhibit 2.7
ACQUISITION AND ASSIGNMENT AGREEMENT
This Acquisition and Assignment Agreement, dated as of January 15, 2018 ("Assignment Agreement") is by and among CCS Holding Company Inc., Corporate Collection Services, Inc., and Call Center Resources Inc. ("Assignor") and Innovest Global, Inc. ("Assignee").
WITNESSETH
WHEREAS, Assignor are businesses in good standing in the state of Ohio which are generally in the call center business, and own assets and goodwill associated with best practices, operations, and customers; and
WHEREAS, Assignor has entered into a variety of agreements with Crestwood MMNT LLC (Ohio LLC) and CW Financial LLC (Delaware LLC), and principal Leonard C Rayford Jr., between February 24, 2009 and current. These include an "Asset Purchase Agreement, a "Guarantee" and a "Third Amended and Restated Subordinated Seller Note", which is the most recent dated December 9, 2014. These and others as the same may have from time to time been modified, amended and supplemented and which has been furnished by Assignor in its entirety to Assignee; and
WHEREAS, Assignor desires to irrevocably assign and delegate to Assignee all of its rights, and privileges as provided by all agreements. Assignee desires to accept such assignment, in accordance with the terms hereof; and
WHEREAS, Assignor desires to sell all of its goodwill to Assignee and Assignee desires to buy said goodwill.
NOW, THEREFORE, in consideration of the premises and of the mutual Assignment Agreements herein contained, the parties hereto agree as follows:
1. Assignment. (a) From the date of this Agreement ("Effective Date"), Assignor and Assignee finalize that all of Assignor' s rights, and Privileges and goodwill are transferred to Assignee and Assignee hereby accepts such assignment and delegation and assumes same; provided, however, that Assignee is successful in employing Sally Emch. Such affirmation shall be provided in writing to Assignor within three business days of the employ; and shall be within ten days of the signing of this agreement or it is null and void.
2. Termination. Once effectuated in accordance with 1.a above, this Agreement may not be terminated. In the event that the Assignment Agreement is terminated, any and all associated addenda shall also be terminated automatically effective the same date the Assignment Agreement is terminated.
3. Representation. Each of the Assignor and the Assignee hereby represents and warrants to the other parties hereto that the execution, delivery and performance hereof by it are within its corporate powers, and have been duly authorized by all necessary corporate or other action and that this Assignment Agreement constitutes its legal, valid and binding obligation.
4. Consideration. At the Closing (as hereinafter defined), Assignor shall receive 2,500,000 shares of IVST Restricted Common Stock (Two-Million Five-Hundred Thousand). The certificates shall represent the pro rata ownership of the Principals of Assignee as provided in Appendix "A" attached hereto. Any fractional shares that would result from such pro-rata ownership will be rounded up to the next highest whole number.
5. Guarantee. Assignee shall guarantee the shares to be worth $1 per share by the second (2nd) anniversary of the issuance. In the event that the price is not $1 per share by the second anniversary, on the second anniversary Assignee shall issue the number of additional shares necessary to achieving an aggregate value of $2,500,000 for the shares. This guarantee is in full force and effect unless there is a "Guarantee Disqualifying Event", which would be any one of the following: A) Liquidation of more than 27% of the shares prior to the second anniversary of the issuance, B) Material misrepresentations.
6. Further Actions. Assignor and Assignee will execute, acknowledge and deliver all such other and additional instruments, notices, releases and other documents and will do all such other acts as may be necessary or advisable to fully assign to Assignee all of the respective rights and interests herein and hereby granted or intended to be granted and to carry out their respective obligations under this Assignment Agreement.
7. Governing Law. This Assignment Agreement shall be governed by and construed in accordance with the laws of the State of Ohio.
8. Addresses. Any notice, request, demand. bill, or payment provided for in this Assignment Agreement shall be in writing and shall be considered as duly delivered when mailed by registered, certified or regular mail to the addresses of the parties hereto as follows:
Innovest Global Inc.:
8456 Washington St.
Chagrin Falls, OH 44023
ASSIGNOR
Jack J. Grdina
973 Grandview Lane
Aurora, OH 44202
Or such other address as any party shall designate by formal written notice to the other parties.
IN WITNESS WHEREOF, the parties hereto have executed this Assignment Agreement as of the date first above written.
CCS Holding Company Inc., Corporate Collection Services. Inc., and Call Center Resources Inc. (Assignor)
Authorized Signatory, Majority Owner
/s/ Jack J. Grdina
Innovest Global Inc. (Assignee)
Name: Daniel G. Martin
Chairman, Chief Executive Officer
/s/ Daniel G. Martin
Appendix "A” Pro-Rata Distribution
| Jack J. Grdina: | 51% | 1,275,000 |
| Andrew J. Grdina: | 33% | 825,000 |
| Dean Dudley: | 8% | 200,000 |
| James Mitch: | 8% | 200,000 |
Exhibit 2.8
Amendment and Termination Agreement
THIS AMENDMENT AND TERMINATION AGREEMENT (this "Agreement") is entered into as of March 18th, 2019 by and among Innovest Global, Inc., a Nevada corporation ("Innovest" ), Shepherd Energy, LLC an Ohio corporation ("SE"), and ("Damon Mintz, Jeff Simler and Steve Mintz").
A. Innovest and SE entered into an agreement and share exchange dated as of December 28, 2017 (the " Exchange Agreement");
B. Capitalized terms used in this Agreement without definition have the meanings assigned to them in the Exchange Agreement;
C. In Section 1.2 of the Exchange Agreement, Innovest guaranteed that the Exchange Shares would be worth $1.00 per share by the second anniversary of issuance (the "Price Guarantee"); and
D. Innovest, SE and Mintz, Simler and Mintz (each a "Party" and collectively the "Parties") have agreed to terminate the Price Guarantee pursuant to the terms of this Agreement.
1. Issuance of Stock. lnnovest agrees to issue to Mintz, Simler and Mintz, 1,500,000 (500,000 each) shares of Innovest common stock, par value $0.00 per share (the "New Shares"). Upon issuance, the New Shares will be duly authorized, validly issued, fully paid and non-assessable. Mintz, Simler and Mintz acknowledge that the New Shares will be unregistered and subject to transfer restrictions under Rule 144 promulgated under the Securities Act of 1933.
2. Amendment of Exchange Agreement. The Parties agree that Section 1.2 of the Exchange Agreement is deleted in its entirety. The remainder of the Exchange Agreement remains unchanged, in full force and effect.
3. Termination of Price Guarantee. The Parties agree that the Price Guarantee is terminated and of no further force and effect. The Parties agree that any agreements related to or dependent upon the Price Guarantee are terminated and of no further effect as well.
4. Additional Actions. Each party agrees to take any action reasonably necessary to effectuate the purpose of and agreements provided for in this Agreement.
<Signatures Appear on Next Page>
IN WITNESS WHEREOF, the Parties have executed this Agreement as of the date listed above.
INNOVEST GLOBAL, INC.
By Dan Martin, Chairman & CEO
/s/Daniel G. Martin
SHEPHERD ENERGY, LLC
By Damon Mintz, Member
/s/ Damon Mintz
By, Damon Mintz, Individually
/s/ Damon Mintz
By, Jeff Simler, Individually
/s/ Jeff Simler
By, Steve Mintz, Individually
/s/ Steve Mintz
Exhibit 2.9
EXCLUSIVE LICENSE AGREEMENT
THIS EXCLUSIVE LICENSE AGREEMENT ("Agreement") is entered into as of this 23rd day of July 2018 (" Effective Date") by and between CEDARS-SINAI MEDICAL CENTER, a California nonprofit public benefit corporation ("CSMC"), with offices at 8700 Beverly Boulevard, Los Angeles, California 90048-1865, and STEMVAX LLC, a California limited liability company (" Licensee"), with offices at 2265 East Foothill Blvd Pasadena, California 91107.
RECITALS
A. CSMC owns and/or is entitled to grant license rights with respect to certain Patent Rights (as defined below) invented or developed in the course of certain research at CSMC conducted under the direction of Drs. Keith Black, Dwain Morris-Irvin and Moshe Arditi (hereinafter collectively referred to as the " Inventors").
B. CSMC desires to have the Patent Rights developed, used and commercialized in the Field of Use (as defined below) by Licensee, and Licensee desires to obtain an exclusive, worldwide license to conduct research in the Field of Use, and to develop, manufacture, use and sell Products (as defined below) in the Field of Use, using the Patent Rights in accordance with the terms of this Agreement. Other than the rights expressly granted by CSMC hereunder within the Field of Use, Licensee acknowledges that CSMC shall retain all other rights with respect to the Patent Rights.
C. CSMC and Licensee intend that the execution, delivery and performance of this Agreement by each party, and the consummation of the transactions contemplated hereunder, shall not at any time threaten CSMC's tax-exempt status under Section 501(c)(3) of the Internal Revenue Code and Section 23701d of the California Revenue and Taxation Code, or cause CSMC to be in default under any of CSMC' s issued and outstanding tax-exempt bonds.
Now, THEREFORE, in consideration of the mutual covenants and premises herein contained, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto hereby agree as follows:
1. DEFINITIONS
1.1 "Affiliate" or "Affiliates" shall mean any corporation, person or entity, which controls, is controlled by, or is under common control with, a party to this Agreement without regard to stock or other equity ownership. For purposes hereof, the terms "control" and "controls" mean the possession, direct or indirect, of the power to direct or cause the direction of the management and policies of a corporation, person or entity, whether through the ownership of voting securities, by contract or otherwise.
1.2 "Confidential Information" shall mean any confidential or proprietary information furnished by one party (the "Disclosing Party") to the other party (the "Receiving Party") in connection with this Agreement, including, without limitation, all specifications, know-how, trade secrets, technical information, drawings, software, models, business information and patent applications pertaining to the Patent Rights, and as further provided in Section 10 hereof.
1.3 "FDA" shall mean the United States Food and Drug Administration, or any successor agency thereof.
1.4 "Field of Use" shall mean the therapeutic treatment thereof in patients suffering from cancer, including glioblastoma.
1.5 "Funding Agencies" shall mean any public or private granting agencies which have provided funding to CSMC or to any of the Inventors for the development of any of the Patent Rights prior to the Effective Date.
1.6 "Improvements" shall mean all improvements or enhancements to the Patent Rights that, after the Effective Date, are conceived and reduced to practice if patentable, or reduced to practice if not patentable, by at least one Inventor.
1.7 "Licensee Developments" shall mean any and all processes, uses, designs, applications, methods and compositions-of-matter, indications, improvements, enhancements and modifications in the Field of Use directly based upon or directly created using the Patent Rights and which were discovered or developed by or on behalf of Licensee (exclusive of work performed by CSMC or the Inventors) during the term of this Agreement.
1.8 "Net Sales" shall mean the gross amount invoiced by Licensee, its Affiliates, Permitted Sublicensees, affiliates of Permitted Sublicensees, or any of them, to third parties for all sales of Products less (a) discounts actually allowed; (b) credits for claims, allowances, retroactive price reductions or returned goods; (c) prepaid freight; and (d) sales taxes or other governmental charges actually paid in connection with sales of Products (but excluding what are commonly known as income taxes and value-added taxes). Sales of Products by Licensee, or a Permitted Sublicensee of Licensee, to any Affiliate or Permitted Sublicensee which is a reseller thereof shall be excluded, and only the subsequent sale of such Products by Affiliates or Permitted Sublicensees of Licensee to unrelated parties shall be deemed Net Sales hereunder. If a Product is sold or provided as part of a system, package, or combination product or service that involve one or more products or services not covered by the definition of Product (each, a "Combination Product"), Net Sales shall be calculated by multiplying the Net Sales of such Combination Product, by the fraction A/B, where "A" is the price of the Product included in such Combi nation Product when sold separately from any other products or services not covered by the definition of Product and "B" is the price of the Combination Product. In the event that no market price is available for the Product included in such Combination Product when supplied or priced separately, CSMC and Licensee shall determine in good faith the fair market value thereof.
1.9 "Non-Royalty Sublicense Revenues" shall mean, but is not limited to, upfront fees, license maintenance fees, and milestone payments, or other payments, including the fair market value of any non-cash consideration, received by Licensee in consideration for any rights granted to Patent Rights under a sublicense agreement, and excludes any and all sales-based royalties paid to Licensee.
1.10 "Patent Rights" shall mean the patents and/or patent applications existing on the Effective Date which are described on Schedule A attached hereto, and all patents and/or patent applications (including provisional patent applications) existing as of the Effective Date in any other country corresponding to any of the foregoing, and all divisions, continuation s, reissues, reexaminations, supplementary protection certificates and extensions thereof, whether domestic or foreign, all claims of continuations-in-part that are entitled to the benefit of the priority date of any of the foregoing, and any patent that issues thereon. The Patent Rights are all owned by CSMC.
1.11 "Product" or "Products" shall mean any products and/or services in the Field of Use that, except for the license granted hereunder, would infringe a Valid Claim.
1.12 "Territory" shall mean worldwide.
1.13 "Valid Claim" shall mean a claim of an issued patent included within the Patent Rights, which claim has not (a) lapsed, been canceled or become abandoned, (b) been declared invalid or unenforceable by a non-appealable decision or judgment of a court or other appropriate body or authority of competent jurisdiction, or (c) been admitted to be invalid or unenforceable through reissue, disclaimer or otherwise. The term Valid Claim shall also include the claims of a pending patent application within the Patent Rights for a period of ten (10) years from the actual filing date of that patent application.
2. LICENSE
2.1 Grant of Exclusive Rights. Subject to the terms of this Agreement, CSMC hereby grants to Licensee, and Licensee hereby accepts from CSMC, the exclusive license, with the right to grant sublicenses (subject to the terms of Section 2.2 hereof), under and to the Patent Rights during the term of this Agreement (as provided in Section 6 hereof) to conduct research in the Field of Use and to make, have made, use, import , offer for sale, sell and/or have sold Products in the Field of Use in the Territory. The foregoing grant of exclusivity is made expressly subject to the following:
(a) All applicable laws and regulations, including, without limitation, the requirements of federal law as pertains to the manufacture of products within the United States;
(b) All applicable rules of the Funding Agencies which have provided funding to CSMC or to any of its employees (including any of the Inventors) for the development of the Patent Rights; and
(c) The following non-exclusive rights to the Patent Rights, which are retained by CSMC within the Field of Use:
(i) the right to submit for publication the scientific findings from research conducted by or through CSMC or its investigators (including the Inventors) related to the Patent Rights; and
(ii) the right (A) to use any tangible or intangible information contained m the Patent Rights or any Improvements (so long as CSMC shall treat such information as Confidential Inf01mation and maintain its confidentiality in accordance with Sect ion 10 hereof), for CSMC's non-commercial research, internal teaching and other educationally-related and non-commercial (except for charges to its own patients) clinical purposes, where clinical use does not involve a third party funding grant to commercialize such information, and (B) to obtain research funding for further study and development thereof from governmental and other nonprofit organizations (including grant applications).
(d) Notwithstanding any other provision hereof to the contrary, all rights to the Patent Rights and Improvements outside of the Field of Use are retained by CSMC. Furthermore, this Agreement confers no license or rights by implication, estoppel, or otherwise under any patent applications or patents of CSMC other than Patent Rights regardless of whether such patents are dominant or subordinate to Patent Rights.
2.2 Sublicensing. Licensee shall have the right to grant sublicenses or to assign any or all of the rights granted hereunder only to an entity which has been approved in writing by CSMC (each, " Permitted Sublicensee"), which approval shall not be unreasonably withheld or delayed. Any such Permitted Sublicensee shall be subject in all respects to the provisions contained in this Agreement and Licensee will remain primarily liable to CSMC for, and shall be responsible for monitoring and enforcing, performance of all of Licensee' s obligations hereunder by any such Permitted Sublicensee. Without limiting the generality of the foregoing, as an express condition of any such sublicense, any such Pe1mitted Sublicensee shall be required to agree in writing to be bound by commercially reasonable reporting and record keeping, indemnification and inspection provisions, and the applicable provisions of this Agreement, including, without limitation, those pertaining to the use of CSMC's name and marks, indemnification of CSMC and the use of CSMC's Confidential Information. Permitted Sublicensees may not further sublicense without CSMC's prior written consent, which consent shall not be unreasonably withheld or delayed. Licensee shall promptly forward to CSMC a copy of any and all fully executed sublicense agreements, any subsequent amendments, and all copies of Permitted Sublicensees ' profit sharing or royalty reports, in no event more than thirty (30) days following execution or receipt thereof, as applicable. Licensee shall also keep CSMC reasonably informed with respect to the progress of any relations entered into with any Pe1mitted Sublicensees. If Licensee shall conduct one or more audits of its Permitted Sublicensees hereunder during the term hereof, Licensee shall provide copies of all audit reports to CSMC on a timely basis. The covenants pertaining to the use of CSMC's name and marks, the indemnification of CSMC and the use of CSMC's Confidential Information in any sublicense or assignment shall run for the benefit of CSMC, who shall be expressly stated as being a third- party beneficiary thereof with respect to the covenants set forth in this Agreement. Licensee understands and agrees that none of its permitted sublicenses hereunder shall reduce in any manner any of its obligations set forth in this Agreement.
(a) Royalty-Free Sublicenses. If, and only if, Licensee pays all royalties due CSMC from a Permitted Sublicensee's Net Sales, Licensee may grant that Permitted Sublicensee a royalty-free or non-cash sublicense or cross-license.
2.3 Improvements. Subject to the rights and applicable rules of the Funding Agencies, Licensee shall have, for a period of sixty (60) days after receipt by Licensee of written notice from CSMC disclosing an Improvement, the exclusive first right to negotiate with CSMC to obtain one or more licenses to the Improvement in the Field of Use upon such terms and conditions as shall be agreed by the parties hereto, which terms and conditions shall include provisions for fair market value consideration for the grant of any such licenses. If Licensee declines or fails to pursue, or if the parties fail to conclude negotiations for a license to, such Improvement in the Field of Use during the sixty (60) day period specified above, then CSMC shall have the right to commence discuss ions with any other party concerning such Improvement. Subject to the provisions of this Section 2.3, Licensee acknowledges and agrees that CSMC expressly retains and reserves any and all right, title and interest in and to the Improvement, whether or not in the Field of Use and, accordingly, no license to any Improvement is granted to Licensee under this Agreement.
2.4 Licensee Developments. Licensee hereby grants, and shall require its Permitted Sublicensee(s) to grant to CSMC a nonexclusive, royalty-free, irrevocable, paid-up license, with the right to grant sublicenses to non-profit research institutions and governmental agencies, to practice and use Licensee Developments for non-commercial research purposes, which license shall include, without limitation, the rights to: (a) subject to the publication obligations in Section 5.5, publish the scientific findings from research conducted by or through CSMC or on its behalf, (b) use any tangible or intangible
information contained in the Licensee Developments (so long as CSMC shall treat such information as Confidential Information and maintain its confidentiality in accordance with Section 10 hereof), for CSMC's internal teaching and other educationally-related and non-commercial (except for charges to its own patients) clinical purposes , where clinical use does not involve a third party funding grant to commercialize such information, and (c) obtain research funding from governmental and other nonprofit organizations (including grant applications).
2.5 Diligent Commercialization. Licensee acknowledges that it is important to CSMC, and a requirement of the United States Government under Title 35, Section 203 of the United States Code, that Licensee pursue the development, commercialization and marketing of Products and otherwise exercise commercially reasonable efforts to maximize the value of this Agreement to CSMC. Without limiting the foregoing, Licensee shall maintain a bona fide, funded, ongoing and active research, development, manufacturing, regulatory, marketing or sales program (all as commercially reasonable) to make Products commercially available to the public as soon as commercially practicable in the Territory. Should CSMC determine that Licensee fails to use commercially reasonable efforts to maximize the Patent Rights in any national political jurisdiction in the Territory at any time following the two (2) year anniversary of the Effective Date of this Agreement, CSMC shall provide Licensee with notice of such determination and give Licensee a period of ninety (90) days to provide written evidence reasonably satisfactory to CSMC that Licensee or its Permitted Sublicensee(s) has sales of Products in such jurisdiction in question or an effective, ongoing and active research, development, manufacturing, marketing or sales program, as appropriate, directed toward obtaining regulatory approval, and/or production and/or sales of Products in such jurisdiction in accordance with Licensee's business, legal, medical and scientific judgment and Licensee's normal practices and procedures for products having similar technical and commercial potential. Should Licensee fail to provide such written evidence reasonably satisfactory to CSMC within such ninety (90) day period, CSMC shall have the right, at CSMC's sole and absolute discretion, to either: (i) terminate this Agreement with respect to the applicable national political jurisdiction within the Territory or (ii) require Licensee to negotiate in good faith a sublicense with a Permitted Sublicensee(s) in the applicable national jurisdiction to maximize the Patent Rights in such jurisdiction.
2.6 Milestones. As part of Licensee's diligent commercialization efforts under Section 2.5, CSMC and Licensee have agreed on the Milestones set forth on Schedule B, with each such Milestone being deemed a separate and independent condition. Within sixty (60) days after each anniversary of the Effective Date, Licensee shall prepare and deliver to CSMC an annual written repo rt (to be certified by an executive officer of Licensee) indicating its compliance with the Milestones. If Licensee believes that it is or will be unable to achieve such Milestones despite its diligent efforts, Licensee may request amendments or reasonable extensions to Schedule B in writing for CSMC’s consideration. Licensee agrees to provide an y additional information reasonably required by CSMC to evaluate Licensee's performance under this Agreement. If Licensee fails to meet any annual Milestone designated in Schedule B here to, and has not obtained an extension or amendment to such Milestone(s), CSMC may, at its option and as its sole remedy for Licensee's breach of this Section 2.6, upon written notice to Licensee, convert the exclusive license granted under Section 2.1 hereof to a non-exclusive license or to a co-exclusive license, or terminate the license.
2.7 Preference for United States Industry. To the extent that the Patent Rights have been developed using funding from the United States Government, Licensee agrees that any Products made, used or sold in the United States shall be manufactured substantially in the United States.
3. REPRESENTATIONS AND WARRANTIES
3.1 Rights to Technology. Except for the rights, if any, of the Funding Agencies or the United States Government, CSMC represents and warrants to Licensee that, to the best of its actual, current knowledge (without investigation outside of CSMC as to such representations and warranties) (a) it has the right to grant the licenses in this Agreement, (b) it has not granted licenses to the Patent Rights to any other party that would restrict the rights granted hereunder except as stated herein and (c) there are no claims, judgments or settlements to be paid by CSMC with respect the Patent Rights or pending claims or litigation relating to the Patent Rights. Except for any potential or actual rights of Funding Agencies or the United States Government, CSMC is not aware that any additional rights or licenses are necessary for Licensee to exercise its licensed rights granted by CSMC under this Agreement.
3.2 Limited Warranty; Certain Damages.
(a) Limited Warranty. CSMC makes no representation or warranty other than those expressly specified in this Agreement. Licensee accepts the Patent Rights on an "AS- IS" basis. CSMC MAKES NO OTHER WARRANTIES CONCERNING PATENT RIGHTS COVERED BY THIS AGREEMENT, INCLUDING WITHOUT LIMITATION, ANY EXPRESS OR IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE AS TO PATENT RIGHTS OR ANY PRODUCT. CSMC MAKES NO WARRANTY OR REPRESENTATION AS TO THE VALIDITY OR SCOPE OF PATENT RIGHTS, OR THAT ANY PRODUCT WILL BE FREE FROM AN INFRINGEMENT ON PATENTS OR OTHER INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES, OR THAT NO THIRD PARTIES ARE IN ANY WAY INFRINGING PATENT RIGHTS COVERED BY THIS AGREEMENT. LICENSEE HEREBY AGREES THAT LICENSEE WILL NOT GIVE AND SHALL NOT PERMIT ANY AFFILIATES OR SUBLICENSEES OR AFFILIATES THEREOF TO GIVE, ANY SUCH WARRANTY OR REPRESENTATION TO THIRD PARTIES ON BEHALF OF CSMC.
(b) Certain Damages. EXCEPT FOR THE BJ.IBACH OF THE CONFIDENTIALITY PROVISIONS IN SECTION 10 OR IN ACCORDANCE WITH THE OBLIGATION TO INDEMNIFY SET FORTH IN SECTION 8, IN NO EVENT SHALL CSMC BE LIABLE FOR ANY INDIRECT, SPECIAL OR CONSEQUENTIAL DAMAGES (INCLUD ING, WITHOUT LIMITATION, DAMAGES FOR LOSS OF PROFITS OR EXPECTED SAVINGS OR OTHER ECONOMIC LOSSES, OR FOR INJURY TO PERSONS OR PROPERTY) ARISING OUT OF OR IN CONNECTION WITH THIS AGREEMENT OR ITS SUBJECT MATTER, REGARDLESS OF WHETHER CSMC KNOWS OR SHOULD KNOW OF THE POSSIBILITY OF SUCH DAMAGES. EXCEPT FOR THE BREACH OF THE CONFIDENTIALITY PROVISIONS IN SECTION 10 OR IN ACCORDANCE WITH THE OBLIGATION TO INDEMNIFY SET FORTH IN SECTION 8, CSMC' S AGGREGATE LIABILITY FOR ALL DAMAGES OF ANY KIND RELATING TO THIS AGREEMENT OR ITS SUBJECT MATTER SHALL NOT EXCEED THE AMOUNT PAID BY LICENSEE TO CSMC UNDER THIS AGREEMENT. THE FOREGOING EXCLUSIONS AND LIMITATIONS SHALL APPLY TO ALL CLAIMS AND ACTIONS OF ANY KIND, WHETHER BASED ON CONTRACT, TORT (INCLUDING, BUT NOT LIMITED TO NEGLIGENCE), OR ANY OTHER GROUNDS.
3.3 Rights Retained by Funding Agencies. Licensee acknowledges that to the extent that the Patent Rights have been developed in part under one or more funding agreements (" Fund in g Agreements") with one or more Funding Agencies, such Funding Agencies have certain statutory, non-exclusive rights relative thereto for use for government purposes as well as regulatory or statutory "march-in rights" (collectively, "Statutory Rights" ). Licensee also acknowledges that to the extent that the Improvements may be developed in part under one or more Funding Agreements with one or more Funding Agencies, such Funding Agencies may have certain Statutory Rights relative thereto. This Agreement is explicitly made subject to such Statutory Rights and, to the extent of any conflict between any such Statutory Rights and this Agreement, such Statutory Rights shall prevail.
4. CONSIDERATION
In consideration of the execution and delivery by CSMC of this Agreement, Licensee agrees as follows:
4.1 License Fee. Within thirty (30) days of the execution of this Agreement, Licensee shall pay to CSMC a non-refundable license fee in an amount equivalent to five thousand dollars ($5,000.00).
4.2 Reimbursement of Patent Prosecution Costs. Licensee shall reimburse CSMC for all of the costs, including attorneys' fees, actually incurred by CSMC in the prosecution of the Patent Rights through the date on which CSMC transfers responsibility for prosecution of the Patent Rights to Licensee (" Prosecution Costs "), which as of the Effective Date total to $59,644.07. The Prosecution Costs shall be payable in three (3) installment payments in accordance with the following schedule: (i) $9,241.87 shall be due within thirty (30) days of the Effective Date; (ii) ten thousand dollars ($10,000) shall be due within six (6) months of the Effective Date and (iii) the remaining balance of the Prosecution Costs shall be due when Licensee has raised $250,000.00 in cumulative funding. Commencing on the Effective Date and continuing until the Prosecution Costs are paid in full, interest shall accrue and be payable on all outstanding amounts due at the rate, per annum, of two percent (2%) over the rate of interest announced by Bank of America in Los Angeles, California (or any successor in interest thereto or any commercially equivalent financial institution if no such successor exists) to be its "prime rate". Licensee shall have the right to pay the outstanding Prosecution Costs in full in an accelerated manner at any time without penalty; provided, that interest shall accrue on any outstanding amounts until such time as all outstanding amounts are paid in full. In the event of any termination of this Agreement by Licensee in accordance with the terms and conditions of this Agreement, Licensee shall promptly pay to CSMC all of its outstanding payment obligations under this Agreement, including without limitation, the full reimbursement of patent expenses, upon the date of termination.
4.3 Royalties and Non-Royalty Revenue.
(a) Running Royalties for Products. Licensee agrees to pay and shall pay to CSMC a non-refundable running royalty (each, a " Royalty" ) in the amount of two percent (2%) on Net Sales of Products made, used, sold or otherwise distributed by Licensee or any Permitted Sublicensee hereunder ("Product Royalty Rate").
(b) Minimum Royalties. Beginning on the third (3rd anniversary of the Effective Date, Licensee shall pay to CSMC annual minimum royalty payments ("Minimum Royalties") in the amount of five thousand dollars ($5,000.00) per year. Each annual Minimum Royalty paid by Licensee hereunder shall be credited against Royalties payable under Section 4.3(a) during the calendar year in which the Minimum Royalty is due; provided, however, that Licensee may not
carry over to the following year any amount by which the Minimum Royalty paid exceeds the actual amount of Royalties payable hereunder during the applicable calendar year. Licensee's failure to pay the Minimum Royalty payment to CSMC in accordance with this Section shall constitute a material breach of this Agreement by Licensee, and CSMC shall have the right to terminate the Agreement in accordance with Section 6.2(c) thereof, or at Licensor's sole discretion, upon written notice to Licensee, convert the exclusive license granted under Section 2. l hereof to a non-exclusive license or to a co-exclusive license.
(c) Permitted Deductions. If Licensee is required to make any payment to a third party to obtain a license for the manufacture, use, sale or import of a Product or otherwise exploit the Patent Rights, Licensee shall be entitled to deduct up to fifty percent (50%) of such third party payments made in a particular calendar year against Royalties payable to CSMC for that year; provided, however, that in no event shall the Royalties payable to CSMC hereunder for any one-year period be reduced by operation of this section by more than fifty percent (50%); and provided, further, that such third party payments shall only be creditable against Royalties payable to CSMC for the calendar year in which the third party payment was actually made by Licensee.
(d) Licensee Challenge of Patent Rights. Should Licensee bring, directly or through a third party indirectly, an action challenging the validity, scope or enforceability of any Patent Rights, Licensee will first provide CSMC with at least ninety (90) days' prior written notice that it intend s so to do before filing such a challenge. Following the giving of such notice, Licensee will pay to CSMC the Royalties and Non-Royalty Sublicense Revenue due hereunder at the rate of two times the applicable rate during the pendency of such action. Should the outcome of such action determine that any claim of a patent challenged by Licensee is valid and/or infringed and/or enforceable, as applicable, Licensee will thereafter pay to CSMC the Royalties and Non -Royalty Sublicense Revenue due hereunder at the rate of three times the applicable rate for all Products sold that would infringe such claim and/or transactions that include a grant of rights to such claim. Such increased royalty reflects the increased value of the Patent Rights upheld in such action. In the event that a challenge to the Patent Rights brought by Licensee is partially or entirely successful, Licensee will have no right to recoup any Royalties or other amounts paid before or during the period of the challenge. Additionally, Licensee agrees to disburse any and all proceeds received from any sublicense of the applicable Patent Rights throughout the duration of any such challenge to CSMC and agrees to reimburse CSMC for all costs actually incurred by CSMC in connection with the applicable legal proceedings. In the event that all or any portion of this Section 4.3(d) is invalid, illegal or unenforceable, then the parties will use their best efforts to replace the invalid, illegal or unenforceable provision (s) with valid, legal and enforceable provision(s) which, insofar as practical, gives effect to the intent of this Section 4.3(d).
(e) Arm's-Length Transactions. On sales of Products which are made in other than an arms' length transaction, the value of the Net Sales attributed under this Section 4.3 to such a transaction shall be that which would have been received in an arms'-length transaction, based on sales of like quality and quantity products on or about the time of such transaction.
(f) Duration of Royalty Obligations. The royalty obligations of Licensee as to each Product shall terminate on a country-by-country and product-by-product basis concurrently with the expiration of the last to expire Valid Claim that covers such Product in a country, including any term extensions thereof.
(g) Non-Royalty Revenues.
(i) Non-Royalty Sublicense Revenues. Any and all "Non-Royalty Sublicense Revenues" shall be reported and paid to CSMC by Licensee at a rate of five percent (5%) of all Non-Royalty Sublicense Revenues from any third party to CSMC within sixty (60) days of receipt by Licensee. Any non-cash consideration received by Licensee from Permitted Sublicensees shall be valued at its fair market value as of the date of receipt and such amount shall be paid in cash to CSMC in accordance with the schedule above. In the event that the Patent Rights are sublicensed in combination with one or more patented technologies that are not covered under this Agreement, Non-Royalty Sublicense Revenues for the purposes of this Section 4.3(g) shall be calculated on a pro-rata basis in a manner to be mutually agreed by CSMC and Licensee (which agreement may be a condition of approval under Section 2.2).
(ii) Product Development Milestones. Licensee agrees to pay and shall pay to CSMC the following non-creditable, non-refundable product development milestone payments within ninety (90) days of the first occurrence of the following milestones (or their equivalents):
|
Milestone Event |
Milestone Payment |
|
Successful completion of phase 2 of clinical trial |
$250,000 |
|
Successful completion of phase 3 of clinical trial |
$350,000 |
|
New drug application (NDA) approval by FDA in the United States or an equivalent agency in a major market outside of the United States |
$350,000 |
|
First commercial sale of a Product |
$1,000,000 |
|
Licensee's achievement of aggregated Net Sales of $75,000,000 |
$1,500,000 |
(h) Payment and Accounting.
(i) Reports. Each payment of Royalties shall be accompanied by a report in the form attached as Schedule C hereto, which sets forth in reasonable detail the number and each type of Product sold and the calculation of Net Sales applicable thereto, and such additional details as may be reasonably requested by CSMC for the determination of Royalties payable hereunder. Products shall be considered as being sold for the purpose of the calculation of Royalties under this Agreement when the Products have been invoiced. Each payment of Non-Royalty Sublicense Revenue shall be accompanied by a report in the form attached as Schedule C hereto setting forth in reasonable detail the basis for the calculation of such amounts, and such additional details as may be reasonably requested by CSMC for the determination of Non-Royalty Sublicense Revenue payable hereunder. All copies of reports under this Section shall be sent by electronic mail to CSTechTransfer@cshs.org. Except as otherwise provided herein, all amounts due hereunder shall be paid in United States dollars and shall be made without set off and free and clear of (and without any deduction or withholding for) any taxes, duties, levies, imposts or similar fees or charges. Royalties shall be payable by Licensee quarterly, within forty-five (45) days after the end of each calendar quarter, based upon revenues accrued during the immediately preceding calendar quarter. Licensee agrees to pay and shall pay to CSM C, or cause its Permitted Sublicensees to pay to CSMC, all Royalties resulting from the activities of its Permitted Sublicensees, within forty-five (45) days after the end of each calendar quarter.
(ii) Notice of Payment. Licensee shall provide prompt written notice to CSMC that it has paid the licensee fee required by Section 4.1 or any product development milestone payment required by Section 4.3(h) by electronic mail to CSTechTransfer@cshs.org.
(iii) Wire Transfer Instructions. All payments due hereunder shall be made by Licensee to CSMC in accordance with the following wire transfer instructions:
City National Bank
400 N. Roxbury Drive
Beverly Hills, CA 90210
ABA# 122 016 066
Account Number: 210-132260
Account Name: Cedars-Sinai Medical Center-Tech Transfer
Reference: Tech Transfer- StemVax
(iv) Records and Audits. Licensee shall create and maintain complete and accurate records and documentation concerning all sales of Products by Licensee, its Affiliates and Permitted Sublicensees as well as transactions based upon which Non-Royalty Sublicense Revenue is due, in sufficient detail to enable the Royalties and Non-Royalty Sublicense Revenue, respectively, that is payable hereunder to be determined. Licensee shall retain such records and documentation for not less than seven (7) years from the date of their creation. During the term of this Agreement and for a period of three (3) years thereafter, CSMC and its representatives shall have the right to audit such records and documentation as shall pertain to the determination and payment of Royalties and Non-Royalty Sublicense Revenue. Such examiners shall have
reasonable access during regular business hours to Licensee's offices and the relevant records, files and books of account, and shall have the right to examine any other records reasonably necessary to determine the accuracy of the calculations provided by Licensee. The costs of any such audit shall be borne by CSMC, unless as a result of such inspection it is determined that the amounts payable by Licensee for any period are in error by greater than five percent (5%), in which case the costs of such audit shall be borne by Licensee. CSMC shall report the results of any such audit to Licensee within forty-five (45) days of completion. Thereafter, Licensee shall promptly pay to CSMC the amount of any underpayment discovered in such audit, or CSMC shall credit to Licensee against future Royalty payments the amount of any overpayment discovered in such audit, as the case may be. In addition, Licensee shall pay interest on any underpayment at the rate that is the lower of (i) two percent (2%) over the rate of interest announced by Bank of America in Los Angeles, California (or any successor in interest thereto or any commercially equivalent financial institution if no such successor exists) to be its " prime rate", or (ii) the highest rate permitted by applicable law, from the date such amount was underpaid to the date payment is actually received.
(v) Currency Transfer Restrictions. If any restnct10ns on the transfer of currency exist in any country or other jurisdiction so as to prevent Licensee from making payments to CSMC, Licensee shall take all commercially reasonable steps to obtain a waiver of such restrictions or to otherwise enable Licensee to make such payments. If Licensee is unable to do so, Licensee shall make such payments to CSMC in a bank account or other depository designated by CSMC in such country or jurisdiction, which payments shall be in the local currency of such country or jurisdiction, unless payment in United States dollars is permitted. Any payment by Licensee to CSMC in currencies other than United States dollars shall be calculated using the appropriate foreign exchange rate for such currency quoted in the California edition of The Wall Street Journal for the close of business of the last banking day of the calendar quarter in which such payment is being made.
(vi) Late Charges. A serv ice charge of two percent (2%) per month, not to exceed the maximum rate allowed by applicable law, shall be payable by Licensee on any portion of Licensee 's outstanding Royalty or Non-Royalty Sublicense Revenue balance or any other amount payable by Licensee hereunder (including, without limitation, reimbursement for Prosecution costs as set forth in Section 4.1 hereof) that is not paid to CSMC within thirty (30) days past the due date.
(vii) Taxes. Licensee shall pay, or cause to be paid, any and all taxes required to be paid or withheld on any sales, licenses or other transfers for value of Products or Patent Rights (other than taxes imposed on the income or revenues of CSMC); provided, however, that under no circumstances shall the amounts of such taxes be deducted from the total amount of payments otherwise due to CSMC hereunder. Upon CSMC's request, Licensee shall secure and send to CSMC proof of any such taxes withheld and paid by Licensee, its Affiliates or Permitted Sublicensees.
(viii) No Escrow. Licensee shall pay all Royalties and Non-Royalty Sublicense Revenue directly to CSMC and shall not pay royalties into any escrow or other similar account, including in the event of a validity or non-infringement challenge to the Patent Rights.
5. PATENT AND INTELLECTUAL PROPERTY RIGHTS
5.1 Prosecution. Commencing on the Effective Date, Licensee shall assume, in coordination with CSMC, full responsibility for the application, maintenance, reexamination, reissue, opposition and prosecution of any kind (collectively "Prosecution") relating to the Patent Rights in the Territory, including, but not limited to, payment of all costs, fees and expenses related thereto. Subject to the approval of CSMC (which approval shall not be unreasonably withheld), Licensee shall have the right to select counsel with respect to the responsibility, assumed by Licensee in this Section 5.1, and Licensee shall diligently pursue the Prosecution of the Patent Rights to the benefit of CSMC. For all purposes of the patent Prosecution, CSMC shall be the named "client" of such patent counsel. Each party shall provide the other with copies of any and all material or communications with the United States Patent and Trademark Office, or any foreign patent office, and CSMC shall be afforded the opportunity of prior review and comment on such action or paper.
(a) Foreign Filings. Should Licensee elect not to file for patent protection for the Patent Rights in a certain national jurisdiction in the Territory, Licensee shall notify CSMC of such election at least forty-five (45) days before a final due date which would result in the bar of patent protection for the Patent Rights in such national jurisdiction. In such event, CSMC may, at its sole option and expense, file for patent protection for the Patent Rights in the applicable national jurisdiction, and Licensee's license under this Agreement with respect to such national jurisdiction shall terminate, allowing CSMC to freely dispose of its Patent Rights in the applicable national jurisdiction as it sees fit in its sole discretion.
5.2 Abandonment, Disclaimers, etc. Licensee shall obtain the prior written consent of CSMC (which consent shall not be unreasonably withheld), prior to abandoning, disclaiming, withdrawing, seeking reissue, seeking reexamination or allowing to lapse any patent or patent application within the Patent Rights. In the event that Licensee shall elect to abandon the Prosecution (including the payment of maintenance fees or annuities) of any patent or patent application included in the Patent Rights, Licensee shall notify CSMC of such election at least forty-five (45) days before a final due date which would result in abandonment or bar of patentability of the patent or patent application. In such event, CSMC may, at its sole option and expense, continue Prosecution of the patent application or patent. Licensee further agrees that it shall not file any continuation-in-part application relating to the Patent Rights unless the additional disclosure or material to be included in the continuation-in- part application is necessary or appropriate to support the patentability of a claim recited in a parent application on which the continuation-in-part application is based. Licensee shall not file any continuation-in - part application without CSMC's prior written consent, which shall not be unreasonably withheld.
5.3 Expenses. Licensee shall pay all expenses resulting from its obligations in Section 5.1 hereof. CSMC shall exercise reasonable efforts to cause the Inventors (to the extent they are available and on CSMC 's staff as employees) to cooperate fully with Licensee with respect to the Prosecution of the Paten t Rights, and CSMC shall be reimbursed for all reasonable out-of-pocket expenses as such expenses are incurred.
5.4 CREATE Act. Licensee shall not invoke the Cooperative Research and Technology Enhancement Act of 2004, as set forth under Title 35, Section 102(c) of the United States Code (the "CREATE Act"), with respect to the Patent Rights without first obtaining the prior written consent of CSMC.
5.5 Publications. CSMC shall furnish Licensee with a written copy of any proposed publication or disclosure that relates to the Patent Rights and/or Licensee’s Confidential Information or discloses and/or describes any Improvement that Licensee has certain active rights to as described in Section 2.3, including without limitation, disclosures at research seminars, lectures and professional meetings and the submission of papers for publication at least forty-five (45) days prior to submission for publication or disclosure so that Licensee may have a reasonable opportunity to protect the proprietary rights to information, inventions, or products identified in such publication or disclosure. Further, if Licensee indicates that such publication or disclosure contains Licensee’s Confidential Information, CSMC agrees to remove such Confidential Information from the proposed publication or disclosure. Notwithstanding the preceding, in the event that Licensee requires any deletion of information, in no event will the deletion compromise the objective medical or scientific integrity of the manuscript. CSMC further shall, upon Licensee’s request, delay publication or presentation for an additional period of up to forty-five (45) days to allow Licensee to protect its interest in any inventions described in any such manuscripts or materials.
6. TERM AND TERMINATION
6.1 Term. Unless earlier terminated as provided in Section 6.2 hereof, the term of this Agreement shall commence on the Effective Date and shall expire, on a country-by-country and product-by-product basis, on the date upon which the last to expire Valid Claim shall exp ire.
6.2 Termination. Except as provided by Section 6.3 hereof, and in addition to the termination provisions of Sections 2.5, 2.6 and 5.l(a), this Agreement shall terminate upon the earliest to occur of the following:
(a) Automatically if Licensee shall enter into a liquidating bankruptcy, be adjudged in solvent, liquidate, dissolve and/or if the business of Licensee shall be placed in the hands of a receiver, assignee, or trustee, whether by voluntary act of Licensee or otherwise; provided, however, that if any such action is involuntary, termination shall not take place unless the action is not reversed within thirty (30) days. Further, Licensee shall give CSMC at least forty-five (45) days' prior written notice before Licensee initiates any bankruptcy proceeding, and CSMC shall have the right to terminate this Agreement immediately upon receipt of such notice;
(b) Automatically if the performance by either party to this Agreement of any term, covenant, condition or provision hereof (i) shall jeopardize (A) the licensure of CSMC, (B) CSMC's participation in the Medicare, Medi-Cal or other reimbursement or payment programs, (C) the full accreditation of CSMC by the Joint Commission on Accreditation of Healthcare Organizations or any other state or nationally recognized accreditation organization, or (D) CSMC's tax-exempt status; or (ii) is deemed illegal or unethical by any recognized governmental agency or body. Upon the occurrence of any of the items set forth in this subparagraph (b), CSMC shall provide written notice to Licensee setting forth the reason for such termination (which termination shall be effective immediately);
(c) Upon thirty (30) days' written notice from CSMC if, within such thirty (30) day period (i) Licensee shall fail to pay fully any Royalty or Non-Royalty Sublicense Revenue payment required by Section 4.3 hereof, or (ii) Licensee shall fail to undertake commercially reasonable efforts to exploit the Patent Rights in the Field of Use in the Territory, regardless of Licensee's satisfaction of the Milestones provided in Schedule B hereto;
(d) Upon sixty (60) days' written notice from CSMC if, within such sixty (60) day period, Licensee shall fail to cure fully any breach or default of any material obligation under this Agreement as described in such written notice detailing the facts of such breach with reasonable specificity; provided, however, that Licensee may avoid such termination if, before the end of such 60-day period, such breach or default has been cured by Licensee to the reasonable satisfaction of CSMC;
(e) Upon ninety (90) days' written notice from Licensee if, within such ninety (90) day period, CSMC shall fail to cure fully any breach or default of any material obligation under this Agreement as described in such written notice detailing the facts of such breach with reasonable specificity; provided, however, that CSMC may avoid such termination if, before the end of such 90-day period, such breach or default has been cured by CSMC to the reasonable satisfaction of Licensee;
(f) Upon ninety (90) days' written notice from Licensee, in the event that Licensee has determined that it would not be commercially reasonable to continue to develop and/or commercialize Products for any of the following reasons: (i) scientific or technical reasons or (ii) unduly burdensome obligations imposed by regulatory authorities; provided that, such written notice to CSMC under this Section 6.2(f) must provide CSMC with a reasonable explanation for Licensee's termination under this Section 6.2(f); and
(g) Upon the mutual written agreement of the parties hereto (such termination to be effective as of the date mutually agreed upon in such written agreement).
6.3 Obligations Upon Termination. Upon any termination of this Agreement pursuant to Section 6.2 hereof, nothing herein shall be construed to release any party from any liability for any obligation incurred through the effective date of termination (e.g., confidentiality, reimbursement of patent expenses incurred prior to such date, etc.) or for any breach of this Agreement prior to the effective date of such termination. Licensee may, for a period of one ( I ) year after the effective date of such termination, sell all tangible Products customarily classified as " inventory" that it has on hand at the date of termination, subject to payment by Licensee to CSMC of the applicable Royalty and Non-Royalty Sublicense Revenue; provided, however, that any such action by Licensee does not subject CSMC to any of the occurrences set forth in Section 6.2(b) hereof.
6.4 Effect of Termination. In the event of any termination of this Agreement pursuant to Section 6.2 hereof, where such termination has not been caused by any action or inaction on the part of any Permitted Sublicensee of Licensee or by any breach by such Permitted Sublicensee of its obligations under its sublicense from Licensee, such termination of this Agreement shall be without prejudice to the rights of each non-breaching Permitted Sublicensee of Licensee and each non-breaching Permitted Sublicensee shall be deemed to be a licensee of CSMC thereunder, and CSMC shall be entitled to all rights, but shall not be subject to any obligations (other than the grant of license and appurtenant obligations under this Agreement to the extent provided for in such sublicense) of Licensee thereunder. This Section 6.4, however, shall not be applicable if this Agreement has been terminated under Section 6.2(b) under circumstances where the application of this Section 6.4 would subject CSMC to any of the occurrences set forth in Section 6.2(b).
6.5 Right to Institute Legal Actions. Notwithstanding the provisions of Section 6.2 hereof, CSMC, on the one hand, and Licensee, on the other hand, may institute any other legal action or pursue any other remedy against the other party permitted by applicable law if the other party does not substantially cure any breach or default of any material obligation as provided herein.
6.6 Reversion of Rights. Notwithstanding anything to the contrary set forth herein (including, but not limited to, Section 5 hereof), full responsibility for Prosecution of the Patent Rights shall, at the option of CSMC (exercisable in its sole and absolute discretion), and at its sole expense from the date of reversion, revert to CSMC upon any termination of this Agreement.
6.7 Return of Data. In the event of any termination or expiration of this Agreement, Licensee shall promptly provide CSMC with copies of all data, information and materials obtained or generated by or on behalf of Licensee in the course of conducting research and developing Products using the Patent Rights.
7. INFRINGEMENT BY THIRD PARTIES
7.1 Enforcement. Licensee shall have the first right and the obligation to enforce, at its so le expense, any Patent Rights to the extent licensed hereunder against infringement by third parties and shall notify CSMC in writing in advance of all such enforcement efforts. Upon Licensee ' s undertaking to pay all expenditures reasonably incurred by CSMC, CSMC shall reasonably cooperate in any such enforcement and, as necessary, join as a party therein. Licensee shall reimburse CSMC for all expenses, including reasonable attorneys’ fees, incurred in connection with any such enforcement. In the event that Licensee does not file suit against or commence and conclude settlement negotiations with a substantial infringer of Patent Rights within ninety (90) days of receipt of a written demand from CSMC that Licensee bring suit, then the parties will consult with one another in an eff01t to determine whether a reasonably prudent licensee would institute litigation to enforce the patent in question in light of all relevant business and economic factors (including, but not limited to, the projected cost of such litigation, the likelihood of success on the merits, the probable amount of any damage award, the prospects for satisfaction of any judgment against the alleged infringer, the possibility of counterclaims against the parties hereto, the impact of any possible adverse outcome on Licensee and the effect any publicity might have on the parties' respective reputations and goodwill). If, after such process, it is determined that a suit should be filed and Licensee does not file suit or commence settlement negotiations forthwith against the infringer, then CSMC shall have the right, at its own expense, to enforce any Patent Rights license d hereunder on behalf of itself and Licensee. Any damages or other recovery from an infringement action undertaken by Licensee shall first be used to reimburse the parties, on a pro rata pari passu basis, for the costs and expenses incurred in such action, and shall thereafter be allocated between the parties as follows: (i) twenty percent (20%) to CSMC and (ii) eighty percent (80%) to Licensee. If Licensee fails to prosecute any such action to completion, then any damages or other recovery net of the parties’ costs and expenses incurred in such infringement action shall be the sole property of CSMC.
7.2 Defense of Patent Rights. In the event that any Patent Rights are the subject of a legal action seeking declaratory relief or of any reexamination or opposition proceeding instituted by a third party, the parties agree to promptly consult with each other concerning the defense of such actions or proceedings. If the parties agree that such defense should be undertaken, then Licensee shall bear the expenses, including attorneys’ fees, associated with such defense and in any recoupment of expenses. If the parties disagree, then the party desiring to defend the action or proceeding may proceed with such defense and will bear its own expenses and be entitled to all sums recovered.
8. INDEMNIFICATION
8.1 Indemnification by Licensee. Subject to Section 8.2 hereof, Licensee shall hold harmless, defend and indemnify CSMC and each of its officers, directors, employees (including the Inventors), agents and sponsors of the research (except Licensee) (each, an "Indemnified Party", and collectively, the "Indemnified Parties") from and against any and all claims, damages, losses, liabilities , costs and expenses (including reasonable attorneys' fees and expenses and costs of investigation, whether or not suit is filed) suffered or incurred by any of the Indemnified Parties in any action, suit, litigation, arbitration or dispute of any kind ("Action ") arising or resulting from any negligence or willful acts or omissions on the part of Licensee, its Affiliates or Permitted Sublicensees in connection with (a) their use of the Patent Rights and/or (b) the exercise of their rights hereunder or under any sublicense, including, but not limit ed to (i) the preclinical development and clinical testing of Products, and (ii) the manufacture, sale, use, marketing, or other disposition of Products developed, manufactured, sold, marketed, used or otherwise disposed of under this Agreement. As part of its obligations hereunder, Licensee shall defend any Action brought against any of the Indemnified Parties with counsel of its own choosing and reasonably acceptable to CSMC, and neither CSMC nor any other Indemnified Party shall enter into any settlement of any such Action without first obtaining prior approval of Licensee. Licensee shall pay all costs, including attorney's fees, incurred in enforcing this indemnification provision. Should CSMC or any other Indemnified Party not afford Licensee the right to defend any such Action, or should CSMC or any other Indemnified Party not obtain the approval of Licensee to any such settlement, Licensee shall have no obligation to indemnify CSMC or any other Indemnified Party hereunder. Should Licensee fail to provide a defense for the Indemnified Parties as required hereunder, then Licensee shall reimburse CSMC for its out-of-pocket expenses (including reasonable attorneys' fees and expenses and costs of investigation) which are incurred as a result of any investigation, defense or settlement relating to the foregoing, which reimbursement shall be made to CSMC upon receipt by Licensee of invoices reflecting in reasonable detail such expenses incurred by CSMC. Licensee shall obtain and maintain insurance policies (including products liability and general liability policies at such time as is appropriate) which are reasonable and necessary to cover its activities and to comply with the indemnification obligations set forth above. Such insurance policies shall name CSMC as an additional insured party and shall provide a minimum of $2,000,000 in coverage per occurrence. Upon initiation of any human clinical studies of Products, Licensee shall have first increased its insurance coverage to a minimum of $5,000,000 in the aggregate. Licensee shall provide CSMC with prompt written notice of any material change in coverage under such policies. If the parties determine that evidence of Licensee's insurance coverage is necessary and appropriate, within thirty (30) days of the Effective Date (subject to extension if reasonably required) and annually thereafter, Licensee shall provide CSMC with a certificate of insurance issued by the appropriate insurance company evidencing the insurance coverage required by this Section 8.1, together with copies of the endorsement which specifies CSMC as an additional insured and the declarations page for each such insurance policy. The certificate of insurance, endorsements and declarations pages (and any renewals or replacements thereof), if required, shall be sent to CSMC's Technology Transfer Office by electronic mail at CSTechTransfer@cshs.org.
8.2 Notice of Claim. CSMC shall promptly notify Licensee in writing of any claim or Action or material threat thereof brought against any Indemnified Party in respect of which indemnification may be sought and, to the extent allowed by law, shall reasonably cooperate with Licensee in defending or settling any such claim or Action. No settlement of any claim, Action or threat thereof received by CSMC and for which CSMC intends to seek indemnification (for itself or on behalf of any other Indemnified Party) shall be made without the prior joint written approval of Licensee and CSMC.
9. USE OF NAMES
9.1 CSMC Names and Marks. Licensee shall not, unless as required by any law or governmental regulation, use the name of CSMC, and/or any of its trademarks, service marks, trade names or fictitious business names or the name of any CSMC officer, faculty member, employee , student or volunteer (collectively, "CSMC Names and Marks") without express prior written consent of the Vice President for Public Relations and Marketing of CSMC. Further, prior to any reference by Licensee to CSMC Names and Marks in any manner, Licensee shall provide CSMC with a writing reflecting the proposed reference so that CSMC can review the reference within a reasonable period of time prior to the proposed use thereof by Licensee. This limitation includes, but is not limited to, use by Licensee in any regulatory filing, advertising, offering circular, prospectus, sales presentation, news release or trade publication. Subject to compliance by Licensee with the foregoing, which shall be deemed conditions precedent to any use of CSMC Names and Marks by Licensee, Licensee shall ensure that the CSMC Names and Marks are used as scientifically or academically appropriate in the "byline" of any article, abstract, manuscript or any other publication related to the subject matter hereof.
9.2 No Endorsements by CSMC. By entering into this Agreement, CSMC does not directly or indirectly endorse any product or service provided, or to be provided, by Licensee whether directly or indirectly related to this Agreement. Licensee shall not state or imply that this Agreement is an endorsement by CSMC.
10. CONFIDENTIALITY
10.1 Non-Disclosure. The parties hereto shall keep the terms of this Agreement and all business and scientific discussions relating to the business of the parties strictly confidential. All patient information to which a party is given access by the other party shall be subject to the provisions of the Confidentiality of Medical Information Act (Cal. Civ. Code §§56, et seq.) and the Health Insurance Portability and Accountability Act of 1996 , and all regulations promulgated thereunder. It may, from time to time, be necessary for the parties, in connect ion with performance under this Agreement, to disclose Confidential Information (including know-how) to each other. The Receiving Party (as defined in Section 1.2 hereof) shall keep in strictest confidence the Confidential Information of the Disclosing Party (as defined in Section 1.2 hereof), using the standard of care it normally uses for information of like character, and shall not disclose the Confidential Information to any third party or use it except as expressly authorized by the prior written consent of the Disclosing Party or as otherwise permitted by this Agreement; provided, however, that Licensee may disclose the Confidential Information received from CSMC to its Affiliates and Permitted Sublicensees as shall be reasonably necessary to carry out the intent of this Agreement or any sublicense granted by Licensee as contemplated by this Agreement if, but only if, such Affiliates and/or Permitted Sublicensees each execute a confidentiality agreement containing confidentiality provisions no less restrictive than those confidentiality provisions contained in this Section 10. The Receiving Party's obligation hereunder shall not apply to Confidential Information that the Receiving Party can show:
(a) Is or later becomes part of the public domain through no fault or neglect of the Receiving Party;
(b) Is received in good faith from a third party having no obligations of confidentiality to the Disclosing Party, provided that the Receiving Party complies with any restrictions imposed by the third party;
(c) Is independently developed by the Receiving Party without use of the Disclosing Party's Confidential Information; or
(d) Is required by law or regulation to be disclosed (including, without limitation, in connection with FDA filings, filings with another government agency or as required under the California Public Records Act), provided that the Receiving Party uses reasonable efforts to restrict disclosure and to obtain confidential treatment.
10.2 Limits on Permitted Disclosures. Each party agrees that any disclosure or distribution of the other party's Confidential Information within its own organization shall be made only as is reasonably necessary to carry out the intent of this Agreement. The parties further agree that all of their respective officers, employees, agents, representatives or approved sub licensees to whom any Confidential Information is disclosed or distributed shall have agreed to maintain its confidentiality. In such event, the Receiving Party shall identify with reasonable particularity, upon request by the Disclosing Party, each person within the Receiving Party's organization to whom the Receiving Party has disclosed or distributed Confidential Information.
10.3 Legally Required Disclosures. If a subpoena or other legal process concerning Confidential Information is served upon any party hereto pertaining to the subject matter hereof, the party served shall notify the other party immediately, the other party shall cooperate with the party served, at the other party's expense, in any effort to contest the validity of such subpoena or other legal process. This Section 10.3 shall not be construed in any way to limit any party's ability to satisfy any disclosure of its relationship with the other party required by any governmental authority.
10.4 Patent Rights as Confidential Information. The Patent Rights are understood by Licensee to be the Confidential Information of CSMC to the extent "unpublished" as such term is construed under the United States Patent Laws. As such, Licensee' s confidentiality obligations hereunder automatically extend to any and all patent applications of CSMC relating to any Patent Rights and Improvements and to any and all communications with the United States Patent Office, and any foreign patent office relating to any Patent Rights Improvements.
10.5 Return of Confidential Information. In the event of any termination of this Agreement, the Receiving Party shall promptly return all Confidential Information and any copies made thereof previously made available to the Receiving Party by the Disclosing Party.
10.6 Remedies. Both parties acknowledge and agree that it would be difficult to measure damages for breach by either party of the covenants set forth in this Section l 0, and that injury from any such breach would be incalculable, and that money damages would therefore be an inadequate remedy for any such breach. Accordingly, either party shall be entitled, in addition to all other remedies available hereunder or under law or equity, to injunctive or such other equitable relief as a court may deem appropriate to restrain or remedy any breach of such covenants.
11. INFORMATION EXCHANGE
In addition to the Patent Rights, the parties shall cooperate to exchange such non-confidential information as may be appropriate and necessary to facilitate Licensee's development and commercialization of Products incorporating any Patent Rights.
12. PATENT MARKING
Licensee shall actually or virtually mark all Products made, sold or otherwise disposed of by or on behalf of it or any of its Permitted Sublicensees as set forth under Title 35, Section 287(a) of the United States Code and shall respond to any request or disclosure under Title 35, Section 287(6)(4)(B) of the United States Code by only notifying CSMC of the request for disclosure.
13. MISCELLANEOUS
13.1 Notices. Any notice, request, instruction or other document required by this Agreement shall be in writing and shall be deemed to have been given (a) if mailed with the United States Postal Service by prepaid, first class, certified mail, return receipt requested, at the time of receipt by the intended recipient, (b) if sent by Federal Express or other overnight carrier, signature of delivery required, at the time of receipt by the intended recipient, or (c) if sent by facsimile transmission, when so sent and when receipt has been acknowledged by appropriate telephone or facsimile receipt, addressed as follows:
In the case of CSMC to:
Cedars-Sinai Medical Center
8700 Beverly Boulevard
Los Angeles, California 90048-1865
Attention: Executive Vice President for Finance & CFO
with a copy to Vice President for Technology & Business Affairs
or in the case of Licensee to:
Stemvax, LLC
1850 N New Hampshire Ave
Los Angeles, CA 90027
Attention: Dwain Morris-Irvin, co-Founder, CSO
or to such other address or to such other person(s) as may be given from time to time under the terms of this Section 13.1.
13.2 Compliance with Laws. Each party shall comply with all applicable federal, state and local laws and regulations in connection with its activities pursuant to this Agreement.
13.3 Governing Law. For any dispute between the parties to this Agreement which arises from or relates to this Agreement, the Agreement shall be construed and enforced in accordance with the laws of the United States of America and of the State of California, irrespective of choice of law’s provisions. The parties agree that Los Angeles County, California shall be the situs of any legal
proceeding arising out of or relating to this Agreement. Each party hereby waives any right it may have to assert the doctrine of forum non conveniens or similar doctrine or to object to venue with respect to any proceeding brought in accordance with this Section , and stipulates that the state and federal courts located in Los Angeles, California shall have in personam jurisdiction and venue over each of them for the purpose of litigating any dispute, controversy, or proceeding arising out of or related to this Agreement. Each party hereby authorizes and accepts service of process sufficient for personal jurisdiction in any action against it as contemplated by this Section by registered or certified mail, return receipt requested, postage prepaid, to its address for the giving of notices as set forth in this Agreement.
13.4 Waiver. Failure of any party to enforce a right under this Agreement shall not act as a waiver of that right or the ability to assert that right relative to the particular situation involved.
13.5 Enforceability. If any provision of this Agreement shall be found by a court of competent jurisdiction to be void, invalid or unenforceable, the same shall be reformed to comply with applicable law or stricken if not so conformable, so as not to affect the validity or enforceability of the remainder of this Agreement.
13.6 Modification. No change, modification, or addition or amendment to this Agreement, or waiver of any term or condition of this Agreement, is valid or enforceable unless in writing and signed and dated by the authorized officers of the parties to this Agreement.
13.7 Entire Agreement. This Agreement and the Schedules hereto (which are incorporated herein by this reference as if fully set forth herein) constitute the entire agreement between the parties with respect to the subject matter hereof and thereof, and replace and supersede as of the date hereof and thereof any and all prior agreements and understandings, whether oral or written, between the parties with respect to the subject matter of such agreements.
13.8 Construction. This Agreement has been prepared, examined, negotiated and revised by each party and their respective attorneys, and no implication shall be drawn and no provision shall be construed against any party to this Agreement by virtue of the purported identity of the drafter of this Agreement or any portion thereof.
13.9 Counterparts. This Agreement may be executed simultaneously in one or more counterparts, each of which shall constitute one and the same instrument. This Agreement may be executed by facsimile or in .pdf format.
13.10 Attorneys' Fees. In the event of any action at law or in equity between the parties hereto to enforce any of the provisions hereof, the unsuccessful party to such litigation shall pay to the successful party all reasonable costs and expenses, including reasonable attorneys ' fees, incurred therein by such successful party; and if such successful party shall recover a judgment in any such action or proceeding, such reasonable costs, expenses and attorneys' fees may be included in and as part of such judgment.
13.11 Assignment; Successors.
(a) Subject to Section 13.11(b), Licensee may assign this Agreement as part of a sale, regardless of whether such a sale occurs through an asset sale, stock sale, merger or other combination, or any other transfer of Licensee's entire business, or that part of Licensee's business that exercises all rights granted under this Agreement. Any other attempt to assign this
Agreement by Licensee without CSMC's written consent, which shall not be unreasonably withheld or delayed, is null and void. In the event of a bankruptcy, assignment is permitted only to a party that can provide adequate assurance of future performance, including diligent development and sales, of Products.
(b) Prior to any assignment , the following conditions must be met: (i) Licensee must give CSMC thirty (30) days prior written notice of the assignment, including the new assignee's contact information, (ii) the new assignee must agree in writing to CSMC to be bound by this Agreement, and (iii) CSMC must have received a $25,000.00 assignment fee.
(c) Subject to the limitations on assignment herein, this Agreement shall be binding upon and inure to the benefit of any successors in interest and assigns of CSMC and Licensee. CSMC shall have the right to assign its rights hereunder as part of any reorganization or bond financing.
13.12 Further Assurances. At any time and from time to time after the Effective Date, each party shall do, execute, acknowledge and deliver, and cause to be done, executed, acknowledged or delivered, all such further acts, transfers, conveyances, assignments or assurances as may be reasonably required to consummate the transactions contemplated by this Agreement.
13.13 Survival. The following sections shall survive any expiration or earlier termination of this Agreement: 4.3(h), 6.3, 8, 9, 10, 12 and 13.
[signature page follows]
IN WITNESS WHEREOF, the parties have caused their duly authorized representatives to execute this Agreement as of the date first above written.
"LICENSEE":
StemVax, LLC, A California Limited Liability Company
By: Dwain Morris-Irwin
Title: CSO, Chief Scientific Officer
Date: 7/20/2018
/s/Dwain Morris-Irwin
"CSMC":
Cedars-Sinai Medical Center, A California Non-Profit Benefit Corporation
By: Edward M. Prunchunas
Title: Executive Vice President for Finance and CFO
Date: 7/25/2018
/s/ Edward M. Prunchunas
By: James D. Laur, JD
Title: Vice President, Technology & Business Affairs
Date: 7/24/2018
/s/ James D. Laur, JD
ACKNOWLEDGED AND AGREED:
"INVENTORS":
Dr. Keith Black
/s/ Dr. Keith Black
Dr. Dwain Morris-Irvin
/s/ Dr. Dwain Morris-Irvin
Dr. Moshe Arditi
/s/Dr. Moshe Arditi
Schedule A
Patent Rights
|
1.Title: |
USE OF TOLL-LIKE RECEPTOR LIGANDS AS ADJUVANTS TO VACCINATION THERAPY FOR BRAIN TUMORS |
|
Patent Application: |
61/073,205 |
|
Filing Date: |
June 17, 2008 |
|
CSMC Tech ID: |
bla000322 |
|
2.Title: |
USE OF TOLL-LIKE RECEPTOR LIGANDS AS ADJUVANTS TO VACCINATION THERAPY FOR BRAIN TUMORS |
|
Patent Application: |
PCT/US2009/047640 |
|
Filing Date: |
June 17, 2009 |
|
CSMC Tech ID: |
bla000322 |
|
3.Title: |
USE OF TOLL-LIKE RECEPTOR LIGANDS AS ADJUVANTS TO VACCINATION THERAPY FOR BRAIN TUMORS |
|
Patent Application: |
12/995,434 |
|
Filing Date: |
November 30, 2011 |
|
CSMC Tech ID: |
bla000322 |
|
4.Title: |
USE OF TOLL-LIKE RECEPTOR LIGANDS AS ADJUVANTS TO VACCINATION THERAPY FOR BRAIN TUMORS |
|
Patent Application: |
14,247,028 |
|
Filing Date: |
April 7, 2014 |
|
CSMC Tech ID: |
bla000322 |
Schedule B
Milestones
1. Commercially reasonable diligence for partnering, fund raising, preclinical development, FDA interactions for clinical development and pre-IND meeting in the first two (2) years of the Agreement
2. Initiation of Phase 1 trial within three (3) to four (4) years of Effective Date of the Agreement
3. Initiation of Phase 2 trial within six (6) years of Effective Date of the Agreement
4. Initiation of Phase 3 trial within eight (8) years of Effective Date of the Agreement
Schedule C
Royalty Reporting Form
Licensee name:
Reporting period:
Date of report:
Date of first commercial sale:
Royalty Report
|
Product (list products by name) |
No. of units sold |
Invoiced price per unit |
Gross Sales |
Allowable deductions (attached itemized detail) |
Country of sale/foreign currency/conversion rate |
Net sales |
|
Product Name |
||||||
|
Product Name |
||||||
|
Product Name |
||||||
|
Total |
|
Total net sales |
$ |
|
Royalty rate |
|
|
Royalty due |
$ |
Total royalty due: $_________________________
Non-Royalty Sublicense Revenue Report
|
Total Non-Royalty Sublicense Revenue received |
$ |
|
Date received |
|
|
Applicable percentage payable to CSMC |
|
|
Total Non-Royalty Sublicense Revenue payable to CSMC |
$ |
Report prepared by:
Title:
Date:
Please send electronic copy of report to CSTechTransfer@cshs.org.
Exhibit 2.10
Interest Purchase Agreement
This Unit Purchase Agreement (this “Agreement”) is entered into effective February 1, 2020 (the “Effective Date”) by Innovest Global, Inc., a Nevada corporation (“Buyer”), and Dr. Dwain Morris-Irvin (“Seller”).
Recitals
A. Seller and Buyer are the sole owners of StemVax, LLC, a California limited liability company (“StemVax”).
B. Buyer desires to purchase Seller’s membership interest in StemVax, and Seller desires to sell to Buyer his interest in StemVax.
Seller and Buyer (together, the “Parties”) agree as follows:
1 Sale and Purchase of Interest
1.1 Sale of Interest. On the Effective Date, Buyer sells and transfers all of his membership interest in StemVax (the “Interest”) to Buyer free and clear of all liens, encumbrances, charges and assessments of every nature.
1.2 Payment of Purchase Price. On the Effective Date, Buyer issues to Seller a warrant to purchase 7.5 million shares of Buyer’s common stock, par value $0.001 per share (the “Shares”), for $0.16 a Share (the “Warrant”).
2 Representations and Covenants of Seller
2.1 The Interests. Other than the Interests and the StemVax membership interests owned by Buyer, StemVax has not issued any other membership interest or other securities (“Securities”). StemVax has not issued and there is not outstanding any option, warrant or convertible securities or other right to purchase or convert any obligation into Securities, and StemVax has not agreed to issue or sell any additional Securities. The Interests are free and clear of all liens, encumbrances, charges and assessments of every nature. No person or entity has any right to acquire the Interests.
2.2 Authority; No Conflict. Seller is authorized to execute, deliver and perform this Agreement. The execution of this Agreement and the consummation of the transactions contemplated by this Agreement will not result in the breach of any term or provision of, or constitute a default under, any indenture, mortgage, deed of trust, or other agreement or instrument to which Seller or StemVax or any of its subsidiaries is a party or to which it or any of its assets, operations or subsidiaries are subject.
2.3 Accuracy of Information. The diligence information provided by Seller to Buyer relating to StemVax and the Interests is complete and accurate in all material respects and does not contain
any untrue statement of a material fact or omit to state a material fact required to make the statements made, in light of the circumstances under which they were made, not misleading as of the Effective Date.
2.4 Securities Matters. Seller understands that the sale of the Warrant and Shares is intended to be exempt from registration under Section 4(a)(2) of the Securities Act, and Seller represents and warrants that: (a) Seller has been advised that the Warrant and Shares have not been registered under the Securities Act and, therefore, cannot be resold unless they are registered under the Securities Act or unless an exemption from registration is available; (b) Seller is acquiring the Warrant and Shares solely for his own benefit and not with a view to, or for resale in connection with, the distribution thereof, and Seller has no present intention of distributing or reselling the Warrant and Shares; and (c) Seller represents and warrants that he has knowledge and experience in financial and business matters, that he is capable of evaluating the merits and risks of investing in the Warrant and Shares and that he is able to bear the economic risk of such investment.
2.5 Further Actions. After the Effective Date, Seller agrees to take all actions reasonably necessary to effectuate the transactions contemplated by this Agreement.
3 Representations and Covenants of Buyer
3.1 The Warrant. Buyer has the power and authority to issue the Warrant and the Shares to Seller. The Shares when issued to Seller in accordance with the Warrant will be duly authorized, validly issued, fully paid and nonassessable.
3.2. Authority; No Conflict. The board of directors of Buyer has authorized the execution, delivery and performance of this Agreement by Buyer and has authorized and approved the issuance of the Warrant. The execution of this Agreement and the consummation of the transactions contemplated by this Agreement will not result in the breach of any term or provision of, or constitute a default under, any indenture, mortgage, deed of trust, or other agreement or instrument to which Buyer or any of its subsidiaries is a party or to which it or any of its assets, operations or subsidiaries are subject.
3.3 Accuracy of Information. The diligence information provided by Buyer to Seller relating to Buyer and the Warrant is complete and accurate in all material respects and does not contain any untrue statement of a material fact or omit to state a material fact required to make the statements made, in light of the circumstances under which they were made, not misleading as of the Effective Date.
3.4 Securities Matters. Buyer understands that the sale of the Interests is intended to be exempt from registration under Section 4(a)(1) of the Securities Act, and Buyer represents and warrants that: (a) Buyer has been advised that the Interests have not been registered under the Securities Act and, therefore, cannot be resold unless they are registered under the Securities Act or unless
an exemption from registration is available; (b) and Buyer represents and warrants that it has knowledge and experience in financial and business matters, that it is capable of evaluating the merits and risks of investing in the Interests and that it is able to bear the economic risk of such investment.
3.5 Further Actions. After the Effective Date, Buyer agrees to take all actions reasonably necessary to effectuate the transactions contemplated by this Agreement.
4 Indemnification
4.1 By Buyer. Buyer agrees to indemnify, defend and hold harmless Seller against any and all claims, demands, losses, costs, expenses, obligations, liabilities and damages, including interest, penalties and reasonable attorneys’ fees and costs (“Losses”) incurred by Seller, arising, resulting from or relating to any breach of, or failure by, Buyer to perform, any of its representations, warranties, covenants or agreements in this Agreement.
4.2 By Seller. Seller agrees to indemnify, defend and hold harmless Seller against any and all Losses incurred by Buyer, arising, resulting from or relating to any breach of, or failure by, Seller to perform, any of its representations, warranties, covenants or agreements in this Agreement.
5 Miscellaneous
5.1 Entire Agreement. This Agreement constitutes the entire agreement between the Parties and supersedes all other agreements, whether oral or written, with respect to the subject matter of this Agreement. This Agreement may be modified or amended only by a written agreement signed by the Parties against whom the amendment is sought to be enforced.
5.2 Governing Law. This Agreement will be governed by the laws of Ohio without giving effect to applicable conflict of law provisions. With respect to any litigation arising out of or relating to this Agreement, each party agrees that it will be filed in and heard by the state or federal courts with jurisdiction to hear such suits located in Geauga County, Ohio.
18. Assignment. Except in the case of an affiliate of the Buyer, this Agreement may not be assignable by either Party without prior written consent of the other Party.
5.4 Counterparts. This Agreement may be executed in any number of counterparts, including electronically, each of which counterparts will be deemed to be an original, and such counterparts will constitute but one and the same instrument.
< Signatures on Next Page >
In witness whereof, the Parties have singed this Agreement as of the Effective Date.
| “Buyer” | “Seller” | |
| Innovest Global, Inc. | ||
| By Daniel G. Martin, Chief Executive Officer | Dwain Morris-Irvin, Individually | |
| /s/Daniel G. Martin | /s/Dwain Morris-Irvin |
THIS WARRANT AND THE SECURITIES ISSUABLE UPON EXERCISE HEREOF HAVE BEEN ACQUIRED FOR INVESTMENT AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR ANY STATE SECURITIES LAW. THIS WARRANT AND SUCH SECURITIES MAY NOT BE OFFERED, SOLD OR OTHERWISE PLEDGED, TRANSFERRED OR HYPOTHECATED IN THE ABSENCE OF SUCH REGISTRATION OR DELIVERY OF AN OPINION OF COUNSEL IN FORM AND SUBSTANCE REASONABLY SATISFACTORY TO THE COMPANY THAT SUCH OFFER, SALE OR TRANSFER, PLEDGE OR HYPOTHECATION IS IN COMPLIANCE WITH THE ACT.
Innovest Global, Inc.
Warrant for the Purchase of
7,500,000 Shares of Common Stock
For Value Received, Innovest Global, Inc., a Nevada corporation (the “Company”), hereby grants to Dr. Dwain Morris-Irvin, his designee or permitted assigns, warrants to purchase from the Company, at any time or from time to time commencing on February 1, 2020 (the “Issuance Date”) and prior to 5:00 P.M., Cleveland time, on February 1, 2030 (the “Exercise Period”), 7,500,000 fully paid and non-assessable shares of common stock, $0.001 par value per share, of the Company for a purchase price per share of $0.16. In this Warrant, (i) the common stock, $0.001 par value per share, of the Company is referred to as the “Common Stock;” (ii) the shares of the Common Stock (subject to adjustment as set forth below) purchasable under this Warrant are referred to as the “Warrant Shares;” (iii) the aggregate purchase price payable for the Warrant Shares purchasable under this Warrant is referred to as the “Aggregate Warrant Price;” (iv) the price payable (initially $0.16 per share subject to adjustment as set forth below) for each of the Warrant Shares is referred to as the “Per Share Warrant Price;” and (v) the holder of this Warrant is referred to as the “Holder.”
1. Exercise of Warrant
(a) This Warrant may be exercised in whole at any time, or in part from time to time, by the Holder during the Exercise Period by the surrender of this Warrant (with the exercise notice, in the attached form (the “Exercise Notice”), duly executed) at the address set forth in Section 8, together with proper payment of the Aggregate Warrant Price, or the proportionate part thereof if this Warrant is exercised in part, to the Company.
(b) If this Warrant is exercised in part, this Warrant must be exercised for a number of whole shares of Common Stock and the Holder is entitled to receive a new Warrant covering the Warrant Shares that have not been exercised and setting forth the proportionate part of the Aggregate Warrant Price applicable to such Warrant Shares. Upon surrender of this Warrant in connection with the exercise of this Warrant pursuant to the terms hereof, the Company will (i) issue a certificate or certificates in the name of the Holder for the largest number of whole shares of the Common Stock to which the Holder shall be entitled upon such exercise and, if this
Warrant is exercised in whole, in lieu of any fractional share of Common Stock, the number of shares of Common Stock to which the Holder shall be entitled shall be rounded to the nearest whole share, and (ii) deliver the other securities and properties receivable upon the exercise of this Warrant, or the proportionate part thereof, if this Warrant is exercised in part, pursuant to the provisions of this Warrant.
(c) Notwithstanding anything contained herein to the contrary, the Holder may, in its sole discretion, exercise this Warrant, in whole or in part and, in lieu of making the cash payment otherwise contemplated to be made to the Company upon such exercise in payment of the Aggregate Warrant Price, and elect instead to receive upon such exercise the “Net Number” of shares of Common Stock determined according to the following formula (a “Cashless Exercise”):
Net Number = (A x B) - (A x C)
B
For purposes of this formula:
A = the total number of shares of Common Stock with respect to which this Warrant is then being exercised.
B = the Fair Market Value of the Common Stock on the date immediately preceding the date of the written notice of exercise.
C = the Exercise Price then in effect for the applicable Warrant Shares at the time of such exercise.
“Fair Market Value” means: (i) if the Common Stock is listed on any established stock exchange or a national market system, the Fair Market Value shall be the closing price of a share of Common Stock (or if no sales were reported the closing price on the date immediately preceding such date) as quoted on such exchange or system on the day of determination; or (ii) in the absence of an established market for the Common Stock, the Fair Market Value shall be determined in good faith by the board of directors of the Company.
(d) Upon exercise of this Warrant, the Company shall promptly (but in no event later than five business days after the date the Exercise Notice is delivered to the Company (the “Exercise Date”)) issue or cause to be issued and cause to be delivered to the Holder a certificate for the Warrant Shares.
(e) To the extent permitted by law, the Company’s obligations to issue and deliver Warrant Shares in accordance with the terms hereof are absolute and unconditional, irrespective of any action or inaction by the Holder to enforce the same, any waiver or consent with respect to any provision hereof. Nothing herein shall limit the Holder’s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Company’s failure to timely deliver
certificates representing shares of Common Stock upon exercise of this Warrant as required pursuant to the terms hereof.
2. Reservation of Warrant Shares. The Company agrees that, prior to the expiration of this Warrant, the Company shall at all times (a) have authorized and in reserve, and shall keep available, solely for issuance and delivery upon the exercise of this Warrant, 100% of the shares of Common Stock and other securities and properties as from time to time shall be receivable upon the exercise of this Warrant, free and clear of all restrictions on sale or transfer, other than under Federal or state securities laws, and free and clear of all preemptive rights and rights of first refusal. The Company covenants that all Warrant Shares so issuable and deliverable shall, upon issuance and the payment of the applicable Exercise Price in accordance with the terms hereof, be duly and validly authorized, issued and fully paid and nonassessable.
3. Certain Adjustments
(a) In case the Company shall hereafter (i) pay a dividend or make a distribution on its Common Stock in shares of Common Stock, (ii) subdivide its outstanding shares of Common Stock into a greater number of shares, (iii) combine or reverse-split its outstanding shares of Common Stock into a smaller number of shares, or (iv) issue by reclassification of its Common Stock any shares of capital stock of the Company, then the Per Share Warrant Price and the number of Warrant Shares shall forthwith be proportionately decreased and increased, respectively, in the case of a subdivision, distribution or stock dividend, or proportionately increased and decreased, respectively, in the case of a combination or reverse stock split. The Aggregate Warrant Price payable for the then total number of Warrant Shares available for exercise under this Warrant shall remain the same. Adjustments made pursuant to this Section 3(a) shall become effective on the record date in the case of a dividend or distribution, and shall become effective immediately after the effective date in the case of a subdivision, combination or reclassification. If such dividend, distribution, subdivision or combination is not consummated in full, the Per Share Warrant Price and Warrant Shares shall be readjusted accordingly.
(b) In case of any capital reorganization or reclassification, or any consolidation or merger to which the Company is a party other than a merger or consolidation in which the Company is the continuing corporation, or in case of any sale or conveyance to another entity of all or substantially all of the assets of the Company, or in the case of any statutory exchange of securities with another corporation (including any exchange effected in connection with a merger of a third corporation into the Company but excluding any exchange of securities or merger with another corporation in which the Company is a continuing corporation and that does not result in any reclassification of or similar change in the Common Stock), the Holder of this Warrant shall have the right thereafter to receive on the exercise of this Warrant the kind and amount of securities, cash or other property which the Holder would have owned or have been entitled to receive immediately after such reorganization, reclassification, consolidation, merger, statutory exchange, sale or conveyance had this Warrant been exercised immediately prior to the effective date of such reorganization, reclassification, consolidation, merger, statutory exchange, sale or conveyance and in any such case, if necessary, appropriate adjustment shall be made in the application of the provisions set forth in this Section 3 with respect to the rights and interests thereafter of the Holder of this Warrant to the end that the provisions set forth in this Section 3
shall thereafter correspondingly be made applicable, as nearly as may reasonably be, in relation to any shares of stock or other securities or property thereafter deliverable on the exercise of this Warrant. The above provisions of this Section 3(b) shall similarly apply to successive reorganizations, reclassifications, consolidations, mergers, statutory exchanges, sales or conveyances. The Company shall require the issuer of any shares of stock or other securities or property thereafter deliverable on the exercise of this Warrant to be responsible for all of the agreements and obligations of the Company hereunder. Notice of any such reorganization, reclassification, consolidation, merger, statutory exchange, sale or conveyance and of said provisions so proposed to be made, shall be provided to the Holder not more than five business days after such event. A sale of all or substantially all of the assets of the Company for a consideration consisting primarily of securities shall be deemed a consolidation or merger for the foregoing purposes.
(c) Whenever the Per Share Warrant Price or the number of Warrant Shares is adjusted as provided in this Section 3 and upon any other modification of the rights of the Holder in accordance with this Section 3, the Company shall promptly prepare a brief statement of the facts requiring such adjustment or modification and the manner of computing the same and provide such statement to Holder.
(d) In case any event shall occur as to which the other provisions of this Section 3 are not strictly applicable but as to which the failure to make any adjustment would not fairly protect the purchase rights represented by this Warrant in accordance with the essential intent and principles of the adjustments set forth in this Section 3 then, in each such case, the board of directors of the Company shall in good faith determine the adjustment, if any, on a basis consistent with the essential intent and principles established herein, necessary to preserve the purchase rights represented by the Warrants. Upon such determination, the Company will promptly notify the Holder and shall make the adjustments described therein.
4. Fully Paid Stock; Taxes. The shares of the Common Stock represented by each and every certificate for Warrant Shares delivered on the exercise of this Warrant shall, subject to compliance by the Holder with the terms hereof, at the time of such delivery, be duly authorized, validly issued and outstanding, fully paid and nonassessable, and not subject to preemptive rights or rights of first refusal imposed by any agreement to which the Company is a party, and the Company will take all such actions as may be necessary to assure that the par value, if any, per share of the Common Stock is at all times equal to or less than the then Per Share Warrant Price. The Company shall pay, when due and payable, any and all Federal and state stamp, original issue or similar taxes which may be payable in respect of the issue of any Warrant Share or any certificate thereof to the extent required because of the issuance by the Company of such security.
5. Investment Intent; Limited Transferability
(a) By accepting this Warrant, the Holder represents to the Company that it understands that this Warrant and any securities obtainable upon exercise of this Warrant have not been registered for sale under Federal or state securities laws and are being offered and sold to the Holder pursuant to one or more exemptions from the registration requirements of such securities laws. In
the absence of an effective registration of such securities or an exemption therefrom, any certificates for such securities shall bear the legend set forth on the first page hereof. The Holder understands that it must bear the economic risk of its investment in this Warrant and any securities obtainable upon exercise of this Warrant for an indefinite period of time, as this Warrant and such securities have not been registered under Federal or state securities laws and therefore cannot be sold unless subsequently registered under such laws, unless an exemption from such registration is available. The Holder further represents to the Company, by accepting this Warrant, that it has full power and authority to accept this Warrant and make the representations set forth herein.
(b) The Holder, by its acceptance of this Warrant, represents to the Company that it is acquiring this Warrant and will acquire any securities obtainable upon exercise of this Warrant for its own account for investment and not with a view to, or for sale in connection with, any distribution thereof in violation of the Act. The Holder agrees, by acceptance of this Warrant, that this Warrant and any such securities will not be sold or otherwise transferred unless (i) a registration statement with respect to such transfer is effective under the Act and any applicable state securities laws or (ii) such sale or transfer is made pursuant to one or more exemptions from the Act.
6. Loss, etc., of Warrant. Upon receipt of evidence reasonably satisfactory to the Company of the loss, theft, destruction or mutilation of this Warrant, and of indemnity reasonably satisfactory to the Company, if lost, stolen or destroyed, and upon surrender and cancellation of this Warrant, if mutilated, the Company shall execute and deliver to the Holder a new Warrant of like date, tenor and denomination.
7. Warrant Holder Not Stockholder. This Warrant does not confer upon the Holder any right to vote on or consent to or receive notice as a stockholder of the Company, as such, in respect of any matters whatsoever, relating to the Warrant Shares, prior to the exercise hereof.
8. Communication. No notice or other communication under this Warrant shall be effective or deemed to have been given unless, the same is in writing and is mailed by first-class mail, postage prepaid, or via recognized overnight courier with confirmed receipt, addressed to:
(a) the Company at Innovest Global, Inc., 8834 Mayfield Road, Chesterland, Ohio 44026, Dan Martin, or such other address as the Company has designated in writing to the Holder; or
(b) the Holder at Dr. Dwain Morris-Irvin, 1852 North New Hampshire Avenue, Los Angeles, California 90027, or such other address as the Holder has designated in writing to the Company.
9. Applicable Law. This Warrant will be governed by and interpreted in accordance with the laws of the State of Ohio without regard to the principles of conflict of laws. The parties hereby submit to the exclusive jurisdiction of the United States federal and state courts located in the State of Ohio with respect to any dispute arising under this Warrant or the transactions contemplated hereby or thereby.
10. Amendment, Waiver, etc. Except as expressly provided herein, neither this Warrant nor any term hereof may be amended, waived, discharged or terminated other than by a written instrument signed by the party against whom enforcement of any such amendment, waiver, discharge or termination is sought.
In Witness Whereof, the Company has caused this Warrant to be signed by the undersigned duly authorized officer, effective February 1, 2020.
Innovest Global, Inc.
_____________________________________
By Daniel G. Martin, Chief Executive Officer
/s/ Daniel G. Martin
FORM OF EXERCISE NOTICE
(To be executed by the Holder to exercise the right to purchase shares of Common Stock under the foregoing Warrant)
Ladies and Gentlemen:
(1) The undersigned is the Holder of a warrant dated February 1, 2020 (the “Warrant”) issued by Innovest Global, Inc., a Nevada corporation (the “Company”). Capitalized terms used herein and not otherwise defined herein have the respective meanings set forth in the Warrant.
(2) The undersigned hereby exercises its right to purchase __________ Warrant Shares pursuant to the Warrant.
(3) The Holder intends that payment of the Exercise Price shall be made as (check one):
☐ Cash Exercise
☐ “Cashless Exercise” under Section 1(c) in accordance with the terms of the Warrant
(4) If the Holder has elected a Cash Exercise, the Holder shall pay the sum of $_______ to the Company in accordance with the terms of the Warrant.
(5) Pursuant to this Exercise Notice, the Company shall deliver to the Holder _____________ Warrant Shares in accordance with the terms of the Warrant.
Dated: _______________, _____
_________________________________
Dr. Dwain Morris-Irvin
Exhibit 3.1
FILED # C25630-99
OCT 14 1999
ARTICLES OF INCORPORATION
OF
International Sports Marketing Group, Inc.
The undersigned subscriber to these Articles of Incorporation, a natural person competent to contract, hereby forms a corporation under the laws of the State of Nevada
ARTICLE I NAME
The name of the corporation shall be International Sports Marketing Group, Inc.
ARTICLE II NATURE OF BUSINESS
This corporation may engage in or transact any and all lawful activities or business permitted under the laws of the United States, the State of Nevada, or any other state, county, territory or nation.
ARTICLE III CAPITAL STOCK
The maximum number of shares of stock that this corporation is authorized to have outstanding at any one time is twenty-five million (25,000,000) shares of common stock having a par value of $0.001 per share.
ARTICLE IV ADDRESS
The street address of the initial registered office of the corporation shall be 2921 N. Tenaya Way, Suite 208, Las Vegas, Clark County, Nevada 89128 and the name of the initial Registered Agent for the corporation at that address is CORPORATE CAPITAL FORMATION, INC.
ARTICLE V TERM OF EXISTENCE
This corporation shall exist perpetually.
ARTICLE VI
DIRECTORS' AND OFFICERS' LIABILITY
A director or officer of the corporation shall not be personally liable to the corporation or its stockholders for damages for breach of fiduciary duty as a director or officer, but this article shall not eliminate or limit the liability of a director or officer for (i) acts or omissions which involve intentional misconduct, fraud or a knowing violation of law or (ii) the payment of distributions in violation of NRS 78.300. Any repeal or modification of this Article by stockholders of the Corporation shall be prospective only, and shall not adversely affect any limitation on the personal liability of a director or officer of the corporation for acts or omissions prior to such repeal or modification.
ARTICLE VII
INDEMNITY
Every person who was or is a party to, or is threatened to be made a party to, or is involved in any action, suit, or proceeding, whether civil, criminal, administrative, or investigative, by reason of the fact that he, or a person of whom he is a legal representative, is or was a director or officer of the corporation, or is or was serving at the request of the corporation as a director or officer of another corporation, or as its representative in a partnership, joint venture, trust or other enterprise, shall be indemnified and held harmless to the fullest extent legally permissible under the law of the State of Nevada from time to time against all expenses, liability and loss (including attorneys’ fees, judgments, fines, and amounts paid or to be paid in settlement), reasonably incurred or suffered by him in connection therewith. Such right of indemnification shall be a contract right which may be enforced in any manner desired by such person. The expenses of officers and directors incurred in defending a civil or criminal action, suit or proceeding must be paid by the corporation as they are incurred and in advance of the final disposition of the action, suit or proceeding, upon receipt of an undertaking by or on behalf of the director or officer to repay the amount if it is ultimately determined by a court of competent jurisdiction that he is not entitled to be indemnified by the corporation. Such right shall not be exclusive of any other right which such directors, officers or representatives may have or hereafter acquire, and, without limiting the generality of such statement, they shall be entitled to their respective rights of indemnification under any By-law agreement, vote of stockholder, provision of law or otherwise, as well as their rights under this Article.
ARTICLE VIII SELF DEALING
No contract or other transaction between the corporation and other corporations, in the absence of fraud, shall be affected or invalidated by the fact that any one or more of the directors of the corporation is or are interested in a contract or transaction, or are directors or officers of any other corporation, and any director or directors, individually or jointly, may be a party or parties to, or may be interested in such contract, act or transaction, or in any way connected with such person or person’s firm or corporation, and each and every person who may become a director of the corporation is hereby relieved from any liability that might otherwise exist from this contracting with the corporation for the benefit of himself or any firm, association or corporation i.1 which he may be in any way interested. Any director of the corporation may vote upon any transaction with the corporation without regard to the fact that he is also a director of such subsidiary or corporation.
This corporation shall have a minimum of one director and a maximum of nine. The initial Board of Directors shall consist of Michael E. Smith, 2921 N. Tenaya Way, suite 208 Las Vegas, Nevada 89128
ARTICLE IX INCORPORATOR
The name and address of the incorporator is: Corporate Capital Formation, Inc.
Michael E. Smith, Secretary
2921 N, Tenaya Way, Suite 208
Las Vegas, Nevada 89128
IN WITNESS WHEREOF, the undersigned has hereunto set his hand and seal on this 13 day of October, 1999.
Incorporator:
Corporate Capital Formation, Inc.
Michael Smith, Secretary
STATE OF NEVADA
COUNTY OF CLARK
The foregoing instrument was executed and acknowledged before me this 13th day of October, 1999, by Michael E. Smith.
Notary Public
State of Nevada
My Commission Expires:
Oct. 7, 2001
DESIGNATION OF AND ACCEPTANCE
BY REGISTERED AGENT
The following is submitted in compliance with the laws of the State of Nevada International Sports Marketing Group, Inc., a corporation organizing under the laws of the State of Nevada, with its principal office located at 2921 N. Tenaya Way, Suite 208, Las Vegas, Nevada 89128, has named Corporate Capital Formation, Inc., whose address is 2921 N. Tenaya Way, Suite 208, Las Vegas, Nevada 89128, as its Agent to accept service of process within this State.
ACCEPTANCE:
I agree as Resident Agent to accept service of process; to keep the office open during prescribed hours; to post my name (and any other officers of said corporation authorized to accept service of process at the above designated address) in some conspicuous place in the office as required by law.
Resident
Corporate Capital Formation, Inc.
Michael E Smith, Secretary
Exhibit 3.2
|
|
DEAN HELLER Secretary of State 204 North Carson Street, Suite 1 Carson City, Nevada 89701-4299 (775) 684-5708 Website: www.nvsos.gov |
|
Certificate of Amendment (PURSUANT TO NRS 78.385 AND 78.390) |
|
|
|
Filed in the office of
Dean Heller Secretary of State State of Nevada |
Document Number 20050217992-07 |
|
|
|||||
|
Filing Date and Time 06/06/2005 8:18AM |
|||||
|
|
|||||
|
Entity Number C25630-1999 |
|||||
|
|
|
|
|
|
|
|
Important: Read attached instructions before completing form. |
ABOVE SPACE IS FOR OFFICE USE ONLY |
Certificate of Amendment to Articles of Incorporation
For Nevada Profit Corporations
(Pursuant to NRS 78.385 and 78.390 - After Issuance of Stock)
|
1. |
Name of corporation: |
INTERNATIONAL SPORTS MARKETING GROUP, INC. C25630-99
|
2. |
The articles have been amended as follows: (provide article numbers, if available) |
ARTICLE I – NAME THE NAME OF THE CORPORATION SHALL BE CAL ALTA AUTO GLASS, INC.
|
3. |
The vote by which the stockholders holding shares in the corporation entitling them to exercise at least a majority of the voting power, or such greater proportion of the voting power as may be required in the case of a vote by classes or series, or as may be required by the provisions of the articles of incorporation* have voted in favor of the amendment is: |
1,230,000 63%
|
4. |
Effective date and time of filing: (optional) |
Date: 6/1/05 |
|
(must not be later than 90 days after the certificate is filed) |
|
5. |
Officer Signature (required):
|
*If any proposed amendment would alter or change any preference or any relative or other right given to any class or series of outstanding shares, then the amendment must be approved by the vote. In addition to the affirmative vote otherwise required of the holders of shares representing a majority of the voting power of each class or series affected by the amendment regardless to limitations or restrictions on the voting power thereof.
IMPORTANT: Failure to include any of the above information and submit with the proper fees may cause this filing to be rejected.
|
This form must be accompanied by appropriate fees. See attached fee schedule. |
Nevada Secretary of State AM 78.385 Amend 2003 Revised on: 11/03/03 |
Exhibit 3.3
|
|
ROSS MILLER Secretary of State 204 North Carson Street, Ste 1 Carson City, Nevada 89701-4239 (775) 684-5708 Website: www.nvsos.gov |
|
Certificate of Amendment (PURSUANT TO NRS 78.385 AND 78.390) |
|
|
|
Filed in the office of
Ross Miller Secretary of State State of Nevada |
Document Number 20080825950-59 |
|
Filing Date and Time 12/22/2008 10:40AM |
|||||
|
Entity Number C25630-1999 |
|||||
|
|
|
|
|
|
|
|
USE BLACK INK ONLY • DO NOT HIGHLIGHT |
ABOVE SPACE IS FOR OFFICE USE ONLY |
Certificate of Amendment to Articles of Incorporation
For Nevada Profit Corporations
(Pursuant to NRS 78.385 and 78.390 - After Issuance of Stock)
|
1. |
Name of corporation: |
CAL ALTA AUTO GLASS, INC.
|
2. |
The articles have been amended as follows: (provide article numbers, if available) |
|
A.) |
Amendment to Article V of the Articles of Incorporation to increase authorized Common Stock to 250,000,000 (par value $0.001) and Preferred Stock to 10,000,000 (par value $0.001) |
|
3. |
The vote by which the stockholders holding shares in the corporation entitling them to exercise at least a majority of the voting power, or such greater proportion of the voting power as may be required in the case of a vote by classes or series, or as may be required by the provisions of the articles of incorporation* have voted in favor of the amendment is: |
11,090,000
|
4. |
Effective date and time of filing: (optional) |
|
(must not be later than 90 days after the certificate is filed) |
|
5. |
Signature: (required) |
|
X
|
|
|
Signature of Officer |
|
*If any proposed amendment would alter or change any preference or any relative or other right given to any class or series of outstanding shares, then the amendment must be approved by the vote. In addition to the affirmative vote otherwise required of the holders of shares representing a majority of the voting power of each class or series affected by the amendment regardless to limitations or restrictions on the voting power thereof.
IMPORTANT: Failure to include any of the above information and submit with the proper fees may cause this filing to be rejected.
|
This form must be accompanied by appropriate fees. |
Nevada Secretary of State Amend/Profit-After Revised: 7-1-09 |
CERTIFICATE OF AMENDEMENT
OF
ARTICLES OF INCORPORATION
OF
CAL ALTA AUTO GLASS, INC.
The undersigned President and Secretary of Cal Alta Auto Glass, Inc., a corporation organized and existing under and by virtue of the Nevada General Corporation Law, do hereby certify that:
FIRST: That the Board of Directors of Naturally Iowa, Inc., at a meeting duly convened, held on December 18, 2008, adopted a resolution to amend the Articles of Incorporation as set forth below.
SECOND: That by action of the majority of the Shareholders of Naturally Iowa, Inc., resolutions were duly adopted setting forth a proposed amendment to Article numbered “V” of the Articles of Incorporation of said corporation. The resolution setting forth the proposed amendment is as follows:
RESOLVED: The Shareholders of this Company hereby approve an amendment to Article “V” of this Company’s Articles of Incorporation so that, as amended, it shall be and read as follows:
‘Section 1. Authorized Shares. The aggregate number of Common Shares that this Corporation shall have the authority to issue is 250,000,000 Shares with a par value of $0.001 per Share. The Corporation shall also have the authority to issue 10,000,000 Shares of Preferred Stock with a par value of $0.001 per Share. The description of the Preferred Stock with the preferences, conversion and other rights, voting powers, restrictions, limitations as to dividends, and qualifications and rights thereof are as follows:
(A) Preferred Stock may be issued, from time to time, in one or more Series, each of such Series to have such terms as are stated and expressed herein and in the resolutions providing for the issue of such Series adopted by the Board of Directors as hereinafter provided.
Cal Alta Auto Glass, Inc.: Amendment
December 18, 2008
(B) The Board of Directors, subject to the provisions here of, may classify or reclassify any unissued Shares of Preferred Stock into one or more Series of Preferred Stock by fixing or altering in any one or more respects, form time to time, before issuance of such unissued Shares:
(i) The distinctive designation of such Series and the number of Share to constitute such Series;
(ii) The annual dividend rate on the Shares of such Series, the time of payment, whether or not dividends thereon shall be cumulative, and, if cumulative, the date or dates from which such dividends shall be cumulative;
(iii) The price at and any terms and conditions on which Shares may be redeemed;
(iv) The sinking fund provisions for the redemption or purchase of Shares;
(v) The amount payable on the Shares of such Series in the event of voluntary liquidation, dissolution, or winding up of the Corporation;
(vi) The amount payable on the Shares of such Series in the event of involuntary liquidation;
(vii) Whether or not the Shares of such Series shall be convertible into Shares of stock of any other class or classes, and if so convertible, the terms and conditions of such conversion;
(viii) The limitations and restrictions, if any, to be effective while any Shares of such Series are outstanding, upon the payment of dividends or making of other distributions on the Common Stock or any other class or classes of stock of the Corporation ranking junior to the Shares of such Series;
(ix) The conditions or restrictions, if any, upon the creation of indebtedness of the Corporation or any subsidiary and the conditions or restrictions, if any, upon the issuance of any additional stock (including additional Shares of such Series or of any other Series) ranking on a parity with or prior to the Shares of such Series as to dividends or upon liquidation;
Cal Alta Auto Glass, Inc.: Amendment
December 18, 2008
(x) Any right to vote with holders of Shares of any other Series or class and any right to vote as a class, either generally or as a condition to specified corporate action; and
(xi) Such other preferences, rights, restrictions, and qualifications as shall not be inconsistent herewith.
(C) All Shares of any Series of Preferred Stock shall be identical with each other in all respects, except that Shares of any one Series issued at different times may differ as to the dates from which dividends thereon shall be cumulative, if cumulative dividends have been designated for such Series, and all Series shall rank equally and be identical in all respects, except as permitted by the foregoing provisions of Section (2) hereof.
(D) The Preferred Stock is senior to the Common Stock, and the Common Stock is subject to the rights and preferences of the Preferred Stock as herein set forth.
(E)(i) The holders of Preferred Stock of each Series shall be entitled to receive, and the Corporation shall be bound to pay, out of any funds legally available for such purpose, when and as declared by the Board of Directors, cash dividends thereon at such rate and payable at such times as shall be fixed and determined for such Series as herein set forth. Dividends with respect to each Series of Preferred Stock shall be cumulative or non-cumulative, as determined by the Board of Directors, and shall accrue from such date or dates as shall have been fixed and determined with respect to such Series by the Board of Directors as herein provided.
(ii) In no event, so long as any Preferred Stock shall remain outstanding, shall any dividend whatsoever be declared or paid upon, or any distribution be made or ordered in respect of, the Common Stock or any other class of stock ranking junior to the Preferred Stock, or any moneys be set aside for or applied to the purchase or redemption (through a sinking fund or otherwise) of Shares of Common Stock or of any other such junior class of stock, unless:
(a) Full cumulative dividends on the Preferred Stock of all Series for all past dividend periods shall have been paid with respect to any outstanding Preferred Shares having cumulative dividend rights, and the full dividend on all outstanding Share of Preferred Stock of all Series for the then current dividend period, if any, shall have been paid or declared and set apart for payment; and
Cal Alta Auto Glass, Inc.: Amendment
December 18, 2008
(b) The corporation shall have set aside all amounts, if any, theretofore required to be set aside as and for sinking funds, if any, for the Preferred Stock of all Series for the then current year, and all defaults, if any, in complying with any such sinking fund requirements in respect of previous years shall have been made good.
(iii) Subject to the foregoing provisions respecting the Preferred Stick, and not otherwise, dividends, payable in cash, stock, or otherwise, as may be determined by the Board of Directors, may be declared and paid upon the Common Stock, from time to time, out of any funds legally available therefore, and no holder of any Shares of any Series of Preferred Stock, as such, shall be entitled to participate in any such dividend.
(F) The Corporation, at the option of the Board of Directors, may, at any time permitted by the resolution or resolutions adopted by the Board of Directors providing for the issuance of any Series of Preferred Stock, and at the redemption price per Share fixed and determined for such Series, redeem the whole or any part of the Shares of such Series at the time outstanding (the total sum so payable on any such redemption being herein referred to as the “redemption price”). Notice of every such redemption shall be mailed to the holders of record of the Shares of such Series so to be redeemed at their respective addresses as the same shall appears on the books of the Corporations. Such notice shall be mailed at least 30 days in advance of the date designated for such redemption to the holders of record of Shares so to be redeemed. In case of the redemption of a part only of any Series at the time outstanding, the Shares of such Series to be redeemed shall be selected by lot or pro rate in such manner as the Board of Directors may determine.
(G) If, on the redemption date specified in such notice, the funds necessary for such redemption shall have been set aside by the Corporation, separate and apart from its other funds, in trust for the pro rata benefit of the holders of the Shares so called for redemption, then, notwithstanding that any certificates for Shares of Preferred Stock so called for redemption shall not have been surrendered for cancellation, the Shares represented thereby shall no longer be deemed outstanding, the right to receive dividends thereon shall cease to accrue from and after the date of redemption so designated, and all rights of holders of the Shares of Preferred Stock so called for redemption shall forthwith, after such redemption date, cease and terminate, excepting only the right of the holders thereof to receive the redemption price therefore but without interest. Any moneys so set aside by the
Cal Alta Auto Glass, Inc.: Amendment
December 18, 2008
Corporation and unclaimed at the end of six years from the date designated for such redemption shall revert to the general funds of the Corporation; after which reversion, the holders of such Shares so called for redemption shall look only to the Corporation for payment of the redemption price, and such Shares shall not still be deemed to be outstanding.
(H) Upon any liquidation, dissolution, or winding up of the Corporation, whether voluntary or involuntary, the Preferred Stock of each Series shall be entitled, before any distribution shall be made to the Common Stock or to any other class of stock junior to the Preferred Stock, to be paid the amount fixed and determined by the board of Directors for such Series as herein provided, plus accrued and unpaid dividends thereon to the date of distribution, but the Preferred Stock shall not be entitled to any further payment, and any remaining net assets shall be distributed ratably to the outstanding Common Stock. If, upon such liquidation, dissolutions, or winding up of the Corporation, whether voluntary or involuntary, the net assets of the Corporation shall be insufficient to permit the payment to all outstanding Shares of Preferred Stock of all Series of the full preferential amounts to which they are respectively entitled, then the entire net assets of the Corporation shall be distributed ratably to all outstanding Shares of Preferred Stock of all Series in proportion to the full preferential amount to which each Share is entitled. Neither a consolidation nor a merger of the Corporation with or into any other corporation or corporations, nor the sale of all or substantially all of the assets of the Corporation, shall be deemed to be a liquidation, dissolution, or winding up within the meaning of this section.
(I) The Preferred Stock shall not be convertible, except to the extent that any one or more Series thereof may be issued with the privilege of conversion as may be determined by the Board of Directors prior to issuance of any Shares of such Series as herein set forth. If the Shares of any Series are so issued with the privilege of conversion, then, at the option of the respective holders thereof, the Preferred Stock of such Series shall be convertible into a number of fully paid and non-assessable Shares of the Common Stock or any other class of stock of the Corporation at the conversion rate, or upon payment to the Corporation of the conversion price, which is in effect for the Preferred Stock of such Series at the time of such conversion.
The initial conversion rate or conversion price (including, in the latter case, the number of Shares of Common Stock or other class of stock
Cal Alta Auto Glass, Inc.: Amendment
December 18, 2008
issuable upon conversion), and the terms and conditions of conversion for each Series issued with the privilege of conversion shall be fixed and determined by the Board of Directors as hereinafter provided. Such conversion price or conversion rate, with respect to any such Series, may be subject, from time to time, to adjustment by virtue of issuance of securities or rights to purchase securities of the Corporation, or upon any capital reorganization or reclassification of the Common Stock of the Corporation, or the consolidation or merger of the Corporation, or the sale, conveyance, lease, or other transfer by the Corporation of all or substantially all of its property, or in other circumstances, all to the extent and in the manner fixed and determined by the Board of Directors as herein set forth.
(J) Shares of any Series of Preferred Stock which have been issued and reacquired in any manner by the Corporation (including Shares redeemed, Shares purchased and retired, and Shares which, if convertible or exchangeable, have been converted into or exchanged for Shares of stock of any other class, classes, or Series) shall have the status of authorized and unissued Shares of Preferred Stock and may be reissued as a part of the Series of which they were originally a part, or may be reclassified and reissued as part of a new Series of Preferred Stock to be created by resolution or resolutions of the Board of Directors, or as part of any other Series of Preferred Stock, all subject to the conditions or restrictions on issuance set forth in any resolution or resolutions adopted by the Board of Directors provided for the issue of any Series of Preferred Stock.
(K) None of the holders of Preferred Stock of any Series shall have any voting powers for any purpose, except as may be specifically required by law, or except as any such right to vote may be fixed and determined by the Board of Directors prior to issuance of any Shares of such Series as herein provided.
(L) In order the Board of Directors to establish a Series of Preferred Stock, the Board of Directors shall adopt a resolution or resolutions setting forth the designation and the number of Shares of such Series and the relative rights and preferences thereof in respect of the foregoing particulars. The Board of Directors may redesignate any Shares of any Series theretofore established that have not been issued, or that have been issued and retired, as Shares of some other Series, or change the designation of outstanding Shares where desired to prevent confusion.
Cal Alta Auto Glass, Inc.: Amendment
December 18, 2008
(M) For the purposes hereof and of any resolution of the Board of Directors providing for the classification or reclassification of any Shares of Preferred Stock:
(i) The term “outstanding,” when used in reference to Shares of stock, shall mean issued Shares, excluding Shares hold by the Corporation or a subsidiary, and Shares called for redemption; funds for the redemption of which shall have been deposited in trust;
COMMON STOCK
Subject to the foregoing provisions, dividends may be declared on the Common Stock, and each Share of Common Stock shall entitle the holder thereof to one vote in all proceedings in which action shall be taken by stockholders of the Corporation.
THIRD: That said amendment was duly adopted in accordance with provisions of Section 78.390 of the Nevada General Corporation Law.
The number of shares of the corporation outstanding and entitled to vote on an amendment to the Articles of Incorporation is 18,800,000; that said changes and amendment have been consented to and approved by a majority vote of the stockholders holding a majority of each class of stock outstanding and entitled to vote thereon.
Frank Aiello, President
Denise Aiello, Secretary
Cal Alta Auto Glass, Inc.: Amendment
December 18, 2008
Exhibit 3.4
|
|
ROSS MILLER Secretary of State 204 North Carson Street, Ste 1 Carson City, Nevada 89701-4520 (775) 684-5708 Website: www.nvsos.gov |
Filed in the office of
Ross Miller Secretary of State State of Nevada |
Document Number 20100698452-67 |
|
Filing Date and Time 09/15/2010 2:06PM |
|||
|
Entity Number C25630-1999 |
|
Certificate of Designation (PURSUANT TO NRS 78.1955) |
|
USE BLACK INK ONLY • DO NOT HIGHLIGHT |
ABOVE SPACE IS FOR OFFICE USE ONLY |
Certificate of Designation For
Nevada Profit Corporations
(Pursuant to NRS 78.1955)
|
1. |
Name of corporation: |
Cal Alta Auto Glass Inc.
|
2. |
By resolution of the board of directors pursuant to a provision in the articles of incorporation this certificate establishes the following regarding the voting powers, designations, preferences, limitations, restrictions and relative rights of the following class or series of stock. |
|
3. |
That pursuant to the authority conferred on the Board of Directors by the Corporation’s Articles of Incorporation, creating inter alia, a class of 10,000,000 shares of preferred stock, par value $0.001 per share (the “Preferred Stock”), of the corporation, and the Board of Directors desires to establish and fix the number of shares to be included in a new series of 6,000,000 shares of Preferred Stock and to fix the voting powers, designation, and relative, participating, optional and other special rights, and the qualifications, limitations and restriction of such shares as follows: |
|
A. |
Number of Shares; Designation. A total of 6,000,000 shares of preferred stock, par value $0.001 per share, of the Corporation are hereby designated as Supervoting Preferred Stock (the “Supervoting Stock”) |
|
3. |
Effective date and time of filing: (optional) |
October 1, 2010 |
|
(must not be later than 90 days after the certificate is filed) |
|
4. |
Signature: (required) |
|
X
|
|
|
Signature of Officer |
|
Filing Fee: $175.00
IMPORTANT: Failure to include any of the above information and submit with the proper fees may cause this filing to be rejected.
|
This form must be accompanied by appropriate fees. |
Nevada Secretary of State Stock Designation Revised: 3-6-08 |
Exhibit 3.5
|
|
ROSS MILLER Secretary of State 204 North Carson Street, Ste 1 Carson City, Nevada 89701-4520 (775) 684-5708 Website: www.nvsos.gov |
|
Certificate of Amendment (PURSUANT TO NRS 78.385 AND 78.390) |
|
|
|
Filed in the office of
Ross Miller Secretary of State State of Nevada |
Document Number 20120258450-69 |
|
Filing Date and Time 04/12/2012 11:24AM |
|||||
|
Entity Number C25630-1999 |
|||||
|
|
|
|
|
|
|
|
USE BLACK INK ONLY • DO NOT HIGHLIGHT |
ABOVE SPACE IS FOR OFFICE USE ONLY |
Certificate of Amendment to Articles of Incorporation
For Nevada Profit Corporations
(Pursuant to NRS 78.385 and 78.390 - After Issuance of Stock)
|
1. |
Name of corporation: |
CAL ALTA AUTO GLASS, INC
|
2. |
The articles have been amended as follows: (provide article numbers, if available) |
THE NAME HAS BEEN CHANGED TO MINING MINERALS OF MEXICO CORP.
|
3. |
The vote by which the stockholders holding shares in the corporation entitling them to exercise at least a majority of the voting power, or such greater proportion of the voting power as may be required in the case of a vote by classes or series, or as may be required by the provisions of the articles of incorporation* have voted in favor of the amendment is: 70% |
|
4. |
Effective date and time of filing: (optional) |
Date: 4-12-2012 Time: |
|
(must not be later than 90 days after the certificate is filed) |
|
5. |
Signature: (required) |
|
X
|
|
|
Signature of Officer |
|
*If any proposed amendment would alter or change any preference or any relative or other right given to any class or series of outstanding shares, then the amendment must be approved by the vote. In addition to the affirmative vote otherwise required of the holders of shares representing a majority of the voting power of each class or series affected by the amendment regardless to limitations or restrictions on the voting power thereof.
IMPORTANT: Failure to include any of the above information and submit with the proper fees may cause this filing to be rejected.
|
This form must be accompanied by appropriate fees. |
Nevada Secretary of State Amend Profit-After Revised: 3-31-11 |
Exhibit 3.6
|
|
ROSS MILLER Secretary of State 204 North Carson Street, Ste 1 Carson City, Nevada 89701-4520 (775) 684-5708 Website: www.nvsos.gov |
|
Certificate of Amendment (PURSUANT TO NRS 78.385 AND 78.390) |
|
|
|
Filed in the office of
Ross Miller Secretary of State State of Nevada |
Document Number 20140451819-55 |
|
Filing Date and Time 06/23/2014 10:40AM |
|||||
|
Entity Number C25630-1999 |
|||||
|
|
|
|
|
|
|
|
USE BLACK INK ONLY • DO NOT HIGHLIGHT |
ABOVE SPACE IS FOR OFFICE USE ONLY |
Certificate of Amendment to Articles of Incorporation
For Nevada Profit Corporations
(Pursuant to NRS 78.385 and 78.390 - After Issuance of Stock)
|
1. |
Name of corporation: |
Mining Minerals of Mexico Corp.
|
2. |
The articles have been amended as follows: (provide article numbers, if available) |
“Article I: The name of the corporation is Aurum Resource and Asset Management, Inc.”
“Article IV: The authorized capital stock of the Corporation shall be Two Hundred Sixty Million (260,000,000) shares. The capital stock of the Corporation is divided into two classes: (1) Common Stock in the amount of Two Hundred Fifty Million (250,000,000) shares, $0.001 par value per share and (2) Preferred Stock in the amount of Ten Million (10,000,000) shares, $0.001 par value per share.
[Continued on Attachment Page]
|
3. |
The vote by which the stockholders holding shares in the corporation entitling them to exercise at least a majority of the voting power, or such greater proportion of the voting power as may be required in the case of a vote by classes or series, or as may be required by the provisions of the articles of incorporation* have voted in favor of the amendment is: |
50.7%
|
4. |
Effective date and time of filing: (optional) |
Date: 7/10/14 Time: 9:00AM |
|
(must not be later than 90 days after the certificate is filed) |
|
5. |
Signature: (required) |
|
X
|
|
|
Signature of Officer |
|
*If any proposed amendment would alter or change any preference or any relative or other right given to any class or series of outstanding shares, then the amendment must be approved by the vote. In addition to the affirmative vote otherwise required of the holders of shares representing a majority of the voting power of each class or series affected by the amendment regardless to limitations or restrictions on the voting power thereof.
IMPORTANT: Failure to include any of the above information and submit with the proper fees may cause this filing to be rejected.
|
This form must be accompanied by appropriate fees. |
Nevada Secretary of State Amend Profit-After Revised: 11-27-13 |
Mining Minerals of Mexico Corp.
Certificate of Amendment to Articles of Incorporation
Attachment Page
The Board of Directors is also authorized to determine or alter the rights, preferences, privileges and restrictions granted to or imposed upon any wholly unissued series of Preferred Stock and, within the limits and restrictions stated in any resolution or resolutions of the board of directors originally fixing the number of shares constituting any series, to increase or decrease (but not below the number of shares of any such series then outstanding) the number of shares subsequent to the issues of shares of that series.
As of the effective date of this Amendment, there shall be a 1-for-100 Reverse Split of the issued and outstanding shares of Common Stock, such that each One Hundred (100) shares of Common Stock, $0.001 par value, issued and outstanding immediately prior to the effective date (the “Old Common Stock”) shall be recombined, reclassified and changed into One (1) share of the Corporation’s Common Stock, $0.001 par value (the “New Common Stock”), with any fractional interest rounded up to the nearest whole share.
Exhibit 3.7
|
|
BARBARA K. CEGAVSKE Secretary of State 202 North Carson Street Carson City, Nevada 89701-4201 (775) 684-5708 Website: www.nvsos.gov |
Filed in the office of
Barbara K. Cegavske Secretary of State State of Nevada |
Document Number 20160016483-11 |
|
Filing Date and Time 01/13/2016 3:06PM |
|||
|
Entity Number C25630-1999 |
|
Certificate of Designation (PURSUANT TO NRS 78.1955) |
|
USE BLACK INK ONLY • DO NOT HIGHLIGHT |
ABOVE SPACE IS FOR OFFICE USE ONLY |
Certificate of Designation For
Nevada Profit Corporations
(Pursuant to NRS 78.1955)
|
1. |
Name of corporation: |
Aurum Resource and Asset Management, Inc.
|
2. |
By resolution of the board of directors pursuant to a provision in the articles of incorporation this certificate establishes the following regarding the voting powers, designations, preferences, limitations, restrictions and relative rights of the following class or series of stock. |
One Million Seven Hundred Fifty Thousand (1,750,000) shares of preferred stock, $0.001 par value per share are hereby designated Series A Preferred Stock, having preferences as to dividends and distributions, and rights and preferences as more particularly described in the attachment hereto. The Series A Preferred Stock shall have voting rights as required by the Nevada Revised Statues and as set forth in Section 5 of the attachment. [See Attachment]
|
3. |
Effective date and time of filing: (optional) |
|
|
(must not be later than 90 days after the certificate is filed) |
|
4. |
Signature: (required) |
|
X
|
|
|
Signature of Officer |
|
Filing Fee: $175.00
IMPORTANT: Failure to include any of the above information and submit with the proper fees may cause this filing to be rejected.
|
This form must be accompanied by appropriate fees. |
Nevada Secretary of State Stock Designation Revised: 1-5-15 |
CERTIFICATE OF DESIGNATIONS, PREFERENCES AND RIGHTS
OF THE
SERIES A PREFERRED STOCK
($0.001 Par Value Per Share)
OF
AURUM RESOURCE AND ASSET MANAGEMENT, INC.
The undersigned, a duly authorized officer of Aurum Resource and Asset Management, Inc., a Nevada corporation, and hereinafter referred to as the “Company”, DOES HEREBY CERTIFY that the following resolution was duly adopted by the Board of Directors of the Company (the “Board”) by unanimous written consent on January 12, 2016:
WHEREAS, the Company has Ten Million (10,000,000) shares of preferred stock authorized; and
WHEREAS, effective January 12, 2016, the Board of the Directors of the Company approved a resolution amending and restating the Certificate of Designation for the Series A Preferred Stock such that the Series A Preferred Stock shall have the following powers, designations, preferences and relative, participating, optional and other special rights:
SECTION 1 – DESIGNATION AND RANK
1.01 Designation. This resolution shall provide for a single series of preferred stock, the designation of which shall be “Series A Preferred Stock”, $0.001 par value per share. The number of authorized shares constituting the Series A Preferred Stock is One Million Seven Hundred Fifty Thousand (1,750,000) shares.
1.02 Rank. Except as provided elsewhere in the Certificate, with respect to the payment of dividends and other distributions on the capital stock of the Company, including the distribution of the assets of the Company upon liquidation, the Series A Preferred Stock shall rank pari passu with the Common Stock on an “as converted” basis and senior to all other series of preferred stock.
SECTION 2 – DIVIDEND RIGHTS
2.01 Dividends or Distributions. Each share of Series A Preferred Stock shall be entitled to receive dividends or distributions on his share of Series A Preferred Stock on an “as converted” basis as provided in Section 4 hereof when and if dividends are declared on the Common Stock by the Board. Dividends shall be paid in cash or property, as determined by the Board.
SECTION 3 – LIQUIDATION RIGHTS
3.01 Liquidation Preference. Upon any liquidation, dissolution, or winding up of the Company, whether voluntary or involuntary (collectively, a “Liquidation”), before any distribution or payment shall be made to any of the holders of Common Stock or any other series of preferred stock, the holders of Series A Preferred Stock shall be entitled to receive out of the assets of the Company, whether such assets are capital, surplus or earnings, an amount equal to $0.001 per share of Series A Preferred Stock (the “Liquidation Amount”) plus all declared and unpaid dividends thereon, for each share of Series A Preferred Stock held by them.
3.02 Pro Rata Distribution. If, upon any Liquidation, the assets of the Company shall be insufficient to pay the Liquidation Amount, together with declared and unpaid dividends thereon, in full to all holders of Series A Preferred Stick, then the entire net assets of the Corporation shall be distributed among the holders of the Series A Preferred Stock, ratably in proportion to the full amounts to which they would otherwise be respectively entitled and such distributions may be made in cash or in property taken at its fair value (as determined in good faith by the Company’s Board of Directors), or both, at the election of the Company’s Board of Directors.
3.03 Merger, Consolidation or Reorganization. For purposes of this Section 3, a Liquidation shall be deemed to be occasioned by or to include the merger, consolidation or reorganization of the Company into or with another entity through one or a series of related transactions, or the sale, transfer or lease of all or substantially all of the assets of the Company.
SECTION 4 – CONVERSION RIGHTS
4.01 Conversion. Subject to the limitations set forth herein below, each share of Series A Preferred Stock shall be convertible (the “Conversion Rights”), at the option of the holder thereof at any time and from time to time into One Hundred (100) shares of the Company’s Common Stock (“Conversion Shares”) at the time of the conversion. The shares of Common Stock received upon conversion shall be fully paid and non-assessable shares of Common Stock.
4.02 Adjustments. The Conversion Rights of the Series A Preferred Stock as described in Section 4.01 above shall be adjusted from time to time as follows:
(a) In the event of any reclassification of the Common Stock or recapitalization involving Common Stock (including a subdivision, or combination of shares or any other event described in this Section 4.02) the holder of Series A Preferred Stock shall thereafter be entitled to receive, and provision shall be made therefore in any agreement relating to the reclassification or recapitalization, upon conversion of the Series A Preferred Stock, the kind and number of shares of Common Stock or other securities or property (including cash) to which such holder of Series A Preferred Stock would have been entitled if he had held the number of shares of Common Stock into which the Series A Preferred Stock was convertible immediately prior to such reclassification or
recapitalization; and in any such case appropriate adjustment shall be made in the application of the provisions herein set forth with respect to the rights and interests thereafter of the holder of the Series A Preferred Stock, to the end that the provisions set forth herein shall thereafter be applicable, as nearly as reasonably may be, in relation to any shares, other securities, or property thereafter receivable upon conversion of the Series A Preferred Stock. An adjustment made pursuant to this subparagraph (a) shall become effective at the time as which such reclassification or recapitalization becomes effective.
(b) In the event the Company shall declare a distribution payable in securities of other entities or persons, evidences of indebtedness issued by the Company or other entities or persons, assets (excluding cash dividends) or options or rights not referred to in Section 4.02(a) above, the holder of the Series A Preferred Stock shall be entitled to a proportionate share of any such distribution as though he was the holder of the number of shares of Common Stock of the Company into which his shares of Series A Preferred Stock are convertible as of the record date fixed for the determination of the holders of shares of Common Stock of the Company entitled to receive such distribution or if no such record date is fixed, as of the date such distribution is made.
4.03 Procedures for Conversion.
(a) In order to exercise the Conversion Rights pursuant to Section 4.01 above, the holder shall deliver an irrevocable written notice of such exercise to the Company at its principal office. The holder shall, upon the conversion of Series A Preferred Stock in accordance with this Section 4, surrender the certificate representing such share of Series A Preferred Stock to the Company, at is principal office, and specify the name or names in which the holder wishes the certificate or certificates for shares of Common Stock to be issued. In case the holder shall specify a name or names other than that of the Investor, such notice shall be accompanied by payment of all transfer taxes (if transfer is to a person or entity other than the holder thereof) payable upon the issuance of shares of Common Stock in such name or names. As promptly as practicable, and, if applicable, after payment of all transfer taxes (if transfer is to a person or entity other than the holder thereof), the Company shall deliver or cause to be delivered certificates representing the number of validly issued, fully paid and non-assessable shares of Common Stock to which the holder shall be entitled. Such conversion, to the extent permitted by law, shall be deemed to have been effected as of the date of receipt by the Company of any notice of conversion pursuant to this Section 4.03(a), upon the occurrence of any event specified therein. Upon conversion of a share of Series A Preferred Stock, such share shall cease to constitute a share of Series A Preferred Stock and shall represent only a right to receive share of Common Stock into which it has been converted.
(b) Beginning as of the date hereof, the Company shall at all times reserve and keep available out of its authorized Common Stock the full number of shares of Common Stock of the Company issuable upon the conversion of the share of Series A Preferred Stock. In the event that the Company does not have a sufficient number of shares of authorized but unissued Common Stock necessary to satisfy the full conversion of shares of Series A Preferred Stock, then the Company shall call and hold a meeting of the stockholders within thirty (30) days of such occurrence of the sole purpose of increasing the number
of authorized shares of Common Stock. The Board shall recommend to stockholders a vote in favor of such proposal and shall vote all shares held by them, in proxy or otherwise, in favor of such proposal. This remedy is not intended to limit the remedies available to the holder of the Series A Preferred Stock, but is intended to be in addition to any other remedies, whether in contract, at law or in equity.
4.04 Notice of Record Date. In the event that the Company shall propose at any time: (i) to declare any dividend or distribution upon any class or series of capital stock, whether in cash, property, stock or other securities; (ii) to effect any reclassification or recapitalization of is Common Stock outstanding involving a change in the Common Stock; or (iii) to merge or consolidate with or into any other corporation, or to sell. Lease or convey all or substantially all of its property or business, or to liquidate, dissolve or wind up; then, in connection with each such event, the Company shall mail to the holder of Series A Preferred Stock : at least twenty (20 days’ prior written notice of the date on which a record shall be taken for such dividend or distribution (and specifying the date on which the holders of the affected class or series of capital stock shall be entitled thereto) or for determining the rights to vote, if any, in respect of the matters referred to in clauses (ii) and (iii) in this Section 4.04, and in the case of the matters referred to in this Section 4.04 (ii) and (iii), written notice of such impending transaction not later than twenty (20) days prior to the stockholders’ meeting called to approve such transaction, or twenty (20) days prior to the closing of such transaction, whichever is earlier, and shall also notify such holder in writing of the final approval of such transaction. The first of such notices shall describe the material terms and conditions of the impending transaction (and specify the date on which the holders of shares of Common Stock shall be entitled to exchange their Common Stock for securities or other property deliverable upon the occurrence of such event) and the Company shall thereafter give such holders prompt notice of any material changes. The transaction shall in no event take place sooner than twenty (20) days after the Company has given the first notice provided for herein or sooner than ten (10) days after the Company has given notice of any material changes provided for herein.
4.05 Limitations of Conversion. The Conversion Rights specified herein shall be subject to the following limitations:
(i) The holders of the shares of Series A Preferred Stock may exercise their Conversion Rights at any time after the date hereof; and
(ii) No holder of the shares of Series A Preferred Stock shall be entitled to convert the Series A Preferred Stock to the extent, but only to the extent, that such conversion would, upon giving effect to such conversion, cause the aggregate number of shares of Common Stock beneficially owned by such holder to exceed 9.99% of the outstanding shares of Common Stock following such conversion (which provision may be waived by such holder by written notice form such holder to the Company, which notice shall be effective 61 days after the date of such notice).
SECTION 5 – VOTING RIGHTS
5.01 General. Except as otherwise provided herein or required by law, the holders of Series A Preferred Stock and the holders of Common Stock shall vote together and not as separate classes and the Series A Preferred Stock shall be counted on an “as converted” basis times Ten (10).
SECTION 6 – MISCELLANEOUS
6.01 Headings of Subdivisions. The headings of the various Sections hereof are for convenience of reference only and shall not affect the interpretation of any of the provisions hereof.
6.02 Severability of Provisions. If any right, preference or limitation of the Series A Preferred Stock set forth herein (as this resolution may be amended from time to time) is invalid, unlawful or incapable of being enforced by reason of any rule of law or public policy, all other rights, preferences and limitations set forth in this resolution (a so amended) which can be given effect without the invalid, unlawful or unenforceable right, preference or limitation shall, nevertheless, remain in full force and effect, and no right, preference or limitation herein set forth shall be deemed dependent upon any other such right, preference or limitation unless so expressed herein.
6.03 Stock Transfer Taxes. The Corporation shall pay any and all stock transfer and documentary stamp taxes that may be payable in respect of any issuance or delivery of the share of Series A Preferred Stock or shares of Common Stock or other securities issued on account of Series A Preferred Stock pursuant hereto or certificates representing such shares or securities.
6.04 Transfer Agent. The Corporation may appoint, and from time to time discharge and/or replace, a transfer agent of the Series A Preferred Stock. Upon any such appointment or discharge of a transfer agent, the Corporation shall send notice thereof by first-class mail, postage prepaid, to the holder of record of Series A Preferred Stock.
6.05 Transferability. Subject to any transfer restriction agreements that may be entered into by the holder of Series A Preferred Stock, the Series A Preferred Stock shall be transferable by the holder, provided that such transfer is made in compliance with applicable federal and state securities laws.
Exhibit 3.8
|
|
BARBARA K. CEGAVSKE Secretary of State 202 North Carson Street Carson City, Nevada 89701-4201 (775) 684-5708 Website: www.nvsos.gov |
|
Certificate of Amendment (PURSUANT TO NRS 78.385 AND 78.390) |
|
|
|
Filed in the office of
Barbara K. Cegavske Secretary of State State of Nevada |
Document Number 20160098012-49 |
|
Filing Date and Time 03/02/2016 8:49AM |
|||||
|
Entity Number C25630-1999 |
|||||
|
|
|
|
|
|
|
|
USE BLACK INK ONLY • DO NOT HIGHLIGHT |
ABOVE SPACE IS FOR OFFICE USE ONLY |
Certificate of Amendment to Articles of Incorporation
For Nevada Profit Corporations
(Pursuant to NRS 78.385 and 78.390 - After Issuance of Stock)
|
1. |
Name of corporation: |
Aurum Resource and Asset Management, Inc.
|
2. |
The articles have been amended as follows: (provide article numbers, if available) |
Article I: The name of the corporation is Global Organics, Inc.
|
3. |
The vote by which the stockholders holding shares in the corporation entitling them to exercise at least a majority of the voting power, or such greater proportion of the voting power as may be required in the case of a vote by classes or series, or as may be required by the provisions of the articles of incorporation* have voted in favor of the amendment is: 96.6% |
|
4. |
Effective date and time of filing: (optional) |
Date: 3-24-16 Time: 9:00AM |
|
(must not be later than 90 days after the certificate is filed) |
|
5. |
Signature: (required) |
|
X
|
|
|
Signature of Officer |
|
*If any proposed amendment would alter or change any preference or any relative or other right given to any class or series of outstanding shares, then the amendment must be approved by the vote. In addition to the affirmative vote otherwise required of the holders of shares representing a majority of the voting power of each class or series affected by the amendment regardless to limitations or restrictions on the voting power thereof.
IMPORTANT: Failure to include any of the above information and submit with the proper fees may cause this filing to be rejected.
|
This form must be accompanied by appropriate fees. |
Nevada Secretary of State Amend Profit-After Revised: 1-5-15 |
Exhibit 3.9
|
|
BARBARA K. CEGAVSKE Secretary of State 202 North Carson Street Carson City, Nevada 89701-4201 (775) 684-5708 Website: www.nvsos.gov |
|
Certificate of Correction (PURSUANT TO NRS CHAPTERS 78, 78A, 80, 81, 82, 84, 86, 87, 87A, 88, 88A, 89 AND 92A) |
|
|
|
Filed in the office of
Barbara K. Cegavske Secretary of State State of Nevada |
Document Number 20160238162-31 |
|
Filing Date and Time 05/26/2016 1:21PM |
|||||
|
Entity Number C25630-1999 |
|||||
|
|
|
|
|
|
|
|
USE BLACK INK ONLY • DO NOT HIGHLIGHT |
ABOVE SPACE IS FOR OFFICE USE ONLY |
Certificate of Correction
(Pursuant to NRS Chapters 78, 78A, 80, 81, 82, 84, 86, 87, 87A, 88, 88A, 89 and 92A)
|
1. |
The name of the entity for which correction is being made: |
Global Organics, Inc.
|
2. |
Description of the original document for which correction is being made: |
Certificate of Amendment to Articles of Incorporation for Nevada Profit Corporations
|
3. |
Filing date of the original document for which correction is being made: 03/02/2016 |
|
4. |
Description of the inaccuracy or defect: |
Subsequent to the filing of the Certificate of Amendment to change the name of the Corporation from Aurum Resource and Asset Management, Inc. to Global Organics, Inc., the change of name was denied by a regulatory authority. Accordingly, the name of the Corporation should revert back to Aurum Resource and Asset Management, Inc.
|
5. |
Correction of the inaccuracy or defect: |
Article I: The name of the corporation is Aurum Resource and Asset Management, Inc.
|
6. |
Signature: (required) |
|
X
|
President |
May 26, 2016 |
|
Authorized Signature |
Title* |
Date |
*If entity is a corporation, it must be signed by an officer if stock has been issued, OR an incorporator or director if stock has not been issued; a limited-liability company, by a manager or managing members; a limited partnership or limited-liability limited partnership, by a general partner; a limited-liability partnership, by a managing partner; a business trust, by a trustee.
IMPORTANT: Failure to include any of the above information and submit with the proper fees may cause this filing to be rejected.
|
This form must be accompanied by appropriate fees. |
Nevada Secretary of State Correction Revised: 1-5-15 |
Exhibit 3.10
|
|
BARBARA K. CEGAVSKE Secretary of State 202 North Carson Street Carson City, Nevada 89701-4201 (775) 684-5708 Website: www.nvsos.gov |
|
Certificate of Amendment (PURSUANT TO NRS 78.385 AND 78.390) |
|
|
|
Filed in the office of
Barbara K. Cegavske Secretary of State State of Nevada |
Document Number 20160367278-52 |
|
Filing Date and Time 08/18/2016 3:22PM |
|||||
|
Entity Number C25630-1999 |
|||||
|
|
|
|
|
|
|
|
USE BLACK INK ONLY • DO NOT HIGHLIGHT |
ABOVE SPACE IS FOR OFFICE USE ONLY |
Certificate of Amendment to Articles of Incorporation
For Nevada Profit Corporations
(Pursuant to NRS 78.385 and 78.390 - After Issuance of Stock)
|
1. |
Name of corporation: |
Aurum Resource and Asset Management, Inc.
|
2. |
The articles have been amended as follows: (provide article numbers, if available) |
“Article I: The name of the corporation is Innovest Global, Inc.”;
“Article IV: The authorized capital stock of the Corporation shall be Five Hundred Ten Million (510,000,000) shares. The capital stock of the Corporation is divided into two classes: (1) Common Stock in the amount of Five Hundred Million (500,000,000) shares, $0.001 par value per share and (2) Preferred Stock in the amount of Ten Million (10,000,000) shares, $0.001 par value per share.
[Continued on Attachment Page]
|
3. |
The vote by which the stockholders holding shares in the corporation entitling them to exercise at least a majority of the voting power, or such greater proportion of the voting power as may be required in the case of a vote by classes or series, or as may be required by the provisions of the articles of incorporation* have voted in favor of the amendment is: 96.6% |
|
4. |
Effective date and time of filing: (optional) |
Date: 9/19/2016 Time: 9:00AM |
|
(must not be later than 90 days after the certificate is filed) |
|
5. |
Signature: (required) |
|
X
|
|
|
Signature of Officer |
|
*If any proposed amendment would alter or change any preference or any relative or other right given to any class or series of outstanding shares, then the amendment must be approved by the vote. In addition to the affirmative vote otherwise required of the holders of shares representing a majority of the voting power of each class or series affected by the amendment regardless to limitations or restrictions on the voting power thereof.
IMPORTANT: Failure to include any of the above information and submit with the proper fees may cause this filing to be rejected.
|
This form must be accompanied by appropriate fees. |
Nevada Secretary of State Amend Profit-After Revised: 1-5-15 |
Aurum Resource and Asset Management, Inc.
Certificate of Amendment to Articles of Incorporation
Attachment Page
The Preferred Share may be issued from time to time in one or more series. The board of directors is authorized to fix the number of shares of any series of Preferred Shares and to determine the designation of any such series. The board of directors is also authorized to determine or alter the rights, preferences, privileges and restrictions granted to or imposed upon any wholly unissued series of Preferred Shares and, within the limits and restrictions stated in any resolution or resolutions of the board of directors originally fixing the number of shares constituting any series, to increase or decrease (but not below the number of shares of any such series then outstanding) the number of shares of any series subsequent to the issue of shares of that series.”
Exhibit 3.11
AURUM RESOURCE AND ASSET MANAGEMENT, INC.
Incorporated in the State of Nevada
Series A Convertible Preferred Stock
|
P/A – 002 |
1,750,000 Shares |
THIS CERTIFIES that TN3 LLC, a Wyoming corporation, is the registered holder of One Million Seven Hundred Fifty Thousand (1,750,000) shares, fully-paid and non-assessable, transferable only on the books of the Corporation by the holder thereof in person or by Attorney upon surrender of this Certificate properly endorsed.
The designations, preferences, limitations, restrictions and relative rights are set forth on the attachment to this Certificate.
IN WITNESS WHEREOF, the said Corporation has caused this Certificate to be signed by a duly authorized officer this 8th day of August, 2016.
Daniel G. Martin, President
THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “1933 ACT”), OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE 1933 ACT, OR APPLICABLE STATE SECURITIES LAWS, OR AN OPINION OF COUNSEL IN FORM, REASONABLY ACCEPTABLE TO THE ISSUER THAT REGISTRATION IS NOT REQUIRED UNDER THE 1933 ACT OR UNLESS SOLD PURSUANT TO RULE 144 UNDER SAID ACT. ANY SUCH OFFER, SALE, ASSIGNMENT, OR TRANSFER MUST ALSO COMPLY WITH THE APPLICABLE STATE SECURITIES LAWS.
|
|
BARBARA K. CEGAVSKE Secretary of State 202 North Carson Street Carson City, Nevada 89701-4201 (775) 684-5708 Website: www.nvsos.gov |
Filed in the office of
Barbara K. Cegavske Secretary of State State of Nevada |
Document Number 20160016483-11 |
|
Filing Date and Time 01/13/2016 3:06PM |
|||
|
Entity Number C25630-1999 |
|
Certificate of Designation (PURSUANT TO NRS 78.1955) |
|
USE BLACK INK ONLY • DO NOT HIGHLIGHT |
ABOVE SPACE IS FOR OFFICE USE ONLY |
Certificate of Designation For
Nevada Profit Corporations
(Pursuant to NRS 78.1955)
|
1. |
Name of corporation: |
Aurum Resource and Asset Management, Inc.
|
2. |
By resolution of the board of directors pursuant to a provision in the articles of incorporation this certificate establishes the following regarding the voting powers, designations, preferences, limitations, restrictions and relative rights of the following class or series of stock. |
One Million Seven Hundred Fifty Thousand (1,750,000) shares of preferred stock, $0.001 par value per share are hereby designated Series A Preferred Stock, having preferences as to dividends and distributions, and rights and preferences as more particularly described in the attachment hereto. The Series A Preferred Stock shall have voting rights as required by the Nevada Revised Statues and as set forth in Section 5 of the attachment. [See Attachment]
|
3. |
Effective date and time of filing: (optional) |
|
|
(must not be later than 90 days after the certificate is filed) |
|
4. |
Signature: (required) |
|
X
|
|
|
Signature of Officer |
|
Filing Fee: $175.00
IMPORTANT: Failure to include any of the above information and submit with the proper fees may cause this filing to be rejected.
|
This form must be accompanied by appropriate fees. |
Nevada Secretary of State Stock Designation Revised: 1-5-15 |
CERTIFICATE OF DESIGNATIONS, PREFERENCES AND RIGHTS
OF THE
SERIES A PREFERRED STOCK
($0.001 Par Value Per Share)
OF
AURUM RESOURCE AND ASSET MANAGEMENT, INC.
The undersigned, a duly authorized officer of Aurum Resource and Asset Management, Inc., a Nevada corporation, and hereinafter referred to as the “Company”, DOES HEREBY CERTIFY that the following resolution was duly adopted by the Board of Directors of the Company (the “Board”) by unanimous written consent on January 12, 2016:
WHEREAS, the Company has Ten Million (10,000,000) shares of preferred stock authorized; and
WHEREAS, effective January 12, 2016, the Board of the Directors of the Company approved a resolution amending and restating the Certificate of Designation for the Series A Preferred Stock such that the Series A Preferred Stock shall have the following powers, designations, preferences and relative, participating, optional and other special rights:
SECTION 1 – DESIGNATION AND RANK
1.01 Designation. This resolution shall provide for a single series of preferred stock, the designation of which shall be “Series A Preferred Stock”, $0.001 par value per share. The number of authorized shares constituting the Series A Preferred Stock is One Million Seven Hundred Fifty Thousand (1,750,000) shares.
1.02 Rank. Except as provided elsewhere in the Certificate, with respect to the payment of dividends and other distributions on the capital stock of the Company, including the distribution of the assets of the Company upon liquidation, the Series A Preferred Stock shall rank pari passu with the Common Stock on an “as converted” basis and senior to all other series of preferred stock.
SECTION 2 – DIVIDEND RIGHTS
2.01 Dividends or Distributions. Each share of Series A Preferred Stock shall be entitled to receive dividends or distributions on his share of Series A Preferred Stock on an “as converted” basis as provided in Section 4 hereof when and if dividends are declared on the Common Stock by the Board. Dividends shall be paid in cash or property, as determined by the Board.
SECTION 3 – LIQUIDATION RIGHTS
3.01 Liquidation Preference. Upon any liquidation, dissolution, or winding up of the Company, whether voluntary or involuntary (collectively, a “Liquidation”), before any distribution or payment shall be made to any of the holders of Common Stock or any other series of preferred stock, the holders of Series A Preferred Stock shall be entitled to receive out of the assets of the Company, whether such assets are capital, surplus or earnings, an amount equal to $0.001 per share of Series A Preferred Stock (the “Liquidation Amount”) plus all declared and unpaid dividends thereon, for each share of Series A Preferred Stock held by them.
3.02 Pro Rata Distribution. If, upon any Liquidation, the assets of the Company shall be insufficient to pay the Liquidation Amount, together with declared and unpaid dividends thereon, in full to all holders of Series A Preferred Stick, then the entire net assets of the Corporation shall be distributed among the holders of the Series A Preferred Stock, ratably in proportion to the full amounts to which they would otherwise be respectively entitled and such distributions may be made in cash or in property taken at its fair value (as determined in good faith by the Company’s Board of Directors), or both, at the election of the Company’s Board of Directors.
3.03 Merger, Consolidation or Reorganization. For purposes of this Section 3, a Liquidation shall be deemed to be occasioned by or to include the merger, consolidation or reorganization of the Company into or with another entity through one or a series of related transactions, or the sale, transfer or lease of all or substantially all of the assets of the Company.
SECTION 4 – CONVERSION RIGHTS
4.01 Conversion. Subject to the limitations set forth herein below, each share of Series A Preferred Stock shall be convertible (the “Conversion Rights”), at the option of the holder thereof at any time and from time to time into One Hundred (100) shares of the Company’s Common Stock (“Conversion Shares”) at the time of the conversion. The shares of Common Stock received upon conversion shall be fully paid and non-assessable shares of Common Stock.
4.02 Adjustments. The Conversion Rights of the Series A Preferred Stock as described in Section 4.01 above shall be adjusted from time to time as follows:
(a) In the event of any reclassification of the Common Stock or recapitalization involving Common Stock (including a subdivision, or combination of shares or any other event described in this Section 4.02) the holder of Series A Preferred Stock shall thereafter be entitled to receive, and provision shall be made therefore in any agreement relating to the reclassification or recapitalization, upon conversion of the Series A Preferred Stock, the kind and number of shares of Common Stock or other securities or property (including cash) to which such holder of Series A Preferred Stock would have been entitled if he had held the number of shares of Common Stock into which the Series A Preferred Stock was convertible immediately prior to such reclassification or
recapitalization; and in any such case appropriate adjustment shall be made in the application of the provisions herein set forth with respect to the rights and interests thereafter of the holder of the Series A Preferred Stock, to the end that the provisions set forth herein shall thereafter be applicable, as nearly as reasonably may be, in relation to any shares, other securities, or property thereafter receivable upon conversion of the Series A Preferred Stock. An adjustment made pursuant to this subparagraph (a) shall become effective at the time as which such reclassification or recapitalization becomes effective.
(b) In the event the Company shall declare a distribution payable in securities of other entities or persons, evidences of indebtedness issued by the Company or other entities or persons, assets (excluding cash dividends) or options or rights not referred to in Section 4.02(a) above, the holder of the Series A Preferred Stock shall be entitled to a proportionate share of any such distribution as though he was the holder of the number of shares of Common Stock of the Company into which his shares of Series A Preferred Stock are convertible as of the record date fixed for the determination of the holders of shares of Common Stock of the Company entitled to receive such distribution or if no such record date is fixed, as of the date such distribution is made.
4.03 Procedures for Conversion.
(a) In order to exercise the Conversion Rights pursuant to Section 4.01 above, the holder shall deliver an irrevocable written notice of such exercise to the Company at its principal office. The holder shall, upon the conversion of Series A Preferred Stock in accordance with this Section 4, surrender the certificate representing such share of Series A Preferred Stock to the Company, at is principal office, and specify the name or names in which the holder wishes the certificate or certificates for shares of Common Stock to be issued. In case the holder shall specify a name or names other than that of the Investor, such notice shall be accompanied by payment of all transfer taxes (if transfer is to a person or entity other than the holder thereof) payable upon the issuance of shares of Common Stock in such name or names. As promptly as practicable, and, if applicable, after payment of all transfer taxes (if transfer is to a person or entity other than the holder thereof), the Company shall deliver or cause to be delivered certificates representing the number of validly issued, fully paid and non-assessable shares of Common Stock to which the holder shall be entitled. Such conversion, to the extent permitted by law, shall be deemed to have been effected as of the date of receipt by the Company of any notice of conversion pursuant to this Section 4.03(a), upon the occurrence of any event specified therein. Upon conversion of a share of Series A Preferred Stock, such share shall cease to constitute a share of Series A Preferred Stock and shall represent only a right to receive share of Common Stock into which it has been converted.
(b) Beginning as of the date hereof, the Company shall at all times reserve and keep available out of its authorized Common Stock the full number of shares of Common Stock of the Company issuable upon the conversion of the share of Series A Preferred Stock. In the event that the Company does not have a sufficient number of shares of authorized but unissued Common Stock necessary to satisfy the full conversion of shares of Series A Preferred Stock, then the Company shall call and hold a meeting of the stockholders within thirty (30) days of such occurrence of the sole purpose of increasing the number
of authorized shares of Common Stock. The Board shall recommend to stockholders a vote in favor of such proposal and shall vote all shares held by them, in proxy or otherwise, in favor of such proposal. This remedy is not intended to limit the remedies available to the holder of the Series A Preferred Stock, but is intended to be in addition to any other remedies, whether in contract, at law or in equity.
4.04 Notice of Record Date. In the event that the Company shall propose at any time: (i) to declare any dividend or distribution upon any class or series of capital stock, whether in cash, property, stock or other securities; (ii) to effect any reclassification or recapitalization of is Common Stock outstanding involving a change in the Common Stock; or (iii) to merge or consolidate with or into any other corporation, or to sell. Lease or convey all or substantially all of its property or business, or to liquidate, dissolve or wind up; then, in connection with each such event, the Company shall mail to the holder of Series A Preferred Stock : at least twenty (20 days’ prior written notice of the date on which a record shall be taken for such dividend or distribution (and specifying the date on which the holders of the affected class or series of capital stock shall be entitled thereto) or for determining the rights to vote, if any, in respect of the matters referred to in clauses (ii) and (iii) in this Section 4.04, and in the case of the matters referred to in this Section 4.04 (ii) and (iii), written notice of such impending transaction not later than twenty (20) days prior to the stockholders’ meeting called to approve such transaction, or twenty (20) days prior to the closing of such transaction, whichever is earlier, and shall also notify such holder in writing of the final approval of such transaction. The first of such notices shall describe the material terms and conditions of the impending transaction (and specify the date on which the holders of shares of Common Stock shall be entitled to exchange their Common Stock for securities or other property deliverable upon the occurrence of such event) and the Company shall thereafter give such holders prompt notice of any material changes. The transaction shall in no event take place sooner than twenty (20) days after the Company has given the first notice provided for herein or sooner than ten (10) days after the Company has given notice of any material changes provided for herein.
4.05 Limitations of Conversion. The Conversion Rights specified herein shall be subject to the following limitations:
(i) The holders of the shares of Series A Preferred Stock may exercise their Conversion Rights at any time after the date hereof; and
(ii) No holder of the shares of Series A Preferred Stock shall be entitled to convert the Series A Preferred Stock to the extent, but only to the extent, that such conversion would, upon giving effect to such conversion, cause the aggregate number of shares of Common Stock beneficially owned by such holder to exceed 9.99% of the outstanding shares of Common Stock following such conversion (which provision may be waived by such holder by written notice form such holder to the Company, which notice shall be effective 61 days after the date of such notice).
SECTION 5 – VOTING RIGHTS
5.01 General. Except as otherwise provided herein or required by law, the holders of Series A Preferred Stock and the holders of Common Stock shall vote together and not as separate classes and the Series A Preferred Stock shall be counted on an “as converted” basis times Ten (10).
SECTION 6 – MISCELLANEOUS
6.01 Headings of Subdivisions. The headings of the various Sections hereof are for convenience of reference only and shall not affect the interpretation of any of the provisions hereof.
6.02 Severability of Provisions. If any right, preference or limitation of the Series A Preferred Stock set forth herein (as this resolution may be amended from time to time) is invalid, unlawful or incapable of being enforced by reason of any rule of law or public policy, all other rights, preferences and limitations set forth in this resolution (a so amended) which can be given effect without the invalid, unlawful or unenforceable right, preference or limitation shall, nevertheless, remain in full force and effect, and no right, preference or limitation herein set forth shall be deemed dependent upon any other such right, preference or limitation unless so expressed herein.
6.03 Stock Transfer Taxes. The Corporation shall pay any and all stock transfer and documentary stamp taxes that may be payable in respect of any issuance or delivery of the share of Series A Preferred Stock or shares of Common Stock or other securities issued on account of Series A Preferred Stock pursuant hereto or certificates representing such shares or securities.
6.04 Transfer Agent. The Corporation may appoint, and from time to time discharge and/or replace, a transfer agent of the Series A Preferred Stock. Upon any such appointment or discharge of a transfer agent, the Corporation shall send notice thereof by first-class mail, postage prepaid, to the holder of record of Series A Preferred Stock.
6.05 Transferability. Subject to any transfer restriction agreements that may be entered into by the holder of Series A Preferred Stock, the Series A Preferred Stock shall be transferable by the holder, provided that such transfer is made in compliance with applicable federal and state securities laws.
Exhibit 3.12
Aurum Resource and Asset Management, Inc.
(a Nevada Corporation)
BY LAWS
ARTICLE I
Principal Executive Office
The principal executive office of Aurum and Asset Management, Inc. (the "Corporation") shall be at 930 S 4th Street Suite 150 Las Vegas, NV 89101. The Corporation may also have offices at such other places within or without the State of Nevada as the board of directors shall from time to time determine.
ARTICLE II
Stockholders
SECTION 1. Place of Meetings. All annual and special meetings of stockholders shall be held at the principal executive office of the Corporation or at such other place within or without the State of Nevada as the board of directors may determine and as designated in the notice of such meeting.
SECTION 2. Annual Meeting. Annual meetings of the stockholders of the Corporation for the election of directors and for the transaction of any other business of the Corporation shall be held annually at such date and time as the board of directors may determine.
SECTION 3. Special Meetings. Special meeting of the stockholders of the Corporation for any purpose of purposes may be called at any time by the board of directors of the Corporation, or by a committee of the board of directors which has been duly designated by the board of directors and whose powers and authorities, as provided in a resolution of the board of directors or in the By Laws of the Corporation, include the power and authority to call such meetings but such special meetings may not be called by another person or persons.
SECTION 4. Conduct of Meetings. Annual and special meetings shall be conducted in accordance with these By Laws or as otherwise prescribed by the board of directors. The chairman or the chief executive officer of the Corporation shall preside at such meetings.
SECTION 5. Notice of Meeting. Written notice stating the place, day and hour of the meeting and the purpose or purposes for which the meeting is called shall be mailed by the secretary or the officer performing his duties, not less than ten days nor more than sixty days before the meeting to each stockholder of record entitled to vote at such meeting. If mailed, such notice shall be deemed to be delivered when deposited in the United States mail, records of the Corporation as of the record date prescribed in Section 6, with postage thereon prepaid. If a stockholder be present at a meeting, or in writing waive notice thereof before
or after the meeting, to such stockholder shall be unnecessary. When any stockholders’ meeting, either annual or special, is adjourned for thirty days or more, notice of the adjourned meeting shall be given as in the case of an original meeting. It shall not be necessary to give any notice of the time and place of any meeting adjourned for less than thirty days or of the business to be transacted at such adjourned meeting, other than an announcement at the meeting at which such adjournment is taken.
SECTION 6. Fixing of Record Date. For the purpose of determining stockholders entitled to notice of or to vote at any meeting of stockholders, or any adjournment thereof, or stockholders entitled to receive payment of any dividend, or in order to make a determination of stockholders for any other proper purpose, the board of directors shall fix in advance a date as the record date for any such determination of stockholders. Such date in any case shall be not more than sixty days, and in case of a meeting of stockholders, not less than ten days prior to the date on which the particular action, requiring such determination of stockholders, is to be taken.
When a determination of stockholders entitled to vote at any meeting of stockholders has been made as provided in this section, such determination shall apply to any adjournment thereof.
SECTION 7. Voting Lists. The officer or agent having charge of the stock transfer books for shares of the Corporation shall make, at least ten days before each meeting of stockholders, a complete record of the stockholders entitled to vote at such meeting or any adjournment thereof, with the address of and the number of shares held by each. The record, for a period of ten days before such meeting, shall be kept on file at the principal executive office of the Corporation, whether within or outside the State of Nevada, and shall be subject to inspection by any stockholder for any purpose germane to the meeting at any time during usual business hours. Such record shall also be produced and kept open at the time and place of the meeting and shall be subject to the inspection of any stockholder for any purpose germane to the meeting during the whole time of the meeting. The original stock transfer books shall be prima facie evidence as to who are the stockholders entitled to examine such record or transfer books tr to vote at any meeting of stockholders.
SECTION 8. Quorum. One-fourth of the outstanding shares of the Corporation entitled to vote, represented in person or by proxy, shall constitute a quorum at a meeting of stockholders. If less than one-fourth of the outstanding shares are represented at a meeting, a majority of the shares so represented may adjourn the meeting from time to time without further notice. At such adjourned meeting at which a quorum shall be present or represented, any business may be transacted which might have been transacted at the meeting as originally notified. The stockholders present at a duly organized meeting may continue to transact business until adjournment, notwithstanding the withdrawal of enough stockholders to leave less than a quorum.
SECTION 9. Proxies. At all meetings of stockholders, a stockholder may vote by proxy executed in writing by the stockholder or by his duly authorized attorney in fact. Proxies solicited on behalf of the management shall be voted as directed by the stockholder or, in the absence of such direction, as determined by a majority of the board of directors. No proxy shall be valid after eleven months from the date of its execution unless otherwise provided in the proxy.
SECTION 10. Voting. At each election for directors every stockholder entitled to vote at such election shall be entitled to one vote for each share of stock held. Unless otherwise provided by the Articles of Incorporation, by statute, or by these By Laws, a majority of those votes cast by stockholders at a lawful meeting shall be sufficient to pass on a transaction or matter, except in the election of directors, which election shall be determined by a plurality of the votes of the shares present in person or by proxy at the meeting and entitled to vote on the election of directors.
SECTION 11. Voting of Shares in the Name of Two or More Persons. When ownership of stock stands in the name of two or more persons, in the absence of written directions to the Corporation to the contrary, at any meeting of the stockholders of the Corporation any one or more of such stockholders may cast, in person or by proxy, all votes to which such ownership is entitled. In the event an attempt is made to cast conflicting votes, in person or by proxy, by the persons are entitled shall be cast as directed by a majority of those holding such stock and present in person or by proxy at such meeting, but no votes shall be cast for such stock if a majority cannot agree.
SECTION 12. Voting of Shares by Certain Holders. Shares standing in the name of another corporation may be voted by any officer, agent or proxy as the By Laws of such corporation may prescribe, or, in the absence of such provision, as the board of directors of such corporation may determine. Shares held by an administrator, executor, guardian or conservator may be voted by him, either in person or by proxy, without a transfer of such shares into his name. Shares standing in the name of a trustee may be voted by him, either in person or by proxy, but no trustee shall be entitled to vote shares held by him without a transfer or such shares into his name. Shares standing in the name of a receiver may be voted by such receiver, and shares held by or under the control of a receiver may be voted by such receiver without the transfer thereof into his name if authority to do so is contained in an appropriate order of the court or other public authority by which such receiver was appointed.
A stockholder whose shares are pledged shall be entitled to vote such shares until the shares have been transferred into the name of the pledgee and thereafter the pledgee shall be entitled to vote the shares so transferred.
Neither treasury shares of its own stock held by the Corporation, nor shares held by another corporation, if a majority of the shares entitled to vote for the election of directors of such other corporation are held by the Corporation, shall be voted at any meeting or counted in determining the total number of outstanding shares at any given time for purposes of any meeting.
SECTION 13. Inspectors of Election. In advance of any meeting of stockholders, the chairman of the board or the board of directors may appoint any persons, other than nominees for office, as inspectors of election to act at such meeting or any adjournment thereof. The number of inspectors shall be either one or three. If the board of directors so appoints either one or three
inspectors, that appointment shall not be altered at the meeting. If inspectors of election are not so appointed, the chairman of the board may make such appointment at the meeting. In case any person appointed as inspector fails to appear or fails or refuses to act, the vacancy may be filled by appointment in advance of the meeting or at the meeting by the chairman of the board or the president.
Unless otherwise prescribed by applicable law, the duties of such inspectors shall include: determining the number of shares of stock and voting power of each share, the shares of stock represented at the meeting, the existence of a quorum, the authenticity, validity and effect of proxies; receiving votes, ballots or consents; hearing and determining all challenges and questions in any way arising in connection with the right to vote; counting and tabulating all votes or consents; determining the result; and such acts as may be proper to conduct the election or vote with fairness to all stockholders.
SECTION 14. Nominating Committee. The board of directors or a committee appointed by the board of directors shall act as nominating committee for selecting the management nominees for election as directors. Except in the case of a nominee substituted as a result of the death or other incapacity of a management nominee, the nominating committee shall deliver written nominations to the secretary at least twenty days prior to the date of the annual meeting. Provided such committee makes such nominations, no nominations for directors except those made by the nominating committee shall be voted upon at the annual meeting unless other nominations by stockholders are made in writing and delivered to the secretary of the Corporation in accordance with the provisions of the Corporation’s Articles of Incorporation.
SECTION 15. New Business. Any new business to be taken up at the annual meeting shall be stated in writing and filed with the secretary of the Corporation in accordance with the provisions of the Corporation’s Articles of Incorporation. This provision shall not prevent the consideration and approval or disapproval at the annual meeting of reports of officers, directors and committees, but in connection with such reports n new business shall be acted upon at such annual meeting unless stated and filed as provided in the Corporation’s Articles of Incorporation.
ARTICLE III
Board of Directors
SECTION 1. General Powers. The business and affairs of the Corporation shall be under the direction of its board of directors. The chairman shall preside at all meetings of the board of directors.
SECTION 2. Number, Term and Election. The number of directors of the Corporation shall be such number, not less than one nor more than 15 (exclusive of directors, if any, to be elected by holders of preferred stock of the Corporation), as shall be provided from time to time in a resolution adopted by the board of directors, provided that no decrease in the number of directors shall have the effect of shortening the term of any incumbent director, and provided further that no action shall be taken to decrease or increase the number of directors from time to time unless at least two-thirds of the directors then in office shall concur in said action. Exclusive of directors, in any, elected by holders of preferred stock, vacancies in the board of
directors of the Corporation, however caused, and newly created directorships shall be filled by a vote of two-thirds of the directors then in office, whether or not a quorum, and any director so chosen shall hold office for a term expiring at the annual meeting of stockholders at which the term of the class to which the director has been chosen expires and when the director’s successor is elected and qualified.
SECTION 3. Regular Meetings. A regular meeting of the board of directors shall be held at such time and place as shall be determined by resolution of the board of directors without other notice than such resolution.
SECTION 4. Special Meetings. Special meeting of the board of directors may be called by or at the request of the chairman, the chief executive officer or one-third of the directors. The person calling the special meeting of the board of directors may fix any place as the place for holding any special meeting of the board of directors called such persons.
Members of the board of the directors may participate in special meeting by means of telephone conference or similar communications equipment by which all persons participating in the meeting can hear each other. Such participation shall constitute presence in person.
SECTION 5. Notice. Written notice of any special meeting shall be given to each director at least two days previous thereto delivered personally or by telegram or at least seven days previous thereto delivered by mail at the address at which the director is most likely to be reached. Such notice shall be deemed to be delivered when deposited in the United States mail so addressed, with postage thereon prepaid if mailed or when delivered to the telegraph company if sent by telegram. Any director may waive notice of any meeting by a writing filed with the secretary. The attendance of a director at a meeting shall constitute a waiver of notice of such meeting, except where a director attends a meeting for the express purpose of objecting to the transaction of any business because the meeting is not lawfully called or convened. Neither the business to be transacted at, nor the purpose of, any meeting of the board of directors need be specified in the notice or waiver of notice of such meeting.
SECTION 6. Quorum. A majority of the number of directors fixed by Section 2 shall constitute a quorum for the transaction of business at any meeting of the board of directors, but if less than such majority is present at a meeting, a majority of the directors present may adjourn the meeting from time to time. Notice of any adjourned meeting shall be given in the same manner as prescribed by Section 5 of this Article III.
SECTION 7. Manner of Acting. The act of the majority of the directors present at a meeting at which a quorum is present shall be the act of the board of directors, unless a greater number is prescribed by these By Laws, the Articles of incorporation, or the Nevada Revised Statutes.
SECTION 8. Action Without a Meeting. Any action required or permitted to be taken by the board of directors at a meeting may be taken without a meeting if a consent in writing, setting forth the action so taken, shall be signed by all of the directors.
SECTION 9. Resignation. Any director may resign at any time by sending a written notice of such resignation to the home office of the Corporation addressed to the chairman. Unless otherwise specified therein such resignation shall take effect upon receipt thereof by the chairman.
SECTION 10. Vacancies. Any vacancy occurring on the board of directors shall be filled in accordance with the provisions of the Corporations Articles of Incorporation. Any directorship to be filled by reason of an increase in the number of directors may be filled by the affirmative vote of two-thirds of the directors then in office or by election at an annual meeting or at a special meeting of the stockholders held for that purpose. The term of such director shall be in accordance with the provisions of the Corporation’s Articles of Incorporation.
SECTION 11. Removal of Directors. Any director or the entire board of directors may be removed only in accordance with the provisions of the Corporation’s Articles of Incorporation.
SECTION 12. Compensation. Directors, as such, may receive compensation for service on the board of directors. Members of either standing or special committees may be allowed such compensation as the board of directors may determine.
ARTICLE IV
Committees of the Board of Directors
The board of directors may, by resolution passed by a majority of the whole board, designate one or more committees, as they may determine to be necessary or appropriate for the conduct of the business of the Corporation, and may prescribe the duties, constitution and procedures thereof. Each committee shall consist of one or more directors of the Corporation appointed by the chairman. The chairman may designate one or more directors as alternate members of any committee, who may replace any absent or disqualified member at any meeting of the committee.
The chairman shall have power at any time to change the members of, to fill vacancies in, and to discharge any committee of the board. Any member of any such committee may resign at any time by giving notice to the Corporation; provided, however, that notice to the board, the chairman of the board, the chief executive officer, the chairman of such committee, or the secretary shall be deemed to constitute notice to the Corporation. Such resignation shall take effect upon receipt of such notice or at any later time specified therein; and, unless otherwise specified therein, acceptance of such resignation shall not be necessary to make it effective. Any member of any such committee may be removed at any time, either with or without cause, b the affirmative vote of a majority of the authorized number of directors at any meeting of the board called for that purpose.
ARTICLE V
Officers
SECTION 1. Positions. The officers of the Corporation shall be a chairman, a president, one or more vice presidents, a secretary and a treasurer, each of whom shall be elected by the
board of directors. The board of directors may designate one or more vice presidents as executive vice president or senior vice president. The board of directors may also elect or authorize the appointment of such other officers as the business of the Corporation may require. The officers shall have such authority and perform such duties as the board of directors may from time to time authorize or determine. In the absence of action by the board of directors, the officers shall have such powers and duties as generally pertain to their respective offices.
SECTION 2. Election of Term of Office. The officers of the Corporation shall be elected annually by the board of directors at the first meeting of the board of directors held after each annual meeting of the stockholders. If the election of officers is not held at such meeting, such election shall be held as soon thereafter as possible. Each officer shall hold office until his successor shall have been duly elected and qualified or until his death or until he shall resign or shall have been removed in the manner hereinafter provided. Election or appointment of an officer, employee or agent shall not of itself create contract rights. The board of directors may authorize the Corporation to enter into an employment contract with any officer in accordance with state law; but no such contract shall impair the right of the board of directors to remove any officer at any time in accordance with Section 3 of this Article V.
SECTION 3. Removal. Any officer may be removed by vote of two-thirds of the board of directors whenever, in its judgment, the best interests of the Corporation will be served thereby, but such removal, other than for cause, shall be without prejudice to the contract rights, if any, of the person so removed.
SECTION 4. Vacancies. A vacancy in any office because of death , resignation, removal, disqualification or otherwise, may be filled by the board of directors for the unexpired portion of the term.
SECTION 5. Remuneration. The Remuneration of the officers shall be fixed from time to time by the board of directors, and no officer shall be prevented from receiving such salary by reason of the fact that he is also a director of the Corporation.
ARTICLE VI
Contracts, Loans, Checks and Deposits
SECTION 1. Contracts. To the extent permitted by applicable law, and except as otherwise prescribed by the Corporation’s Articles of Incorporation or these By Laws with respect to certificates for shares, the board of directors or the executive committee may authorize any officer, employee, or agent of the Corporation to enter into any contract or execute and deliver any instrument in the name of and on behalf of the Corporation. Such authority may be general or confined to specific instances.
SECTION 2. Loans. No loans shall be contracted on behalf of the Corporation and no evidence of indebtedness shall be issued in its name unless authorized by the board of directors. Such authority may be general or confined to specific instances.
SECTION 3. Checks, Drafts, Etc. All checks, drafts or other orders for the payment of money, notes or other evidences of indebtedness issued in the name of the Corporation shall be signed by one of more officers, employees or agents of the Corporation in such manner, including in facsimile form, as shall from time to time be determined by resolution of the board of directors.
SECTION 4. Deposits. All funds of the Corporation not otherwise employed shall be deposited from time to time to the credit of the Corporation in any of its duly authorized depositories as the board of directors may select.
ARTICLE VII
Certificates for Shares and Their Transfer
SECTION 1. Certificates for Shares. The shares of the Corporation shall be represented by certificates signed by the chairman of the board of directors or the president or a vice president and by the treasurer or an assistant treasurer or the secretary or an assistant secretary of the Corporation, and may be sealed with the seal of the Corporation or a facsimile thereof. Any or all of the signatures upon a certificate may be facsimiles if the certificate is countersigned by a transfer agent, or registered by a registrar, other than the Corporation itself or an employee of the Corporation. If any officer who has signed or whose facsimile signature has been placed upon such certificate shall have ceased to be such officer before the certificate is issued, it may be issued by the Corporation with the same effect as if he were such officer at the date of its issue.
SECTION 2. Form of Share Certificates. All certificates representing shares issued by the Corporation shall set forth upon the face or back that the Corporation will furnish to any stockholder upon request and without charge a full statement of the designations, preferences, limitations, and relative rights of the shares of each class authorized to be issued, the variations in the relative rights and preferences between the shares of each such series so far as the same have been fixed and determined, and the authority of the board of directors to fix and determine the relative rights and preferences of subsequent series.
Each certificate representing shares shall state upon the face thereof: that the Corporation is organized under the laws of the State of Nevada; the name of the person to whom issued; the number and class of shares, the designation of the series, if any, which such certificate represents; the par value of each share represented by such certificate, or a statement that the shares are without par value. Other matters in regard to the form of the certificates shall be determined by the board of directors.
SECTION 3. Payment for Shares. No certificate shall be issued for any share until such share is fully paid.
SECTION 4. Form of Payment for Shares. The consideration for the issuance of shares shall be paid in accordance with the provisions of the Corporation’s Articles of Incorporation.
SECTION 5. Transfer of Shares. Transfer of shares of capital stock of Corporation shall be made only on its stock transfer books. Authority for such transfer shall be given only
to the holder of record thereof or by his legal representative, who shall furnish proper evidence of such authority, or by his attorney thereunto authorized by power of attorney duly executed and filed with the Corporation. Such transfer shall be made only on surrender for cancellation of the certificate for such shares. The person in whose name shares of capital stock stand on the books of the Corporation shall be deemed by the Corporation to be the owner thereof for all purposes.
SECTION 6. Lost Certificates. The board of directors may direct a new certificate to be issued in place of any certificate theretofore issued by the Corporation alleged to have been lost, stolen, or destroyed, upon the making of an affidavit of that fact by the person claiming the certificate of stock to be lost, stolen, or destroyed. When authorizing such issue of a new certificate, the board of directors may, in its discretion and as a condition precedent to the issuance thereof, require the owner of such lost, stolen, or destroyed certificate, or his legal representative, to give the Corporation a bond in such sum as it may direct as indemnity against any claim that may be made against the Corporation with respect to the certificate alleged to have been lost, stolen, or destroyed.
SECTION 7. Book-entry of Shares. The Corporation through its Transfer Agent is authorized to issue shares of its common or preferred stock through Book-entry on the records of the Transfer Agent.
ARTICLE VIII
Fiscal Year; Annual Audit
The fiscal year of the Corporation shall end on the last day of December of each year. The Corporation shall be subject to an annual audit as of the end of its fiscal year by independent public accountants appointed by and responsible to the board of directors.
ARTICLE IX
Dividends
Dividends upon the stock of the Corporation, subject to the provisions of the Articles of Incorporation, if any, may be declared by the board of directors at any regular or special meeting, pursuant to law. Dividends may be paid in cash, in property or in the Corporation’s own stock.
ARTICLE X
Corporation Seal
The corporate seal of the Corporation shall be in such form as the board of directors shall prescribe.
ARTICLE XI
Amendments
These By Laws may be repealed, altered, amended or rescinded by the stockholders of the Corporation only by vote of not less than 75% of the voting power of the outstanding shares of
capital stock of the Corporation entitled to vote generally in the election of directors (considered for this purpose as one class) cast at a meeting of the stockholders called for that purpose (provided that notice of such proposed repeal, alteration, amendment or rescission is included in the notice of such meeting). In addition, the board of directors may repeal, alter, amend or rescind these By Laws by a majority vote of the board of directors at a legal meeting held in accordance with the provisions of these By Laws.
Certification
I, Daniel G. Martin, Secretary of Aurum Resource and Asset Management, Inc., a Nevada corporation, hereby certify that the foregoing is a true and correct copy of By Laws which were duly adopted by the Board of Directors of Aurum Resource and Asset Management, Inc. on August 8, 2016.
Dated: August 8, 2016
/s/ Daniel G Martin
Daniel G Martin, Secretary
UNANIMOUS WRITTEN CONSENT OF THE
BOARD OF DIRECTORS
OF
AURUM RESOURCE AND ASSET MANAGEMENT, INC.
a Nevada corporation,
IN LIEU OF A SPECIAL MEETING
I, the undersigned, being the sole member of the board of directors, as presently constituted, (the “Board”) of Aurum Resource and Asset Management, Inc., a corporation organized under the laws of the State of Nevada (the “Company”), do by this writing unanimously consent to take the following actions and adopt the following resolutions in accordance with the terms of Section 78.315 of the Nevada Revised Statues (the “NRS”):
WHEREAS, the Board seems it to be in the best interests of the Company to adopt new Bylaws for the Company;
NOW THEREFORE, BE IT RESOLVED, that the undersigned hereby authorize, consent to, and approve the Bylaws for the Company, a copy of which is attached; and be it
FURTHER RESOLVED, that the proper officers and directors of the Company be and each of them hereby is, authorized, empowered and directed to do all such acts and things and to execute, acknowledge and deliver all such documents as may, in their reasonable discretion, be deemed necessary or desirable to carry out and comply with the terms and provisions of these resolutions, such approval to be conclusively evidenced by the execution and delivery thereof; and be it
FURTHER RESOLVED, that any action taken by any director, officer, employee, or agent of the Company on or prior to the date hereof in furtherance of any of the foregoing matters be, and each such action hereby is, approved, ratified, and confirmed in all respects as the action and deed of the Company; and be it
FURTHER RESOLVED, that this written consent may be received as a signed confirmed facsimile or via email which shall constitute the original; and be it
FURTHER RESOLVED, that an executed copy of this written consent shall be placed in the minute book of the Company.
**Signature Page Follows**
IN WITNESS WHEREOF, the undersigned has executed this Unanimous Written Consent of the Board of Directors, this 8th day of August, 2016.
Daniel G Martin
|
|
BARBARA K. CEGAVSKE Secretary of State 202 North Carson Street Carson City, Nevada 89701-4201 (775) 684-5708 Website: www.nvsos.gov |
|
Certificate of Amendment (PURSUANT TO NRS 78.385 AND 78.390) |
|
|
|
|
|
USE BLACK INK ONLY • DO NOT HIGHLIGHT |
ABOVE SPACE IS FOR OFFICE USE ONLY |
Certificate of Amendment to Articles of Incorporation
For Nevada Profit Corporations
(Pursuant to NRS 78.385 and 78.390 - After Issuance of Stock)
|
1. |
Name of corporation: |
Aurum Resource and Asset Management, Inc.
|
2. |
The articles have been amended as follows: (provide article numbers, if available) |
“Article I: The name of the corporation is Innovest Global, Inc.”;
“Article IV: The authorized capital stock of the Corporation shall be Five Hundred Ten Million (510,000,000) shares. The capital stock of the Corporation is divided into two classes: (1) Common Stock in the amount of Five Hundred Million (500,000,000) shares, $0.001 par value per share and (2) Preferred Stock in the amount of Ten Million (10,000,000) shares, $0.001 par value per share.
[Continued on Attachment Page]
|
3. |
The vote by which the stockholders holding shares in the corporation entitling them to exercise at least a majority of the voting power, or such greater proportion of the voting power as may be required in the case of a vote by classes or series, or as may be required by the provisions of the articles of incorporation* have voted in favor of the amendment is: 96.6% |
|
4. |
Effective date and time of filing: (optional) |
Date: 9/19/2016 Time: 9:00AM |
|
(must not be later than 90 days after the certificate is filed) |
|
5. |
Signature: (required) |
|
X
|
|
|
Signature of Officer |
|
*If any proposed amendment would alter or change any preference or any relative or other right given to any class or series of outstanding shares, then the amendment must be approved by the vote. In addition to the affirmative vote otherwise required of the holders of shares representing a majority of the voting power of each class or series affected by the amendment regardless to limitations or restrictions on the voting power thereof.
IMPORTANT: Failure to include any of the above information and submit with the proper fees may cause this filing to be rejected.
|
This form must be accompanied by appropriate fees. |
Nevada Secretary of State Amend Profit-After Revised: 1-5-15 |
Aurum Resource and Asset Management, Inc.
Certificate of Amendment to Articles of Incorporation
Attachment Page
The Preferred Share may be issued from time to time in one or more series. The board of directors is authorized to fix the number of shares of any series of Preferred Shares and to determine the designation of any such series. The board of directors is also authorized to determine or alter the rights, preferences, privileges and restrictions granted to or imposed upon any wholly unissued series of Preferred Shares and, within the limits and restrictions stated in any resolution or resolutions of the board of directors originally fixing the number of shares constituting any series, to increase or decrease (but not below the number of shares of any such series then outstanding) the number of shares of any series subsequent to the issue of share of that series.”
Exhibit 10.1
Innovest Global, Inc. 2019 Equity Incentive Plan
1. Purpose; Eligibility.
1.1 General Purpose. The name of this plan is the Innovest Global, Inc. 2019 Equity Incentive Plan (the “Plan”). The purposes of the Plan are to (a) enable Innovest Global, Inc., a Nevada corporation (the “Company”), and any Affiliate to attract and retain the types of Employees, Consultants and Directors who will contribute to the Company’s long range success; (b) provide incentives that align the interests of Employees, Consultants and Directors with those of the shareholders of the Company; and (c) promote the success of the Company’s business.
1.2 Eligible Award Recipients. The persons eligible to receive Awards are the Employees, Consultants and Directors of the Company and its Affiliates and such other individuals designated by the Committee who are reasonably expected to become Employees, Consultants and Directors after the receipt of Awards.
1.3 Available Awards. Awards that may be granted under the Plan include: (a) Incentive Stock Options, (b) Non-qualified Stock Options, (c) Stock Appreciation Rights, (d) Restricted Awards, (e) Performance Share Awards, and (f) Other Equity-Based Awards.
2. Definitions.
“Affiliate” means a corporation or other entity that, directly or through one or more intermediaries, controls, is controlled by or is under common control with, the Company.
“Applicable Laws” means the requirements related to or implicated by the administration of the Plan under applicable state corporate law, United States federal and state securities laws, the Code, any stock exchange or quotation system on which the shares of Common Stock are listed or quoted, and the applicable laws of any foreign country or jurisdiction where Awards are granted under the Plan.
“Award” means any right granted under the Plan, including an Incentive Stock Option, a Non-qualified Stock Option, a Stock Appreciation Right, a Restricted Award, a Performance Share Award, or an Other Equity-Based Award.
“Award Agreement” means a written agreement, contract, certificate or other instrument or document evidencing the terms and conditions of an individual Award granted under the Plan which may, in the discretion of the Company, be transmitted electronically to any Participant. Each Award Agreement shall be subject to the terms and conditions of the Plan.
“Beneficial Owner” has the meaning assigned to such term in Rule 13d-3 and Rule 13d-5 under the Exchange Act, except that in calculating the beneficial ownership of any particular Person, such Person shall be deemed to have beneficial ownership of all securities that such Person has the right to acquire by conversion or exercise of other securities, whether such right is currently exercisable or is exercisable only after the passage of time. The terms “Beneficially Owns” and “Beneficially Owned” have a corresponding meaning.
“Board” means the Board of Directors of the Company, as constituted at any time.
“Cause” means:
With respect to any Employee or Consultant, unless the applicable Award Agreement states otherwise:
(a) If the Employee or Consultant is a party to an employment or service agreement with the Company or its Affiliates and such agreement provides for a definition of Cause, the definition contained therein; or
(b) If no such agreement exists, or if such agreement does not define Cause: (i) the commission of, or plea of guilty or no contest to, a felony or a crime involving moral turpitude or the commission of any other act involving willful malfeasance or material fiduciary breach with respect to the Company or an Affiliate; (ii) conduct that results in or is reasonably likely to result in harm to the reputation or business of the Company or any of its Affiliates; (iii) gross negligence or willful misconduct with respect to the Company or an Affiliate; or (iv) material violation of state or federal securities laws.
With respect to any Director, unless the applicable Award Agreement states otherwise, a determination by a majority of the disinterested Board members that the Director has engaged in any of the following:
(a) malfeasance in office;
(b) gross misconduct or neglect;
(c) false or fraudulent misrepresentation inducing the director’s appointment;
(d) willful conversion of corporate funds; or
(e) repeated failure to participate in Board meetings on a regular basis despite having received proper notice of the meetings in advance.
The Committee, in its absolute discretion, shall determine the effect of all matters and questions relating to whether a Participant has been discharged for Cause.
“Change in Control”
(a) The direct or indirect sale, transfer, conveyance or other disposition (other than by way of merger or consolidation), in one or a series of related transactions, of all or substantially all of the properties or assets of the Company and its subsidiaries, taken as a whole, to any Person that is not a subsidiary of the Company;
(b) The Incumbent Directors cease for any reason to constitute at least a majority of the Board;
(c) The date which is 10 business days prior to the consummation of a complete liquidation or dissolution of the Company;
(d) The acquisition by any Person of Beneficial Ownership of 50% or more (on a fully diluted basis) of either (i) the then outstanding shares of Common Stock of the Company, taking into account as outstanding for this purpose such Common Stock issuable upon the
exercise of options or warrants, the conversion of convertible stock or debt, and the exercise of any similar right to acquire such Common Stock (the “Outstanding Company Common Stock”) or (ii) the combined voting power of the then outstanding voting securities of the Company entitled to vote generally in the election of directors (the “Outstanding Company Voting Securities”); provided, however, that for purposes of this Plan, the following acquisitions shall not constitute a Change in Control: (A) any acquisition by the Company or any Affiliate, (B) any acquisition by any employee benefit plan sponsored or maintained by the Company or any subsidiary, (C) any acquisition which complies with clauses, (i), (ii) and (iii) of subsection (e) of this definition or (D) in respect of an Award held by a particular Participant, any acquisition by the Participant or any group of persons including the Participant (or any entity controlled by the Participant or any group of persons including the Participant); or
(e) The consummation of a reorganization, merger, consolidation, statutory share exchange or similar form of corporate transaction involving the Company that requires the approval of the Company’s shareholders, whether for such transaction or the issuance of securities in the transaction (a “Business Combination”), unless immediately following such Business Combination: (i) more than 50% of the total voting power of (A) the entity resulting from such Business Combination (the “Surviving Company”), or (B) if applicable, the ultimate parent entity that directly or indirectly has beneficial ownership of sufficient voting securities eligible to elect a majority of the members of the board of directors (or the analogous governing body) of the Surviving Company (the “Parent Company”), is represented by the Outstanding Company Voting Securities that were outstanding immediately prior to such Business Combination (or, if applicable, is represented by shares into which the Outstanding Company Voting Securities were converted pursuant to such Business Combination), and such voting power among the holders thereof is in substantially the same proportion as the voting power of the Outstanding Company Voting Securities among the holders thereof immediately prior to the Business Combination; (ii) no Person (other than any employee benefit plan sponsored or maintained by the Surviving Company or the Parent Company) is or becomes the Beneficial Owner, directly or indirectly, of 50% or more of the total voting power of the outstanding voting securities eligible to elect members of the board of directors of the Parent Company (or the analogous governing body) (or, if there is no Parent Company, the Surviving Company); and (iii) at least a majority of the members of the board of directors (or the analogous governing body) of the Parent Company (or, if there is no Parent Company, the Surviving Company) following the consummation of the Business Combination were Board members at the time of the Board’s approval of the execution of the initial agreement providing for such Business Combination.
“Code” means the Internal Revenue Code of 1986, as it may be amended from time to time. Any reference to a section of the Code shall be deemed to include a reference to any regulations promulgated thereunder.
“Committee” means a committee of one or more members of the Board appointed by the Board to administer the Plan in accordance with Section 3.3 and Section 3.4.
“Common Stock” means the common stock, $0.001 par value per share, of the Company, or such other securities of the Company as may be designated by the Committee from time to time in substitution thereof.
“Company” means Innovest Global, Inc., a Nevada corporation, and any successor thereto.
“Consultant” means any individual or entity which performs bona fide services to the Company or an Affiliate, other than as an Employee or Director, and who may be offered securities registerable pursuant to a registration statement on Form S-8 under the Securities Act.
“Continuous Service” means that the Participant’s service with the Company or an Affiliate, whether as an Employee, Consultant or Director, is not interrupted or terminated. The Participant’s Continuous Service shall not be deemed to have terminated merely because of a change in the capacity in which the Participant renders service to the Company or an Affiliate as an Employee, Consultant or Director or a change in the entity for which the Participant renders such service, provided that there is no interruption or termination of the Participant’s Continuous Service; provided further that if any Award is subject to Section 409A of the Code, this sentence shall only be given effect to the extent consistent with Section 409A of the Code. For example, a change in status from an Employee of the Company to a Director of an Affiliate will not constitute an interruption of Continuous Service. The Committee or its delegate, in its sole discretion, may determine whether Continuous Service shall be considered interrupted in the case of any leave of absence approved by that party, including sick leave, military leave or any other personal or family leave of absence. The Committee or its delegate, in its sole discretion, may determine whether a Company transaction, such as a sale or spin-off of a division or subsidiary that employs a Participant, shall be deemed to result in a termination of Continuous Service for purposes of affected Awards, and such decision shall be final, conclusive and binding.
“Deferred Stock Units (DSUs)” has the meaning set forth in Section 7.2 hereof.
“Director” means a member of the Board.
“Disability” means, unless the applicable Award Agreement says otherwise, that the Participant is unable to engage in any substantial gainful activity by reason of any medically determinable physical or mental impairment; provided, however, for purposes of determining the term of an Incentive Stock Option pursuant to Section 6.10 hereof, the term Disability shall have the meaning ascribed to it under Section 22(e)(3) of the Code. The determination of whether an individual has a Disability shall be determined under procedures established by the Committee. Except in situations where the Committee is determining Disability for purposes of the term of an Incentive Stock Option pursuant to Section 6.10 hereof within the meaning of Section 22(e)(3) of the Code, the Committee may rely on any determination that a Participant is disabled for purposes of benefits under any long-term disability plan maintained by the Company or any Affiliate in which a Participant participates.
“Disqualifying Disposition” has the meaning set forth in Section 14.9.
“Effective Date” shall mean December 20, 2019.
“Employee” means any person, including an Officer or Director, employed by the Company or an Affiliate; provided, that, for purposes of determining eligibility to receive Incentive Stock Options, an Employee shall mean an employee of the Company or a parent or subsidiary corporation within the meaning of Section 424 of the Code. Mere service as a Director or payment of a director’s fee by the Company or an Affiliate shall not be sufficient to constitute “employment” by the Company or an Affiliate.
“Exchange Act” means the Securities Exchange Act of 1934, as amended.
“Fair Market Value” means, as of any date, the value of the Common Stock as determined below. If the Common Stock is listed on any established stock exchange or a national market system, the Fair Market Value shall be the closing price of a share of Common Stock (or if no sales were reported the closing price on the date immediately preceding such date) as quoted on such exchange or system on the day of determination. In the absence of an established market for the Common Stock, the Fair Market Value shall be determined in good faith by the Committee and such determination shall be conclusive and binding on all persons.
“Fiscal Year” means the Company’s fiscal year.
“Free Standing Rights” has the meaning set forth in Section 7.1(a).
“Good Reason” means, unless the applicable Award Agreement states otherwise:
(a) If an Employee or Consultant is a party to an employment or service agreement with the Company or its Affiliates and such agreement provides for a definition of Good Reason, the definition contained therein; or
(b) If no such agreement exists or if such agreement does not define Good Reason, the occurrence of one or more of the following without the Participant’s express written consent, which circumstances are not remedied by the Company within thirty (30) days of its receipt of a written notice from the Participant describing the applicable circumstances (which notice must be provided by the Participant within ninety (90) days of the Participant’s knowledge of the applicable circumstances): (i) any material, adverse change in the Participant’s duties, responsibilities, authority, title, status or reporting structure; (ii) a material reduction in the Participant’s base salary or bonus opportunity; or (iii) a geographical relocation of the Participant’s principal office location by more than fifty (50) miles.
“Grant Date” means the date on which the Committee adopts a resolution, or takes other appropriate action, expressly granting an Award to a Participant that specifies the key terms and conditions of the Award or, if a later date is set forth in such resolution, then such date as is set forth in such resolution.
“Incentive Stock Option” means an Option that is designated by the Committee as an incentive stock option within the meaning of Section 422 of the Code and that meets the requirements set out in the Plan.
“Incumbent Directors” means individuals who, on the Effective Date, constitute the Board, provided that any individual becoming a Director subsequent to the Effective Date whose election or nomination for election to the Board was approved by a vote of at least two-thirds of the Incumbent Directors then on the Board (either by a specific vote or by approval of the proxy statement of the Company in which such person is named as a nominee for Director without objection to such nomination) shall be an Incumbent Director. No individual initially elected or nominated as a director of the Company as a result of an actual or threatened election contest with respect to Directors or as a result of any other actual or threatened solicitation of proxies by or on behalf of any person other than the Board shall be an Incumbent Director.
“Non-Employee Director” means a Director who is a “non-employee director” within the meaning of Rule 16b-3.
“Non-qualified Stock Option” means an Option that by its terms does not qualify or is not intended to qualify as an Incentive Stock Option.
“Officer” means a person who is an officer of the Company within the meaning of Section 16 of the Exchange Act and the rules and regulations promulgated thereunder.
“Option” means an Incentive Stock Option or a Non-qualified Stock Option granted pursuant to the Plan.
“Optionholder” means a person to whom an Option is granted pursuant to the Plan or, if applicable, such other person who holds an outstanding Option.
“Option Exercise Price” means the price at which a share of Common Stock may be purchased upon the exercise of an Option.
“Other Equity-Based Award” means an Award that is not an Option, Stock Appreciation Right, Restricted Stock, Restricted Stock Unit, or Performance Share Award that is granted under Section Error! Reference source not found. and is payable by delivery of Common Stock and/or which is measured by reference to the value of Common Stock.
“Participant” means an eligible person to whom an Award is granted pursuant to the Plan or, if applicable, such other person who holds an outstanding Award.
“Performance Goals” means, for a Performance Period, the one or more goals established by the Committee for the Performance Period based upon business criteria or other performance measures determined by the Committee in its discretion.
“Performance Period” means the one or more periods of time, as the Committee may select, over which the attainment of one or more Performance Goals will be measured for the purpose of determining a Participant’s right to and the payment of a Performance Share Award.
“Performance Share” means the grant of a right to receive a number of actual shares of Common Stock or share units based upon the performance of the Company during a Performance Period, as determined by the Committee.
“Performance Share Award” means any Award granted pursuant to Section 7.3 hereof.
“Permitted Transferee” means: (a) a member of the Optionholder’s immediate family (child, stepchild, grandchild, parent, stepparent, grandparent, spouse, former spouse, sibling, niece, nephew, mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law, or sister-in-law, including adoptive relationships), any person sharing the Optionholder’s household (other than a tenant or employee), a trust in which these persons have more than 50% of the beneficial interest, a foundation in which these persons (or the Optionholder) control the management of assets, and any other entity in which these persons (or the Optionholder) own more than 50% of the voting interests; (b) third parties designated by the Committee in connection with a program established and approved by the Committee pursuant to which Participants may receive a cash payment or other consideration in consideration for the transfer of a Non-qualified Stock Option; and (c) such other transferees as may be permitted by the Committee in its sole discretion.
“Person” means a person as defined in Section 13(d)(3) of the Exchange Act.
“Plan” means this Innovest Global, Inc. 2019 Equity Incentive Plan, as amended and/or amended and restated from time to time.
“Related Rights” has the meaning set forth in Section 7.1(a).
“Restricted Award” means any Award granted pursuant to Section 7.2(a).
“Restricted Period” has the meaning set forth in Section 7.2(a).
“Rule 16b-3” means Rule 16b-3 promulgated under the Exchange Act or any successor to Rule 16b-3, as in effect from time to time.
“Securities Act” means the Securities Act of 1933, as amended.
“Stock Appreciation Right” means the right pursuant to an Award granted under Section 7.1 to receive, upon exercise, an amount payable in cash or shares equal to the number of shares subject to the Stock Appreciation Right that is being exercised multiplied by the excess of (a) the Fair Market Value of a share of Common Stock on the date the Award is exercised, over (b) the exercise price specified in the Stock Appreciation Right Award Agreement.
“Stock for Stock Exchange” has the meaning set forth in Section 6.4.
“Substitute Award” has the meaning set forth in Section 4.5.
“Ten Percent Shareholder” means a person who owns (or is deemed to own pursuant to Section 424(d) of the Code) stock possessing more than 10% of the total combined voting power of all classes of stock of the Company or of any of its Affiliates.
“Total Share Reserve” has the meaning set forth in Section 4.1.
3. Administration.
3.1 Authority of Committee. The Plan shall be administered by the Committee or, in the Board’s sole discretion, by the Board. Subject to the terms of the Plan, the Committee’s charter and Applicable Laws, and in addition to other express powers and authorization conferred by the Plan, the Committee shall have the authority:
(a) to construe and interpret the Plan and apply its provisions;
(b) to promulgate, amend, and rescind rules and regulations relating to the administration of the Plan;
(c) to authorize any person to execute, on behalf of the Company, any instrument required to carry out the purposes of the Plan;
(d) to delegate its authority to one or more Officers of the Company with respect to Awards that do not involve “insiders” within the meaning of Section 16 of the Exchange Act;
(e) to determine when Awards are to be granted under the Plan and the applicable Grant Date;
(f) from time to time to select, subject to the limitations set forth in this Plan, those eligible Award recipients to whom Awards shall be granted;
(g) to determine the number of shares of Common Stock to be made subject to each Award;
(h) to determine whether each Option is to be an Incentive Stock Option or a Non-qualified Stock Option;
(i) to prescribe the terms and conditions of each Award, including, without limitation, the exercise price and medium of payment and vesting provisions, and to specify the provisions of the Award Agreement relating to such grant;
(j) to determine the target number of Performance Shares to be granted pursuant to a Performance Share Award, the performance measures that will be used to establish the Performance Goals, the Performance Period(s) and the number of Performance Shares earned by a Participant;
(k) to amend any outstanding Awards, including for the purpose of modifying the time or manner of vesting, or the term of any outstanding Award; provided, however, that if any such amendment impairs a Participant’s rights or increases a Participant’s obligations under his or her Award or creates or increases a Participant’s federal income tax liability with respect to an Award, such amendment shall also be subject to the Participant’s consent;
(l) to determine the duration and purpose of leaves of absences which may be granted to a Participant without constituting termination of their employment for purposes of the Plan, which periods shall be no shorter than the periods generally applicable to Employees under the Company’s employment policies;
(m) to make decisions with respect to outstanding Awards that may become necessary upon a change in corporate control or an event that triggers anti-dilution adjustments;
(n) to interpret, administer, reconcile any inconsistency in, correct any defect in and/or supply any omission in the Plan and any instrument or agreement relating to, or Award granted under, the Plan; and
(o) to exercise discretion to make any and all other determinations which it determines to be necessary or advisable for the administration of the Plan.
The Committee also may modify the purchase price or the exercise price of any outstanding Award, provided that if the modification effects a repricing, shareholder approval shall be required before the repricing is effective.
3.2 Committee Decisions Final. All decisions made by the Committee pursuant to the provisions of the Plan shall be final and binding on the Company and the Participants, unless such decisions are determined by a court having jurisdiction to be arbitrary and capricious.
3.3 Delegation. The Committee or, if no Committee has been appointed, the Board may delegate administration of the Plan to a committee or committees of one or more members of the Board, and the term “Committee” shall apply to any person or persons to whom such authority has been delegated. The Committee shall have the power to delegate to a subcommittee any of the administrative powers the Committee is authorized to exercise (and references in this Plan to the Board or the Committee shall thereafter be to the committee or subcommittee), subject, however, to such resolutions, not inconsistent with the provisions of the Plan, as may be adopted from time to time by the Board. The Board may abolish the Committee at any time and revest in the Board the administration of the Plan. The members of the Committee shall be appointed by and serve at the pleasure of the Board. From time to time, the Board may increase or decrease the size of the Committee, add additional members to, remove members (with or without cause) from, appoint new members in substitution therefor, and fill vacancies, however caused, in the Committee. The Committee shall act pursuant to a vote of the majority of its members or, in the
case of a Committee comprised of only two members, the unanimous consent of its members, whether present or not, or by the written consent of the majority of its members and minutes shall be kept of all of its meetings and copies thereof shall be provided to the Board. Subject to the limitations prescribed by the Plan and the Board, the Committee may establish and follow such rules and regulations for the conduct of its business as it may determine to be advisable.
3.4 Committee Composition. Except as otherwise determined by the Board, the Committee shall consist solely of two or more Non-Employee Directors. The Board shall have discretion to determine whether or not it intends to comply with the exemption requirements of Rule 16b-3. However, if the Board intends to satisfy such exemption requirements, with respect to any insider subject to Section 16 of the Exchange Act, the Committee shall be a compensation committee of the Board that at all times consists solely of two or more Non-Employee Directors. Within the scope of such authority, the Board or the Committee may delegate to a committee of one or more members of the Board who are not Non-Employee Directors the authority to grant Awards to eligible persons who are not then subject to Section 16 of the Exchange Act. Nothing herein shall create an inference that an Award is not validly granted under the Plan in the event Awards are granted under the Plan by a compensation committee of the Board that does not at all times consist solely of two or more Non-Employee Directors.
3.5 Indemnification. In addition to such other rights of indemnification as they may have as Directors or members of the Committee, and to the extent allowed by Applicable Laws, the Committee shall be indemnified by the Company against the reasonable expenses, including attorney’s fees, actually incurred in connection with any action, suit or proceeding or in connection with any appeal therein, to which the Committee may be party by reason of any action taken or failure to act under or in connection with the Plan or any Award granted under the Plan, and against all amounts paid by the Committee in settlement thereof (provided, however, that the settlement has been approved by the Company, which approval shall not be unreasonably withheld) or paid by the Committee in satisfaction of a judgment in any such action, suit or proceeding, except in relation to matters as to which it shall be adjudged in such action, suit or proceeding that such Committee did not act in good faith and in a manner which such person reasonably believed to be in the best interests of the Company, or in the case of a criminal proceeding, had no reason to believe that the conduct complained of was unlawful; provided, however, that within 60 days after the institution of any such action, suit or proceeding, such Committee shall, in writing, offer the Company the opportunity at its own expense to handle and defend such action, suit or proceeding.
4. Shares Subject to the Plan.
4.1 Subject to adjustment in accordance with Section 11, no more than 25,000,000 shares of Common Stock shall be available for the grant of Awards under the Plan (the “Total Share Reserve”). During the terms of the Awards, the Company shall keep available at all times the number of shares of Common Stock required to satisfy such Awards.
4.2 Shares of Common Stock available for distribution under the Plan may consist, in whole or in part, of authorized and unissued shares, treasury shares or shares reacquired by the Company in any manner.
4.3 Subject to adjustment in accordance with Section 11, no more than 25,000,000 shares of Common Stock may be issued in the aggregate pursuant to the exercise of Incentive Stock Options under the Plan (the “ISO Limit”).
4.4 Any shares of Common Stock subject to an Award that expires or is canceled, forfeited, or terminated without issuance of the full number of shares of Common Stock to which the Award related will again be available for issuance under the Plan. Notwithstanding anything to the contrary contained herein: shares subject to an Award under the Plan shall not again be made available for issuance or delivery under the Plan if such shares are (a) shares tendered in payment of an Option, (b) shares delivered or withheld by the Company to satisfy any tax withholding obligation, or (c) shares covered by a stock-settled Stock Appreciation Right or other Awards that were not issued upon the settlement of the Award.
4.5 Awards may, in the sole discretion of the Committee, be granted under the Plan in assumption of, or in substitution for, outstanding awards previously granted by an entity acquired by the Company or with which the Company combines (“Substitute Awards”). Substitute Awards shall not be counted against the Total Share Reserve; provided, that, Substitute Awards issued in connection with the assumption of, or in substitution for, outstanding options intended to qualify as Incentive Stock Options shall be counted against the ISO limit. Subject to applicable stock exchange requirements, available shares under a shareholder-approved plan of an entity directly or indirectly acquired by the Company or with which the Company combines (as appropriately adjusted to reflect such acquisition or transaction) may be used for Awards under the Plan and shall not count toward the Total Share Limit.
5. Eligibility.
5.1 Eligibility for Specific Awards. Incentive Stock Options may be granted only to Employees. Awards other than Incentive Stock Options may be granted to Employees, Consultants and Directors and those individuals whom the Committee determines are reasonably expected to become Employees, Consultants and Directors following the Grant Date.
5.2 Ten Percent Shareholders. A Ten Percent Shareholder shall not be granted an Incentive Stock Option unless the Option Exercise Price is at least 110% of the Fair Market Value of the Common Stock on the Grant Date and the Option is not exercisable after the expiration of five years from the Grant Date.
6. Option Provisions. Each Option granted under the Plan shall be evidenced by an Award Agreement. Each Option so granted shall be subject to the conditions set forth in this Section 6, and to such other conditions not inconsistent with the Plan as may be reflected in the applicable Award Agreement. All Options shall be separately designated Incentive Stock Options or Non-qualified Stock Options at the time of grant, and, if certificates are issued, a separate certificate or certificates will be issued for shares of Common Stock purchased on exercise of each type of Option. Notwithstanding the foregoing, the Company shall have no liability to any Participant or any other person if an Option designated as an Incentive Stock Option fails to qualify as such at any time or if an Option is determined to constitute “nonqualified deferred compensation” within the meaning of Section 409A of the Code and the terms of such Option do not satisfy the requirements of Section 409A of the Code. The provisions of separate Options need not be identical, but each Option shall include (through incorporation of provisions hereof by reference in the Option or otherwise) the substance of each of the following provisions:
6.1 Term. Subject to the provisions of Section 5.2 regarding Ten Percent Shareholders, no Incentive Stock Option shall be exercisable after the expiration of 10 years from the Grant Date. The term of a Non-qualified Stock Option granted under the Plan shall be determined by
the Committee; provided, however, no Non-qualified Stock Option shall be exercisable after the expiration of 10 years from the Grant Date.
6.2 Exercise Price of an Incentive Stock Option. Subject to the provisions of Section 5.2 regarding Ten Percent Shareholders, the Option Exercise Price of each Incentive Stock Option shall be not less than 100% of the Fair Market Value of the Common Stock subject to the Option on the Grant Date. Notwithstanding the foregoing, an Incentive Stock Option may be granted with an Option Exercise Price lower than that set forth in the preceding sentence if such Option is granted pursuant to an assumption or substitution for another option in a manner satisfying the provisions of Section 424(a) of the Code.
6.3 Exercise Price of a Non-qualified Stock Option. The Option Exercise Price of each Non-qualified Stock Option shall be not less than 100% of the Fair Market Value of the Common Stock subject to the Option on the Grant Date. Notwithstanding the foregoing, a Non-qualified Stock Option may be granted with an Option Exercise Price lower than that set forth in the preceding sentence if such Option is granted pursuant to an assumption or substitution for another option in a manner satisfying the provisions of Section 409A of the Code.
6.4 Consideration. The Option Exercise Price of Common Stock acquired pursuant to an Option shall be paid, to the extent permitted by applicable statutes and regulations, either (a) in cash or by certified or bank check at the time the Option is exercised or (b) in the discretion of the Committee, upon such terms as the Committee shall approve, the Option Exercise Price may be paid: (i) by delivery to the Company of other Common Stock, duly endorsed for transfer to the Company, with a Fair Market Value on the date of delivery equal to the Option Exercise Price (or portion thereof) due for the number of shares being acquired, or by means of attestation whereby the Participant identifies for delivery specific shares of Common Stock that have an aggregate Fair Market Value on the date of attestation equal to the Option Exercise Price (or portion thereof) and receives a number of shares of Common Stock equal to the difference between the number of shares thereby purchased and the number of identified attestation shares of Common Stock (a “Stock for Stock Exchange”); (ii) a “cashless” exercise program established with a broker; (iii) by reduction in the number of shares of Common Stock otherwise deliverable upon exercise of such Option with a Fair Market Value equal to the aggregate Option Exercise Price at the time of exercise; (iv) by any combination of the foregoing methods; or (v) in any other form of legal consideration that may be acceptable to the Committee. Unless otherwise specifically provided in the Option, the exercise price of Common Stock acquired pursuant to an Option that is paid by delivery (or attestation) to the Company of other Common Stock acquired, directly or indirectly from the Company, shall be paid only by shares of the Common Stock of the Company that have been held for more than six months (or such longer or shorter period of time required to avoid a charge to earnings for financial accounting purposes). Notwithstanding the foregoing, during any period for which the Common Stock is publicly traded (i.e., the Common Stock is listed on any established stock exchange or a national market system) an exercise by a Director or Officer that involves or may involve a direct or indirect extension of credit or arrangement of an extension of credit by the Company, directly or indirectly, in violation of Section 402(a) of the Sarbanes-Oxley Act of 2002 shall be prohibited with respect to any Award under this Plan.
6.5 Transferability of an Incentive Stock Option. An Incentive Stock Option shall not be transferable except by will or by the laws of descent and distribution and shall be exercisable during the lifetime of the Optionholder only by the Optionholder. Notwithstanding the foregoing,
the Optionholder may, by delivering written notice to the Company, in a form satisfactory to the Company, designate a third party who, in the event of the death of the Optionholder, shall thereafter be entitled to exercise the Option.
6.6 Transferability of a Non-qualified Stock Option. A Non-qualified Stock Option may, in the sole discretion of the Committee, be transferable to a Permitted Transferee, upon written approval by the Committee to the extent provided in the Award Agreement. If the Non-qualified Stock Option does not provide for transferability, then the Non-qualified Stock Option shall not be transferable except by will or by the laws of descent and distribution and shall be exercisable during the lifetime of the Optionholder only by the Optionholder. Notwithstanding the foregoing, the Optionholder may, by delivering written notice to the Company, in a form satisfactory to the Company, designate a third party who, in the event of the death of the Optionholder, shall thereafter be entitled to exercise the Option.
6.7 Vesting of Options. Each Option may, but need not, vest and therefore become exercisable in periodic installments that may, but need not, be equal. The Option may be subject to such other terms and conditions on the time or times when it may be exercised (which may be based on performance or other criteria) as the Committee may deem appropriate. The vesting provisions of individual Options may vary. No Option may be exercised for a fraction of a share of Common Stock. The Committee may, but shall not be required to, provide for an acceleration of vesting and exercisability in the terms of any Award Agreement upon the occurrence of a specified event.
6.8 Termination of Continuous Service. Unless otherwise provided in an Award Agreement or in an employment agreement the terms of which have been approved by the Committee, in the event an Optionholder’s Continuous Service terminates (other than upon the Optionholder’s death or Disability), the Optionholder may exercise his or her Option (to the extent that the Optionholder was entitled to exercise such Option as of the date of termination) but only within such period of time ending on the earlier of (a) the date three months following the termination of the Optionholder’s Continuous Service or (b) the expiration of the term of the Option as set forth in the Award Agreement; provided that, if the termination of Continuous Service is by the Company for Cause, all outstanding Options (whether or not vested) shall immediately terminate and cease to be exercisable. If, after termination, the Optionholder does not exercise his or her Option within the time specified in the Award Agreement, the Option shall terminate.
6.9 Extension of Termination Date. An Optionholder’s Award Agreement may also provide that if the exercise of the Option following the termination of the Optionholder’s Continuous Service for any reason would be prohibited at any time because the issuance of shares of Common Stock would violate the registration requirements under the Securities Act or any other state or federal securities law or the rules of any securities exchange or interdealer quotation system, then the Option shall terminate on the earlier of (a) the expiration of the term of the Option in accordance with Section 6.1 or (b) the expiration of a period after termination of the Participant’s Continuous Service that is three months after the end of the period during which the exercise of the Option would be in violation of such registration or other securities law requirements.
6.10 Disability of Optionholder. Unless otherwise provided in an Award Agreement, in the event that an Optionholder’s Continuous Service terminates as a result of the Optionholder’s
Disability, the Optionholder may exercise his or her Option (to the extent that the Optionholder was entitled to exercise such Option as of the date of termination), but only within such period of time ending on the earlier of (a) the date 12 months following such termination or (b) the expiration of the term of the Option as set forth in the Award Agreement. If, after termination, the Optionholder does not exercise his or her Option within the time specified herein or in the Award Agreement, the Option shall terminate.
6.11 Death of Optionholder. Unless otherwise provided in an Award Agreement, in the event an Optionholder’s Continuous Service terminates as a result of the Optionholder’s death, then the Option may be exercised (to the extent the Optionholder was entitled to exercise such Option as of the date of death) by the Optionholder’s estate, by a person who acquired the right to exercise the Option by bequest or inheritance or by a person designated to exercise the Option upon the Optionholder’s death, but only within the period ending on the earlier of (a) the date 12 months following the date of death or (b) the expiration of the term of such Option as set forth in the Award Agreement. If, after the Optionholder’s death, the Option is not exercised within the time specified herein or in the Award Agreement, the Option shall terminate.
6.12 Incentive Stock Option $100,000 Limitation. To the extent that the aggregate Fair Market Value (determined at the time of grant) of Common Stock with respect to which Incentive Stock Options are exercisable for the first time by any Optionholder during any calendar year (under all plans of the Company and its Affiliates) exceeds $100,000, the Options or portions thereof which exceed such limit (according to the order in which they were granted) shall be treated as Non-qualified Stock Options.
7. Provisions of Awards Other Than Options.
7.1 Stock Appreciation Rights.
(a) General
Each Stock Appreciation Right granted under the Plan shall be evidenced by an Award Agreement. Each Stock Appreciation Right so granted shall be subject to the conditions set forth in this Section 7.1, and to such other conditions not inconsistent with the Plan as may be reflected in the applicable Award Agreement. Stock Appreciation Rights may be granted alone (“Free Standing Rights”) or in tandem with an Option granted under the Plan (“Related Rights”).
(b) Grant Requirements
Any Related Right that relates to a Non-qualified Stock Option may be granted at the same time the Option is granted or at any time thereafter but before the exercise or expiration of the Option. Any Related Right that relates to an Incentive Stock Option must be granted at the same time the Incentive Stock Option is granted.
(c) Term of Stock Appreciation Rights
The term of a Stock Appreciation Right granted under the Plan shall be determined by the Committee; provided, however, no Stock Appreciation Right shall be exercisable later than the tenth anniversary of the Grant Date.
(d) Vesting of Stock Appreciation Rights
Each Stock Appreciation Right may, but need not, vest and therefore become exercisable in periodic installments that may, but need not, be equal. The Stock Appreciation
Right may be subject to such other terms and conditions on the time or times when it may be exercised as the Committee may deem appropriate. The vesting provisions of individual Stock Appreciation Rights may vary. No Stock Appreciation Right may be exercised for a fraction of a share of Common Stock. The Committee may, but shall not be required to, provide for an acceleration of vesting and exercisability in the terms of any Stock Appreciation Right upon the occurrence of a specified event.
(e) Exercise and Payment
Upon exercise of a Stock Appreciation Right, the holder shall be entitled to receive from the Company an amount equal to the number of shares of Common Stock subject to the Stock Appreciation Right that is being exercised multiplied by the excess of (i) the Fair Market Value of a share of Common Stock on the date the Award is exercised, over (ii) the exercise price specified in the Stock Appreciation Right or related Option. Payment with respect to the exercise of a Stock Appreciation Right shall be made on the date of exercise. Payment shall be made in the form of shares of Common Stock (with or without restrictions as to substantial risk of forfeiture and transferability, as determined by the Committee in its sole discretion), cash or a combination thereof, as determined by the Committee.
(f) Exercise Price
The exercise price of a Free Standing Right shall be determined by the Committee, but shall not be less than 100% of the Fair Market Value of one share of Common Stock on the Grant Date of such Stock Appreciation Right. A Related Right granted simultaneously with or subsequent to the grant of an Option and in conjunction therewith or in the alternative thereto shall have the same exercise price as the related Option, shall be transferable only upon the same terms and conditions as the related Option, and shall be exercisable only to the same extent as the related Option; provided, however, that a Stock Appreciation Right, by its terms, shall be exercisable only when the Fair Market Value per share of Common Stock subject to the Stock Appreciation Right and related Option exceeds the exercise price per share thereof and no Stock Appreciation Rights may be granted in tandem with an Option unless the Committee determines that the requirements of Section 7.1(b) are satisfied.
(g) Reduction in the Underlying Option Shares
Upon any exercise of a Related Right, the number of shares of Common Stock for which any related Option shall be exercisable shall be reduced by the number of shares for which the Stock Appreciation Right has been exercised. The number of shares of Common Stock for which a Related Right shall be exercisable shall be reduced upon any exercise of any related Option by the number of shares of Common Stock for which such Option has been exercised.
7.2 Restricted Awards.
(a) General
A Restricted Award is an Award of actual shares of Common Stock (“Restricted Stock”) or hypothetical Common Stock units (“Restricted Stock Units”) having a value equal to the Fair Market Value of an identical number of shares of Common Stock, which may, but need not, provide that such Restricted Award may not be sold, assigned, transferred or otherwise disposed of, pledged or hypothecated as collateral for a loan or as security for the performance of any obligation or for any other purpose for such period (the “Restricted Period”) as the Committee shall determine. Each Restricted Award granted under the Plan shall be evidenced by
an Award Agreement. Each Restricted Award so granted shall be subject to the conditions set forth in this Section 7.2, and to such other conditions not inconsistent with the Plan as may be reflected in the applicable Award Agreement.
(b) Restricted Stock and Restricted Stock Units
(i) Each Participant granted Restricted Stock shall execute and deliver to the Company an Award Agreement with respect to the Restricted Stock setting forth the restrictions and other terms and conditions applicable to such Restricted Stock. If the Committee determines that the Restricted Stock shall be held by the Company or in escrow rather than delivered to the Participant pending the release of the applicable restrictions, the Committee may require the Participant to additionally execute and deliver to the Company (A) an escrow agreement satisfactory to the Committee, if applicable and (B) the appropriate blank stock power with respect to the Restricted Stock covered by such agreement. If a Participant fails to execute an agreement evidencing an Award of Restricted Stock and, if applicable, an escrow agreement and stock power, the Award shall be null and void. Subject to the restrictions set forth in the Award, the Participant generally shall have the rights and privileges of a shareholder as to such Restricted Stock, including the right to vote such Restricted Stock and the right to receive dividends.
(ii) The terms and conditions of a grant of Restricted Stock Units shall be reflected in an Award Agreement. No shares of Common Stock shall be issued at the time a Restricted Stock Unit is granted, and the Company will not be required to set aside funds for the payment of any such Award. A Participant shall have no voting rights with respect to any Restricted Stock Units granted hereunder. The Committee may also grant Restricted Stock Units with a deferral feature, whereby settlement is deferred beyond the vesting date until the occurrence of a future payment date or event set forth in an Award Agreement (“Deferred Stock Units”).
(c) Restrictions
(i) Restricted Stock awarded to a Participant shall be subject to the following restrictions until the expiration of the Restricted Period, and to such other terms and conditions as may be set forth in the applicable Award Agreement: (A) if an escrow arrangement is used, the Participant shall not be entitled to delivery of the stock certificate; (B) the shares shall be subject to the restrictions on transferability set forth in the Award Agreement; (C) the shares shall be subject to forfeiture to the extent provided in the applicable Award Agreement; and (D) to the extent such shares are forfeited, the stock certificates shall be returned to the Company, and all rights of the Participant to such shares and as a shareholder with respect to such shares shall terminate without further obligation on the part of the Company.
(ii) Restricted Stock Units and Deferred Stock Units awarded to any Participant shall be subject to (A) forfeiture until the expiration of the Restricted Period, and satisfaction of any applicable Performance Goals during such period, to the extent provided in the applicable Award Agreement, and to the extent such Restricted Stock Units or Deferred Stock Units are forfeited, all rights of the Participant to such Restricted Stock Units or Deferred Stock Units shall terminate without further obligation on the part of the Company and (B) such other terms and conditions as may be set forth in the applicable Award Agreement.
(iii) The Committee shall have the authority to remove any or all of the restrictions on the Restricted Stock, Restricted Stock Units and Deferred Stock Units whenever it may determine that, by reason of changes in Applicable Laws or other changes in circumstances arising after the date the Restricted Stock or Restricted Stock Units or Deferred Stock Units are granted, such action is appropriate.
(d) Restricted Period
With respect to Restricted Awards, the Restricted Period shall commence on the Grant Date and end at the time or times set forth on a schedule established by the Committee in the applicable Award Agreement.
No Restricted Award may be granted or settled for a fraction of a share of Common Stock. The Committee may, but shall not be required to, provide for an acceleration of vesting in the terms of any Award Agreement upon the occurrence of a specified event.
(e) Delivery of Restricted Stock and Settlement of Restricted Stock Units
Upon the expiration of the Restricted Period with respect to any shares of Restricted Stock, the restrictions set forth in Section 7.2(c) and the applicable Award Agreement shall be of no further force or effect with respect to such shares, except as set forth in the applicable Award Agreement. If an escrow arrangement is used, upon such expiration, the Company shall deliver to the Participant, or his or her beneficiary, without charge, the stock certificate evidencing the shares of Restricted Stock which have not then been forfeited and with respect to which the Restricted Period has expired (to the nearest full share) Upon the expiration of the Restricted Period with respect to any outstanding Restricted Stock Units, or at the expiration of the deferral period with respect to any outstanding Deferred Stock Units, the Company shall deliver to the Participant, or his or her beneficiary, without charge, one share of Common Stock for each such outstanding vested Restricted Stock Unit or Deferred Stock Unit (“Vested Unit”); provided, however, that, if explicitly provided in the applicable Award Agreement, the Committee may, in its sole discretion, elect to pay cash or part cash and part Common Stock in lieu of delivering only shares of Common Stock for Vested Units. If a cash payment is made in lieu of delivering shares of Common Stock, the amount of such payment shall be equal to the Fair Market Value of the Common Stock as of the date on which the Restricted Period lapsed in the case of Restricted Stock Units, or the delivery date in the case of Deferred Stock Units, with respect to each Vested Unit.
(f) Stock Restrictions
Each certificate representing Restricted Stock awarded under the Plan shall bear a legend in such form as the Company deems appropriate.
7.3 Performance Share Awards.
(a) Grant of Performance Share Awards
Each Performance Share Award granted under the Plan shall be evidenced by an Award Agreement. Each Performance Share Award so granted shall be subject to the conditions set forth in this Section 7.3, and to such other conditions not inconsistent with the Plan as may be reflected in the applicable Award Agreement. The Committee shall have the discretion to determine: (i) the number of shares of Common Stock or stock-denominated units subject to a Performance Share Award granted to any Participant; (ii) the Performance Period applicable to
any Award; (iii) the conditions that must be satisfied for a Participant to earn an Award; and (iv) the other terms, conditions and restrictions of the Award.
(b) Earning Performance Share Awards
The number of Performance Shares earned by a Participant will depend on the extent to which the performance goals established by the Committee are attained within the applicable Performance Period, as determined by the Committee.
7.4 Other Equity-Based Awards. The Committee may grant Other Equity-Based Awards, either alone or in tandem with other Awards, in such amounts and subject to such conditions as the Committee shall determine in its sole discretion. Each Equity-Based Award shall be evidenced by an Award Agreement and shall be subject to such conditions, not inconsistent with the Plan, as may be reflected in the applicable Award Agreement.
8. Securities Law Compliance. Each Award Agreement shall provide that no shares of Common Stock shall be purchased or sold thereunder unless and until (a) any then applicable requirements of state or federal laws and regulatory agencies have been fully complied with to the satisfaction of the Company and its counsel and (b) if required to do so by the Company, the Participant has executed and delivered to the Company a letter of investment intent in such form and containing such provisions as the Committee may require. The Company shall use reasonable efforts to seek to obtain from each regulatory commission or agency having jurisdiction over the Plan such authority as may be required to grant Awards and to issue and sell shares of Common Stock upon exercise of the Awards; provided, however, that this undertaking shall not require the Company to register under the Securities Act the Plan, any Award or any Common Stock issued or issuable pursuant to any such Award. If, after reasonable efforts, the Company is unable to obtain from any such regulatory commission or agency the authority which counsel for the Company deems necessary for the lawful issuance and sale of Common Stock under the Plan, the Company shall be relieved from any liability for failure to issue and sell Common Stock upon exercise of such Awards unless and until such authority is obtained.
9. Use of Proceeds from Stock. Proceeds from the sale of Common Stock pursuant to Awards, or upon exercise thereof, shall constitute general funds of the Company.
10. Miscellaneous.
10.1 Acceleration of Exercisability and Vesting. The Committee shall have the power to accelerate the time at which an Award may first be exercised or the time during which an Award or any part thereof will vest in accordance with the Plan, notwithstanding the provisions in the Award stating the time at which it may first be exercised or the time during which it will vest.
10.2 Shareholder Rights. Except as provided in the Plan or an Award Agreement, no Participant shall be deemed to be the holder of, or to have any of the rights of a holder with respect to, any shares of Common Stock subject to such Award unless and until such Participant has satisfied all requirements for exercise of the Award pursuant to its terms and no adjustment shall be made for dividends (ordinary or extraordinary, whether in cash, securities or other property) or distributions of other rights for which the record date is prior to the date such Common Stock certificate is issued, except as provided in Section 11 hereof.
10.3 No Employment or Other Service Rights. Nothing in the Plan or any instrument executed or Award granted pursuant thereto shall confer upon any Participant any right to
continue to serve the Company or an Affiliate in the capacity in effect at the time the Award was granted or shall affect the right of the Company or an Affiliate to terminate (a) the employment of an Employee with or without notice and with or without Cause or (b) the service of a Director pursuant to the By-laws of the Company or an Affiliate, and any applicable provisions of the corporate law of the state in which the Company or the Affiliate is incorporated, as the case may be.
10.4 Transfer; Approved Leave of Absence. For purposes of the Plan, no termination of employment by an Employee shall be deemed to result from either (a) a transfer of employment to the Company from an Affiliate or from the Company to an Affiliate, or from one Affiliate to another, or (b) an approved leave of absence for military service or sickness, or for any other purpose approved by the Company, if the Employee’s right to reemployment is guaranteed either by a statute or by contract or under the policy pursuant to which the leave of absence was granted or if the Committee otherwise so provides in writing, in either case, except to the extent inconsistent with Section 409A of the Code if the applicable Award is subject thereto.
10.5 Withholding Obligations. To the extent provided by the terms of an Award Agreement and subject to the discretion of the Committee, the Participant may satisfy any federal, state or local tax withholding obligation relating to the exercise or acquisition of Common Stock under an Award by any of the following means (in addition to the Company’s right to withhold from any compensation paid to the Participant by the Company) or by a combination of such means: (a) tendering a cash payment; (b) authorizing the Company to withhold shares of Common Stock from the shares of Common Stock otherwise issuable to the Participant as a result of the exercise or acquisition of Common Stock under the Award, provided, however, that no shares of Common Stock are withheld with a value exceeding the maximum amount of tax required to be withheld by law; or (c) delivering to the Company previously owned and unencumbered shares of Common Stock of the Company.
11. Adjustments Upon Changes in Stock. In the event of changes in the outstanding Common Stock or in the capital structure of the Company by reason of any stock or extraordinary cash dividend, stock split, reverse stock split, an extraordinary corporate transaction such as any recapitalization, reorganization, merger, consolidation, combination, exchange, or other relevant change in capitalization occurring after the Grant Date of any Award, Awards granted under the Plan and any Award Agreements, the exercise price of Options and Stock Appreciation Rights, the Performance Goals to which Performance Share Awards are subject, the maximum number of shares of Common Stock subject to all Awards stated in Section 4 will be equitably adjusted or substituted, as to the number, price or kind of a share of Common Stock or other consideration subject to such Awards to the extent necessary to preserve the economic intent of such Award. In the case of adjustments made pursuant to this Section 11, unless the Committee specifically determines that such adjustment is in the best interests of the Company or its Affiliates, the Committee shall, in the case of Incentive Stock Options, ensure that any adjustments under this Section 11 will not constitute a modification, extension or renewal of the Incentive Stock Options within the meaning of Section 424(h)(3) of the Code and in the case of Non-qualified Stock Options, ensure that any adjustments under this Section 11 will not constitute a modification of such Non-qualified Stock Options within the meaning of Section 409A of the Code. Any adjustments made under this Section 11 shall be made in a manner which does not adversely affect the exemption provided pursuant to Rule 16b-3
under the Exchange Act. The Company shall give each Participant notice of an adjustment hereunder and, upon notice, such adjustment shall be conclusive and binding for all purposes.
12. Effect of Change in Control.
12.1 Unless otherwise provided in an Award Agreement, notwithstanding any provision of the Plan to the contrary:
(a) In the event of a Change in Control, all outstanding Options and Stock Appreciation Rights shall become immediately exercisable with respect to 100% of the shares subject to such Options or Stock Appreciation Rights, and/or the Restricted Period shall expire immediately with respect to 100% of the outstanding shares of Restricted Stock or Restricted Stock Units.
(b) With respect to Performance Share Awards, in the event of a Change in Control, all incomplete Performance Periods in respect of such Awards in effect on the date the Change in Control occurs shall end on the date of such change and the Committee shall (i) determine the extent to which Performance Goals with respect to each such Performance Period have been met based upon such audited or unaudited financial information then available as it deems relevant and (ii) cause to be paid to the applicable Participant partial or full Awards with respect to Performance Goals for each such Performance Period based upon the Committee’s determination of the degree of attainment of Performance Goals or, if not determinable, assuming that the applicable “target” levels of performance have been attained, or on such other basis determined by the Committee.
To the extent practicable, any actions taken by the Committee under the immediately preceding clauses (a) and (b) shall occur in a manner and at a time which allows affected Participants the ability to participate in the Change in Control with respect to the shares of Common Stock subject to their Awards.
12.2 In addition, in the event of a Change in Control, the Committee may in its discretion and upon at least 10 days’ advance notice to the affected persons, cancel any outstanding Awards and pay to the holders thereof, in cash or stock, or any combination thereof, the value of such Awards based upon the price per share of Common Stock received or to be received by other shareholders of the Company in the event. In the case of any Option or Stock Appreciation Right with an exercise price (or SAR Exercise Price in the case of a Stock Appreciation Right) that equals or exceeds the price paid for a share of Common Stock in connection with the Change in Control, the Committee may cancel the Option or Stock Appreciation Right without the payment of consideration therefor.
12.3 The obligations of the Company under the Plan shall be binding upon any successor corporation or organization resulting from the merger, consolidation or other reorganization of the Company, or upon any successor corporation or organization succeeding to all or substantially all of the assets and business of the Company and its Affiliates, taken as a whole.
13. Amendment of the Plan and Awards.
13.1 Amendment of Plan. The Board at any time, and from time to time, may amend or terminate the Plan. However, except as provided in Section 11 relating to adjustments upon changes in Common Stock and Section 13.3, no amendment shall be effective unless approved by the shareholders of the Company to the extent shareholder approval is necessary to satisfy any
Applicable Laws. At the time of such amendment, the Board shall determine, upon advice from counsel, whether such amendment will be contingent on shareholder approval.
13.2 Shareholder Approval. The Board may, in its sole discretion, submit any other amendment to the Plan for shareholder approval.
13.3 Contemplated Amendments. It is expressly contemplated that the Board may amend the Plan in any respect the Board deems necessary or advisable to provide eligible Employees, Consultants and Directors with the maximum benefits provided or to be provided under the provisions of the Code and the regulations promulgated thereunder relating to Incentive Stock Options or to the nonqualified deferred compensation provisions of Section 409A of the Code and/or to bring the Plan and/or Awards granted under it into compliance therewith.
13.4 No Impairment of Rights. Rights under any Award granted before amendment of the Plan shall not be impaired by any amendment of the Plan unless (a) the Company requests the consent of the Participant and (b) the Participant consents in writing.
13.5 Amendment of Awards. The Committee at any time, and from time to time, may amend the terms of any one or more Awards; provided, however, that the Committee may not affect any amendment which would otherwise constitute an impairment of the rights under any Award unless (a) the Company requests the consent of the Participant and (b) the Participant consents in writing.
14. General Provisions.
14.1 Forfeiture Events. The Committee may specify in an Award Agreement that the Participant’s rights, payments and benefits with respect to an Award shall be subject to reduction, cancellation, forfeiture or recoupment upon the occurrence of certain events, in addition to applicable vesting conditions of an Award. Such events may include, without limitation, breach of non-competition, non-solicitation, confidentiality, or other restrictive covenants that are contained in the Award Agreement or otherwise applicable to the Participant, a termination of the Participant’s Continuous Service for Cause, or other conduct by the Participant that is detrimental to the business or reputation of the Company and/or its Affiliates.
14.2 Clawback. Notwithstanding any other provisions in this Plan, the Company may cancel any Award, require reimbursement of any Award by a Participant, and effect any other right of recoupment of equity or other compensation provided under the Plan in accordance with any Company policies that may be adopted and/or modified from time to time (“Clawback Policy”). In addition, a Participant may be required to repay to the Company previously paid compensation, whether provided pursuant to the Plan or an Award Agreement, in accordance with the Clawback Policy. By accepting an Award, the Participant is agreeing to be bound by the Clawback Policy, as in effect or as may be adopted and/or modified from time to time by the Company in its discretion (including, without limitation, to comply with applicable law or stock exchange listing requirements).
14.3 Other Compensation Arrangements. Nothing contained in this Plan shall prevent the Board from adopting other or additional compensation arrangements, subject to shareholder approval if such approval is required; and such arrangements may be either generally applicable or applicable only in specific cases.
14.4 Unfunded Plan. The Plan shall be unfunded. Neither the Company, the Board nor the Committee shall be required to establish any special or separate fund or to segregate any assets to assure the performance of its obligations under the Plan.
14.5 Delivery. Upon exercise of a right granted under this Plan, the Company shall issue Common Stock or pay any amounts due within a reasonable period of time thereafter. Subject to any statutory or regulatory obligations the Company may otherwise have, for purposes of this Plan, 30 days shall be considered a reasonable period of time.
14.6 No Fractional Shares. No fractional shares of Common Stock shall be issued or delivered pursuant to the Plan. The Committee shall determine whether cash, additional Awards or other securities or property shall be issued or paid in lieu of fractional shares of Common Stock or whether any fractional shares should be rounded, forfeited or otherwise eliminated.
14.7 Other Provisions. The Award Agreements authorized under the Plan may contain such other provisions not inconsistent with this Plan, including, without limitation, restrictions upon the exercise of Awards, as the Committee may deem advisable.
14.8 Section 409A. The Plan is intended to comply with Section 409A of the Code to the extent subject thereto, and, accordingly, to the maximum extent permitted, the Plan shall be interpreted and administered to be in compliance therewith. Any payments described in the Plan that are due within the “short-term deferral period” as defined in Section 409A of the Code shall not be treated as deferred compensation unless Applicable Laws require otherwise. Notwithstanding anything to the contrary in the Plan, to the extent required to avoid accelerated taxation and tax penalties under Section 409A of the Code, amounts that would otherwise be payable and benefits that would otherwise be provided pursuant to the Plan during the six (6) month period immediately following the Participant’s termination of Continuous Service shall instead be paid on the first payroll date after the six-month anniversary of the Participant’s separation from service (or the Participant’s death, if earlier). Notwithstanding the foregoing, neither the Company nor the Committee shall have any obligation to take any action to prevent the assessment of any additional tax or penalty on any Participant under Section 409A of the Code and neither the Company nor the Committee will have any liability to any Participant for such tax or penalty.
14.9 Disqualifying Dispositions. Any Participant who shall make a “disposition” (as defined in Section 424 of the Code) of all or any portion of shares of Common Stock acquired upon exercise of an Incentive Stock Option within two years from the Grant Date of such Incentive Stock Option or within one year after the issuance of the shares of Common Stock acquired upon exercise of such Incentive Stock Option (a “Disqualifying Disposition”) shall be required to immediately advise the Company in writing as to the occurrence of the sale and the price realized upon the sale of such shares of Common Stock.
14.10 Section 16. It is the intent of the Company that the Plan satisfy, and be interpreted in a manner that satisfies, the applicable requirements of Rule 16b-3 as promulgated under Section 16 of the Exchange Act so that Participants will be entitled to the benefit of Rule 16b-3, or any other rule promulgated under Section 16 of the Exchange Act, and will not be subject to short-swing liability under Section 16 of the Exchange Act. Accordingly, if the operation of any provision of the Plan would conflict with the intent expressed in this Section 14.10, such provision to the extent possible shall be interpreted and/or deemed amended so as to avoid such conflict.
14.11 Beneficiary Designation. Each Participant under the Plan may from time to time name any beneficiary or beneficiaries by whom any right under the Plan is to be exercised in case of such Participant’s death. Each designation will revoke all prior designations by the same Participant, shall be in a form reasonably prescribed by the Committee and shall be effective only when filed by the Participant in writing with the Company during the Participant’s lifetime.
14.12 Expenses. The costs of administering the Plan shall be paid by the Company.
14.13 Severability. If any of the provisions of the Plan or any Award Agreement is held to be invalid, illegal or unenforceable, whether in whole or in part, such provision shall be deemed modified to the extent, but only to the extent, of such invalidity, illegality or unenforceability and the remaining provisions shall not be affected thereby.
14.14 Plan Headings. The headings in the Plan are for purposes of convenience only and are not intended to define or limit the construction of the provisions hereof.
14.15 Non-Uniform Treatment. The Committee’s determinations under the Plan need not be uniform and may be made by it selectively among persons who are eligible to receive, or actually receive, Awards. Without limiting the generality of the foregoing, the Committee shall be entitled to make non-uniform and selective determinations, amendments and adjustments, and to enter into non-uniform and selective Award Agreements.
15. Effective Date of Plan. The Plan shall become effective as of the Effective Date
16. Termination or Suspension of the Plan. The Plan shall terminate automatically on December 20, 2029. No Award shall be granted pursuant to the Plan after such date, but Awards theretofore granted may extend beyond that date. The Board may suspend or terminate the Plan at any earlier date pursuant to Section 13.1 hereof. No Awards may be granted under the Plan while the Plan is suspended or after it is terminated.
17. Choice of Law. The law of the State of Ohio shall govern all questions concerning the construction, validity and interpretation of this Plan, without regard to such state’s conflict of law rules.
As adopted by the Board of Directors of Innovest Global, Inc. on December 20, 2019.
As approved by the shareholders of Innovest Global, Inc. on December 20, 2019.
Exhibit 10.5
EXCLUSIVE LICENSE AGREEMENT
THIS EXCLUSIVE LICENSE AGREEMENT ("Agreement") is entered into as of this 23rd day of July 2018 ("Effective Date") by and between CEDARS SINAI MEDICAL CENTER, a California nonprofit public benefit corporation ("CSMC"), with offices at 8700 Beverly Boulevard, Los Angeles, California 90048-1865, and STEMVAX LLC, a California limited liability company ("Licensee"), with offices at 2265 East Foothill Blvd Pasadena, California 91107.
RECITALS
A. CSMC owns and/or is entitled to grant license rights with respect to certain Patent Rights (as defined below) invented or developed in the course of certain research at CSMC conducted under the direction of Ors. Keith Black, Dwain Morris-Irvin and Moshe Arditi (hereinafter collectively referred to as the "Inventors").
B. CSMC desires to have the Patent Rights developed, used and commercialized in the Field of Use (as defined below) by Licensee, and Licensee desires to obtain an exclusive, worldwide license to conduct research in the Field of Use, and to develop, manufacture, use and sell Products (as defined below) in the Field of Use, using the Patent Rights in accordance with the terms of this Agreement. Other than the rights expressly granted by CSMC hereunder within the Field of Use, Licensee acknowledges that CSMC shall retain all other rights with respect to the Patent Rights.
C. CSMC and Licensee intend that the execution, delivery and performance of this Agreement by each party, and the consummation of the transactions contemplated hereunder, shall not at any time threaten CSMC's tax-exempt status under Section 50l(c)(3) of the Internal Revenue Code and Section 2370 ld of the California Revenue and Taxation Code, or cause CSMC to be in default under any of CSMC' s issued and outstanding tax-exempt bonds.
Now, THEREFORE, in consideration of the mutual covenants and premises herein contained, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto hereby agree as follows:
|
1. |
DEFINITIONS |
1.1 "Affiliate" or "Affiliates" shall mean any corporation, person or entity, which controls, is controlled by, or is under common control with, a party to this Agreement without regard to stock or other equity ownership. For purposes hereof, the terms "control" "controls" mean the possession, direct or indirect, of the power to direct or cause the direction of the management and policies of a corporation, person or entity, whether through the ownership of voting securities, by contract or otherwise.
1.2 "Confidential Information" shall mean any confidential or proprietary information furnished by one party (the "Disclosing Party") to the other party (the "Receiving Party") in connection with this Agreement, including, without limitation, all specifications, know-how, trade secrets, technical information, drawings, software, models, business
information and patent applications pertaining to the Patent Rights, and as further provided in Section 10 hereof.
1.3 "FDA" shall mean the United States Food and Drug Administration, or any successor agency thereof.
1.4 "Field of Use" shall mean the therapeutic treatment thereof in patients suffering from cancer, including glioblastoma.
1.5 "Funding Agencies" shall mean any public or private granting agencies which have provided funding to CSMC or to any of the Inventors for the development of any of the Patent Rights prior to the Effective Date.
1.6 "Improvements" shall mean all improvements or enhancements to the Patent Rights that, after the Effective Date, are conceived and reduced to practice if patentable, or reduced to practice if not patentable, by at least one Inventor.
1.7 "Licensee Developments" shall mean any and all processes, uses, designs, applications, methods and compositions-of-matter, indications, improvements, enhancements and modifications in the Field of Use directly based upon or directly created using the Patent Rights and which were discovered or developed by or on behalf of Licensee (exclusive of work performed by CSMC or the Inventors) during the term of this Agreement.
1.8 "Net Sales" shall mean the gross amount invoiced by Licensee, its Affiliates, Permitted Sublicensees, affiliates of Permitted Sublicensees, or any of them, to third parties for all sales of Products less (a) discounts actually allowed; (b) credits for claims, allowances, retroactive price reductions or returned goods; (c) prepaid freight; and (d) sales taxes or other governmental charges actually paid in connection with sales of Products (but excluding what are commonly known as income taxes and value-added taxes). Sales of Products by Licensee, or a Permitted Sublicensee of Licensee, to any Affiliate or Permitted Sublicensee which is a reseller thereof shall be excluded, and only the subsequent sale of such Products by Affiliates or Permitted Sublicensees of Licensee to unrelated parties shall be deemed Net Sales hereunder. If a Product is sold or provided as part of a system, package, or combination product or service that involve one or more products or services not covered by the definition of Product (each, a "Combination Product"), Net Sales shall be calculated by multiplying the Net Sales of such Combination Product, by the fraction A/B, where "A" is the price of the Product included in such Combination Product when sold separately from any other products or services not covered by the definition of Product and "B" is the price of the Combination Product. In the event that no market price is available for the Product included in such Combination Product when supplied or priced separately, CSMC and Licensee shall determine in good faith the fair market value thereof.
1.9 "Non-Royalty Sublicense Revenues" shall mean, but is not limited to, upfront fees, license maintenance fees, and milestone payments, or other payments, including the fair market value of any non-cash consideration, received by Licensee in consideration for any rights granted to Patent Rights under a sublicense agreement, and excludes any and all sales-based royalties paid to Licensee.
1.10 "Patent Rights" shall mean the patents and/or patent applications existing on the Effective Date which are described on Schedule A attached hereto, and all patents and/or patent applications (including provisional patent applications) existing as of the Effective Date in any other country corresponding to any of the foregoing, and all divisions, continuation s, reissues, reexaminations, supplementary protection certificates and extensions thereof, whether domestic or foreign, all claims of continuations-in-part that are entitled to the benefit of the priority date of any of the foregoing, and any patent that issues thereon. The Patent Rights are all owned by CSMC.
1.11 "Product" or "Products" shall mean any products and/or services in the Field of Use that, except for the license granted hereunder, would infringe a Valid Claim.
1.12 "Territory" shall mean worldwide.
1.13 "Valid Claim" shall mean a claim of an issued patent included within the Patent Rights, which claim has not (a) lapsed, been canceled or become abandoned, (b) been declared invalid or unenforceable by a non-appealable decision or judgment of a court or other appropriate body or authority of competent jurisdiction, or (c) been admitted to be invalid or unenforceable through reissue, disclaimer or otherwise. The term Valid Claim shall also include the claims of a pending patent application within the Patent Rights for a period of ten ( l0) years from the actual filing date of that patent application.
|
2. |
LICENSE |
2.1 Grant of Exclusive Rights . Subject to the terms of this Agreement, CSMC hereby grants to Licensee, and Licensee hereby accepts from CSMC, the exclusive license, with the right to grant sublicenses (subject to the terms of Section 2.2 hereof), under and to the Patent Rights during the term of this Agreement (as provided in Section 6 hereof) to conduct research in the Field of Use and to make, have made, use, import , offer for sale, sell and/or have sold Products in the Field of Use in the Territory. The foregoing grant of exclusivity is made expressly subject to the following:
(a) All applicable laws and regulations, including, without limitation, the requirements of federal law as pertains to the manufacture of products within the United States;
(b) All applicable rules of the Funding Agencies which have provided funding to CSMC or to any of its employees (including any of the Inventors) for the development of the Patent Rights; and
(c) The following non-exclusive rights to the Patent Rights, which are retained by CSMC within the Field of Use:
(i) the right to submit for publication the scientific findings from research conducted by or through CSMC or its investigators (including the Inventors) related to the Patent Rights ; and
(ii) the right (A) to use any tangible or intangible information contained m the Patent Rights or any Improvements (so long as CSMC shall treat such
information as Confidential Information and maintain its confidentiality in accordance with Sect ion 10 hereof), for CSMC's non-commercial research, internal teaching and other educationally-related and non-commercial (except for charges to its own patients) clinical purposes, where clinical use does not involve a third party funding grant to commercialize such information, and (B) to obtain research funding for further study and development thereof from governmental and other nonprofit organizations (including grant applications).
(d) Notwithstanding any other provision hereof to the contrary, all rights to the Patent Rights and Improvements outside of the Field of Use are retained by CSMC. Furthermore, this Agreement confers no license or rights by implication, estoppel, or otherwise under any patent applications or patents of CSMC other than Patent Rights regardless of whether such patents are dominant or subordinate to Patent Rights.
2.2 Sublicensing. Licensee shall have the right to grant sublicenses or to assign any or all of the rights granted hereunder only to an entity which has been approved in writing by CSMC (each, "Permitted Sublicensee"), which approval shall not be unreasonably withheld or delayed. Any such Permitted Sublicensee shall be subject in all respects to the provisions contained in this Agreement and Licensee will remain primarily liable to CSMC for, and shall be responsible for monitoring and enforcing, performance of all of Licensee' s ob ligations hereunder by any such Permitted Sublicensee. Without limiting the generality of the foregoing, as an express condition of any such sublicense, any such Pe1mitted Sublicensee shall be required to agree in writing to be bound by commercially reasonable reporting and record keeping, indemnification and inspection provisions, and the applicable provisions of this Agreement, including, without limitation, those pertaining to the use of CSMC's name and marks, indemnification of CSMC and the use of CSMC's Confidential Information. Permitted Sublicensees may not further sublicense without CSMC's prior written consent, which consent shall not be unreasonably withheld or delayed. Licensee shall promptly forward to CSMC a copy of any and all fully executed sublicense agreements, any subsequent amendments , and all copies of Permitted Sublicensees ' profit sharing or royalty reports, in no event more than thirty days (30) following execution or receipt thereof, as applicable. Licensee shall also keep CSMC reasonably informed with respect to the progress of any relations entered into with any Pe1mitted Sublicensees. If Licensee shall conduct one or more audits of its Permitted Sublicensees hereunder during the term hereof, Licensee shall provide copies of all audit reports to CSMC on a timely basis. The covenants pertaining to the use of CSMC's name and marks, the indemnification of CSMC and the use of CSMC's Confidential Information in any sublicense or assignment shall run for the benefit of CSMC, who shall be expressly stated as being a third- party beneficiary thereof with respect to the covenants set forth in this Agreement. Licensee understands and agrees that none of its permitted sublicenses hereunder shall reduce in any manner any of its obligations set forth in this Agreement.
(a) Royalty-Free Sublicenses. If, and only if, Licensee pays all royalties due CSMC from a Permitted Sublicensee's Net Sales, Licensee may grant that Permitted Sublicensee a royalty-free or non-cash sublicense or cross-license.
2.3 Improvements. Subject to the rights and applicable rules of the Funding Agencies, Licensee shall have, for a period of sixty (60) days after receipt by Licensee of written notice from CSMC disclosing an Improvement, the exclusive first right to negotiate with CSMC
to obtain one or more licenses to the Improvement in the Field of Use upon such terms and conditions as shall be agreed by the parties hereto, which terms and conditions shall include provisions for fair market value consideration for the grant of any such licenses. If Licensee declines or fails to pursue, or if the parties fail to conclude negotiations for a license to, such Improvement in the Field of Use during the sixty (60) day period specified above, then CSMC shall have the right to commence discuss ions with any other party concerning such Improvement. Subject to the provisions of this Section 2.3, Licensee acknowledges and agrees that CSMC expressly retains and reserves any and all right, title and interest in and to the Improvement, whether or not in the Field of Use and, accordingly, no license to any Improvement is granted to Licensee under this Agreement.
2.4 Licensee Developments. Licensee hereby grants, and shall require its Permitted Sublicensee(s) to grant to CSMC a nonexclusive, royalty-free, irrevocable, paid-up license, with the right to grant sublicenses to non-profit research institutions and governmental agencies, to practice and use Licensee Developments for non-commercial research purposes, which license shall include, without limitation, the rights to: (a) subject to the publication obligations in Section 5.5, publish the scientific findings from research conducted by or through CSMC or on its behalf, use any tangible or intangible information contained in the Licensee Developments (so long as CSMC shall treat such information as Confidential Information and maintain its confidentiality in accordance with Section 10 hereof), for CSMC's internal teaching and other educationally-related and non-commercial (except for charges to its own patients) clinical purposes, where clinical use does not involve a third party funding grant to commercialize such information, and (c) obtain research funding from governmental and other nonprofit organizations (including grant applications).
2.5 Diligent Commercialization. Licensee acknowledges that it is important to CSMC, and a requirement of the United States Government under Title 35, Section 203 of the United States Code, that Licensee pursue the development, commercialization and marketing of Products and otherwise exercise commercially reasonable efforts to maximize the value of this Agreement to CSMC. Without limiting the foregoing, Licensee shall maintain a bona fide, funded, ongoing and active research, development, manufacturing, regulatory, marketing or sales program (all as commercially reasonable ) to make Products commercially available to the public as soon as commercially practicable in the Territory. Should CSMC determine that Licensee fails to use commercially reasonable efforts to maximize the Patent Rights in any national political jurisdiction in the Territory at any time following the two (2) year anniversary of the Effective Date of this Agreement, CSMC shall provide Licensee with notice of such determination and give Licensee a period of ninety (90) days to provide written evidence reasonably satisfactory to CSMC that Licensee or its Permitted Sublicensee(s) has sales of Products in such jurisdiction in question or an effective, ongoing and active research, development, manufacturing, marketing or sales program, as appropriate, directed toward obtaining regulatory approval, and/or production and/or sales of Products in such jurisdiction in accordance with Licensee's business, legal, medical and scientific judgment and Licensee's normal practices and procedures for products having similar technical and commercial potential. Should Licensee fail to provide such written evidence reasonably satisfactory to CSMC within such ninety (90) day period, CSMC shall have the right, at CSMC’s sole and absolute discretion, to either: (i) terminate this Agreement with respect to the applicable national political jurisdiction within the Territory or (ii) require
Licensee to negotiate in good faith a sublicense with a Permitted Sublicensee(s) in the applicable national jurisdiction to maximize the Patent Rights in such jurisdiction.
2.6 Milestones. As part of Licensee's diligent commercialization efforts under Section 2.5, CSMC and Licensee have agreed on the Milestones set forth on Schedule B, with each such Milestone being deemed a separate and independent condition. Within sixty (60) days after each anniversary of the Effective Date, Licensee shall prepare and deliver to CSMC an annual written repo rt (to be certified by an executive officer of Licensee) indicating its compliance with the Milestones. If Licensee believes that it is or will be unable to achieve such Milestones despite its diligent efforts, Licensee may request amendments or reasonable extensions to Schedule B in writing for CSMC's consideration. Licensee agrees to provide an y additional information reasonably required by CSMC to evaluate Licensee's performance under this Agreement. If Licensee fails to meet any annual Milestone designated in Schedule B hereto, and has not obtained an extension or amendment to such Milestone(s), CSMC may, at its option and as its sole remedy for Licensee's breach of this Section 2.6, upon written notice to Licensee, convert the exclusive license granted under Section 2.1 hereof to a non-exclusive license or to a co-exclusive license, or terminate the license.
2.7 Preference for United States Industry. To the extent that the Patent Rights have been developed using funding from the United States Government, Licensee agrees that any Products made , used or sold in the United States shall be manufactured substantially in the United States.
|
3. |
REPRESENTATIONS AND WARRANTIES |
3.1 Rights to Technology. Except for the rights, if any, of the Funding Agencies or the United States Government, CSMC represents and warrants to Licensee that, to the best of its actual, current knowledge (without investigation outside of CSMC as to such representations and warranties) (a) it has the right to grant the licenses in this Agreement, (b) it has not granted licenses to the Patent Rights to any other party that would restrict the rights granted hereunder except as stated herein and (c) there are no claims, judgments or settlements to be paid by CSMC with respect the Patent Rights or pending claims or litigation relating to the Patent Rights. Except for any potential or actual rights of Funding Agencies or the United States Government, CSMC is not aware that any additional rights or licenses are necessary for Licensee to exercise its licensed rights granted by CSMC under this Agreement.
|
3.2 |
Limited Warranty; Certain Damages. |
(a) Limited Warranty. CSMC makes no representation or warranty other than those expressly specified in this Agreement. Licensee accepts the Patent Rights on an "AS- IS" basis. CSMC MAKES NO OTHER WARRANTIES CONCERNING PATENT RIGHTS COVERED BY THIS AGREEMENT, INCLUDING WITHOUT LIMITATION, ANY EXPRESS OR IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE AS TO PATENT RIGHTS OR ANY PRODUCT. CSMC MAKES NO WARRANTY OR REPRESENTATION AS TO THE VALIDITY OR SCOPE OF PATENT RIGHTS, OR THAT ANY PRODUCT WILL BE FREE FROM AN INFRINGEMENT ON PATENTS OR OTHER INTELLECTUAL PROPERTY RIGHTS OF
THIRD PARTIES, OR THAT NO THIRD PARTIES ARE IN ANY WAY INFRINGING PATENT RIGHTS COVERED BY THIS AGREEMENT. LICENSEE HEREBY AGREES THAT LICENSEE WILL NOT GIVE, AND SHALL NOT PERMIT ANY AFFILIATES OR SUBLICENSEES OR AFFILIATES THEREOF TO GIVE, ANY SUCH WARRANTY OR REPRESENTATION TO THIRD PARTIES ON BEHALF OF CSMC.
(b) Certain Damages. EXCEPT FOR THE BJ.IBACH OF THE CONFIDENTIALITY PROVISIONS IN SECTION 10 OR IN ACCORDANCE WITH THE OBLIGATION TO INDEMNIFY SET FORTH IN SECTION 8, IN NO EVENT SHALL CSMC BE LIABLE FOR ANY INDIRECT, SPECIAL OR CONSEQUENTIAL DAMAGES (INCLUDING, WITHOUT LIMITATION, DAMAGES FOR LOSS OF PROFITS OR EXPECTED SAVINGS OR OTHER ECONOMIC LOSSES, OR FOR INJURY TO PERSONS OR PROPERTY) ARISING OUT OF OR IN CONNECTION WITH THIS AGREEMENT OR ITS SUBJECT MATTER, REGARDLESS OF WHETHER CSMC KNOWS OR SHOULD KNOW OF THE POSSIBILITY OF SUCH DAMAGES. EXCEPT FOR THE BREACH OF THE CONFIDENTIALITY PROVISIONS IN SECTION 10 OR IN ACCORDANCE WITH THE OBLIGATION TO INDEMNIFY SET FORTH IN SECTION 8, CSMC' S AGGREGATE LIABILITY FOR ALL DAMAGES OF ANY KIND RELATING TO THIS AGREEMENT OR ITS SUBJECT MATTER SHALL NOT EXCEED THE AMOUNT PAID BY LICENSEE TO CSMC UNDER THIS AGREEMENT. THE FOREGOING EXCLUSIONS AND LIMITATIONS SHALL APPLY TO ALL CLAIMS AND ACTIONS OF ANY KIND, WHETHER BASED ON CONTRACT, TORT (INCLUDING, BUT NOT LIMITED TO NEGLIGENCE), OR ANY OTHER GROUNDS.
3.3 Rights Retained by Funding Agencies. Licensee acknowledges that to the extent that the Patent Rights have been developed in part under one or more funding agreements (" Fund in g Agreements") with one or more Funding Agencies, such Funding Agencies have certain statutory, non-exclusive rights relative thereto for use for government purposes as well as regulatory or statutory "march-in rights" (collectively, "Statutory Rights" ). Licensee also acknowledges that to the extent that the Improvements may be developed in part under one or more Funding Agreements with one or more Funding Agencies, such Funding Agencies may have certain Statutory Rights relative thereto. This Agreement is explicitly made subject to such Statutory Rights and, to the extent of any conflict between any such Statutory Rights and this Agreement, such Statutory Rights shall prevail.
|
4. |
CONSIDERATION |
In consideration of the execution and delivery by CSMC of this Agreement, Licensee agrees as follows:
4.1 License Fee. Within thirty (30) days of the execution of this Agreement, Licensee shall pay to CSMC a non-refundable license fee in an amount equivalent to five thousand dollars ($5,000.00).
4.2 Reimbursement of Patent Prosecution Costs. Licensee shall reimburse CSMC for all of the costs, including attorneys' fees, actually incurred by CSMC in the prosecution of the Patent Rights through the date on which CSMC transfers responsibility for prosecution of the
Patent Rights to Licensee (" Prosecution Costs "), which as of the Effective Date total to $59,644.07. The Prosecution Costs shall be payable in three (3) installment payments in accordance with the following schedule: (i) $9,241.87 shall be due within thirty (30) days of the Effective Date; (ii) ten thousand dollars ($10,000) shall be due within six (6) months of the Effective Date and (iii) the remaining balance of the Prosecution Costs shall be due when Licensee has raised $250,000.00 in cumulative funding. Commencing on the Effective Date and continuing until the Prosecution Costs are paid in full, interest shall accrue and be payable on all outstanding amounts due at the rate, per annum, of two percent (2%) over the rate of interest announced by Bank of America in Los Angeles, California (or any successor in interest thereto or any commercially equivalent financial institution if no such successor exists) to be its "prime rate". Licensee shall have the right to pay the outstanding Prosecution Costs in full in an accelerated manner at any time without penalty; provided, that interest shall accrue on any outstanding amounts until such time as all outstanding amounts are paid in full. In the event of any termination of this Agreement by Licensee in accordance with the terms and conditions of this Agreement, Licensee shall promptly pay to CSMC all of its outstanding payment obligations under this Agreement, including without limitation, the full reimbursement of patent expenses, upon the date of termination.
|
4.3 |
Royalties and Non-Royalty Revenue. |
(a) Running Royalties for Products. Licensee agrees to pay and shall pay to CSMC a non-refundable running royalty (each, a " Royalty" ) in the amount of two percent (2%) on Net Sales of Products made, used, sold or otherwise distributed by Licensee or any Permitted Sublicensee hereunder ("Product Royalty Rate").
(b) Minimum Royalties. Beginning on the third (3rd anniversary of the Effective Date, Licensee shall pay to CSMC annual minimum royalty payments ("Minimum Royalties") in the amount of five thousand dollars ($5,000.00) per year. Each annual Minimum Royalty paid by Licensee hereunder shall be credited against Royalties payable under Section 4.3(a) during the calendar year in which the Minimum Royalty is due; provided, however, that Licensee may not carry over to the following year any amount by which the Minimum Royalty paid exceeds the actual amount of Royalties payable hereunder during the applicable calendar year. Licensee's failure to pay the Minimum Royalty payment to CSMC in accordance with this Section shall constitute a material breach of this Agreement by Licensee, and CSMC shall have the right to terminate the Agreement in accordance with Section 6.2(c) thereof, or at Licensor's sole discretion, upon written notice to Licensee, convert the exclusive license granted under Section 2. l hereof to a non-exclusive license or to a co-exclusive license.
(c) Permitted Deductions. If Licensee is required to make any payment to a third party to obtain a license for the manufacture, use, sale or import of a Product or otherwise exploit the Patent Rights, Licensee shall be entitled to deduct up to fifty percent (50%) of such third party payments made in a particular calendar year against Royalties payable to CSMC for that year; provided, however , that in no event shall the Royalties payable to CSMC hereunder for any one-year period be reduced by operation of this section by more than fifty percent (50%); and provided, further, that such third party payments shall only be creditable against Royalties payable to CSMC for the calendar year in which the third party payment was actually made by Licensee.
(d) Licensee Challenge of Patent Rights. Should Licensee bring, directly or through a third party indirectly, an action challenging the validity, scope or enforceability of any Patent Rights, Licensee will first provide CSMC with at least ninety (90) days' prior written notice that it intends so to do before filing such a challenge. Following the giving of such notice, Licensee will pay to CSMC the Royalties and Non-Royalty Sublicense Revenue due hereunder at the rate of two times the applicable rate during the pendency of such action. Should the outcome of such action determine that any claim of a patent challenged by Licensee is valid and/or infringed and/or enforceable, as applicable, Licensee will thereafter pay to CSMC the Royalties and Non -Royalty Sublicense Revenue due hereunder at the rate of three times the applicable rate for all Products sold that would infringe such claim and/or transactions that include a grant of rights to such claim. Such increa sed royalty reflects the incr eased value of the Patent Rights upheld in such action. In the event that a challenge to the Patent Rights brought by Licensee is partially or entirely successful, Licensee will have no right to recoup any Royalties or other amounts paid before or during the period of the challenge. Additionally, Licensee agrees to disburse any and all proceeds received from any sublicense of the applicable Patent Rights throughout the duration of any such challenge to CSMC, and agrees to reimburse CSMC for all costs actually incurred by CSMC in connection with the applicable legal proceedings. In the event that all or any portion of this Section 4.3(d) is invalid, illegal or unenforceable, then the parties will use their best efforts to replace the invalid, illegal or unenforceable provision (s) with valid, legal and enforceable provision(s) which, insofar as practical, gives effect to the intent of this Section 4.3(d).
(e) Arm's-Length Transactions. On sales of Products which are made in other than an arms' -length transaction, the value of the Net Sales attributed under this Section 4.3 to such a transaction shall be that which would have been received in an arms'-length transaction, based on sales of like quality and quantity products on or about the time of such transaction.
(f) Duration of Royalty Obligations. The royalty obligations of Licensee as to each Product shall terminate on a country-by-country and product-by-product basis concurrently with the expiration of the last to expire Valid Claim that covers such Product in a country, including any term extensions thereof.
(g) Non-Royalty Revenues.
(i) Non-Royalty Sublicense Revenues. Any and all "Non-Royalty Sublicense Revenues" shall be reported and paid to CSMC by Licensee at a rate of five percent (5%) of all Non-Royalty Sublicense Revenues from any third party to CSMC within sixty (60) days of receipt by Licensee.
Any non-cash consideration received by Licensee from Permitted Sublicensees shall be valued at its fair market value as of the date of receipt and such amount shall be paid in cash to CSMC in accordance with the schedule above. In the event that the Patent Rights are sublicensed in combination with one or more patented technologies that are not covered under this Agreement, Non-Royalty Sublicense Revenues for the purposes of this Section 4.3(g) shall be calculated on a pro-rata basis in a manner to be mutually agreed by CSMC and Licensee (which agreement may be a condition of approval under Section 2.2).
(ii) Product Development Milestones. Licensee agrees to pay and shall pay to CSMC the following non-creditable, non-refundable product development milestone payments within ninety (90) days of the first occurrence of the following milestones (or their equivalents):
|
Milestone Event |
Milestone Payment |
|
Successful completion of phase 2 of clinical trial |
$250,000 |
|
Successful completion of phase 3 of clinical trial |
$350,000 |
|
New drug application (NDA) approval by FDA in the United States or an equivalent agency in a major market outside of the United States |
$350,000 |
|
First commercial sale of a Product |
$1,000,000 |
|
Licensee's achievement of aggregated Net Sales of $75,000,000 |
$1,500,000 |
|
(h) |
Payment and Accounting. |
(i) Reports. Each payment of Royalties shall be accompanied by a report in the form attached as Schedule C hereto, which sets forth in reasonable detail the number and each type of Product sold and the calculation of Net Sales applicable thereto, and such additional details as may be reasonably requested by CSMC for the determination of Royalties payable hereunder. Products shall be considered as being sold for the purpose of the calculation of Royalties under this Agreement when the Products have been invoiced. Each payment of Non-Royalty Sublicense Revenue shall be accompanied by a report in the form attached as Schedule C hereto setting forth in reasonable detail the basis for the calculation of such amounts, and such additional details as may be reasonably requested by CSMC for the determination of Non-Royalty Sublicense Revenue payable hereunder. All copies of reports under this Section shall be sent by electronic mail to CSTechTransfer(@cshs.org. Except as otherwise provided herein, all amounts due hereunder shall be paid in United States dollars and shall be made without set off and free and clear of (and without any deduction or withholding for) any taxes, duties, levies, imposts or similar fees or charges. Royalties shall be payable by Licensee quarterly, within forty-five (45) days after the end of each calendar quarter, based upon revenues accrued during the immediately preceding calendar quarter. Licensee agrees to pay and shall pay to CSM C, or cause its Permitted Sublicensees to pay to CSMC, all Royalties resulting from the activities of its Permitted Sublicensees , within forty-five (45) days after the end of each calendar quarter.
(ii) Notice of Payment. Licensee shall provide prompt written notice to CSMC that it has paid the licensee fee required by Section 4.1 or any product development milestone payment required by Section 4.3(h) by electronic mail to CSTechTransfer@cshs.org.
(iii) Wire Transfer Instructions. All payments due hereunder shall be made by Licensee to CSMC in accordance with the following wire transfer instructions:
City National Bank
400 N. Roxbury Drive
Beverly Hills, CA 90210
ABA# 122 016 066
Account Number: 210-132260
Account Name: Cedars-Sinai Medical Center-Tech Transfer
Reference: Tech Transfer- StemVax
(iv) Records and Audits. Licensee shall create and maintain complete and accurate records and documentation concerning all sales of Products by Licensee, its Affiliates and Permitted Sublicensees as well as transactions based upon which Non-Royalty Sublicense Revenue is due, in sufficient detail to enable the Royalties and Non-Royalty Sublicense Revenue, respectively, that is payable hereunder to be determined. Licensee shall retain such records and documentation for not less than seven (7) years from the date of their creation. During the term of this Agreement and for a period of three (3) years thereafter, CSMC and its representatives shall have the right to audit such records and documentation as shall pertain to the determination and payment of Royalties and Non-Royalty Sublicense Revenue. Such examiners shall have reasonable access during regular business hours to Licensee's offices and the relevant records, files and books of account, and shall have the right to examine any other records reasonably necessary to determine the accuracy of the calculations provided by Licensee. The costs of any such audit shall be borne by CSMC, unless as a result of such inspection it is determined that the amounts payable by Licensee for any period are in error by greater than five percent (5%), in which case the costs of such audit shall be borne by Licensee. CSMC shall report the results of any such audit to Licensee within forty-five (45) days of completion. Thereafter, Licensee shall promptly pay to CSMC the amount of any underpayment discovered in such audit, or CSMC shall credit to Licensee against future Royalty payments the amount of any overpayment discovered in such audit, as the case may be. In addition, Licensee shall pay interest on any underpayment at the rate that is the lower of (i) two percent (2%) over the rate of interest announced by Bank of America in Los Angeles, California (or any successor in interest thereto or any commercially equivalent financial institution if no such successor exists) to be its " prime rate", or (ii) the highest rate permitted by applicable law, from the date such amount was underpaid to the date payment is actually received.
(v) Currency Transfer Restrictions. If any restrictions on the transfer of currency exist in any country or other jurisdiction so as to prevent Licensee from making payments to CSMC, Licensee shall take all commercially reasonable steps to obtain a waiver of such restrictions or to otherwise enable Licensee to make such payments. If Licensee is unable to do so, Licensee shall make such payments to CSMC in a bank account or other depository designated by CSMC in such country or jurisdiction, which payments shall be in the local currency of such country or jurisdiction, unless payment in United States dollars is permitted. Any payment by Licensee to CSMC in currencies other than United States dollars shall be calculated using the appropriate foreign exchange rate for such currency quoted in the California edition of The Wall Street Journal for the close of business of the last banking day of the calendar quarter in which such payment is being made.
(vi) Late Charges. A service charge of two percent (2%) per month, not to exceed the maximum rate allowed by applicable law, shall be payable by Licensee on any portion of Licensee 's outstanding Royalty or Non-Royalty Sublicense Revenue balance or any
other amount payable by Licensee hereunder (including, without limitation, reimbursement for Prosecution costs as set forth in Section 4.1 hereof) that is not paid to CSMC within thirty (30) days past the due date.
(vii) Taxes. Licensee shall pay, or cause to be paid, any and all taxes required to be paid or withheld on any sales, licenses or other transfers for value of Products or Patent Rights (other than taxes imposed on the income or revenues of CSMC); provided, however, that under no circumstances shall the amounts of such taxes be deducted from the total amount of payments otherwise due to CSMC hereunder. Upon CSMC's request, Licensee shall secure and send to CSMC proof of any such taxes withheld and paid by Licensee, its Affiliates or Permitted Sublicensees.
(viii) No Escrow. Licensee shall pay all Royalties and Non-Royalty Sublicense Revenue directly to CSMC and shall not pay royalties into any escrow or other similar account, including in the event of a validity or non-infringement challenge to the Patent Rights.
|
5. |
PATENT AND INTELLECTUAL PROPERTY RIGHTS |
5.1 Prosecution. Commencing on the Effective Date, Licensee shall assume, in coordination with CSMC, full responsibility for the application, maintenance, reexamination, reissue, opposition and prosecution of any kind (collectively "Prosecution") relating to the Patent Rights in the Territory, including, but not limited to, payment of all costs, fees and expenses related thereto. Subject to the approval of CSMC (which approval shall not be unreasonably withheld), Licensee shall have the right to select counsel with respect to the responsibility . assumed by Licensee in this Section 5.1, and Licensee shall diligently pursue the Prosecution of the Patent Rights to the benefit of CSMC. For all purposes of the patent Prosecution, CSMC shall be the named "client" of such patent counsel. Each party shall provide the other with copies of any and all material or communications with the United States Patent and Trademark Office, or any foreign patent office, and CSMC shall be afforded the opportunity of prior review and comment on such action or paper.
(a) Foreign Filings. Should Licensee elect not to file for patent protection for the Patent Rights in a certain national jurisdiction in the Territory, Licensee shall notify CSMC of such election at least forty-five (45) days before a final due date which would result in the bar of patent protection for the Patent Rights in such national jurisdiction. In such event, CSMC may, at its sole option and expense, file for patent protection for the Patent Rights in the applicable national jurisdiction, and Licensee's license under this Agreement with respect to such national jurisdiction shall terminate, allowing CSMC to freely dispose of its Patent Rights in the applicable national jurisdiction as it sees fit in its sole discretion.
5.2 Abandonment, Disclaimers, etc. Licensee shall obtain the prior written consent of CSMC (which consent shall not be unreasonably withheld), prior to abandoning, disclaiming, withdrawing, seeking reissue, seeking reexamination or allowing to lapse any patent or patent application within the Patent Rights. In the event that Licensee shall elect to abandon the Prosecution (including the payment of maintenance fees or annuities) of any patent or patent application included in the Patent Rights, Licensee shall notify CSMC of such election at least
forty-five (45) days before a final due date which would result in abandonment or bar of patentability of the patent or patent application. In such event, CSMC may, at its sole option and expense, continue Prosecution of the patent application or patent. Licensee further agrees that it shall not file any continuation-in-part application relating to the Patent Rights unless the additional disclosure or material to be included in the continuation-in- part application is necessary or appropriate to support the patentability of a claim recited in a parent application on which the continuation-in-part application is based. Licensee shall not file any continuation-in - part application without CSMC's prior written consent, which shall not be unreasonably withheld.
5.3 Expenses. Licensee shall pay all expenses resulting from its obligations in Section 5.1 hereof. CSMC shall exercise reasonable efforts to cause the Inventors (to the extent they are available and on CSMC 's staff as employees) to cooperate fully with Licensee with respect to the Prosecution of the Patent Rights, and CSMC shall be reimbursed for all reasonable out-of-pocket expenses as such expenses are incurred.
5.4 CREATE Act. Licensee shall not invoke the Cooperative Research and Technology Enhancement Act of 2004, as set forth under Title 35, Section 102(c) of the United States Code (the "CREATE Act"), with respect to the Patent Rights without first obtaining the prior written consent of CSMC.
5.5 Publications. CSMC shall furnish Licensee with a written copy of any proposed publication or disclosure that relates to the Patent Rights and/or Licensee's Confidential Information or discloses and/or describes any Improvement that Licensee has certain active rights to as described in Section 2.3, including without limitation, disclosures at research seminars, lectures and professional meetings and the submission of papers for publication at least forty-five (45) days prior to submission for publication or disclosure so that Licensee may have a reasonable opportunity to protect the proprietary rights to information, inventions, or products identified in such publication or disclosure. Further, if Licensee indicates that such publication or disclosure contains Licensee's Confidential Information, CSMC agrees to remove such Confidential Information from the proposed publication or disclosure. Notwithstanding the preceding, in the event that Licensee requires any deletion of information, in no event will the deletion compromise the objective medical or scientific integrity of the manuscript. CSMC further shall, upon Licensee's request, delay publication or presentation for an additional period of up to forty-five (45) days to allow Licensee to protect its interests in any inventions described in any such manuscripts or materials .
|
6. |
TERM AND TERMINATION |
6.1 Term. Unless earlier terminated as provided in Section 6.2 hereof, the term of this Agreement shall commence on the Effective Date and shall expire, on a country-by-country and product-by-product basis, on the date upon which the last to expire Valid Claim shall expire.
6.2 Termination. Except as provided by Section 6.3 hereof, and in addition to the termination provisio ns of Sections 2.5, 2.6 and 5.l(a), this Agreement shall terminate upon the earliest to occur of the following:
(a) Automatically if Licensee shall enter into a liquidating bankruptcy, be adjudged in so lvent, liquidate, dissolve and/or if the business of Licensee shall be placed in the hands of a receiver, assignee, or trustee, whether by voluntary act of Licensee or otherwise; provided, however, that if any such action is involuntary, termination shall not take place unless the action is not reversed within thirty (30) days. Further, Licensee shall give CSMC at least forty-five (45) days' prior written notice before Licensee initiates any bankruptcy proceeding, and CSMC shall have the right to terminate this Agreement immediately upon receipt of such notice;
(b) Automatically if the performance by either party to this Agreement of any term, covenant, condition or provision hereof (i) shall jeopardize (A) the licensure of CSMC, (B) CSMC's participation in the Medicare, Medi-Cal or other reimbursement or payment programs,
(C) the full accreditation of CSMC by the Joint Commission of Accreditation of Healthcare Organizations or any other state or nationally recognized accreditation organization, or (D) CSMC's tax-exempt status; or (ii) is deemed illegal or unethical by any recognized governmental agency or body. Upon the occurrence of any of the items set forth in this subparagraph (b), CSMC shall provide written notice to Lice nsee setting forth the reason for such termination (which termination shall be effective immediately);(d)
(c) Upon thirty (30) days' written notice from CSMC if, within such thirty (30) day period (i) Licensee shall fail to pay fully any Royalty or Non-Royalty Sublicense Revenue payment required by Section 4.3 hereof, or (ii) Licensee shall fail to undertake commercially reasonable efforts to exploit the Patent Rights in the Field of Use in the Territory, regardless of Licensee's satisfaction of the Milestones provided in Schedule B hereto;
(d) Upon sixty (60) days' written notice from CSMC if, within such sixty (60) day period, Licensee shall fail to cure fully any breach or default of any material obligation under this Agreement as desc1ibed in such written notice detailing the facts of such breach with reasonable specificity; provided , however, that Licensee may avoid such termination if, before the end of such 60-day period, such breach or default has been cured by Licensee to the reasonable satisfaction of CSMC;
(e) Upon ninety (90) days' written notice from Licensee if, within such ninety(90) day period, CSMC shall fail to cure fully any breach or default of any material obligation under this Agreement as described in such written notice detailing the facts of such breach with reasonable specificity; provided, however, that CSMC may avoid such termination if, before the end of such 90-day period, such breach or default has been cured by CSMC to the reasonable satisfaction of Licensee;
(f) Upon ninety (90) days' written notice from Licensee, in the event that Licensee has determined that it would not be commercially reasonable to continue to develop and/or commercialize Products for any of the following reasons: (i) scientific or technical reasons or (ii) unduly burdensome obligations imposed by regulatory authorities; provided that,
such written notice to CSMC under this Section 6.2(f) must provide CSMC with a reasonable explanation for Licensee's termination under this Section 6.2(f); and
(g) Upon the mutual written agreement of the parties hereto (such termination to be effective as of the date mutually agreed upon in such written agreement).
6.3 Obligations Upon Termination. Upon any termination of this Agreement pursuant to Section 6.2 hereof, nothing herein shall be construed to release any party from any liability for any obligation incurred through the effective date of termination (e.g., confidentiality, reimbursement of patent expenses incurred prior to such date, etc.) or for any breach of this Agreement prior to the effective date of such termination. Licensee may, for a period of one ( I ) year after the effective date of such termination, sell all tangible Products customarily classified as " inventory" that it has on hand at the date of termination, subject to payment by Licensee to CSMC of the applicable Royalty and Non-Royalty Sublicense Revenue; provided, however, that any such action by Licensee does not subject CSMC to any of the occurrences set forth in Section 6.2(b) hereof.
6.4 Effect of Termination. In the event of any termination of this Agreement pursuant to Section 6.2 hereof, where such termination has not been caused by any action or inaction on the part of any Permitted Sublicensee of Licensee or by any breach by such Permitted Sublicensee of its obligations under its sublicense from Licensee, such termination of this Agreement shall be without prejudice to the rights of each non-breaching Permitted Sublicensee of Licensee and each non-breaching Permitted Sublicensee shall be deemed to be a licensee of CSMC thereunder, and CSMC shall be entitled to all rights, but shall not be subject to any obligations (other than the grant of license and appurtenant obligations under this Agreement to the extent provided for in such sublicense) of Licensee thereunder. This Section 6.4, however, shall not be applicable if this Agreement has been terminated under Section 6.2(b) under circumstances where the application of this Section 6.4 would subject CSMC to any of the occurrences set forth in Section 6.2(b).
6.5 Right to Institute Legal Actions. Notwithstanding the provisions of Section 6.2 hereof, CSMC, on the one hand, and Licensee, on the other hand, may institute any other legal action or pursue any other remedy against the other party permitted by applicable law if the other party does not substantially cure any breach or default of any material obligation as provided herein.
6.6 Reversion of Rights. Notwithstanding anything to the contrary set forth herein (including, but not limited to, Section 5 hereof), full responsibility for Prosecution of the Patent Rights shall, at the option of CSMC (exercisable in its sole and absolute discretion), and at its sole expense from the date of reversion, revert to CSMC upon any termination of this Agreement.
6.7 Return of Data. In the event of any termination or expiration of this Agreement, Licensee shall promptly provide CSMC with copies of all data, information and materials obtained or generated by or on behalf of Licensee in the course of conducting research and developing Products using the Patent Rights.
|
7. |
INFRINGEMENT BY THIRD PARTIES |
7.1 Enforcement. Licensee shall have the first right and the obligation to enforce, at its sole expense, any Patent Rights to the extent licensed hereunder against infringement by third parties and shall notify CSMC in writing in advance of all such enforcement efforts. Upon Licensee ' s undertaking to pay all expenditures reasonably incurred by CSMC, CSMC shall reasonably cooperate in any such enforcement and, as necessary, join as a party therein. Licensee shall reimburse CSMC for all expenses, including reasonable attorneys' fees, incurred in connection with any such enforcement. In the event that Licensee does not file suit against or commence and conclude settlement negotiations with a substantial infringer of Patent Rights within ninety (90) days of receipt of a written demand from CSMC that Licensee bring suit, then the parties will consult with one another in an effort to determine whether a reasonably prudent licensee would institute litigation to enforce the patent in question in light of all relevant business and economic factors (including, but not limited to, the projected cost of such litigation, the likelihood of success on the merits, the probable amount of any damage award, the prospects for satisfaction of any judgment against the alleged infringer, the possibility of counterclaims against the parties hereto, the impact of any possible adverse outcome on Licensee and the effect any publicity might have on the parties' respective reputations and goodwill). If, after such process, it is determined that a suit should be filed and Licensee does not file suit or commence settlement negotiations forthwith against the infringer, then CSMC shall have the right, at its own expense, to enforce any Patent Rights license d hereunder on behalf of itself and Licensee. Any damages or other recovery from an infringement action undertaken by Licensee shall first be used to reimburse the parties, on a pro rata pari passu basis, for the costs and expenses incurred in such action, and shall thereafter be allocated between the parties as follows: (i) twenty percent (20%) to CSMC and (ii) eighty percent (80%) to Licensee. If Licensee fails to prosecute any such action to completion, then any damages or other recovery net of the parties' costs and expenses incurred in such infringement action shall be the sole property of CSMC.
7.2 Defense of Patent Rights. In the event that any Patent Rights are the subject of a legal action seeking declaratory relief or of any reexamination or opposition proceeding instituted by a third party, the parties agree to promptly consult with each other concerning the defense of such actions or proceedings. If the parties agree that such defense should be undertaken, then Licensee shall bear the expenses, including attorneys' fees, associated with such defense and in any recoupment of expenses. If the parties disagree, then the party desiring to defend the action or proceeding may proceed with such defense and will bear its own expenses, and be entitled to all sums recovered.
|
8. |
INDEMNIFICATION |
8.1 Indemnification by Licensee. Subject to Section 8.2 hereof, Licensee shall hold harmless, defend and indemnify CSMC and each of its officers, directors, employees (including the Inventors), agents and sponsors of the research (except Licensee) (each, an "Indemnified Party", and collectively, the "Indemnified Parties") from and against any and all claims, damages, losses, liabilities , costs and expenses (including reasonable attorneys' fees and expenses and costs of investigation, whether or not suit is filed) suffered or incurred by any of the Indemnified Parties in any action, suit, litigation, arbitration or dispute of any kind ("Action ") arising or resulting from any negligence or willful acts or omissions on the part of
Licensee, its Affiliates or Permitted Sublicensees in connection with (a) their use of the Patent Rights and/or (b) the exercise of their rights hereunder or under any sublicense, including, but not limit ed to (i) the preclinical development and clinical testing of Products, and (ii) the manufacture, sale, use, marketing, or other disposition of Products developed, manufactured, sold, marketed, used or otherwise disposed of under this Agreement. As part of its obligations hereunder, Licensee shall defend any Action brought against any of the Indemnified Parties with counsel of its own choosing and reasonably acceptable to CSMC, and neither CSMC nor any other Indemnified Party shall enter into any settlement of any such Action without first obtaining prior approval of Licensee. Licensee shall pay all costs, including attorney's fees, incurred in enforcing this indemnification provision. Should CSMC or any other Indemnified Party not afford Licensee the right to defend any such Action, or should CSMC or any other Indemnified Party not obtain the approval of Licensee to any such settlement, Licensee shall have no obligation to indemnify CSMC or any other Indemnified Party hereunder. Should Licensee fail to provide a defense for the Indemnified Parties as required hereunder, then Licensee shall reimburse CSMC for its out-of-pocket expenses (including reasonable attorneys' fees and expenses and costs of investigation) which are incurred as a result of any investigation, defense or settlement relating to the foregoing, which reimbursement shall be made to CSMC upon receipt by Licensee of invoices reflecting in reasonable detail such expenses incurred by CSMC. Licensee shall obtain and maintain insurance policies (including products liability and general liability policies at such time as is appropriate) which are reasonable and necessary to cover its activities and to comply with the indemnification obligations set forth above. Such insurance policies shall name CSMC as an additional insured party and shall provide a minimum of $2,000,000 in coverage per occurrence. Upon initiation of any human clinical studies of Products, Licensee shall have first increased its insurance coverage to a minimum of $5,000,000 in the aggregate. Licensee shall provide CSMC with prompt written notice of any material change in coverage under such policies. If the parties determine that evidence of Licensee's insurance coverage is necessary and appropriate, within thirty (30) days of the Effective Date (subject to extension if reasonably required) and annually thereafter, Licensee shall provide CSMC with a certificate of insurance issued by the appropriate insurance company evidencing the insurance coverage required by this Section 8.1, together with copies of the endorsement which specifies CSMC as an additional insured and the declarations page for each such insurance policy. The certificate of insurance, endorsements and declarations pages (and any renewals or replacements thereof), if required, shall be sent to CSMC's Technology Transfer Office by electronic mail at CSTechTransfer@cshs.org.
8.2 Notice of Claim. CSMC shall promptly notify Licensee in writing of any claim or Action or material threat thereof brought against any Indemnified Party in respect of which indemnification may be sought and, to the extent allowed by law, shall reasonably cooperate with Licensee in defending or settling any such claim or Action. No settlement of any claim, Action or threat thereof received by CSMC and for which CSMC intends to seek indemnification (for itself or on behalf of any other Indemnified Party) shall be made without the prior joint written approval of Licensee and CSMC.
|
9. |
USE OF NAMES |
9.1 CSMC Names and Marks. Licensee shall not, unless as required by any law or governmental regulation, use the name of CSMC, and/or any of its trademarks, service marks,
trade names or fictitious business names or the name of any CSMC officer, faculty member, employee , student or volunteer (collectively, "CSMC Names and Marks") without express prior written consent of the Vice President for Public Relations and Marketing of CSMC. Further, prior to any reference by Licensee to CSMC Names and Marks in any manner, Licensee shall provide CSMC with a writing reflecting the proposed reference so that CSMC can review the reference within a reasonable period of time prior to the proposed use thereof by Licensee. This limitation includes, but is not limited to, use by Licensee in any regulatory filing, advertising, offering circular , prospectus, sales presentation, news release or trade publication. Subject to compliance by Licensee with the foregoing, which shall be deemed conditions precedent to any use of CSMC Names and Marks by Licensee, Licensee shall ensure that the CSMC Names and Marks are used as scientifically or academically appropriate in the "byline" of any article, abstract, manuscript or any other publication related to the subject matter hereof.
9.2 No Endorsements by CSMC. By entering into this Agreement, CSMC does not directly or indirectly endorse any product or service provided, or to be provided, by Licensee whether directly or indirectly related to this Agreement. Licensee shall not state or imply that this Agreement is an endorsement by CSMC.
|
10. |
CONFIDENTIALITY |
10.1 Non-Disclosure. The parties hereto shall keep the terms of this Agreement and all business and scientific discussions relating to the business of the parties strictly confidential. All patient information to which a party is given access by the other party shall be subject to the provisions of the Confidentiality of Medical Information Act (Cal. Civ. Code §§56, et seq.) and the Health Insurance Portability and Accountability Act of 1996 , and all regulations promulgated thereunder. It may, from time to time, be necessary for the parties, in connect ion with performance under this Agreement, to disclose Confidential Information (including know-how) to each other. The Receiving Party (as defined in Section 1.2 hereof) shall keep in strictest confidence the Confidential Information of the Disclosing Party (as defined in Section 1.2 hereof), using the standard of care it normally uses for information of like character, and shall not disclose the Confidential Information to any third party or use it except as expressly authorized by the prior written consent of the Disclosing Party or as otherwise permitted by this Agreement; provided, however, that Licensee may disclose the Confidential Information received from CSMC to its Affiliates and Permitted Sublicensees as shall be reasonably necessary to carry out the intent of this Agreement or any sublicense granted by Licensee as contemplated by this Agreement if, but only if, such Affiliates and/or Permitted Sublicensees each execute a confidentiality agreement containing confidentiality provisions no less restrictive than those confidentiality provisions contained in this Section 10. The Receiving Party's obligation hereunder shall not apply to Confidential Information that the Receiving Party can show:
(a) Is or later becomes part of the public domain through no fault or neglect of the Receiving Party;
(b) Is received in good faith from a third party having no obligations of confidentiality to the Disclosing Party, provided that the Receiving Party complies with any restrictions imposed by the third party;
(c) Is independently developed by the Receiving Party without use of the Disclosing Party's Confidential Information; or
(d) Is required by law or regulation to be disclosed (including, without limitation , in connection with FDA filings, filings with another government agency or as required under the California Public Records Act), provided that the Receiving Party uses reasonable efforts to restrict disclosure and to obtain confidential treatment.
10.2 Limits on Permitted Disclosures. Each party agrees that any disclosure or distribution of the other party's Confidential Information within its own organization shall be made only as is reasonably necessary to carry out the intent of this Agreement. The parties further agree that all of their respective officers, employees, agents, representatives or approved sublicensees to whom any Confidential Information is disclosed or distributed shall have agreed to maintain its confidentiality. In such event, the Receiving Party shall identify with reasonable particularity, upon request by the Disclosing Party, each person within the Receiving Party's organization to whom the Receiving Party has disclosed or distributed Confidential Information.
10.3 Legally Required Disclosures. If a subpoena or other legal process concerning Confidential Information is served upon any party hereto pertaining to the subject matter hereof, the party served shall notify the other party immediately, the other party shall cooperate with the party served, at the other party's expense, in any effort to contest the validity of such subpoena or other legal process. This Section 10.3 shall not be construed in any way to limit any party's ability to satisfy any disclosure of its relationship with the other party required by any governmental authority.
10.4 Patent Rights as Confidential Information. The Patent Rights are understood by Licensee to be the Confidential Information of CSMC to the extent "unpublished" as such term is construed under the United States Patent Laws. As such, Licensee' s confidentiality obligations hereunder automatically extend to any and all patent applications of CSMC relating to any Patent Rights and Improvements and to any and all communications with the United States Patent Office, and any foreign patent office relating to any Patent Rights Improvements.
10.5 Return of Confidential Information. In the event of any termination of this Agreement, the Receiving Party shall promptly return all Confidential Information and any copies made thereof previously made available to the Receiving Party by the Disclosing Party.
10.6 Remedies. Both parties acknowledge and agree that it would be difficult to measure damages for breach by either party of the covenants set forth in this Section l 0, and that injury from any such breach would be incalculable, and that money damages would therefore be an inadequate remedy for any such breach. Accordingly, either party shall be entitled, in addition to all other remedies available hereunder or under law or equity, to injunctive or such other equitable relief as a court may deem appropriate to restrain or remedy any breach of such covenants.
|
11. |
INFORMATION EXCHANGE |
In addition to the Patent Rights, the parties shall cooperate to exchange such non-confidential information as may be appropriate and necessary to facilitate Licensee's development and commercialization of Products incorporating any Patent Rights.
|
12. |
PATENT MARKING |
Licensee shall actually or virtually mark all Products made, sold or otherwise disposed of by or on behalf of it or any of its Permitted Sublicensees as set forth under Title 35, Section 287(a) of the United States Code and shall respond to any request or disclosure under Title 35, Section 287(6)(4)(B) of the United States Code by only notifying CSMC of the request for disclosure.
|
13. |
MISCELLANEOUS |
13.1 Notices. Any notice, request, instruction or other document required by this Agreement shall be in writing and shall be deemed to have been given (a) if mailed with the United States Postal Service by prepaid, first class, certified mail, return receipt requested, at the time of receipt by the intended recipient, (b) if sent by Federal Express or other overnight carrier, signature of delivery required, at the time of receipt by the intended recipient, or (c) if sent by facsimile transmission, when so sent and when receipt has been acknowledged by appropriate telephone or facsimile receipt, addressed as follows:
In the case of CSMC to:
Cedars-Sinai Medical Center
8700 Beverly Boulevard
Los Angeles, California 90048-1865
Attention: Executive Vice President for Finance & CFO
with a copy to Vice President for Technology & Business Affairs
or in the case of Licensee to:
Stemvax, LLC
1850 N New Hampshire Ave
Los Angeles, CA 90027
Attention: Dwain Morris-Irvin, co-Founder, CSO
or to such other address or to such other person(s) as may be given from time to time under the terms of this Section 13.1.
13.2 Compliance with Laws. Each party shall comply with all applicable federal, state and local laws and regulations in connection with its activities pursuant to this Agreement.
13.3 Governing Law. For any dispute between the parties to this Agreement which arises from or relates to this Agreement, the Agreement shall be construed and enforced in
accordance with the laws of the United States of America and of the State of California, irrespective of choice of laws provisions. The parties agree that Los Angeles County, California shall be the situs of any legal proceeding arising out of or relating to this Agreement. Each party hereby waives any right it may have to assert the doctrine of forum non conveniens or similar doctrine or to object to venue with respect to any proceeding brought in accordance with this Section , and stipulates that the state and federal courts located in Los Angeles, California shall have in personam jurisdiction and venue over each of them for the purpose of litigating any dispute, controversy, or proceeding arising out of or related to this Agreement. Each party hereby authorizes and accepts service of process sufficient for personal jurisdiction in any action against it as contemplated by this Section by registered or certified mail, return receipt requested, postage prepaid, to its address for the giving of notices as set forth in this Agreement.
13.4 Waiver. Failure of any party to enforce a right under this Agreement shall not act as a waiver of that right or the ability to assert that right relative to the particular situation involved.
13.5 Enforceability. If any provision of this Agreement shall be found by a court of competent jurisdiction to be void, invalid or unenforceable, the same shall be reformed to comply with applicable law or stricken if not so conformable, so as not to affect the validity or enforceability of the remainder of this Agreement.
13.6 Modification. No change, modification, or addition or amendment to this Agreement, or waiver of any term or condition of this Agreement, is valid or enforceable unless in writing and signed and dated by the authorized officers of the parties to this Agreement.
13.7 Entire Agreement. This Agreement and the Schedules hereto (which are incorporated herein by this reference as if fully set forth herein) constitute the entire agreement between the parties with respect to the subject matter hereof and thereof, and replace and supersede as of the date hereof and thereof any and all prior agreements and understandings, whether oral or written, between the parties with respect to the subject matter of such agreements.
13.8 Construction. This Agreement has been prepared, examined, negotiated and revised by each party and their respective attorneys, and no implication shall be drawn and no provision shall be construed against any party to this Agreement by virtue of the purported identity of the drafter of this Agreement or any portion thereof.
13.9 Counterparts. This Agreement may be executed simultaneously in one or more counterparts, each of which shall constitute one and the same instrument. This Agreement may be executed by facsimile or in .pdf format.
13.10 Attorneys' Fees. In the event of any action at law or in equity between the parties hereto to enforce any of the provisions hereof, the unsuccessful party to such litigation shall pay to the successful party all reasonable costs and expenses, including reasonable attorneys ' fees, incurred therein by such successful party; and if such successful party shall recover a judgment in any such action or proceeding, such reasonable costs, expenses and attorneys' fees may be included in and as part of such judgment.
|
13.11 |
Assignment; Successors. |
(a) Subject to Section 13. 1 l(b), Licensee may assign this Agreement as part of a sale, regardless of whether such a sale occurs through an asset sale, stock sale, merger or other combination, or any other transfer of Licensee's entire business, or that part of Licensee's business that exercises all rights granted under this Agreement. Any other attempt to assign this Agreement by Licensee without CSMC's written consent, which shall not be unreasonably withheld or delayed, is null and void. In the event of a bankruptcy, assignment is permitted only to a party that can provide adequate assurance of future performance, including diligent development and sales, of Products.
(b) Prior to any assignment , the following conditions must be met: (i) Licensee must give CSMC thirty (30) days prior written notice of the assignment, including the new assignee's contact information, (ii) the new assignee must agree in writing to CSMC to be bound by this Agreement, and (iii) CSMC must have received a $25,000.00 assignment fee.
(c) Subject to the limitations on assignment herein, this Agreement shall be binding upon and inure to the benefit of any successors in interest and assigns of CSMC and Licensee. CSMC shall have the right to assign its rights hereunder as part of any reorganization or bond financing.
13.12 Further Assurances. At any time and from time to time after the Effective Date, each party shall do, execute, acknowledge and deliver, and cause to be done, executed, acknowledged or delivered, all such further acts, transfers, conveyances, assignments or assurances as may be reasonably required to consummate the transactions contemplated by this Agreement.
13.13 Survival. The following sections shall survive any expiration or earlier termination of this Agreement: 4.3(h), 6.3, 8, 9, 10, 12 and 13.
[signature page follows]
IN WITNESS WHEREOF, the parties have caused their duly authorized representatives to execute this Agreement as of the date first above written.
| "LICENSEE": | |
|
STEMVAX, LLC, A CALIFORNIA LIMITED LIABILITY COMPANY |
|
| By: /s/ Dwain Morris-Irvin | |
| Name: Dwain Morris-Irvin | |
| Title: CSO, Chief Scientific Officer | |
| Date: | |
| "CSMC" | |
|
CEDARS SINAI MEDICAL CENTER, A CALIFORNIA NONPROFIT PUBLIC BENEFIT |
|
| /s/ Edward M. Prunchunas | |
| Edward M. Prunchunas | |
| Executive Vice President for Finance and CFO | |
| Date: | |
| By: /s/ James D. Laur, JD | |
| James D. Laur, JD | |
| Vice President, Technology & Business Affairs | |
| Date: | |
| ACKNOWLEDGED AND AGREED: | |
| "INVENTORS": | |
| /s/ Keith Black | |
| Dr. Keith Black | |
| /s/ Dwain Morris-Irvin | |
| Dr. Dwain Morris-Irvin | |
| /s/ Moshe Arditi | |
| Dr. Moshe Arditi |
Schedule A
Patent Rights
| 1. Title | USE OF TOLL-LIKE RECEPTOR LIGANDS AS ADJUVANTS TO VACCINATION THERAPY FOR BRAIN TUMORS |
| Patent Application: | 61/073,205 |
| Filing Date: | June 17, 2008 |
| CSMC Tech ID: | bla000322 |
| 2. Title | USE OF TOLL-LIKE RECEPTOR LIGANDS AS ADJUVANTS TO VACCINATION THERAPY FOR BRAIN TUMORS |
| Patent Application: | PCT/US2009/047640 |
| Filing Date: | June 17, 2009 |
| CSMC Tech ID: | bla000322 |
| 3. Title | USE OF TOLL-LIKE RECEPTOR LIGANDS AS ADJUVANTS TO VACCINATION THERAPY FOR BRAIN TUMORS |
| Patent Application: | 12/995,434 |
| Filing Date: | November 30, 2011 |
| CSMC Tech ID: | bla000322 |
| 4. Title | USE OF TOLL-LIKE RECEPTOR LIGANDS AS ADJUVANTS TO VACCINATION THERAPY FOR BRAIN TUMORS |
| Patent Application: | 14,247,028 |
| Filing Date: | April 7, 2014 |
| CSMC Tech ID: | bla000322 |
Schedule B
Milestones
|
1. |
Commercially reasonable diligence for partnering, fund raising, preclinical development, FDA interactions for clinical development and pre-IND meeting in the first two (2) years of the Agreement |
|
2. |
Initiation of Phase 1 trial within three (3) to four (4) years of Effective Date of the Agreement |
|
3. |
Initiation of Phase 2 trial within six (6) years of Effective Date of the Agreement |
|
4. |
Initiation of Phase 3 trial within eight (8) years of Effective Date of the Agreement |
Schedule C
Royalty Reporting Form
Licensee name:
Reporting period:
Date of report:
Date of first commercial sale:
Royalitv Report
|
Product (list products by name) |
No. units sold |
Invoiced price per unit |
Gross sales |
Allowable deductions (attached itemized detail) |
Country of sale/foreign currency/ conversion rate |
Net sales |
|
Product name |
||||||
|
Product name |
||||||
|
Product name |
||||||
|
Total |
|
Total net sales |
$ |
|
Royalty rate |
|
|
Royalty due |
$ |
Total royalty due: $_ _ _ _ _ _ _ _ _ _ _ _
Non-Rovalty Sublicense Revenue Report
|
Total Non-Royalty Sublicense Revenue received |
$ |
|
Date received |
|
|
Applicable percentage payable to CSMC |
|
|
Total Non-Royalty Sublicense Revenue paya ble to CSMC |
$ |
Report prepared by:
Title:
Date:
Please send electronic copy of report to CSTechTransfer@cshs.org .
Exhibit 21.1
Innovest Subsidiaries
|
Name |
State of Jurisdiction of Entity |
|
Innovest Energy Group, LLC |
Ohio |
|
H.P. Technologies, Inc. |
Ohio |
|
Midwest Curtainwalls, Inc. |
Ohio |
|
Chagrin Safety Supply, LLC |
Ohio |
|
Contact Source Solutions, LLC |
Ohio |
|
Authority National Supply, LLC |
Ohio |